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ABSTRACT	
Cancer	 is	 one	 of	 the	 leading	 causes	 of	 death	 in	 Australia.	 Current	 therapeutic	 options	
include	 the	 administration	 of	 harsh	 chemotherapeutics,	 tumour	 resection	 and	 stem	 cell	
transplantation.	Whilst	these	therapies	have	been	successfully	used	to	treat	cancer	patients,	
there	is	a	need	to	develop	novel	cancer	therapies	with	reduced	toxicities.	
One	approach	to	treat	cancer	is	blood	dendritic	cell	(BDC)	vaccination	that	may	use	peptides	
restricted	for	major	histocompatibility	complex	(MHC)	class	I,	or	may	use	monocyte-derived	
dendritic	 cells	 (Mo-DC)	 instead	 of	 BDC.	 A	 novel	 cancer	 therapy	 is	 autologous	 BDC	
vaccination	transfected	with	tumour	antigen	mRNA.	One	of	the	key	benefits	to	transfecting	
BDC	with	tumour	antigen	mRNA	is	the	ability	to	translate	and	present	the	tumour	antigen	
via	MHC	class	I	and	II.	 It	 is	thought	that	presenting	antigen	to	CD4+	T	cells	assists	with	the	
generation	a	strong	tumour	antigen	specific	CD8+	T	cell	immune	response.	Transfecting	Mo-
DC	with	tumour	antigen	has	demonstrated	increased	survival	with	acute	myeloid	leukaemia	
patients.	 Due	 to	 difficulties	 associated	 with	 isolating	 BDC,	 minimal	 studies	 exist	 that	
transfect	BDC	with	 tumour	antigen	mRNA	compared	 to	Mo-DC.	CMRF-56	 is	a	monoclonal	
antibody	 (mAb)	 that	 isolates	 a	 heterogeneous	 population	 of	 BDC,	 and	 other	 antigen	
presenting	cells.	The	mAb	was	engineered	as	a	human	chimeric	(h)	IgG4	mAb	in	preparation	
for	future	clinical	studies.	
This	thesis	describes	the	optimisation	of	BDC	isolation	with	hCMRF-56	and	transfected	with	
tumour	antigen	mRNA	in	preparation	of	future	clinical	studies.	The	results	from	this	thesis	
demonstrate	that	BDC	can	be	 isolated	and	transfected	with	tumour	mRNA	with	no	 loss	of	
antigen	presentation	and	chemotaxis	function.	Transfection	of	hCMRF-56c	isolated	cells	with	
tumour	antigen	mRNA	initiated	a	tumour	antigen	specific	T	cell	immune	response.	
The	 efficacy	 of	 mAbs	 targeting	 immune	 regulatory	 cell	 surface	 molecules,	 such	 as	
Nivolumab,	has	been	proved	to	be	a	promising	immune	therapy	option	for	several	cancers.	
The	mechanism	of	action	for	Nivolumab	inhibits	the	binding	of	PD-1	to	its	ligand	and	results	
in	the	increased	T	cell	proliferation	and	cytokine	production	by	T	cells.	BDC	transfected	with	
tumour	antigen	mRNA	were	cultured	in	the	presence	of	Nivolumab	with	no	enhanced	T	cell	
immune	 response.	 Furthermore,	 an	 optimal	 clinically	 activation	 strategy	 that	 can	 be	
translated	 to	 future	 clinical	 studies	 was	 investigated	 and	 Pam3CSK4	 was	 identified	 as	 a	
reagent	that	increases	hCMRF-56+	immune	selected	BDC	expression	of	CD80	and	secretion	
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of	cytokines.	The	increased	activation	of	hCMRF-56+	immune	selected	BDC	by	Pam3CSK4	is	
required	 to	 be	 compared	 to	 conventional	 activation	 by	 granulocyte	 monocyte-colony	
stimulating	factor.	
The	 results	 from	 this	 study	 demonstrate	 that	 a	 heterogeneous	 population	 of	 antigen	
presenting	 cells	 can	 be	 immune	 selected	 by	 hMRF-56	 immune	 selection.	 Furthermore,	
hCMRF-56+	 immune	 cells	 can	 be	 transfected	 with	 tumour	 antigen	 mRNA	 and	 is	 an	
appropriate	method	to	load	BDC	with	tumour	antigen	without	loss	of	function.		 	
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1 INTRODUCTION	
1.1 Cancer	therapeutic	options	
Cancer	 is	 a	 leading	 cause	 of	 death	 in	 Australia.	 In	 2014	 there	 were	 more	 than	 123,000	
Australians	 diagnosed	 with	 cancer	 and	 45,700	 deaths	 related	 to	 cancer	 (Welfare,	 2014).	
Therapeutic	options	for	cancer	include:	chemotherapy,	radiotherapy,	surgical	resection	and	
haematopoietic	stem	cell	transplantation	(Fridle	et	al.,	2017,	Jacobson	et	al.,	1995,	Luke	et	
al.,	2003,	Woods	et	al.,	2001).	These	treatment	options	are	dependent	on	factors	including	
cytogenetic	 characteristics	 of	 the	 cancer,	 age	 of	 the	 patient	 or	 expression	 of	 cell	 surface	
molecules	(Anders	et	al.,	2009,	Li	et	al.,	2013,	Zhao	et	al.,	2015).	 In	2009,	a	Swedish	study	
highlighted	 the	 complications	 associated	 with	 treating	 acute	 myeloid	 leukaemia	 (AML)	
patients	using	intensive	chemotherapy	and	found	that	elderly	AML	patients	have	a	greater	
risk	 of	 mortality	 than	 younger	 AML	 patient	 groups	 (Juliusson	 et	 al.,	 2009).	 This	 is	 one	
example	that	highlights	the	need	for	current	cancer	therapies	to	evolve	and	new	therapies	
to	be	discovered	that	accommodate	treating	difficult	patient	groups.	Immune	therapies	are	
a	new	cancer	treatment	that	stimulates	the	immune	system	to	initiate	an	immune	response	
directed	toward	the	cancer.	 Immune	therapies	when	used	to	supplement	common	cancer	
therapeutics,	or	as	a	stand-alone	treatment,	have	the	potential	to	minimise	harmful	adverse	
effects	or	fatalities	by	utilising	the	patient’s	own	immune	system	to	treat	the	disease.		
1.2 Current	cancer	immune	therapies	
As	 the	 2013	 “Breakthrough	 of	 the	 Year”	 by	 Science	 Magazine,	 immune	 therapies	 have	
created	 much	 hype	 for	 the	 treatment	 of	 cancer	 (Couzin-Frankel,	 2013).	 Cancer	 immune	
therapies	are	a	diverse	field	of	therapeutic	strategies	that	treat	cancer	by	triggering	one	of	
the	 immune	 system’s	 biological	 processes.	 Examples	 of	 immune	 therapies	 described	 in	
Figure	1.1	have	been	successfully	implemented	as	treatment	for	cancer	including;	the	use	of	
monoclonal	 antibodies	 (mAbs),	 vaccination	 with	 tumour	 antigen	 peptides,	 adoptive	 cell	
transfer	and	immune	stimulating	cytokines	(Ali	et	al.,	2016,	Noguchi	et	al.,	2013,	Topalian	et	
al.,	 2012,	 Zeidner	 et	 al.,	 2014).	 Dependent	 on	 the	 immune	 stimulating	 agent,	 immune	
therapies	are	classified	as	being	active	or	passive	based	on	their	ability	to	engage	with	the	
immune	system	(Galluzzi	et	al.,	2014).	
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Immune	therapies	are	classified	based	on	their	ability	to	engage	with	the	immune	system;	
active	 or	 passive,	 and	 how	 the	 therapy	 interacts	 with	 the	 cancer	 target;	 specific	 or	 non-
specific.	 	
Figure	1.1	Classification	of	immune	therapies	
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In	 addition	 to	 being	 classified	 as	 active	 or	 passive,	 immune	 therapies	 can	 be	 further	
classified	as	specific	or	non-specific	based	on	target	specificity.	
1.2.1 Non-specific	and	active	immune	therapy:	monoclonal	antibodies	
Hybridoma	 technology	pioneered	 in	 the	 1970s	provided	 the	 foundation	 for	mAb	 immune	
therapy	from	the	 in	vitro	production	of	antigen	specific	mAbs	(Kohler	and	Milstein,	1975).	
Antigen	 specific	 mAbs	 were	 secreted	 from	 hybridomas	 comprising	 of	 splenocytes	 from	
BALB/c	 mice	 immunised	 with	 an	 antigen	 fused	 with	 a	 murine	 myeloma	 cell	 line.	 The	
secreted	 mAb	 from	 the	 hybridoma	 is	 comprised	 of	 murine	 immunoglobulin	 (Ig)	
components,	which	are	xenogeneic	in	humans	(Hosono	et	al.,	1992).	Nowadays,	molecular	
engineering	 and	 the	 production	 of	 mAbs	 in	 eukaryotic	 systems	 have	 developed	 less	
xenogeneic	mAbs	for	the	use	in	patients	(Bernett	et	al.,	2010,	Rader	et	al.,	1998).	In	addition	
to	creating	 less	xenogeneic	mAbs,	 Immunoglobulin	G	(IgG)	residues	have	been	engineered	
to	improve	the	specificity,	functionality	and	stability	of	the	mAb	(Lazar	et	al.,	2006,	Shields	
et	al.,	2001).	These	mAb	 improvements	to	functionality	and	stability	have	the	potential	 to	
enhance	the	in	vivo	mAb	functionality.	
In	 the	 context	 of	 immune	 therapy,	 the	uses	of	 fully	 human	mAbs	 are	described	 as	multi-
functional	 as	 they	 can	 be	 used	 to:	 bind	 to	 cells	 for	 antibody	 dependent	 cell-mediated	
cytotoxicity	(ADCC)	or	complement	dependent	cytotoxicity	(CDC),	conjugated	to	toxic	drugs	
for	specific	drug	delivery,	engage	between	receptor-ligand	interactions	and	immune	select	
specific	cell	populations	for	adoptive	cell	therapy.	Adoptive	cell	therapy	will	be	discussed	in	
1.2.4.	 The	 success	 of	 the	 first	 humanised	 mAb,	 Rituximab,	 for	 treating	 non-Hodgkin	
lymphoma	demonstrated	the	potential	of	mAb	immune	therapy.	 Its	cytotoxic	effect	 is	due	
to	 Rituximab	 binding	 to	 Cluster	 of	 Differentiation	 (CD)	 20+	 cells	 followed	 by	 initiation	 of	
ADCC	and	CDC	directed	towards	CD20+	cells	(Marcus	and	Hagenbeek,	2007).	ADCC	relies	on	
Rituximab	complementarity	determining	region	(CDR)	binding	to	CD20	antigen	expressed	by	
the	target	cell,	followed	with	engagement	between	Rituximab	FC	and	immune	effector	cells	
FCγR.	 The	 effector	 cell	 FCγR	 is	 phosphorylated	 and	 activated	 that	 results	 in	 release	 of	
cytotoxic	 cytokines,	 eventuating	 to	CD20+	 cell	 death.	ADCC	activity	 is	 usually	 greater	with	
IgG1	and	IgG3	mAb	isotypes,	compared	to	IgG2	and	IgG4	mAb	isotypes	(Wang	et	al.,	2015).	
Alternatively,	 CDC	 relies	 on	 Rituximab	 CDR	 binding	 to	 CD20	 antigen,	 and	 C1q	 protein	
complex	 binding	 to	 Rituximab.	 Upon	 binding	 of	 C1q	 to	 the	 Rituximab	 opsonised	 cell,	
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complement	 proteins	 C5b,	 C6,	 C7,	 C8	 and	 C9	 bind	 to	 C1q	 to	 create	 a	 transmembrane	
channel	 resulting	 in	cell	 lysis.	Strong	CDC	activity	 is	observed	with	 IgG3	and	 IgG1	 isotypes	
(Moore	et	al.,	2010).	
Brentuximab	vedotin	is	a	mAb	conjugated	to	monomethyl	auristatin	E	(MMAE)	that	targets	
CD30+	Reed-Sternberg	 cells	 in	Hodgkin’s	 Lymphoma	patients.	MMAE	 is	 a	 toxic	 compound	
that	 possesses	 strong	 anti-mitotic	 activity	 by	 inhibiting	 the	 polymerisation	 of	 tubulin.	
Brentuximab	 vedotin	 binds	 specifically	 to	 CD30+	 Reed-Sternberg	 cells	 so	 that	MMAE	 only	
affects	Reed-Sternberg	 cells	 (Francisco	et	al.,	 2003).	Nowadays	mAbs	 that	 target	different	
cell	 surface	 molecules	 are	 conjugated	 to	 other	 compounds,	 including	 radionuclides	 for	
antigen	specific	radiotherapy	(Koechli	et	al.,	2015,	Lossos	et	al.,	2015).	
Identification	of	 immune	 regulatory	cell	 surface	molecules	has	provided	a	method	 for	 the	
positive	or	negative	control	of	cells	by	binding	or	blocking	interactions	between	cell	surface	
receptor	 and	 its	 ligand.	 An	 example	 of	 an	 immune	 regulatory	 mAb	 is	 the	 immune	
therapeutic	 Nivolumab	 (Bristol-Myers	 Squibb,	 USA)	 that	 binds	 to	 Programmed	 cell	 Death	
protein	1	(PD-1)	(Wang	et	al.,	2014).	Usually	PD-1	binds	to	its	ligand,	Programmed	cell	Death	
Ligand	 (PD-L)	 1	 or	 PD-L2,	 expressed	 by	 the	 tumour	 or	 other	 immune	 cells	 that	 inhibits	
cellular	proliferation	and	cytokine	production	by	the	PD1+	cell.	However,	Nivolumab	binding	
to	 PD-1	 blocks	 the	 ligation	 to	 PD-L1	 or	 PD-L2	 and	 allows	 proliferation	 and	 production	 of	
cytokines	by	the	PD1+	cell.	Nivolumab	has	been	approved	for	 the	treatment	of	melanoma	
(Johnson	et	al.,	2015).	Other	mAbs	for	interacting	with	other	immune	regulatory	pathways	
are	now	being	investigated	for	their	efficacy	treating	cancer	and	other	diseases	(Grenga	et	
al.,	2016,	O'Day	et	al.,	2007,	Reichert,	2016).	Encouraging	improvements	to	overall	survival	
and	progression	free	survival	were	observed	with	combination	cancer	therapies	for	treating	
non-small	cell	lung	cancer	and	acute	lymphoblastic	leukaemia	(Brahmer	et	al.,	2015,	Maude	
et	al.,	2015).	A	treatment	regime	involving	a	combination	of	 immune	therapeutics	has	the	
potential	 to	 enhance	 anti-cancer	 responses.	 Examples	 of	 combination	 immune	 therapies	
include:	 IL-21	 and	 Ipilimumab	 (Bristol-Myers	 Squibb),	 and	 Nivolumab	 and	 Ipilimumab	
(Chapuis	 et	 al.,	 2016,	 Postow	 et	 al.,	 2015).	 Additional	 new	 combinations	 are	 now	 being	
investigated	 to	 establish	 new	 cancer	 treatment	 options	 (Fong	 et	 al.,	 2006,	 Larkin	 et	 al.,	
2015,	Rizvi	et	al.,	2016).		
1.2.2 Non-specific	and	passive	immune	therapy:	cytokine	therapy	
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Cytokines	 are	 small	 proteins	 that	 play	 an	 integral	 role	 in	 activation,	 differentiation	 and	
cellular	 growth	 influencing	 the	 cellular	 compartment	 upon	 binding	 to	 their	 receptor.	
Understanding	 the	 cytokines	 present	 in	 the	 tumour	microenvironment	 (TME)	 presents	 its	
own	challenges	as	challenges	arise	due	to	the	autocrine	or	paracrine	cytokine	secretion	by	
the	TME	 that	 supports	 immune	 cell	 function	 in	 addition	 to	 tumour	 growth	 (Hsu	and	Hsu,	
1994,	 Lazar-Molnar	 et	 al.,	 2000).	 Understanding	 the	 cytokine	 profile	 for	 immune	 cells,	 in	
particular	effector	immune	cells,	and	the	TME	is	critical	so	that	effective	use	of	therapeutic	
cytokines	can	be	exploited.	
The	T	cell	growth	 factor	 interleukin	 IL-2	 is	an	autocrine	cytokine	 that	 is	produced	by	both	
CD4+	 and	 CD8+	 T	 cell	 subsets,	 although	 CD4+	 T	 cells	 produce	more	 IL-2	 than	 CD8+	 T	 cells	
(Bich-Thuy	 et	 al.,	 1987).	 Consumption	 of	 IL-2	 results	 in	 T	 cell	 activation,	 in	 addition	 to	
production	 of	 IL-2	 and	 therefore	 increased	 cellular	 proliferation	 (Bich-Thuy	 et	 al.,	 1987,	
Williams	 et	 al.,	 2006).	 In	 a	 phase	 II	 trial,	 it	was	 investigated	 if	 either	 600,000	 or	 720,000	
International	Units	(IU)/kg	of	IL-2	administered	into	metastatic	renal	cell	carcinoma	patients	
would	 result	 in	 a	 favourable	patient	outcome	 (Fyfe	et	 al.,	 1995).	Overall,	 14%	of	patients	
responded	to	cytokine	therapy	and	achieved	complete	or	partial	responses.	Responses	were	
achieved	from	patients	with	multiple	metastatic	sites	and	varying	levels	of	tumour	burden.	
This	 study	 proceeded	 to	 a	 phase	 III	 trial	 comparing	 the	 efficacy	 of	 high	 dose	 IL-2	 in	
combination	with	tumour	necrosis	 factor	 (TNF)	or	single	high	dose	 IL-2	 (McDermott	et	al.,	
2005).	 Response	 rates	 for	 high	 dose	 IL-2	 or	 IL-2	 combined	with	 TNF	were	 23%	 and	 10%,	
respectively.	 No	 T	 cell	 data	 such	 as:	 T	 cell	 subsets,	 expression	 of	 activation	 cell	 surface	
molecules	 or	 cytokine	 profile	 was	 collected	 from	 responsive	 patients	 in	 either	 trial.	
Considering	the	role	of	IL-2,	it	would	have	been	beneficial	to	examine	the	T	cell	subsets	and	
their	 role	 in	 this	 disease.	 Other	 growth	 factors	 such	 as	 granulocyte	 monocyte	 colony-
stimulating	factor	(GM-CSF)	induce	the	stimulation	and	differentiation	of	myeloid	cells	such	
as	blood	dendritic	cells	(BDC)	(Eksioglu	et	al.,	2007,	Shi	et	al.,	2006).	GM-CSF	regulates	BDC	
development	 through	 interactions	 between	 ERK,	 PI3K,	 NFκB	 and	 STAT5	 signalling,	 which	
results	in	BDC	survival	and	differentiation	(van	de	Laar	et	al.,	2012).	GM-CSF	has	been	used	
as	 an	 adjuvant	 for	 cancer	 vaccination	 by	 promoting	 BDC	 survival	 and	 maturation	 with	
positive	 results	 (Arellano	 and	 Lonial,	 2008,	 Dang	 et	 al.,	 2012,	 Dranoff,	 2002).	 Fusion	 of	
tumour	 antigen	 proteins	 to	 GM-CSF	 has	 demonstrated	 an	 increase	 in	 median	 survival	
(Kantoff	 et	 al.,	 2010).	 In	 vitro	 studies	 using	 FMS-like	 tyrosinase	 kinase	 3	 ligand	 (FLT3L)	
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generated	dendritic	cells	(DC)	describe	induction	of	CD80	and	CD86	co-stimulatory	surface	
molecules	and	secretion	of	cytokines	such	as	CCL2	after	stimulation	with	GM-CSF	(Min	et	al.,	
2010).	 This	 demonstrates	 that	 GM-CSF	 is	 able	 to	 induce	 a	 mature	 phenotype	 for	 FLT3L	
generated	dendritic	cells	DC,	and	potentially	BDC.	
1.2.3 Specific	and	active	immune	therapy:	peptide	loading	
Peptides	 are	 short	 or	 long	 amino	 acid	 sequences	 of	 proteins	 that	 can	 be	 made	 to	 elicit	
antigen	specific	T	cell	immune	responses	by	in	vivo	or	in	vitro	administration	of	the	peptide	
(Slingluff,	2011).	Peptide	vaccination	using	in	vivo	administration	requires	the	peptide	to	be	
directly	 injected	 into	 the	 patient,	 relying	 on	 circulating	 antigen	 presenting	 cell	 (APC)	
phagocytose	the	peptide	and	to	process	the	peptide	before	antigen	is	presented	by	major	
histocompatibility	 complex	 (MHC)	 class	 I	 or	 II	 (Noguchi	 et	 al.,	 2013,	 Phan	 et	 al.,	 2003).	
However,	 inflammatory	cytokines	such	as	TNF,	 IL-1β	and	IL-6	secreted	by	the	TME	inhibits	
antigen	presentation	by	APC	 to	T	cells,	 therefore	suppressing	 the	T	cell	 immune	response	
(Landskron	 et	 al.,	 2014,	 Germano	 et	 al.,	 2008,	 Mantovani	 et	 al.,	 2008).	 Ex	 vivo	 peptide	
vaccination	 isolates	 APC	 from	 the	 patient	 followed	 by	 introducing	 the	 peptide	 to	 APC.	
Isolation	of	APC	requires	additional	handling	of	cells	before	administration	into	the	patient	
that	presents	 its	own	challenges	 (Kantoff	et	al.,	2010,	Prue	et	al.,	2015,	Tel	et	al.,	2013b).	
However,	isolation	of	APC	before	in	vitro	loading	may	be	seen	as	advantageous	as	APC	are	
removed	 from	peripheral	 blood,	 followed	by	 loading	APC	with	 peptide	 and	 thus	 avoiding	
immune	suppression	from	the	TME	(Tacken	et	al.,	2007).	
Antigen	 presentation	 by	 MHC	 class	 I	 is	 usually	 reserved	 for	 cytoplasmic	 antigens	 with	
cytoplasmic	peptides	of	eight	to	nine	mers	 in	 length	(Rist	et	al.,	2013).	These	peptides	are	
degraded	 by	 proteosomes	 and	 transported	 to	 MHC	 class	 I	 where	 MHC	 class	 I-peptide	
complexes	 are	 transported	 to	 the	 cell	 surface	 via	 the	 endoplasmic	 reticulum	 for	 antigen	
presentation	(Villadangos	and	Schnorrer,	2007).		Alternatively,	exogenous	peptides	14	to	20	
mers	 in	 length	are	phagocytosed	by	APC	where	 the	peptide	undergoes	proteolysis	 (Thery	
and	 Amigorena,	 2001).	 After	 peptide	 proteolysis,	 the	 trimmed	 peptide	 fragment	 is	
transported	to	intracellular	MHC	class	II	and	in	turn	the	MHC	class	II-peptide	complex	before	
it	 is	 translocated	 to	 the	 cell	 surface	 (Villadangos	 and	 Schnorrer,	 2007).	 Exogenous	 longer	
peptides	20	to	30	mers	in	length	can	be	presented	by	MHC	class	I	in	a	process	called	cross	
presentation	 (Jongbloed	 et	 al.,	 2010,	 Segura	 et	 al.,	 2013,	 Tel	 et	 al.,	 2013b).	 These	 long	
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peptides	are	used	to	generate	CD8+	T	cell	responses	following	a	similar	antigen	presentation	
process	by	peptides	used	to	generate	a	CD4+	T	cell	response	(Welters	et	al.,	2008).	Simply,	
these	 longer	 peptides	 are	 phagocytosed	by	APC	 and	 transported	 to	 the	 cytoplasm	where	
here	the	protein	undergoes	proteolysis	and	trimmed	peptide	fragments	are	transported	by	
endoplasmic	reticulum	to	MHC	class	I.	MHC-peptide	complexes	are	transported	to	the	cell	
surface	in	preparation	for	antigen	presentation	to	CD8+	T	cells	(Joffre	et	al.,	2012).		
Vaccination	 using	 peptides	 are	 a	 more	 desirable	 approach	 than	 traditional	 vaccination	
methods	using	live	or	attenuated	pathogens	due	to	their	versatility,	safety	and	production	
methods	 (Purcell	 et	 al.,	 2007).	 Custom	peptide	 synthesis	 allows	 the	 introduction	 of	 post-
translational	modifications	 to	 create	peptides	 that	 favour	 or	 inhibit	 proteolysis	 at	 specific	
sites,	 and	 improve	 peptide	 stability	 allowing	 more	 effective	 peptide	 administration	
(Marschutz	et	al.,	2002).	Human	immunodeficiency	virus	(HIV)	and	influenza	T	cell	immune	
responses	 were	 observed	 by	 vaccinating	 patients	 with	 peptides	 for	 HIV	 and	 influenza	
(Herbinger	 et	 al.,	 2014,	 Karlsson	 et	 al.,	 2013).	 Peptides	 have	 now	been	 used	 to	 generate	
leukaemia	and	melanoma	immune	responses,	which	demonstrates	the	versatility	and	ability	
of	peptides	to	generate	cancer	specific	immune	responses	(Kawakami	et	al.,	1994,	Rezvani	
et	al.,	2008).	
1.2.4 Specific	and	passive	immune	therapy:	adoptive	cell	transfer	
Haematopoietic	 stem	 cell	 transplantation	 has	 existed	 as	 a	 therapeutic	 option	 for	 the	
treatment	 of	 haematological	 malignancies	 since	 the	 1950s	 (Thomas	 et	 al.,	 1957).	 The	
process	of	 transferring	harvested	autologous	or	 allogeneic	haematopoietic	 stem	cells	 into	
the	recipient	is	known	as	adoptive	cell	transfer.	Haematopoietic	stem	cell	transplantation	is	
an	effective	therapy	as	 the	healthy	donor	cells	 reconstitute	the	malignant	haematopoietic	
system	with	 the	grafted	 immune	system	thus	killing	 the	cancer.	Nowadays	single	 immune	
cell	 populations	 such	 as:	 T	 cells,	 tumour	 infiltrating	 lymphocytes,	 NK	 cells	 and	 BDC	 are	
transplanted	into	patients	for	the	purpose	of	adoptive	cell	transfer	(Ali	et	al.,	2016,	De	Vries	
et	al.,	2003,	Prue	et	al.,	2015,	Riddell	et	al.,	1992,	Rosenberg	et	al.,	1988,	Sakamoto	et	al.,	
2015,	Tel	et	al.,	2013a).	
Magnetic	bead	mAb	immune	selection	of	 immune	cells	 is	a	useful	and	clinically	applicable	
method	 for	adoptive	 cell	 transfer	of	 immune	cell	populations.	mAbs	 specifically	allow	 the	
identification	and	 immune	selection	of	specific	 immune	cells	by	using	mAbs	conjugated	to	
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magnetic	beads.	Specific	immune	cells	can	be	isolated	or	depleted	by	passing	cells	through	a	
magnetic	column	before	adoptive	cell	transfer.	The	United	States	of	America	Food	and	Drug	
Administration	 (FDA)	 approved	 this	 method	 for	 isolating	 Granulocyte-Colony	 Stimulating	
Factor	 mobilised	 CD34+	 stem	 cells	 (Devine	 et	 al.,	 2011).	 CD34+	 cells	 were	 isolated	 and	
transplanted	 in	 to	 AML	 patients	 who	 were	 in	 complete	 remission	 after	 myeloablative	
conditioning	(Barba	et	al.,	2017).	The	protective	immunity	provided	by	the	haematopoietic	
stem	 cell	 transplantation	 against	 the	 cancer	 is	 due	 to	 the	 graft	 versus	 leukaemia	 effect	
(Barrett,	1997,	Horowitz	et	al.,	1990,	Kolb,	2008).	It	is	believed	that	donor	CD4+	and	CD8+	T	
cells	provide	protection	against	the	leukaemia.	In	a	study	it	was	found	that	donor	T	cells	are	
responsible	for	graft	versus	host	disease	where	the	donor	T	cells	causes	damage	to	the	skin,	
liver	and	gastrointestinal	 tract	 (Wysocki	et	al.,	 2005).	A	 total	of	28%	of	patients	 from	 this	
study	developed	acute	graft	 versus	host	disease,	which	 is	one	of	 the	major	 complications	
associated	with	 haematopoietic	 stem	 cell	 transplantation.	 Glucocorticoids	 are	 a	 common	
treatment	 for	 acute	 graft	 versus	 host	 disease,	 however	 only	 half	 the	 patients	 on	
glucocorticoids	 therapy	 respond	 to	 this	 treatment	 (MacMillan	 et	 al.,	 2002).	 Depletion	 of	
activated	BDC	is	shown	to	prevent	the	onset	of	graft	versus	host	disease	but	abrogating	T	
cell	activation	(Seldon	et	al.,	2016,	Wilson	et	al.,	2009).	
1.2.5 Active	and	specific	immune	therapy:	adoptive	dendritic	cell	transfer	
The	ability	of	the	immune	system	to	generate	an	adaptive	specific	immune	response	is	due	
to	 the	 co-operation	 between	multiple	 immune	 cells	whereby	 the	 antigen	 is	 processed	by	
APC	and	presented	 to	other	 cells.	 The	 intrinsic	 ability	 of	BDC	 to	present	 antigen	 to	other	
immune	 cells,	 especially	 T	 cells,	 via	 MHC	 class	 I	 or	 II	 connects	 the	 innate	 and	 adaptive	
immune	 systems	 and	 is	 why	 BDC	 are	 referred	 to	 as	 professional	 APC	 (Hart,	 1997,	
Banchereau	 and	 Steinman,	 1998,	 de	 Jong	 et	 al.,	 2006,	 Steinman,	 1991).	 Antigen	 loading,	
antigen	 presentation	 and	 BDC	 migration	 are	 some	 of	 the	 key	 elements	 to	 adoptive	 DC	
transfer,	which	are	 important	 to	 initiate	an	antigen	specific	 immune	response.	Favourable	
immune	 responses	 using	 immune	 selected	 BDC	 and	 loaded	with	 tumour	 antigen	 peptide	
have	been	generated	for	solid	tumours	including	prostate	cancer,	melanoma	and	AML	(Prue	
et	 al.,	 2015,	 Tel	 et	 al.,	 2013a).	 After	 antigen	 presentation	 by	 APC	 to	 T	 cells,	 clonal	 T	 cell	
proliferation	 occurs	 thus	 causing	 the	 T	 cells	 to	 traffic	 through	 the	 periphery	 until	 they	
encounter	 a	 specific	 antigen.	 This	 population	 of	 clonal	 antigen	 specific	 T	 cells	 reduces	 to	
form	 a	 small	 population	 of	 memory	 antigen	 specific	 T	 cells.	 This	 population	 of	 memory	
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antigen	specific	T	cells	are	ready	for	antigen	presentation	by	APC	that	recognises	the	original	
antigen,	which	again	allows	proliferation	of	antigen	specific	T	cells.	Repeated	activation	of	
memory	 antigen	 specific	 T	 cells	 induces	 chronic	 exhaustion	of	 T	 cells	 and	express	 surface	
markers	such	as	CD279	and	CD366	(Yi	et	al.,	2010).	T	cell	exhaustion	is	a	state	of	dysfunction	
by	T	 cells.	Upon	 ligation	of	CD279	or	CD366	 to	 its	 ligand,	 the	ability	of	T	 cells	 to	undergo	
proliferation	reduces.	T	cells	play	an	important	role	in	the	control	of	cancer.	Dysfunctional	T	
cells	 can	 result	 in	 tumour	 escape	 and	 leading	 to	 cancer	 progression.	 The	 use	 of	 mAbs	
binding	to	T	cell	 immune	regulatory	molecules	has	been	shown	improve	patient	outcomes	
for	 treating	 melanoma	 (Larkin	 et	 al.,	 2015,	 Postow	 et	 al.,	 2015,	 Raedler,	 2015).	 Other	
immune	 regulatory	molecules	 are	 being	 investigated	 for	 other	 immune	 and	 tumour	 cells	
(Brahmer	et	al.,	2012,	Grenga	et	al.,	2016,	Juneja	et	al.,	2017).			
Sipuleucel-T	 is	the	only	FDA	approved	adoptive	cell	therapy	for	the	treatment	of	hormone	
refractory	 prostate	 cancer.	 A	 density	 gradient	 is	 used	 to	 harvest	 autologous	 peripheral	
blood	mononuclear	cells	(PBMC)	from	a	leukapheresis	that	contain	APC.	While	BDC	make	up	
a	component	of	PBMC,	other	APC	such	as	monocytes	are	also	present	 in	 the	PBMC.	After	
the	PBMC	are	isolated,	they	are	incubated	with	a	fusion	protein	combining	GM-CSF	with	the	
prostatic	acid	phosphatase	(PAP)	tumour	antigen	and	is	phagocytosed	by	the	APC	(Burch	et	
al.,	2004).	The	GM-CSF	activates	the	APC,	and	the	PAP	peptide	loads	the	APC	with	tumour	
antigen.	Thus	generating	a	PAP	specific	immune	response.	This	treatment	has	been	shown	
to	improve	the	median	survival	by	4.1	months	(Kantoff	et	al.,	2010).		
1.3 Dendritic	cell	options	
1.3.1 Introduction	
BDC	are	a	rare	leucocyte	that	account	for	approximately	1%	of	all	PBMC	(Haller	Hasskamp	et	
al.,	2005,	MacDonald	et	al.,	2002).	BDC	are	known	for	their	antigen	presentation	capability	
with	multiple	BDC	subsets	been	identified.	Classification	has	resulted	in	two	lineages	of	BDC;	
myeloid	(m-)	and	plasmacytoid	(p-)	DC	as	described	in	Figure	1.2	(Banchereau	et	al.,	2000,	
Kohrgruber	et	al.,	1999,	Robinson	et	al.,	1999).	Like	many	immune	cells,	BDC	can	be	further	
divided	in	to	subsets	based	on	functionality	and	expression	of	specific	cell	surface	markers	
and	 identified	 by	 their:	 cell	 surface	 antigen	 phenotype,	 point	 of	 origin	 and	 morphology	
(Hemont	et	al.,	2013,	MacDonald	et	al.,	2002,	Worah	et	al.,	2016).		
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BDC	and	monocytes	differentiate	from	monocyte	and	DC	progenitor	cells	(Breton	et	al.,	2015a,	Breton	et	al.,	2015b,	Bryant	et	al.,	2016,	Liu	and	
Nussenzweig,	2010).	The	lineage	of	the	DC	and	monocyte	progenitor	cell	is	determined	by	differentiation	in	to	a	common	DC	progenitor	or	a	
monocyte.	From	the	common	DC	progenitor	becomes	pDC	and	its	CD2hi	and	CD2lo	subsets,	or	mDC	precursor.	The	mDC	precursor	cell	provides	
the	CD16+,	CD1c+	and	CD141+	mDC	subsets.	
Figure	1.2	A	simplified	schema	illustrating	dendritic	cell	ontogeny	and	nomenclature	
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BDC	 subsets	 have	 unique	 gene	 expression	 profiles	 and	 phenotypic	 differences	 that	 very	
clearly	confirm	their	distinction	 from	other	BDC	subsets	 (Clark	et	al.,	2016b,	Piccioli	et	al.,	
2007,	Schlatzer	et	al.,	2012,	Worah	et	al.,	2016).	Genomic	and	proteomic	characterisation	of	
BDC	 subsets	 is	 important	 as	 further	 functional	 differences	 among	 BDC	 subsets	 may	 be	
revealed	 (Huysamen	 et	 al.,	 2008).	 A	 example	 of	 a	 functional	 difference	 is	 the	 ability	 of	
CD141+	 BDC	 to	 more	 efficiently	 cross	 present	 antigen	 compared	 to	 CD1c+	 BDC	 after	
stimulation	with	Poly(I:C)	(Jongbloed	et	al.,	2010).	Therefore	deciding	which	BDC	to	use	for	
adoptive	DC	therapy	may	affect	the	quality	and	type	of	generated	immune	response.	
1.3.2 Ex	vivo	generated	dendritic	cells	
The	 lack	 of	 specific	 cell	 surface	 molecules	 makes	 it	 difficult	 to	 perform	 BDC	 immune	
selection.	Furthermore,	the	low	frequency	of	BDC	and	an	abundance	of	monocytes	found	in	
peripheral	 blood	 have	 encouraged	 researchers	 to	 use	 ex	 vivo	 generated	 APC	 to	 simulate	
BDC.	 These	 ex	 vivo	 generated	 APC	 can	 be	 cultured	 from	 monocytes	 to	 large	 quantities,	
usually	 to	higher	quantities	 than	circulating	BDC.	Ex	vivo	manufactured	monocyte-derived	
dendritic	 cells	 (Mo-DC)	are	generated	after	 isolating	monocytes	 from	a	blood	 sample	and	
additional	days	 incubation	with	 cytokines	before	 they	 can	be	harvested	 (Wilgenhof	et	 al.,	
2016).	 The	 end	 result	 is	 an	 APC	 with	 the	 phenotype	 of	 HLA-DR+	 CD1a+	 CD11c+	 CD14-	
(Sallusto	and	Lanzavecchia,	1994).	Incubation	of	Mo-DC	with	either	lipopolysaccharide	(LPS),	
a	 combination	 of	 cytokines	 including:	 TNF,	 IL-1β	 and	 IL-6,	 or	 αCD40	 stimulates	 Mo-DC	
resulting	in	the	upregulation	of	CD80,	CD83	and	CD86	(Ardeshna	et	al.,	2000,	Mosca	et	al.,	
2000).	 Generation	 of	 Mo-DC	 from	monocytes	 incubated	 with	 cytokines	 provides	 a	 more	
simple	method	 to	 research	 and	 use	 APC,	 in	 addition	 to	 providing	 a	 potential	 therapeutic	
option.	Other	methods	utilising	different	combinations	of	cytokines	to	produce	Mo-DC	exist,	
each	method	claiming	to	produce	functional	and	morphologically	similar	cells	analogous	to	
BDC	(Jiang	et	al.,	2005,	Sallusto	and	Lanzavecchia,	1994,	Sozzani	et	al.,	1997,	Visintin	et	al.,	
2001,	Dauer	et	al.,	2003).	To	distinguish	between	circulating	and	ex	vivo	manufactured	DC,	
the	names	BDC	and	Mo-DC	refer	to	the	respective	cell	types.	The	lack	of	standardisation	to	
generate	 Mo-DC	 makes	 it	 difficult	 to	 regulate	 Mo-DC	 production.	 As	 with	 different	 BDC	
subsets,	 it	 may	 be	 that	 different	 Mo-DC	 generation	 methods	 may	 be	 more	 suitable	 for	
different	purposes.	
Recent	 analyses	 reveal	 that	 ex	 vivo	 generated	 Mo-DC	 are	 functionally	 and	 genetically	
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dissimilar	to	BDC	as	they	do	not	efficiently	migrate	to	 lymph	nodes,	degrade	proteins	at	a	
more	rapid	pace	and	express	different	surface	molecules	(De	Vries	et	al.,	2003,	Horlock	et	
al.,	2007,	McCurley	and	Mellman,	2010,	Osugi	et	al.,	2002).	It	is	possible	that	Mo-DC	may	be	
considered	 to	 be	 a	 separate	 class	 of	 APC.	 Therefore	 the	 use	 Mo-DC	 for	 clinical	 studies	
should	be	evaluated	and	the	validity	of	Mo-DC	as	a	substitute	for	BDC	should	be	questioned.	
1.3.3 Plasmacytoid	dendritic	cells		
pDC	 are	 HLA-DR+,	 CD11c-,	 CD123+	 and	 CD304+	 and	 lack	 lineage	 (CD3,	 CD14,	 CD19,	 CD20,	
CD56	 and	CD235a)	 and	 are	morphologically	 similar	 to	 plasma	 cells	 (Dzionek	 et	 al.,	 2000).	
pDC	are	typically	known	for	their	immune	response	upon	viral	infection	with	the	secretion	
of	 large	amounts	of	 type	 I	 interferons	 (Coccia	et	al.,	2004).	pDC	are	able	 to	cross	present	
exogenous	antigen	to	both	CD4+	and	CD8+	T	cells	(Tel	et	al.,	2013b).	Clinical	trial	data	using	
pDC	has	demonstrated	the	use	of	pDC	as	an	attractive	therapeutic	opportunity	for	treating	
melanoma	(Tel	et	al.,	2013a).	pDC	from	melanoma	patients	were	isolated	and	loaded	with	
peptide	 before	 intra	 nodal	 administration	 in	 to	 the	 patient.	 Results	 showed	 a	 significant	
increase	in	melanoma	antigen	specific	CD8+	T	cells	after	three	vaccinations	and	a	significant	
improvement	 in	 overall	 survival	 compared	 to	 matched	 controls.	 Recent	 studies	 have	
demonstrated	pDC	can	be	further	classified	in	to	subsets	based	on	CD2	expression	(Matsui	
et	al.,	2009).	Functional	studies	 reveal	greater	survival	and	chemotaxis	 to	CCL21	observed	
between	pDC	subsets	when	stimulated	with	IL-3	and	CpG-A,	favouring	the	CD2hi	pDC	subset	
(Bryant	et	al.,	2016).		
1.3.4 Myeloid	dendritic	cells			
Morphology	of	mDC	is	different	compared	to	pDC	and	show	an	 irregular	shape	with	short	
cytoplasmic	 processes	 and	 hyperlobulated	 nuclei	 (Dzionek	 et	 al.,	 2000,	 Robinson	 et	 al.,	
1999).	 The	phenotype	of	mDC	 is	 lineage-	HLA-DR+,	 CD11c+,	 CD123-,	 CD304-	 and	 also	 lacks	
expression	of	lineage	markers.	Compared	with	pDC,	they	comprise	a	greater	BDC	proportion	
found	and	can	be	further	classified	into	subsets	based	on	the	positive	expression	of	CD16,	
CD1c	and	CD141.	The	most	predominant	mDC	subset	is	CD16+,	followed	by	CD1c+	and	then	
CD141+	BDC	(MacDonald	et	al.,	2002).		
1.3.4.1 CD16+	myeloid	dendritic	cells	
The	most	prevalent	mDC	are	CD16+	BDC.	Classification	of	this	cell	subset	is	controversial	and	
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it	 is	 often	 debated	 if	 CD16+	 BDC	 are	 actually	 non-classical	monocytes	 (NCM)	 (Cros	 et	 al.,	
2010,	 MacDonald	 et	 al.,	 2002).	 Characterisation	 of	 these	 cells	 has	 been	 difficult	 due	 to	
similar	 CD16	 expression	 shared	 between	 CD16+	 BDC	 and	 NCM,	 and	 requires	 fluorescent	
activated	 cell	 sorting	 (FACS)	 combined	with	 a	 stringent	 FACS	 gating	hierarchy	 to	 separate	
CD16+	BDC	from	NCM.	
Expression	of	all	toll	like	receptor	(TLR)	RNA	was	higher	in	CD16+	BDC	than	CD1c+BDC,	with	
the	exception	of	TLR6	and	TLR10,	and	generally	secreted	greater	amounts	of	IL-1β,	IL-6,	TNF,	
CCL3	and	CCL4	when	 stimulated	with	Pam3CSK4,	polyinosinic:polycytidylic	 (Poly(I:C)),	 LPS,	
Flagellin,	 R848,	 Imiquimod	 and	 Poly	 Uracil	 compared	 to	 CD1c+	 BDC	 (Piccioli	 et	 al.,	 2007).	
Expression	of	CD40	and	CD80	by	CD16+	BDC	was	comparable	to	CD1c+	BDC	when	stimulated	
with	Pam3CSK4,	 IFNα	or	 IFNβ	whereas	TNF	stimulation	did	not	 increase	the	expression	of	
CD40	or	CD80	for	CD16+	BDC	(Piccioli	et	al.,	2007).		
1.3.4.2 CD1c+	myeloid	dendritic	cells	
Despite	not	being	the	most	prevalent	mDC,	CD1c+	BDC	are	the	most	characterised	BDC	due	
to	ability	easily	obtain	CD1c+	BDC	populations	using	magnetic	immune	selection	techniques.	
Magnetic	immune	selection	negates	the	need	for	time	consuming	and	labour	intensive	FACS	
to	isolate	CD1c+	BDC.	
Differences	in	expression	of	TLR	have	been	reported	and	it	was	found	CD1c+	BDC	TLR	RNA	
expression	was	less	compared	to	CD16+	BDC	subsets,	except	for	TLR6	and	TLR10	(Piccioli	et	
al.,	 2007).	 Stimulation	 of	 CD1c+	 BDC	 with	 various	 TLR	 agonists	 including:	 Pam3CSK4,	
Poly(I:C),	LPS,	Flagellin,	R848,	Imiquimod	and	Poly	Uracil	resulted	in	the	detection	of	greater	
amounts	of	 IL-8	compared	to	CD16+	BDC.	Soluble	 IL-12p70	was	detected	after	stimulation	
with	Poly(I:C),	R848	and	 IFNγ	 (Nizzoli	 et	 al.,	 2013).	 Expression	of	CD40	by	CD1c+	BDC	was	
greater	than	CD16+	BDC	when	stimulated	with	IL-3	(Piccioli	et	al.,	2007).		
1.3.4.3 CD141+	myeloid	dendritic	cells	
Comprising	 less	 than	 3%	 of	 BDC	 subsets,	 studies	 characterising	 CD141+	 BDC	 are	 rare	 and	
limited	(Huysamen	et	al.,	2008,	Jongbloed	et	al.,	2010,	MacDonald	et	al.,	2002,	Zhang	et	al.,	
2012).	CD141+	BDC	are	thought	to	be	analogous	to	the	cross	presenting	mouse	CD8α+	BDC,	
and	it	has	been	shown	that	both	DC	subsets	cross	present	exogenous	antigen	via	MHC	class	
I	 to	 CD8+	 T	 cells	 (den	 Haan	 et	 al.,	 2000,	 Joffre	 et	 al.,	 2012,	 Robbins	 et	 al.,	 2008).	 More	
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information	 is	being	uncovered	about	 the	 role	of	CD141+	BDC	 in	 the	 immune	 system	and	
their	potential	application	in	adoptive	BDC	therapy	(Villadangos	and	Shortman,	2010).	This	
includes	the	expression	of	cell	surface	molecules	C-type	lectin	(CLEC)	9A	and	DNGR-1	which	
detect	 necrotic	 cells,	 and	 facilitates	 antigen	 cross	 presentation	 (Schreibelt	 et	 al.,	 2012,	
Zelenay	et	al.,	2012).	
Expression	 of	 TLR3	 RNA	 was	 greatest	 in	 CD141+	 BDC	 compared	 to	 other	 mDC	 subsets	
(Piccioli	et	al.,	2007).	TLR3	expression	indicates	CD141+	BDC	can	be	stimulated	with	Poly(I:C).	
This	was	 confirmed	 by	 Poly(I:C)	 stimulation	 of	 peptide	 antigen	 loaded	 CD141+	 and	 CD1c+	
BDC	with	 CD141+	 BDC	 demonstrating	 superior	 antigen	 cross	 presentation	 to	 CD8+	 T	 cells	
than	 CD1c+	 BDC	 (Jongbloed	 et	 al.,	 2010).	 This	 study	 further	 confirmed	 cross	 presentation	
occurred	between	CD141+	BDC	and	virally	infected	necrotic	cells.		
1.3.5 CMRF-56	immune	selection	
Due	 to	 the	 lack	 of	 specific	 cell	 surface	 molecules	 mentioned	 in	 1.3.1,	 other	 cell	 surface	
markers	 were	 investigated	 to	 identify	 BDC.	 CMRF-56	 is	 a	 mAb	 that	 was	 generated	 after	
immunisation	of	BALB/c	mice	with	the	L428	cell	 line	and	the	mAb	was	found	to	react	with	
early	 activated	 B	 cells,	monocytes	 and	 BDC.	 CMRF-56	 is	 used	with	 PBMC	 that	 have	 been	
incubated	 at	 37°C	without	 additives.	 This	 incubation	upregulates	 the	 antigen	detected	by	
CMRF-56	 (Hock	 et	 al.,	 1999).	 The	 kinetics	 of	 the	 antigen	 detected	 by	 CMRF-56+	 BDC	 are	
similar	 to	 CD83	 expression	 by	 BDC,	with	 optimal	 detection	 of	 BDC	 by	 CMRF-56	 occurring	
between	12	and	16	hrs.	The	expression	of	the	antigen	detected	by	CMRF-56	occurs	without	
the	addition	of	cytokines	and	requires	a	shorter	incubation	period,	which	are	both	requisites	
for	generating	Mo-DC	(Lopez	et	al.,	2003).		
The	 use	 of	 CMRF-56	 as	 a	 clinical	 reagent	 was	 identified	 as	 a	 means	 to	 enrich	 a	
heterogeneous	population	of	mDC	and	other	APC	from	PBMC	without	any	additives.	This	is	
different	 to	 alternative	methods	 that	might	 use	multi-step	 immune	 selection	 such	 as	 for	
CD1c+	 BDC,	 or	ex	 vivo	 generation	of	Mo-DC	 (Freeman	et	 al.,	 2007,	 Lopez	 et	 al.,	 2003).	 In	
preparation	for	clinical	use,	murine	Ig	components	of	the	CMRF-56	IgG1	mAb	were	removed	
and	 the	 isotype	was	switched	 from	 IgG1	 to	 IgG4	 (Fromm	et	al.,	2016).	The	 isotype	switch	
was	introduced	to	minimise	any	ADCC	and	CDC	effector	functions	when	hCMRF-56	binds	to	
its	 target	 cell.	 For	easy	 immune	 selection,	hCMRF-56	was	 conjugated	with	biotin	 to	allow	
the	use	of	 anti-biotin	magnetic	 beads	 for	 immune	 selection	with	 a	 single	 step	 (Dr	R	Prue	
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2013,	personal	communication).	
1.4 Dendritic	cell	stimulation	
BDC	are	continually	surveying	the	environment	for	pathogens	using	a	variety	of	cell	surface	
or	endogenous	pattern	recognition	receptor	(PRR)	that	include:	C-type	lectin	receptor	(CLR),	
TLR,	nucleotide-binding	and	leucine-rich	repeat	receptors	(NLR)	and	retinoic	acid-inducible	
gene-1-like	 receptors	 (RLR)	 (Fritz	 et	 al.,	 2007,	Hemont	et	 al.,	 2013,	 Lundberg	et	 al.,	 2014,	
Szabo	et	al.,	2014).	The	use	of	DC	for	cancer	immune	therapy	requires	additional	stimulation	
by	 these	 or	 other	 receptors	 as	 the	 DC	 have	 not	 encountered	 the	 antigen	 in	 vivo.	 Upon	
stimulation	of	the	PRR	to	its	ligand,	complex	signalling	cascades	initiate	immune	responses	
through	transcription	factors	nuclear	factor-kappa-light-chain-enhancer	of	activated	B	cells	
(NF-κB),	 interferon	 regulatory	 factor	 (IRF),	 mitogen-activated	 protein	 kinases	 (MAPK),	
extracellular	signal-regulated	kinases	 (ERK)	and	c-Jun	N-terminal	kinases	 (JNK)	 (Honda	and	
Taniguchi,	2006,	Kawai	and	Akira,	2010,	Mogensen,	2009).	BDC	stimulation	with	via	 these	
signalling	 pathways	 results	 in	 BDC	 maturation	 including	 secretion	 of	 cytokines	 and	 up-
regulation	 cell	 surface	 molecules	 (Jongbloed	 et	 al.,	 2010,	 Sittig	 et	 al.,	 2016).	 Cytokines	
detected	 after	 PRR	 stimulation	 include	 IL-6,	 TNF,	 IL-10	 and	 IL-12p70.	 Activation	 and	 co-
stimulatory	cell	surface	molecules	include	CD40,	CD80,	CD83,	CD86	and	assist	with	antigen	
presentation,	 while	 chemokine	 receptors	 such	 as	 CCR7	 influence	 migration	 to	 lymphatic	
tissue.	Incubation	of	Mo-DC	with	IL-1β,	TNF,	IL-6	and	PGE2	inflammatory	cytokines	has	been	
used	 to	 induce	upregulation	of	activation,	 co-stimulatory	cell	 surface	molecules	and	CCR7	
(Lee	et	al.,	2002).	
1.4.1 C-type	lectin	receptors	
CLR	 are	 a	 large	 superfamily	 of	 PRR	 that	 are	 mainly	 associated	 with	 the	 binding	 of	
carbohydrates.	 The	 CLR	 superfamily	 can	 be	 divided	 based	 on	 structural	 and	 functional	
differences,	in	addition	to	binding	of	proteins	and	lipids	in	the	presence	or	absence	of	Ca2+	
(Zelensky	 and	Gready,	 2005,	Drickamer	 and	 Taylor,	 2015).	 CLR	 are	 not	 only	 expressed	by	
BDC	 but	 other	 immune	 cells	 such	 as	 neutrophils	 and	 monocytes	 (Bonfim	 et	 al.,	 2009).	
Furthermore,	expression	of	CLR	by	Mo-DC	has	also	been	observed	(Kanazawa	et	al.,	2004,	
Ohradanova-Repic	 et	 al.,	 2016).	 Binding	 of	 the	 ligand	 occurs	 at	 the	 carbohydrate	 binding	
domain,	which	 is	 conserved	 across	 all	 family	members.	 CLR	 are	 involved	 in	 cell	 adhesion,	
chemotaxis	and	intracellular	trafficking	(Cambi	and	Figdor,	2003,	Stockert,	1995).	Expression	
18	
	
of	 CLR	 is	 usually	 high	 on	 immature	 BDC,	 and	 upon	 BDC	 maturation	 expression	 of	 CLR	
decreases	 due	 to	 the	 lack	 of	 desire	 for	 antigen	 uptake	 (Ludwig	 et	 al.,	 2004).	Whilst	 CLR	
expression	 decreases,	 induction	 of	 CD83	 and	 CD86	 co-stimulatory	 molecules	 occurs	 in	
preparation	for	antigen	presentation	to	T	cells	(Ludwig	et	al.,	2004).	The	functionality	of	all	
CLR	are	diverse	with	all	signalling	pathways	not	yet	understood	(Geijtenbeek	and	Gringhuis,	
2009).	However,	it	is	this	signalling	diversity	that	will	aid	designing	applications	to	be	used	in	
BDC	immune	therapy.	
1.4.2 Toll	like	receptors	
The	 human	 TLR	 superfamily	 comprises	 of	 ten	 functional	 members	 and	 has	 the	 ability	 to	
detect	 pathogen	 components	 such	 as	 lipopeptides,	 flagellin	 and	 nucleic	 acid	 (Takeda	 and	
Akira,	2005).	TLR	are	 integral	membrane	proteins	with	C-terminal	cytoplasmic	signalling,	a	
single	 transmembrane	 helix	 and	N-terminal	 ligand	 binding	 domain	 (Bell	 et	 al.,	 2003).	 The	
extracellular	 TLR	portions	do	not	 share	 similarity	between	 the	 family	members.	However,	
the	TLR	 family	members	C-terminal	 signalling	domains	 share	homology	with	 IL-1	 receptor	
(O'Neill	and	Bowie,	2007).	TLR	can	be	cytoplasmic	or	expressed	on	the	cell	surface	(Dowling	
and	Mansell,	2016).	Binding	of	TLR	agonists	to	the	receptor	results	in	the	maturation	of	BDC	
leading	 to	 the	 up-regulation	 of	 CD40,	 CD80	 and	 CD86	 co-stimulatory	 molecules	 and	
secretion	of	inflammatory	cytokines	(Sittig	et	al.,	2016,	Kadowaki	et	al.,	2001).	
A	diverse	collection	of	agonists	are	recognised	by	different	TLR	that	generates	much	interest	
as	 a	method	 to	 stimulate	 BDC	with	 the	 intent	 of	 BDC	 immune	 therapy	 (Schreibelt	 et	 al.,	
2010).	TLR	expression	between	Mo-DC	and	mDC	was	investigated	by	Schreibelt	et	al.	(2010)	
and	was	 found	to	be	similar,	except	 for	greater	expression	of	TLR10	by	mDC.	The	authors	
hypothesise	 that	 TLR10	 stimulation	 may	 induce	 tolerogenic	 BDC	 and	 the	 more	 mature	
phenotype	 of	Mo-DC	may	 attribute	 to	 the	 reduced	 TLR10	 expression.	 Differences	 in	 TLR	
expression	between	mDC	subsets	and	pDC	were	described.	
1.4.3 Nucleotide-binding	and	leucine-rich	repeat	receptors	
NLR	 are	 a	 family	 of	 PRR	 that	 respond	 to	 stimulation	 from	 endogenous	 or	 exogenous	
inflammatory	 signals	 including:	 extracellular	 ATP,	 bacterial	 lipoproteins	 or	 heat	 shock	
proteins	(Arthur	et	al.,	2007,	Kofoed	and	Vance,	2011,	Mo	et	al.,	2012).	All	NLR	contain	an	
N-terminal	 effector	 domain,	 NACHT	 nucleotide-binding	 domain	 and	 have	 a	 C-terminal	
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leucine	 rich	 repeat.	However,	NLRP10	 is	 the	only	 family	member	 that	contains	N-terminal	
effector	and	NACHT	nucleotide-binding	domains.	NLR	are	further	classified	based	on	the	N-
terminal	effector	domain	with	 five	subfamilies	established.	These	 five	subfamilies	 include:	
caspase	 recruitment	 domain,	 pyrin	 domain,	 baculoviral	 inhibition	 of	 apoptosis	 protein	
repeat	domain	and	a	domain	that	shares	no	homology	to	any	other	NLR	subfamily	member	
(Ting	et	al.,	2008).		
Expression	of	NLR	by	mDC	subsets	 is	dependent	on	 their	maturation	state.	Stimulation	of	
NLR	results	in	the	secretion	of	inflammatory	cytokines,	such	as	type	1	interferons	and	IL-1β	
(Kanneganti	et	al.,	2007,	Moore	et	al.,	2008,	Worah	et	al.,	2016).	A	study	with	NLR	agonists	
of	Mo-DC	concurrently	occurs	with	 intracellular	 autocrine	TLR	 stimulation	 (Schwarz	et	 al.,	
2013).	While	the	study	by	Schwarz	et	al.	 (2013)	did	not	use	BDC,	 it	does	suggest	that	NLR	
stimulation	 provides	 a	 feedback	 loop	 for	 enhancing	 BDC	 stimulation	 by	 NLR	 and	 TLR	
engagement,	and	may	be	advantageous	for	stimulating	BDC.		
1.4.4 Retinoic	acid-inducible-gene-1-like	receptors	
RLR	are	a	small	family	of	cytoplasmic	PRR	that	detect	viral	nucleic	acid.	Their	structure	are	
comprised	of	two	N-terminal	caspase	recruitment	domains,	a	central	ATPase	domain	and	a	
C-terminal	regulatory	domain	(Loo	and	Gale,	2011).	Ligation	of	nucleic	acid	to	the	ATPase	or	
C-terminal	domain	results	in	secretion	of	inflammatory	cytokines	and	interferons	(Cui	et	al.,	
2008,	Lu	et	al.,	2010).		
pDC	are	the	main	responders	to	viruses	by	secreting	interferons	and	inflammatory	cytokines	
(Hillyer	et	al.,	 2012).	A	 study	 found	 that	TLR7	and	TLR9	 stimulation	 induces	expression	of	
RLR-I	 by	 pDC	 independent	 of	 interferon	 production	 (Szabo	 et	 al.,	 2014).	 Therefore	 RLR-I	
plays	a	role	in	interferon	production	during	stable	viral	infection	and	replication,	and	control	
of	 the	 virus.	 A	 recent	 study	 confirmed	 this	 and	 reported	 TLR7	was	 the	main	 TLR	 for	 pDC	
responsible	 for	 up-regulation	 RLR-I	 (Maria	 et	 al.,	 2016).	mDC	 express	 less	 TLR7	 and	 TLR9	
compared	 to	 pDC	 but	 still	 express	 RLR-I	 (Hemont	 et	 al.,	 2013).	mDC	 and	Mo-DC	 express	
similar	levels	of	RLR-I	with	both	expressing	minimal	TLR7	expression	(Schreibelt	et	al.,	2010,	
Szabo	et	al.,	2012).	
1.4.5 Clinical	dendritic	cell	stimulating	strategies	
When	 considering	 the	 numerous	 strategies	 for	 stimulating	 BDC,	 a	method	 that	 facilitates	
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the	1)	induction	of	appropriate	activation	and	co-stimulatory	cell	surface	molecules	for	T	cell	
stimulation,	 2)	 promotion	 of	 BDC	 migration	 to	 lymph	 nodes,	 3)	 assistance	 antigen	
presentation	 to	both	CD4+	and	CD8+	T	 cells,	4)	 secretion	of	 IL-12p70	 for	differentiation	of	
naïve	T	cells	to	memory	T	cells,	and	5)	compliance	with	GMP	production	protocols	all	need	
to	be	considered.	Therefore,	PRR	agonists	used	to	stimulate	BDC	for	use	in	clinical	trials	are	
different	to	in	vitro	research.	
In	Australia,	biological	medicines	intended	for	clinical	use	are	governed	by	the	Therapeutic	
Goods	 Administration	 and	 are	 required	 to	 adhere	 to	 GMP	 standards	 to	 ensure	 quality	
control	 and	 safety	 for	 therapeutic	 use.	 Stimulation	 to	 induce	 BDC	 activation	 for	 immune	
therapy	requires	the	use	of	a	GMP	compliant	ligand,	or	combination	of	ligands.	Established	
GMP	compliant	PRR	stimulating	reagents	have	been	identified	for	use	in	DC	clinical	studies	
and	 include	 include	 cytokines	and	 lipids	 (Nava	et	 al.,	 2012).	Clinical	 studies	 are	 limited	as	
most	 clinical	 studies	 use	 Mo-DC,	 not	 BDC.	 The	 lack	 of	 GMP	 compliant	 PRR	 stimulating	
reagents	has	lead	to	the	use	of	prophylactic	microbial	and	viral	vaccines	being	investigated	
as	a	strategy	to	stimulate	Mo-DC	and	BDC	(Banchereau	et	al.,	2014,	Bol	et	al.,	2016).		
Bancereau	 et	 al.	 (2014)	 investigated	 the	molecular	 and	 phenotypic	 profile	 of	 CD1c+	 BDC	
after	exposure	to	prophylactic	vaccines	as	CD1c+	BDC	provides	memory	immune	responses.	
Bancereau	et	al.	(2014)	assessed	the	expression	of	activation	and	co-stimulatory	markers	by	
CD1c+	 BDC	 after	 exposure	 to	 prophylactic	 vaccines	 and	 it	 was	 found	 that	 CD1c+	 BDC	
stimulated	 with	 ActHib	 (Sanofi)	 or	 Menomune	 (Sanofi)	 increased	 activation	 and	 co-
stimulatory	markers	the	most.	Transcriptional	profiling	of	maturation	genes	for	Mo-DC	and	
CD1c+	 BDC	 stimulated	 with	 ActHib	 or	 Menomune	 showed	 they	 both	 clustered	 together,	
demonstrating	 the	 vaccines	 stimulate	 via	 similar	 stimulatory	 pathways.	 Bol	 et	 al.	 (2016)	
created	 a	Mo-DC	 activation	 cocktail	 containing	 three	 prophylactic	 vaccines	 comprising	 of	
Bacillus	 Calmette–Guérin	 (Sanofi),	 Typhim	 (Sanofi)	 and	 ActHib.	 In	 addition,	 PGE2	 was	
included	in	the	activation	cocktail	to	facilitate	Mo-DC	migration	to	lymph	nodes.	Whilst	this	
activation	cocktail	was	able	to	induce	antigen	specific	immune	response,	severe	side	effects	
such	 as	 high	 fever	 and	 injection	 site	 reaction	 were	 observed	 using	 the	 combination	
prophylactic	vaccine	cocktail	compared	to	traditional	cytokine	cocktail	containing	TNF,	IL-1β,	
IL-6	and	PGE2.	
Common	cytokines	used	to	mature	both	Mo-DC	and	BDC	include:	TNF,	IL-1β,	IL-6	and	GM-
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CSF	(Han	et	al.,	2009,	Nava	et	al.,	2012,	Schreibelt	et	al.,	2016).	These	cytokines	can	be	used	
individually	or	as	a	cytokine	cocktail	containing	more	than	one	cytokine.	A	cytokine	cocktail	
comprising	of	TNF,	IL-1β	and	IL-6	is	powerful	at	inducing	CD83	and	CD86	expression	on	Mo-
DC	(Jonuleit	et	al.,	1997).	Mature	Mo-DC	stimulated	with	cytokine	cocktail	showed	increase	
proliferation	and	IFNγ	production	for	both	CD4+	and	CD8+	T	cells.	GMP	compliant	cytokines	
for	use	 in	 the	clinic	are	 required	 to	be	used	 to	generate	Mo-DC.	Using	multiple	 cytokines	
adds	to	the	economic	burden	for	producing	Mo-DC.	GM-CSF	is	a	cytokine	that	is	secreted	by	
endothelial,	fibroblasts	and	lymphocytes	known	to	induce	BDC	activation	and	co-stimulatory	
cell	 surface	 molecules	 (Griffin	 et	 al.,	 1990,	 Sittig	 et	 al.,	 2016).	 Sargramostim,	 the	 yeast	
derived	 recombinant	 GM-CSF	 (Sanofi),	 is	 used	 to	 treat	 febrile	 neutropenia	 (Sung	 et	 al.,	
2004).	 PGE2	 is	 often	 included	 to	 facilitate	 Mo-DC	 migration	 but	 is	 not	 essential	 for	 BDC	
migration	 (Luft	 et	 al.,	 2002).	 PGE2	 is	 lipid	 compound	 that	 is	 expressed	 by	 many	 organs	
including	gastrointestinal	tract,	uterus	and	even	Mo-DC	(Dey	et	al.,	2006,	Fogel-Petrovic	et	
al.,	 2004,	 Milne	 et	 al.,	 2001).	 However,	 the	 immunosuppression	 by	 PGE2	 inhibits	 IL-2	
production	and	 skews	CD4+	and	CD8+	T	 cells	 subsets.	 This	makes	 researchers	 reluctant	 to	
use	 PGE2	 to	 induce	 Mo-DC	 maturation	 (Muthuswamy	 et	 al.,	 2010,	 Rincon	 et	 al.,	 1988,	
Walker	et	al.,	1983).	
1.5 Dendritic	cell	surface	activation	and	co-stimulatory	molecules	
Stimulation	 of	 BDC	 is	 important	 as	 it	 induces	 changes	 including:	 expression	 of	 adhesion	
molecules	and	co-stimulatory	molecules,	impede	phagocytic	capacity,	increase	MHC	antigen	
presentation	 and	 increase	 in	 cytoplasmic	 complexity	 all	 of	 which	 assist	 BDC	 antigen	
processing	 and	 presentation	 to	 T	 cells	 (Hertz	 et	 al.,	 2001,	 Osugi	 et	 al.,	 2002).	 However,	
antigen	 presentation	 by	 BDC	 is	 not	 solely	 reliant	 on	 MHC	 and	 T	 cell	 receptor	 (TCR)	
interactions.	 Simultaneous	 interaction	 by	 BDC	 co-stimulatory	 molecules	 and	 their	 T	 cell	
ligands	must	occur	at	the	same	time	as	TCR	engagement	by	MHC-peptide	complex	to	ensure	
efficient	 T	 cell	 activation	 and	 antigen	 presentation	 (Mueller	 et	 al.,	 1989).	 Secretion	 of	
cytokines	 such	 as	 IL-12p70	 facilitates	 the	 generation	 of	 CD4+	 and	 CD8+	 T	 cell	 immune	
responses	(Trinchieri,	1994).	
Expression	of	BDC	activation	and	co-stimulatory	cell	surface	molecules	is	a	method	used	to	
measure	the	potential	ability	of	BDC	to	initiate	an	antigen-specific	T	cell	immune	response.	
Naturally	other	factors	contribute	to	T	cell	activation	and	antigen	presentation,	however	the	
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expression	of	activation	and	co-stimulatory	molecules	as	described	below	in	1.5.1	and	1.5.2	
provides	a	foundation	for	understanding	this	immune	response.	
1.5.1 Dendritic	cell	surface	activation	molecules		
CD54	 is	 a	 cell	 surface	 adhesion	 molecule	 expressed	 by	 APC	 and	 induced	 in	 response	 to	
inflammation	(Roebuck	and	Finnegan,	1999).	In	an	effort	by	Sheikh	and	Jones	(2008)	to	find	
a	biomarker	that	measured	the	efficacy	of	loading	APC	with	Sipuleucel-T,	FITC	conjugated	to	
the	 fusion	 protein	 PAP/GM-CSF	 were	 loaded	 into	 PBMC.	Multiparameter	 flow	 cytometry	
showed	a	single	CD54	population	comprising	of	multiple	APC,	and	expression	was	greater	
than	 other	 activation	 and	 co-stimulatory	 molecules.	 Therefore	 CD54	 was	 adopted	 as	 an	
activation	molecule	relevant	to	the	quality	control	for	Sipuleucel-T	therapy	and	a	biomarker	
for	measuring	efficacy	of	Sipulecuel-T	therapy	(Frohlich,	2012,	Sheikh	and	Jones,	2008).	
Expression	of	CD83	was	originally	concurrently	detected	with	strong	MHC	class	I	expression	
from	 overnight	 incubated	 PBMC	 (Zhou	 and	 Tedder,	 1995).	 Morphological	 and	 functional	
analysis	of	CD83+	 cells	were	 identified	as	 activated	BDC.	Although	CD83	expression	 is	 not	
unique	 to	 BDC,	 CD83	 has	 been	 used	 as	 a	 distinguishing	 cell	 surface	 marker	 for	 BDC	
activation	due	to	its	strong	expression.	Cell	surface	CD83	expression	occurs	across	multiple	
immune	 cell	 populations	 including:	 LPS	 stimulated	 mDC,	 CpG	 stimulated	 pDC,	 CpG	
stimulated	B	 cells	 and	monocytes	 stimulated	with	CpG	or	 IFNα	 (Ju	et	 al.,	 2016,	 Zhou	and	
Tedder,	1995).	Ju	et	al.	(2016)	further	describes	cytoplasmic	and	cell	surface	expression	of	
CD83	by	CD4+	and	CD8+	T	cells	after	stimulation	by	phytohaemagglutinin	and	simultaneous	
engagement	of	CD2,	CD3	and	CD28.		
1.5.2 Dendritic	cell	surface	co-stimulatory	molecules	
CD40	 was	 originally	 found	 to	 be	 expressed	 by	 B	 cells	 and	 upon	 ligation	 to	 its	 ligand	 it	
facilitated	B	cell	proliferation	(Ledbetter	et	al.,	1987).	Later	phenotypic	analysis	showed	that	
BDC	also	expressed	CD40	(Hart	and	McKenzie,	1988).	The	 ligand	for	CD40	 is	CD154	and	 is	
expressed	 by	 multiple	 cells	 including:	 activated	 T	 cells	 and	 platelets,	 and	 monocytes	
(Frentsch	et	al.,	2005,	Henn	et	al.,	1998,	Katsiari	et	al.,	2002).	Ligation	of	CD40	results	in	the	
secretion	 of	 IL-12p70	 and	 polarises	 CD4+	 T	 cells	 to	 support	 CD8+	 T	 cell	 immune	 response	
(Schoenberger	et	al.,	1998,	Schulz	et	al.,	2000).	
CD80	 and	 CD86	 cell	 surface	 molecules	 share	 approximately	 25%	 sequence	 identity	 with	
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each	other,	 in	addition	 to	sharing	 the	same	T	cell	 ligands,	CD28	and	CD152	 (Linsley	et	al.,	
1994).	Ligation	of	CD80	and	CD86	to	CD28	results	in	the	production	of	IL-2,	IL-4	and	IL-5	by	
CD4+	T	cells	with	IL-4	critical	for	secretion	of	T	cell	cytokines	(Linsley	et	al.,	1991,	Rulifson	et	
al.,	 1997).	As	CD80	 and	CD86	 share	 the	 same	T	 cell	 ligands,	 BDC	expression	of	 CD80	 and	
CD86	 are	 differentially	 regulated	 with	 expression	 of	 CD86	 occurring	 before	 CD80	 after	
stimulation	of	BDC	 (McLellan	et	 al.,	 1995).	 The	 strength	of	 the	 interaction	between	CD80	
and	 CD86	 to	 CD28	 influences	 the	 polarisation	 of	 Th17	 cells	 (Purvis	 et	 al.,	 2010).	 Weak	
ligation	 to	 CD28	 resulted	 in	 greater	 amounts	 of	 IL-17	 compared	 to	 strong	 CD28	 ligation.	
Strong	stimulation	of	BDC	is	important	to	ensure	adequate	expression	of	CD80	and	CD86	co-
stimulatory	cell	surface	molecules	to	maximise	antigen	presentation	and	T	cell	immunity.	
1.6 Tumour	antigens	for	cancer	immune	therapy	
Tumour	 cells	 express	 antigens	 unique	 to	 the	 cancer	 allowing	 the	 immune	 system	 to	
recognise	 the	 cancer.	 Targeting	 cancer	 cells	 with	 the	 adaptive	 immune	 system	 is	 an	
appealing	approach	for	cancer	immune	therapy	as	this	method	potentially	reduces	the	side	
effects	of	a	non-specific	 cancer	 therapy	such	as	 chemotherapy	and	 issues	associated	with	
haematopoietic	 stem	 cell	 transplantation.	 However,	 comparative	 morphology	 and	
phenotypic	analysis	between	malignant	and	healthy	cells	is	challenging	due	to	both	of	these	
cells	originating	from	the	same	anatomical	site,	and	often	share	similar	characteristics	(Lee	
and	 Vasioukhin,	 2008,	 Kufe	 et	 al.,	 2006).	 The	 expression	 of	 tumour	 antigens	 assists	 with	
differentiation	 between	 healthy	 and	 malignant	 cells,	 in	 addition	 to	 disease	 prognosis	
(Ostergaard	et	al.,	2004,	Qi	et	al.,	2015).	Therefore	tumour	antigens	are	important	as	they	
play	a	valuable	role	for	managing	the	cancer	by	monitoring	disease	burden	and	can	dictate	
the	treatment.	Furthermore,	tumour	antigens	in	the	context	of	cancer	immune	therapy	are	
important,	 as	 it	 is	 usually	 tumour	 antigens	 that	 a	 specific	 immune	 response	 is	 generated	
against.		
1.6.1 Classification	of	tumour	antigens	
The	classification	of	tumour	antigens	to	initiate	specific	immune	response	has	advanced	due	
to	 recent	 genetic	 and	 biochemical	 characterisation	 of	 malignant	 cells.	 Several	 tumour	
antigen	 categories	 have	 been	 identified	 including:	 specific	 (including	 post-translational	
modification	 and	 absolute	 specific),	 overexpressed	 and	 oncofoetal	 (including	 cancer-germ	
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line)	(Cheever	et	al.,	2009,	Coulie	et	al.,	2014,	Kawakami	et	al.,	2004).	
Tumour	 specific	antigens	are	excellent	 candidates	 for	 cancer	 immune	 therapy	as	 they	are	
not	expressed	by	healthy	cells.	Viral	infection,	glycosylation	and	phosphorylation	of	proteins	
can	induce	site	specific	mutations	and	give	rise	to	altered	proteins	(Hauselmann	and	Borsig,	
2014,	 Poreba	 et	 al.,	 2011,	 Zarling	 et	 al.,	 2006).	 The	 detection	 of	 specific	 tumour	 antigen	
assists	 the	 diagnosis	 and	 monitoring	 for	 cancer	 due	 to	 the	 exclusive	 expression	 of	 the	
tumour	 antigen	 by	 the	 malignant	 cell.	 Examples	 of	 specific	 tumour	 antigen	 detected	 in	
colorectal	cancer	and	melanoma	include:	HPV	E6	and	E7,	mutated	p53	and	CDK4	(Houbiers	
et	al.,	1995,	Wolfel	et	al.,	1995,	Zumbach	et	al.,	2000).	
Overexpression	of	cellular	proteins	compared	to	normal	expression	levels	makes	a	suitable	
target	for	tumour	antigen	specific	immune	therapy.	Although	normal	cells	may	overexpress	
a	tumour	antigen,	increased	threshold	of	the	overexpressed	tumour	antigen	by	cancer	cells	
allows	recognition	by	T	cells	(Vigneron,	2015).	Overexpression	of	tumour	antigen	can	assist	
with	 the	 identification	 and	 monitoring	 of	 cancer,	 however	 the	 comparison	 of	 tumour	
antigen	between	normal	tissue	and	tumour	cells	can	be	difficult	to	establish	due	to	different	
intensities	 for	different	 cancers	 (Nakatsuka	et	al.,	 2006).	 Examples	of	 this	 tumour	antigen	
class	 include	 Wilms’	 tumour	 1	 (WT1),	 Human	 epidermal	 growth	 factor	 2	 (HER2)	 and	
glycoprotein	D2	(GD2)	for	leukaemic	stem	cells,	breast	cancer	and	neuroblastoma	(Mitri	et	
al.,	2012,	Oka	et	al.,	2002,	Yang	and	Sondel,	2010).	
Tumour	cells	expressing	foetal	cell	antigens	are	called	oncofoetal	antigens.	Tumour	cells	can	
also	 express	 antigens	 that	 are	 normally	 expressed	 in	 germ	 cells,	 such	 as	 the	 testis,	 are	
termed	 cancer-germ	 line	antigens	 (Wepsic,	 1983).	Antigens	 restricted	 to	 foetal	 tissue	and	
germ	lines,	and	not	adult	tissue,	make	an	appealing	immune	therapy	option	due	to	limited	
antigen	expression	(Boucher	et	al.,	1989,	Jungbluth	et	al.,	2000).	Male	germ	line	cells	do	not	
express	MHC	class	 I	and	cannot	present	antigen	to	T	cells	 (Haas	et	al.,	1988).	Examples	of	
well-studied	oncofoetal	antigens	are	carcinoembryonic	antigen	and	α-fetoprotein	 that	are	
used	to	detect	colorectal	and	liver	cancers,	respectively	(Boucher	et	al.,	1989,	Seregni	et	al.,	
1995).	 Melanoma	 antigens	 are	 a	 large	 family	 of	 cancer-germ	 line	 antigens	 that	 are	
expressed	by	a	variety	of	different	cancers	including	skin	and	lung	cancers	(Bolli	et	al.,	2002,	
Jungbluth	 et	 al.,	 2000).	 Whilst	 melanoma	 family	 of	 antigens	 are	 expressed	 by	 multiple	
cancers,	 their	 expression	 by	 healthy	 cells	 is	 restricted	 to	 testis	 and	 the	 male	 germ	 line	
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(Jungbluth	et	al.,	2000).	
1.6.2 Immunogenicity	of	tumour	antigens	
Immunogenic	 properties	 of	 tumours	 are	 the	 foundation	 cancer	 immune	 therapy	 and	 are	
variable	 due	 to	 antigen	 presentation	 that	 relies	 on	 1)	 MHC-antigen	 complex	 to	 present	
antigen	 to	 T	 cells,	 2)	 complementary	 TCR	 binding	 to	MHC-antigen	 complexes	 and	 3)	 co-
stimulatory	molecules	expressed	by	APC	and	T	cells	(Stone	et	al.,	2009,	Yu	et	al.,	2004).	BDC	
co-stimulatory	 cell	 surface	molecules	are	discussed	 in	1.5.2.	 Fitting	of	 an	antigen	 into	 the	
MHC	antigen	binding	groove	is	required	for	antigen	presentation.	Kinetic	studies	show	that	
poor	 binding	 of	 MHC-antigen	 complex	 results	 in	 rapid	 antigen	 dissociation	 from	 MHC,	
whereas	strong	binding	of	MHC-antigen	complex	results	in	slow	dissociation	of	MHC-antigen	
complex	(Yu	et	al.,	2004).	Unstable	and	weak	MHC-antigen	interactions	in	combination	with	
the	 upregulation	 of	 CD69	 and	 downregulation	 of	 CD62L	 results	 in	 poor	 T	 cell	 immune	
responses	and	anergy	(Corse	et	al.,	2011,	Skokos	et	al.,	2007).		
Tolerance	 is	 a	major	 challenge	 for	 cancer	 immune	 therapy	as	 tumour	antigens	may	be	of	
self	 origin.	 TCR	 recognising	 self	 antigens	 are	 deleted	 early	 in	 thymic	 development	 in	 the	
process	 of	 negative	 selection	 (Klein	 and	 Monin,	 2009).	 Only	 intermediate	 TCR-antigen	
binding	affinities	result	 in	the	survival	and	proliferation	of	antigen	specific	T	cells,	whereas	
poor	 proliferation,	 or	 even	 apoptosis,	 is	 the	 result	 of	 weak	 or	 high	 TCR-antigen	 binding	
affinities	 (Redmond	 and	 Sherman,	 2005,	 Reichstetter	 et	 al.,	 1999).	 Tolerance	 inhibits	 the	
activation	 of	 T	 cells	 and	 promotes	 a	weak	 T	 cell	 immune	 response	 (Cheung	 et	 al.,	 2008).	
Therefore	breaking	tolerance	of	tumours	expressing	self	antigens	is	required	to	achieve	an	
immune	response.	Intermediate	TCR	binding	affinity	and	eliminating	tolerance	are	critical	to	
achieve	a	 T	 cell	 immune	 response.	With	 the	aid	of	 immune	 therapies	 such	as	CAR-T	 cells	
with	 specific	 tumour	 antigen	 receptor	 and	 checkpoint	 inhibitors	 designed	 to	 prevent	
deletion	 of	 self	 antigen	 recognition,	 tolerance	 can	 be	 broken	 to	maximise	 T	 cell	 immune	
responses.	
Sanger	and	RNA	sequencing	of	tumours	can	detect	mutations	that	encode	new	antigens	not	
expressed	by	normal	tumour	cells	(Brown	et	al.,	2014,	Cai	et	al.,	2012).	A	cancer	neo-antigen	
is	 used	 to	 describe	 a	 genetic	 mutation	 that	 has	 occurred	 in	 a	 tumour	 cell	 and	 is	
immunogenic.	 This	 makes	 them	 an	 excellent	 candidate	 for	 immune	 therapy.	 Previous	
studies	found	favourable	clinical	responses	from	the	use	of	checkpoint	inhibitors	when	high	
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neo-antigens	were	detected	in	melanoma	and	non-small	cell	 lung	cancer	tumours	(Rizvi	et	
al.,	2015,	Snyder	et	al.,	2014).	This	suggests	that	the	presence	of	neo-antigens	make	a	good	
candidate	for	immune	therapy	and	checkpoint	inhibition	as	TCR	reactivity	is	enhanced	with	
neo-antigens.		
1.6.3 WT1	as	a	model	tumour	antigen	
In	2009,	Cheever	et	al.	prioritised	a	 list	of	 tumour	antigens	 for	 the	use	 in	 cancer	 immune	
therapy.	The	list	of	tumour	antigens	were	ranked	and	weighted	based	on	criteria	selected	by	
the	investigators	of	this	study.	The	criteria	included:	therapeutic	function,	immunogenicity,	
specificity,	 oncogenicity,	 expression	 level,	 stem	 cell	 expression,	 number	 of	 patients	 with	
antigen	 positive	 cancers,	 number	 of	 epitopes	 and	 cellular	 location.	 Interestingly,	 not	 one	
single	 tumour	 antigen	obtained	marks	 for	 all	 criteria.	 Based	on	 the	previously	mentioned	
criteria,	WT1	was	ranked	as	the	highest	priority	tumour	antigen	for	cancer	immune	therapy.	
The	ranking	of	WT1	was	not	specific	 for	any	cancer	as	multiple	cancers	express	WT1.	The	
outcome	 from	 this	 ranking	 has	 implications	 for	multiple	WT1	 expressing	 cancers	 such	 as	
AML,	prostate	and	breast	cancers	as	it	highlights	the	use	of	WT1	as	a	model	tumour	antigen	
for	cancer	immune	therapy	(Nakatsuka	et	al.,	2006,	Oka	et	al.,	2002).	
WT1	 is	 a	 zinc	 finger	 domain	 transcription	 factor	 with	 a	 role	 in	 cellular	 development	 and	
survival	(Kreidberg	et	al.,	1993).	It	also	plays	a	critical	role	in	the	urogenital	development	in	
the	developing	embryo.	WT1	expression	by	healthy	tissue	is	low	but	is	minimally	detected	in	
the	urogenital	system,	central	nervous	system	and	bone	marrow	(Kramarzova	et	al.,	2013,	
Ramani	 and	 Cowell,	 1996).	 Elevated	 expression	 is	 observed	 in	 a	 range	 of	 haematological	
malignancies	(AML	and	myelodysplastic	syndrome)	and	solid	tumours	(prostate,	kidney	and	
mesothelioma)	 and	 demonstrates	 the	 diversity	 and	 potential	 applications	 of	 this	 tumour	
antigen	(Nakatsuka	et	al.,	2006,	Rosenfeld	et	al.,	2003).	 In	addition	to	detecting	malignant	
cells,	 WT1	 expression	 is	 used	 as	 a	 biomarker	 associated	 with	 unfavourable	 disease	
prognosis,	 and	 monitoring	 disease	 progression	 in	 haematological	 malignancies	 and	 solid	
tumours	 (Ostergaard	 et	 al.,	 2004,	Ujj	 et	 al.,	 2016).	 These	 results	make	WT1	 an	 attractive	
model	tumour	antigen	for	cancer	immune	therapy.	
1.6.4 Dendritic	cell	tumour	antigen	loading	
Efficient	BDC	 tumour	antigen	 loading	strategies	are	essential	 for	 initiating	 tumour	antigen	
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specific	 immune	responses.	 In	particular,	 strategies	 that	can	be	adopted	adhering	to	GMP	
requirements	for	the	clinic	use	must	be	employed.	Despite	interest	in	BDC	compared	to	Mo-
DC	as	 an	 immune	 therapeutic,	 few	clinical	 studies	utilising	BDC	exist	 that	explore	 tumour	
antigen	 loading	 strategies	using	 immune	 selected	CD1c+	BDC	 loaded	with	 tumour	antigen	
peptides	 (Davis	 et	 al.,	 2017,	 Lesterhuis	 et	 al.,	 2011,	 Prue	 et	 al.,	 2015).	 Several	 strategies	
have	 been	 studied	 for	 loading	Mo-DC	with	 tumour	 antigen	 including:	Mo-DC-tumour	 cell	
fusion	hybrids,	peptide	loading	and	mRNA	transfection	(Bonehill	et	al.,	2009,	Kantoff	et	al.,	
2010,	 Prue	et	 al.,	 2015,	Rosenblatt	 et	 al.,	 2011,	 Thumann	et	 al.,	 2003).	 Each	 strategy	has	
advantages	and	disadvantages,	however	the	most	optimal	strategy	remains	unknown.		
1.6.4.1 Mo-DC-tumour	cell	fusion	hybrids	
Mo-DC	tumour	cell	 fusion	hybrids	are	created	 from	harvesting	autologous	patient	 tumour	
cells	and	 fused	with	Mo-DC.	Tumour	cells	are	 irradiated	 to	ensure	cells	do	not	proliferate	
after	 administration	 into	 the	 patient.	 Two	main	methods	 of	 fusion	 between	 tumour	 cells	
with	 autologous	Mo-DC	are	utilised.	 They	are	 fusion	with	polyethylene	glycol	 (PEG)	or	by	
electrofusion	(Parkhurst	et	al.,	2003,	Rosenblatt	et	al.,	2011).	PEGylation	is	the	most	simple	
and	economical	method	but	is	inconsistent	due	to	manual	technical	participation.	This	can	
produce	giant	cell	hybrid	 fusions	containing	 incorrectly	 fused	hybrids	with	more	 than	 two	
cells	(Pedrazzoli	et	al.,	2011).	The	electrofusion	process	uses:	an	alternating	current	to	align	
the	Mo-DC	and	tumour	cells,	a	direct	current	to	destabilise	the	closely	aligned	cells	followed	
by	 an	 alternating	 current	 to	 fuse	 cells	 together	 (Parkhurst	 et	 al.,	 2003).	 Electrofusion	 is	 a	
consistent	 method	 that	 can	 be	 performed	 using	 constant	 parameters	 reducing	 technical	
error	 (Trevor	 et	 al.,	 2004).	 Viability	 and	 number	 of	 hybrid	 fusions	 is	 also	 improved	 by	
electrofusion	compared	 to	PEGylation.	However,	 the	cost	of	 reagents	 required	PEGylation	
are	economical	compared	to	electrofusion.	
Administration	 of	 Mo-DC-tumour	 cell	 fusion	 hybrids	 initiates	 proliferation	 and	 cytokine	
secretion	of	anti-tumour	CD4+	and	CD8+	T	cells	(Kugler	et	al.,	2000,	Rosenblatt	et	al.,	2011).	
In	a	phase	 I	 study,	Rosenblatt	et	al.	 (2011)	2/12	detected	a	humoral	 immune	 response	 in	
addition	to	expansion	of	CD4+	and	CD8+	T	cells	in	11	patients	who	were	administered	with	a	
multiple	myeloma	Mo-DC-tumour	cell	fusion	hybrid.	Importantly,	there	was	no	incidence	of	
auto-immunity	 after	 administration	 of	 the	 tumour	 cell	 fusion	 hybrid	 into	 patients.	While	
these	results	demonstrate	disease	stabilisation	can	be	obtained,	this	method	has	only	been	
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performed	 with	Mo-DC	 and	 not	 BDC.	 Comparison	 between	Mo-DC	 and	 BDC	 tumour	 cell	
fusion	hybrids	has	yet	to	be	performed	and	would	be	beneficial	to	determine	if	differences	
such	as	migration	are	observed.		
1.6.4.2 Peptide	loading	
Tumour	 antigen	 loading	 with	 exogenous	 peptides	 is	 a	 strategy	 predominantly	 used	 to	
generate	antigen	specific	CD8+	T	cell	immune	responses	but	can	be	used	to	generate	a	CD4+	
T	 cell	 immune	 response.	 The	most	 common	MHC	 class	 I	 peptide	 loading	 strategy	 uses	 a	
peptide	8–12	mers	 in	 length	which	fit	 into	MHC	class	 I	antigen	binding	groove	for	antigen	
presentation	to	CD8+	T	cells	(Mohan	and	Unanue,	2012,	Phan	et	al.,	2003).	Whereas	natural	
MHC	class	I	antigen	presentation	relies	on	cytoplasmic	peptides	to	be	degraded	by	cytosolic	
proteasomes	 (Neefjes	 et	 al.,	 2011).	 Degraded	 peptides	 are	 translocated	 into	 the	
endoplasmic	 reticulum	 by	 transporter	 associated	 with	 antigen	 presentation	 (TAP)	 to	 be	
loaded	with	MHC	class	I	molecules.	MHC	class	I	is	assembled	as	a	heterodimer	combining	a	
polymorphic	 heavy	 chain	 and	 β2-microglobulin.	 Insertion	 of	 the	 peptide	 in	 the	 antigen	
binding	 groove	 stabilises	 MHC	 class	 I	 where	 it	 leaves	 the	 endoplasmic	 reticulum	 for	
translocation	 to	 the	 cell	 surface	 for	 antigen	 presentation	 to	 CD8+	 T	 cells.	Most	 nucleated	
cells	express	MHC	class	 I,	with	expression	greatest	among	APC	such	as	BDC	(Mellman	and	
Steinman,	2001).	Alternatively,	exogenous	long	peptides	14–20	mers	in	length	can	be	used	
for	antigen	presentation	to	CD4+	T	cells	via	MHC	class	II.	Antigen	presentation	by	MHC	class	
II	 requires	 the	 removal	 of	 the	MHC	 class	 II	 invariant	 chain	 and	 leaving	 a	 residual	 class	 II-
associated	 invariant	 chain	 peptide	 (CLIP)	 in	 the	MHC	 class	 II	 peptide-binding	 groove.	HLA	
class	II	molecules	are	required	to	exchange	CLIP	with	a	degraded	peptide	before	MHC	class	
II-peptide	complexes	are	transported	to	the	cell	surface	for	antigen	presentation	to	CD4+	T	
cells.	Loading	APC	with	long	peptides	is	similar	to	MHC	class	I	antigen	presentation	whereby	
peptides	 are	 phagocytosed	 and	 degraded	 by	 proteasomes.	 Polymorphic	MHC	 class	 II	 and	
invariant	 chain	 is	 assembled	 in	 the	 endoplasmic	 reticulum	 and	 transported	 to	 the	
endosomal	 compartment	 (Castellino	 et	 al.,	 1997).	 In	 addition	 to	 these	 natural	 antigen	
presentation	pathways,	exogenous	peptides	greater	than	20	mers	in	length	are	degraded	by	
proteosomes	 to	 smaller	 peptides	 8–12	 mers	 or	 14–20	 mers	 in	 length.	 These	 processed	
peptides	 then	 follow	 the	 appropriate	 MHC	 class	 I	 or	 II	 antigen	 presentation	 pathway	 to	
generate	both	CD4+	and	CD8+	T	cell	immune	responses	(Welters	et	al.,	2008).	
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Clinical	 anti-cancer	 immune	 responses	 improving	 patient	 overall	 survival	 have	 been	
observed	 from	 tumour	antigen	peptide	 loaded	Mo-DC	 for	melanoma	and	prostate	 cancer	
(Schuler-Thurner	 et	 al.,	 2000,	 Thomas-Kaskel	 et	 al.,	 2006).	 Loading	 immune	 selected	 BDC	
with	 tumour	 antigen	 peptides	 has	 been	 the	 only	 strategy	 to	 be	 used	 to	 generate	 clinical	
immune	 responses	 (Prue	 et	 al.,	 2015,	 Schreibelt	 et	 al.,	 2016,	 Tel	 et	 al.,	 2013a).	 In	 these	
studies,	pDC	or	CD1c+	BDC	were	 immune	 selected	 from	 respective	melanoma	or	prostate	
cancer	patients	and	loaded	with:	MHC	class	I,	or	in	combination	with	MHC	class	II	restricted	
tumour	 antigen	 peptides.	 Increased	 cytokine	 producing	 antigen	 specific	 CD8+	 T	 cells	
responses	were	detected	in	patients	resulting	in	improved	long	term	survival.		
Due	 to	MHC	class	 I	 and	 II	 polymorphisms,	 the	use	of	 tumour	antigen	peptides	 for	 cancer	
immune	therapy	is	restricted	to	the	patient’s	MHC	genotype,	and	is	required	to	be	known	
for	antigen	presentation	to	T	cells	(Cole,	2015).	In	addition	MHC	class	I	and	II	have	different	
peptide	 binding	 affinities,	 therefore	 certain	 peptides	 are	 more	 suitable	 for	 peptide	
vaccination	 than	 others	 (Pinilla-Ibarz	 et	 al.,	 2006).	 Multiple	 peptides	 can	 be	 used	 when	
vaccinating	 a	 patient	 to	 generate	 a	multi-antigen	 T	 cell	 response	 (Rosenberg	 et	 al.,	 2006,	
Welters	 et	 al.,	 2008).	 This	 method	 may	 be	 beneficial	 if	 multiple	 tumour	 antigens	 are	
expressed	by	the	malignancy	(Slingluff	et	al.,	2013).	Furthermore,	multiple	peptides	can	be	
co-administered	as	a	peptide	mix	to	accommodate	presentation	by	both	MHC	class	I	and	II	
(Phan	et	al.,	2003).	Peptide	vaccination	dosage	and	scheduling	needs	to	be	addressed	as	the	
peptide	 may	 be	 required	 to	 be	 administered	 multiple	 times	 to	 increase	 the	 vaccination	
efficacy.	
1.6.4.3 mRNA	loading	
Tumour	 antigen	 mRNA	 is	 an	 attractive	 antigen	 loading	 strategy	 that	 induces	 both	 anti-
tumour	 CD4+	 and	 CD8+	 T	 cell	 immune	 responses	 without	 knowing	 the	 patient’s	 HLA	
genotype	(Van	Nuffel	et	al.,	2012a).	Loading	with	tumour	antigen	mRNA	requires	the	APC	to	
translate	 the	mRNA	 in	 to	protein,	where	 it	 can	enter	 antigen	degradation	and	processing	
pathways	as	described	in	1.6.4.2	for	both	MHC	class	I	and	II	antigen	presentation.	Multiple	
tumour	antigen	epitopes	may	be	presented	to	T	cells.	In	addition	to	inducing	both	antigen	
specific	CD4+	and	CD8+	T	cell	 immune	responses,	this	process	 is	not	restricted	to	HLA	type	
like	peptide	 loading.	The	source	of	mRNA	can	be	amplified	from	autologous	tumour,	or	 in	
vitro	transcribed	from	plasmids	containing	tumour	antigen	mRNA	(Boczkowski	et	al.,	1996,	
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Fromm	 et	 al.,	 2016).	 This	 makes	 mRNA	 loading	 an	 exciting	 option	 for	 loading	 BDC	 with	
tumour	antigen.	
Delivery	 of	 mRNA	 to	 BDC	 can	 be	 achieved	 using	 electroporation,	 liposomes	 or	 viral	
transduction	 systems	 (Dietz	and	Vuk-Pavlovic,	1998,	Dull	et	al.,	1998,	Fromm	et	al.,	2016,	
Markov	 et	 al.,	 2012).	 Electroporation	 is	 the	 transfer	 of	 exogenous	mRNA	 into	 the	 cell	 by	
disrupting	the	cell	membrane	to	create	pores	in	the	phospholipid	bilayer	with	high	voltage	
shocks	 (Tieleman,	 2004).	 This	 method	 is	 efficient	 at	 delivering	 mRNA	 to	 cells,	 however	
electroporation	 conditions	 need	 to	 be	 optimised	 to	 ensure	 maximum	 cell	 viability	 after	
electrically	 shocking	 the	 cell.	 Electroporation	 conditions	 are	 consistent	 due	 to	 reliance	on	
using	 electroporation	 instrumentation,	 which	 minimises	 technical	 error.	 Liposomes	 are	
spherical	vesicles	consisting	of	one	or	more	phospholipid	bilayers	that	can	contain	tumour	
antigen	 mRNA	 (Akbarzadeh	 et	 al.,	 2013).	 Fusion	 of	 the	 liposome	 to	 the	 cell	 membrane	
allows	 the	 release	of	 the	mRNA	contained	by	 the	 liposome	 in	 to	 the	 cytoplasm,	 followed	
with	translation	to	protein.	Liposomes	are	considered	foreign	bodies	by	the	immune	system,	
and	 need	 to	 be	 chemically	 treated	 to	 minimise	 non-specific	 immunogenicity.	 Viral	
transduction	 using	 genetically	 engineered	 adenovirus	 or	 lentivirus	 systems	 are	 other	
methods	for	delivering	tumour	antigen	mRNA	to	BDC	(Dietz	and	Vuk-Pavlovic,	1998,	Dull	et	
al.,	1998).	The		use	 of	 viral	 delivery	 systems	 has	 been	 shown	 to	 be	 efficient	 at	 delivering	
genetic	content	for	producing	CAR-T	cells	(An	et	al.,	2016).	Fusion	results	 in	the	release	of	
tumour	antigen	mRNA	in	to	the	BDC,	followed	by	tumour	antigen	protein	translation	by	the	
BDC.	The	tumour	antigen	protein	now	undergoes	proteolysis	described	in	1.6.4.2.	
The	 production	 of	 clinical-grade	 IVT-mRNA	 would	 need	 to	 be	 addressed	 for	 the	 use	 in	
clinical	 trials.	 Currently	 the	 production	method	uses	 a	 T7	 polymerase	 that	 is	 from	 the	 T7	
bacteriophage.	 Therefore	 the	 mass	 production	 of	 this	 enzyme	 will	 need	 to	 be	 free	 of	
bacterial	 contaminants	 before	 used	 with	 humans.	 Upscaling	 the	 IVT-mRNA	 production	
process	in	a	economically	viable	manner	would	also	need	to	be	considered	as	currently	only	
small	amounts	of	IVT-mRNA	are	produced	using	research-use	only	kits.	
1.7 The	current	and	future	of	adoptive	dendritic	cell	therapy		
Anti-cancer	clinical	outcomes	from	DC	immune	therapy	are	listed	in	Table	1.1	and	describe	
the	results	from	melanoma,	AML	and	prostate	cancer	clinical	trials	using	Mo-DC,	mDC	and	
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pDC	utilising	peptide	and	mRNA	loading	strategies	(Davis	et	al.,	2017,	Lesterhuis	et	al.,	2011,	
Mazzolini	 et	 al.,	 2005,	 Prue	 et	 al.,	 2015,	 Schreibelt	 et	 al.,	 2016,	 Tel	 et	 al.,	 2013a,	 Van	
Tendeloo	et	al.,	2010).	The	 reported	clinical	 responses	are	varied,	even	among	 the	use	of	
the	same	APC.	Factors	such	as	administration	route,	number	of	cells	administered	and	the	
maturation	strategy	play	a	critical	 role	 in	migration	 to	draining	 lymph	nodes	 regardless	of	
the	choice	of	APC.	Intranodal	administration	of	Mo-DC	has	demonstrated	poor	migration	to	
distal	 lymph	 nodes	 and	 the	 method	 of	 Mo-DC	 maturation	 was	 found	 to	 impact	 Mo-DC	
migration	(De	Vries	et	al.,	2003).	Mo-DC	migration	from	site	of	administration	was	improved	
when	 the	number	of	 cells	 administered	was	 reduced	 (Aarntzen	et	 al.,	 2013b).	When	pDC	
were	 activated	with	 FSME	and	 intranodally	 administered,	 pDC	were	 found	 at	 other	 distal	
lymph	 nodes	 with	 an	 18%	 increase	 in	 mean	 migration	 from	 site	 of	 injection	 (Tel	 et	 al.,	
2013a).	This	increase	is	still	greater	than	Mo-DC	migration	even	when	Mo-DC	migration	was	
optimised	and	the	number	of	administered	Mo-DC	was	reduced.	Antigen	processing	by	Mo-
DC	is	different	to	BDC.	Mo-DC	are	able	to	process	synthetic	long	peptides	to	initiate	a	CD8+	T	
cell	immune	response	more	efficiently	than	whole	proteins	(Ma	et	al.,	2016,	Menager	et	al.,	
2014,	 Rosalia	 et	 al.,	 2013).	 CD1c+	 and	 CD141+	 BDC	 have	 shown	 the	 ability	 to	 present	
peptides	in	addition	to	whole	protein	(Jongbloed	et	al.,	2010).		
Differences	 in	 antigen	 processing	 and	 presentation	 have	 been	 observed	 between	Mo-DC	
and	BDC	which	may	play	a	role	in	antigen	presentation	to	T	cells.	It	has	been	suggested	that	
using	Mo-DC	for	BDC	studies	may	be	misleading	as	Mo-DC	are	more	related	to	macrophages	
(McCurley	and	Mellman,	2010).	BDC	are	dependent	on	the	proteasome	to	present	antigen	
and	process	cytosolic	antigen	more	efficiently	than	Mo-DC	(Chatterjee	et	al.,	2012,	Chiang	
et	al.,	2016).	A	study	comparing	Mo-DC	mRNA	antigen	delivery	found	that	electroporation	
was	more	effective	at	delivering	antigen	than	lipofectamine	(Schaft	et	al.,	2013).	This	study	
found	that	 fewer	Mo-DC	presenting	high	amounts	of	antigen	 is	more	effective	 than	many	
Mo-DC	presenting	 intermediate	 antigen	 amounts	 at	 initiating	 an	 antigen	 specific	 immune	
response.	 This	 result	 combined	with	 the	 results	 from	Aarntzen	et	 al.	 (2013)	 demonstrate	
that	 large	 quantities	 of	Mo-DC	 in	 clinical	 studies	may	 not	 be	 essential	 for	 an	 anti-cancer	
immune	 response,	 and	 immune	 selected	BDC	 instead	of	Mo-DC	may	be	an	option	 for	DC	
immune	therapy.		
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Cell	type	 Malignancy	 Maturation	and	tumour	antigen	loading	 Doses	 Clinical	outcome	 Reference	
Mo-DC	 Stage	IV	metastatic	melanoma	
TNF	and	PGE2																																															
Peptides:	WT	gp100154-162	and	gp100280-288,	
or	gp100154-162	(Q-A)	and	gp100280-288	(A-
V),	and	tyrosinase369-376	
25x106,	i.v.	
administration	or	
11x106	i.d.	
administration	
9/27	patients	developed	SD	or	CR,											
median	survival	6	months,	3	patients	
developed	tetramer+	T	cells	
(Lesterhuis	et	al.,	2011)	
Mo-DC	 AML	patients	in	remission	
TNF,	KLH	and	PGE2																																													
Electroporation:	WT1	mRNA	
5	or	10	or	20x106,																
i.d.	
administration	
5/10	patients	achieved	molecular	
remission,	median	survival	12	months	
(Van	Tendeloo	et	al.,	
2010)	
Mo-DC	
Metastatic	cancer	
(pancreatic,	
hepatocellular,	
colorectal	and	
cholangiocarcinoma)	
TNF,	PGE2	and	IFNα,																				
Transfection:	Adenovirus	encoding	for	
human	IL-12	
1	or	2.5	or	5x107,																		
i.t.	administration	
3/14	patients	PR	or	SD,																																	
4/11	patients	had	an	increase	in	CD3+	and	
CD8+	T	cells	at	tumour	site	
(Mazzolini	et	al.,	2005)	
pDC	
incubated	
with	IL-3	
Distant	metastatic	
melanoma	
FSME																																																					
Peptides:	gp100154-162,	gp100280-288	and	
tyrosinase369-377	
0.3 or	1	or	3x106,																	
i.n.	
administration	
6/15	patients	developed	SD,																						
median	survival	22	months,	8	patients	
developed	tetramer+	T	cells	
(Tel	et	al.,	2013a)	
CD1c+	mDC	 Hormone	refractory	prostate	cancer	
No	maturation																																								
Peptides:	PSA154-163,	PSMA711-719,	PAP299-307	
and	FMP158-166	
1 or	1-5x106,																									
i.v.	or	i.d.	
administration	
Median	survival	18	months	 (Prue	et	al.,	2015)	
CD1c+	mDC	 Stage	IV	metastatic	melanoma	
Overnight	GM-CSF																															
Peptides:	gp100154-162,	gp100280-288	and	
tyrosinase369-377	
3 or	5	or	10x10e6,																			
i.n.	
administration	
5/14	patients	developed	SD	or	CR,	3x106	
was	sufficient	to	induce	immune	
response,	median	survival	13	months,	5	
patients	developed	tetramer+	T	cells	
(Schreibelt	et	al.,	2016)	
CD1c+	mDC	
Stage	III	or	IV	
metastatic	cancer	
expressing	NY-ESO-1	
or	LAGE-1	
Overnight	CD40L																																										
Full	length	NY-ESO-1	protein	in	
combination	with	ISCOMATRIX	
All	immune	
selected	cells	
used	for	i.d.	
administration	
1/8	CR	at	July	2016	 (Davis	et	al.,	2017)	
CR;	complete	remission,	FSME;	Tick	borne	encephalitis	vaccine,	i.d.;	intradermal,	i.n.;	intranodal,	i.t.;	intratumoural,	i.v.;	intravenous,	KLH;	keyhole	limpet	haemocyanin,	PR;	
partial	response,	SD;	stable	disease,	WT;	wild-type.	
Table	1.1	Examples	of	reported	clinical	trials	using	Mo-DC,	pDC	or	CD1c+	mDC	and	their	clinical	outcome	
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Genomic,	functional	and	phenotypic	differences	are	continuously	being	uncovered	between	
Mo-DC	and	BDC	subsets.	These	differences	pose	the	question	to	which	BDC,	and	other	APC,	
are	required	for	maximal	antigen	presentation	against	a	tumour	antigen.	The	generation	of	
Mo-DC	 results	 in	 a	 homogeneous	 population	 of	 cells	 possessing	 limited	 antigen	
presentation	 capability.	 However,	 multiple	 methods	 to	 produce	 Mo-DC	 exsits,	 and	 a	
consistent	 clinical	 protocol	 for	 Mo-DC	 generation	 has	 not	 been	 established.	 Isolation	 of	
CD1c+	 BDC	 by	 magnetic	 bead	 immune	 selection	 is	 a	 multi-step	 establish	 protocol	 that	
requires	 depletion	 of	 CD19+	 B	 cells,	 followed	with	 CD1c+	 BDC	 immune	 selection,	which	 is	
labour	intensive	and	increases	the	cost	of	the	vaccination	(Prue	et	al.,	2015).	Recent	analysis	
of	 the	costs	 to	produce	Mo-DC	for	 the	purpose	of	AML	 immune	therapy	was	€20,450	per	
patient	(Van	de	Velde	et	al.,	2014).	Sipuleucel-T	was	costed	at	US$93,000	for	the	production	
and	administration	of	three	infusions	of	the	vaccine	(Anassi	and	Ndefo,	2011).	
Safety	 is	 an	 important	 factor	 for	 adoptive	 DC	 therapy	with	Mo-DC,	 pDC	 and	 CD1c+	mDC	
demonstrating	 minimal	 toxic	 adverse	 events	 from	 BDC	 administration	 (Lesterhuis	 et	 al.,	
2011,	Mazzolini	et	al.,	2005,	Tel	et	al.,	2013a).	Common	adverse	events	associated	with	DC	
therapy	include:	fatigue,	influenza	like	symptoms	like	fever,	and	lymphopenia	(Mazzolini	et	
al.,	 2005,	 Schreibelt	 et	 al.,	 2016,	 Tel	 et	 al.,	 2013a).	Minimal	 grade	 three	 or	 four	 adverse	
events	were	 experienced	by	 patients	 treated	with	 either	Mo-DC	or	 BDC.	 Patients	 treated	
with	other	immune	therapies	such	as	Nivolumab	experience	similar	adverse	events	as	found	
in	 early	 studies	 (Brahmer	 et	 al.,	 2010).	 However	 a	 recent	 comprehensive	 review	 has	
discussed	the	adverse	events	associated	with	checkpoint	inhibitors,	such	as	Nivolumab,	and	
found	they	generate	 immune	related	adverse	events	 (Michot	et	al.,	2016).	These	 immune	
related	adverse	events	include	toxicities	to	skin,	gut,	liver	and	lung.	
1.8 Aims	of	this	research	
Immune	selection	of	CMRF-56+	results	in	a	heterogeneous	population	of	B	cells,	monocytes	
and	multiple	 BDC	 subsets	 including:	 CD1c+,	 CD16+	 and	 CD141+	mDC.	 hCMRF-56+	 immune	
selection	may	provide	a	suitable	method	for	isolating	APC,	such	as	BDC,	for	clinical	studies	
and	 as	 a	 future	 anti-cancer	 therapeutic	 option,	 negating	 the	 use	 Mo-DC.	 Transfecting	
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primary	 APC	 with	 tumour	 antigen	 mRNA	 has	 not	 yet	 been	 investigated	 as	 an	 effective	
method	 to	 generate	 an	 antigen	 specific	 immune	 response.	 Recent	 advances	 in	 mRNA	
transfection	are	providing	GMP	compliant	technologies	for	clinical	use.		
Hypothesis:	 Immune	 selection	 of	 hCMRF+	 cells	 can	 be	 electroporated	 with	 IVT-mRNA	 to	
generate	an	antigen	specific	T	cell	response.	
Aim	 1:	 Confirmation	 thaty	 hCMRF-56+	 immune	 selected	 cells	 contain	 a	 heterogeneous	
population	of	BDC,	and	other	APC,	was	performed	by	multiparameter	flow	cytometry.	The	
phenotype	 of	 hCMRF-56+	 BDC	 was	 characterised	 in	 collaboration	 with	 the	 10th	 Human	
Leucocyte	Differentiation	Antigen	Workshop.	
Aim	2:	An	effective	strategy	to	transfect	hCMRF-56+	immune	selected	BDC	with	mRNA	was	
developed,	and	the	effects	of	mRNA	transfection	on	hCMRF-56+	cells	was	determined.	The	
function	 and	 phenotype	 of	 hCMRF-56+	 immune	 selected	 cells	 transfected	with	 IVT-mRNA	
was	 measured	 in	 chapter	 four.	 In	 addition,	 functional	 differences	 between	 hCMRF-56+	
immune	selected	cells	and	Mo-DC	was	also	investigated.	
Aim	 3:	 Antigen	 specific	 T	 cell	 immune	 responses	 were	 generated	 from	 IVT-mRNA	
transfected	hCMRF-56+	immune	selected	cells.	hCMRF-56+	cells	transfected	with	IVT-mRNA	
in	combination	with	Nivolumab	was	also	 investigated.	Other	clinically	applicable	strategies	
for	the	activation	of	hCMRF-56+	immune	selected	BDC	were	investigated.	
The	findings	from	this	research	support	the	use	of	hCMRF-56+	immune	selected	cells	as	an	
enhanced	source	of	APC	compared	to	Mo-DC	and	show	that	hCMRF-56+	 immune	selected	
BDC	are	superior	at	HLA	class	 I	antigen	presentation	and	 in	vitro	chemotaxis	compared	to	
other	 hCMRF-56+	 immune	 selected	 B	 cells	 and	 monocytes.	 Antigen	 loading	 by	 mRNA	
transfection	 of	 hCMRF-56+	 immune	 selected	 cells	 is	 able	 to	 generate	 antigen	 specific	
immune	 responses.	 This	 thesis	 is	 the	 first	 description	 of	 mRNA	 transfected	 primary	 BDC	
used	 to	 generate	 antigen	 specific	 immune	 responses.	 The	 results	 from	 this	 research	 will	
enable	collaborative	pre-clinical	studies	in	preparation	of	a	clinical	trial.	 	
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2 MATERIALS	AND	METHODS	
2.1 Study	ethics	
2.1.1 Donor	recruitment	for	collecting	blood	
Volunteer	HLA-A*0201-	and	HLA-A*0201+	healthy	blood	donors	were	recruited	for	this	study	
in	 accordance	 with	 the	 Sydney	 Local	 Health	 District	 Human	 Research	 Ethics	 Committee	
(HREC/11/CRGH/61)	and	in	accordance	with	the	Declaration	of	Helsinki.	The	donors	were	a	
range	of	people	including	staff,	students	and	local	community	members.	Volunteer	healthy	
blood	 donations	 underwent	 full	 blood	 count,	 biochemical	 analysis	 and	 screening	 for	
infectious	diseases	including	human	immunodeficiency	virus,	syphilis	and	Hepatitis	B	virus.	
Only	blood	donors	that	exhibited	normal	pre-screening	results	were	used	for	experiments.	
2.1.2 Animal	ethics	
Animal	 experiments	were	 approved	 by	 the	 Sydney	 Local	 Health	 District	 Animal	 Care	 and	
Ethics	 Committee	 (2011/209C).	 Animals	 were	 housed	 at	 the	 ANZAC	 Research	 Institute	
Molecular	Physiology	Unit	under	specific	pathogen-free	conditions.	Following	completion	of	
experiments,	 animals	were	euthanised	and	 carcases	were	disposed	of	 in	 accordance	with	
PC2	regulations.	
2.2 Cell	isolations	and	propagation	methods	
2.2.1 Buffers	and	media	
Reagent	
Final	
concentration	
Component	 Supplier	 Country	
Catalogue	
number	
Complete	
RPMI	10%	FCS	
10%v/v	
HI	Foetal	calf	serum	
(HI	FCS)	
Gibco	 Australia	 10099-141	
10,000IU/mL	 Penicillin/Streptomycin	
Life	
Technologies	
Australia	 15140122	
2mM	 Glutamax	 ThermoFisher	 USA	 35050061	
	 RPMI	1640	 ThermoFisher	 USA	 21870092	
Complete	
RPMI	10%	AB	
serum	
10%v/v	 HI	human	AB	serum	 Sigma	Aldrich	 USA	 H4522	
10,000IU/mL	 Penicillin/Streptomycin	 	 	 	
2mM	 Glutamax	 	 	 	
1mM	 Sodium	pyruvate	 ThermoFisher	 USA	 11360070	
Table	2.1	Buffer	and	media	
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0.055mM	 2-mercaptoethanol	 ThermoFisher	 USA	 21985023	
0.1mM	
Non-essential	amino	
acids	
ThermoFisher	 USA	 11140050	
	 RPMI	1640	 	 	 	
LB	broth	 	 Luria-Bertani	(LB)	broth	 Difco	 USA	 244620	
LB	agar	 	 Luria-Bertani	(LB)	agar		 Difco	 USA	 244520	
FACS	buffer	
0.5%w/v	 Bovine	serum	albumin	
Life	
Technologies	
Australia	 30063721	
	 PBS	
Astral	
Scientific	
Australia	 09-8912-100	
MACS	buffer	
0.5%w/v	 Bovine	serum	albumin	 	 	 	
	 PBS	 	 	 	
2mM	 EDTA	 Sigma	Aldrich	 USA	 E9884	
5X	Tris-
Borate-EDTA	
(TBE)	
445mM	 Trizma	 Sigma	Aldrich	 USA	 T1503	
363mM	 Boric	acid	 Sigma	Aldrich	 USA	 B6768	
10mM	 EDTA	 	 	 	
Ammonium	
chloride	
154mM	 Ammonium	chloride	 Sigma	Aldrich	 USA	 A0171	
0.4mM	 Potassium	bicarbonate	 Sigma	Aldrich	 USA	 60339	
0.13mM	 EDTA	 	 	 	
Cryo-	
preservation	
media	
10%v/v	 Dimethyl	sulfoxide	 Sigma	Aldrich	 USA	 D2650	
40%v/v	 HI	FCS	 	 	 	
50%v/v	 RPMI	1640	 	 	 	
2.2.2 Isolation	of	PBMC	from	venous	blood	
PBMC	 were	 isolated	 from	 350-400mLs	 fresh	 healthy	 donor	 venesection	 using	 density	
gradient	 centrifugation.	 Cells	 were	 prepared	 by	 diluting	 blood	 1:1	 with	 sterile	 PBS	
(phosphate	buffered	saline)	(Astral	Scientific,	Australia;	09-8912-100).	Ficoll-Paque	PLUS	(GE	
Healthcare,	 Sweden;	 17-1440-03)	was	 underlayed	 to	 a	 total	 volume	 of	 50mLs	 in	 a	 50mL	
polypropylene	(PP)	tube	(BD	Biosciences,	USA;	352070).	This	suspension	was	centrifuged	at	
470	 x	 g	 for	 25mins	 using	 in	 an	 Allegra	 X-12	 centrifuge	 (Beckman	 Coulter,	 USA;	 SX4750	
ROTOR)	at	room	temperature.	The	centrifuge	brake	and	acceleration	was	turned	off	during	
this	 centrifugation	 process.	 After	 centrifugation	 the	 interface	 layer	 that	 contained	 the	
leucocytes	was	harvested	and	centrifuged	at	200	x	g	 for	10mins	to	remove	contaminating	
platelets.	 PBMC	were	 collected	 into	 a	 separate	 50mL	 PP	 tube	 and	washed	 in	 sterile	 PBS.	
PBMC	were	washed	again	in	PBS	and	counted	for	downstream	application.		
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2.2.3 hCMRF-56+	cell	MACS	immune	selection	
PBMC	were	prepared	using	density	gradient	separation	as	described	 in	2.2.2	using	aseptic	
technique	 and	 then	 incubated	 overnight	 for	 hCMRF-56+	 immune	 selection	 (Fromm	et	 al.,	
2016).	 Briefly,	 PBMC	 were	 prepared	 and	 resuspended	 1.0x107/mL	 in	 X-Vivo	 15	 (Lonza,	
Australia;	 04-744Q).	 PBMC	 were	 transferred	 to	 a	 T75	 tissue	 culture	 flask	 (Corning,	 USA;	
353136)	and	the	T75	tissue	culture	flask	containing	PBMC	was	transferred	to	the	incubator	
(Panasonic,	 The	 Netherlands;	 MCO-19A1C)	 for	 12-16hrs	 at	 37°C	 with	 5%	 CO2.	 Following	
incubation,	the	tissue	culture	flask	was	placed	on	ice	for	20mins	to	dissociate	any	adherent	
cells.	 Cells	were	harvested	and	 the	 tissue	 culture	 flask	was	washed	 three	 times	with	 cold	
sterile	PBS.	Gentle	scraping	using	a	cell	scraper	(BD	Biosciences;	353085)	was	performed	to	
collect	 any	 remaining	 adherent	 cells	 from	 the	 tissue	 culture	 flask.	 Harvested	 cells	 were	
washed	 in	 cold	 sterile	 PBS	 and	 counted.	 Cells	 were	 resuspended	 in	 sterile	 degassed	
magnetic	 antibody	 cell	 separation	 (MACS)	 running	buffer	 (Miltenyi	 Biotec,	Germany;	 130-
091-221)	 to	 a	 concentration	 of	 6.6x107	 cells/mL.	 Biotinylated	 hCMRF-56	 IgG4	 mAb	
(DendroCyte,	Australia)	was	added	to	the	cell	suspension	at	a	concentration	of	1.25μg/mL	
and	incubated	at	4°C	for	15mins.	The	cells	were	washed	in	cold	sterile	PBS	and	resuspended	
at	 1.25x108	 cells/mL	 with	 cold	 MACS	 running	 buffer	 mixed	 with	 anti-biotin	 microbeads	
(Miltenyi	 Biotec;	 130-090-485)	 at	 a	 concentration	 of	 100μL/1x108	 cells	 and	 incubated	 for	
15mins	 at	 4°C.	 Cell	 suspension	was	 gently	 agitated	 after	 5mins	 of	 incubation	 and	 for	 the	
remainder	 of	 the	 incubation	 period.	 Following	 incubation,	 the	 cells	 were	 washed	 in	 cold	
sterile	 PBS	 and	 resuspended	 in	 cold	 MACS	 running	 buffer	 to	 a	 concentration	 of	 2x108	
cells/mL.	 PBMC	were	 loaded	 onto	 the	 AutoMACS	 Pro	 (Miltenyi	 Biotec;	 130-092-545)	 and	
hCMRF-56+	 cells	 were	 immune	 selected	 using	 the	 pre-set	 PosselD2	 program.	 Eluted	 cells	
were	collected	in	a	sterile	14mL	PP	tube	(BD	Biosciences;	352196)	and	washed	in	cold	sterile	
PBS	immediately	after	immune	selection.	hCMRF-56+	and	hCMRF-56-	immune	selected	cells	
were	counted	for	downstream	application.	
Multiparameter	flow	cytometry	was	routinely	used	to	calculate	the	%	hCMRF-56+	 immune	
selected	 BDC,	 the	 %	 yield	 of	 hCMRF-56+	 cells	 was	 calculated	 by	 combining	 all	 immune	
selected	immune	cell	populations	and	the	%	hCMRF-56+	BDC	recovery	was	calculated	from	
the	actual	hCMRF-56+	BDC	count	as	%	of	theoretical	maximum	hCMRF-56+	immune	selected	
BDC.	
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2.2.4 MACS	lineage	depletion	and	FACS	for	isolating	DC	and	monocyte	subsets	
PBMC	were	 isolated	as	described	 in	2.2.2	and	 resuspended	 to	1.25x108/mL	 in	 cold	 sterile	
MACS	buffer.	Titrated	purified	mAbs	described	in	Table	2.2	were	added	to	PBMC	suspension	
and	incubated	for	15mins	at	4°C.		
mAb	 Clone	 Supplier	 Country	 Catalogue	number	
CD3	 HIT3a	 Biolegend	 USA	 300302	
CD14	 RM052	 Beckman	Coulter	 USA	 IM0643	
CD20	 B9E9	 Beckman	Coulter	 	 IM1456	
CD56	 NKH-1	 Beckman	Coulter	 	 6602705	
CD235a	 GA-R2	 BD	Biosciences	 USA	 555569	
Cells	were	washed	in	cold	sterile	PBS	and	resuspended	to	1.25x108/mL	in	cold	sterile	MACS	
buffer.	 Anti-mouse	 IgG	 microbeads	 (Miltenyi	 Biotec;	 130-048-401)	 were	 added	 to	 a	
concentration	of	100μl	microbeads/1x108	PBMC.	Cells	were	incubated	for	15mins	at	4°C	and	
gently	 agitated	 after	 5mins	 of	 incubation	 and	 for	 the	 remainder	 of	 the	 incubation.	 PBMC	
were	 washed	 with	 cold	 sterile	 PBS	 and	 resuspended	 to	 2x108/mL	 in	 cold	 sterile	 MACS	
buffer.	 PBMC	were	 loaded	onto	 the	AutoMACS	Pro	 and	 the	pre-set	Depl025	was	used	 to	
deplete	 linage+	cells	 from	PBMC.	Lineage	depleted	PBMC	were	washed	 in	cold	 sterile	PBS	
and	counted	for	downstream	application.	
2.2.5 Generation	of	monocyte-derived	dendritic	cells	
PBMC	were	isolated	and	CD14+	cells	were	enriched	by	immune	selection	from	PBMC	using	
aseptic	 technique	 and	 incubated	 with	 cytokines	 as	 previously	 described	 (Fromm	 et	 al.,	
2016).	 Briefly,	 PBMC	were	 as	 described	 in	 2.2.2	 and	 resuspended	 to	 1.25x108/mL	 in	 cold	
MACS	 buffer	 with	 anti-CD14	 microbeads	 (Miltenyi	 Biotec;	 130-050-201)	 added	 to	 a	
concentration	of	100μl/1x108	PBMC	and	incubated	for	15mins	at	4°C	with	gentle	agitation	
and	for	the	duration	of	incubation.	After	15mins	the	cells	were	washed	with	cold	sterile	PBS	
and	resuspended	to	2x108/mL	in	cold	sterile	MACS	buffer.	Labelled	cells	were	loaded	onto	
the	AutoMACS	Pro.	CD14+	cells	were	immune	selected,	washed	and	counted	using	the	pre-
set	PosselD	program	on	the	AutoMACS	Pro.	
After	CD14+	immune	selection,	cells	were	cultured	for	five	days	at	3.3x105/mL	in	Complete	
RPMI	10%	FCS	media	supplemented	with	1000U/mL	GM-CSF	(Miltenyi	Biotec;	130-095-372)	
Table	2.2	List	of	purified	mAbs	used	to	deplete	PBMC	of	lineage+	cells	
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and	125	IU/mL	IL-4	(Life	Technologies,	Australia;	PHC0044)	in	6	well	plate	(Corning;	353046)	
incubated	at	37°C	with	5%	CO2.	After	five	days,	immature	Mo-DC	was	harvested	by	washing	
plate	 with	 cold	 sterile	 PBS	 and	 scraping	 wells.	 Multiparameter	 flow	 cytometry	 was	
performed	to	measure	the	cells	surface	expression	of	CD14	and	HLA-DR,	with	immature	Mo-
DC	showing	decreased	expression	of	CD14	and	increased	expression	of	HLA-DR	as	described	
(Toujas	et	al.,	1997).	
When	required,	Mo-DC	were	matured	using	a	standard	clinical	cytokine	cocktail	comprising	
700IU/mL	IL-1β	(In	Vitro	Technologies,	Australia;	201-LB-005),	1μg/mL	PGE2	(Sigma	Aldrich;	
P0409),	1.6x104	IU/mL	IL-6	(In	Vitro	Technologies;	206-IL-010)	and	380	IU/mL	TNF	(In	Vitro	
Technologies;	210-TA-010)	(Lee	et	al.,	2002).	Cytokine	cocktail	was	added	on	day	five	of	Mo-
DC	generation	and	incubated	for	an	additional	two	days	at	37°C	with	5%	CO2.	FACS	analysis	
was	performed	to	measure	the	cells	surface	expression	of	CD14,	CD83	and	HLA-DR.	
2.2.6 Cell	line	maintenance		
Cells	 lines	were	maintained	 in	Complete	RPMI	10%	FCS	at	37°C	 in	5%	CO2.	Cell	 lines	were	
passaged	 when	 confluent	 and	 reseeded	 at	 a	 concentration	 of	 2x105/mL	 in	 a	 T25	 tissue	
culture	 flask	 (Corning;	 353108).	 Adherent	 cells	 were	 dissociated	 from	 tissue	 culture	 flask	
with	 0.25%	 v/v	 trypsin	 (Life	 Technologies;	 15090046)	 and	 collected	 with	 Complete	 RPMI	
10%	FCS	in	50mL	PP	tube.	Cells	were	washed	with	cold	sterile	PBS	and	centrifuged	at	500	x	g	
for	5	mins	in	a	refrigerated	Allegra	X-12R	centrifuge.	The	supernatant	was	removed	and	cells	
were	resuspended	in	Complete	RPMI	10%	FCS	at	2x105/mL.	
2.2.7 Cryopreservation	and	thawing	of	cells	
Cells	 for	 cryopreservation	 were	 harvested	 and	 washed	 in	 sterile	 PBS.	 Cells	 were	
resuspended	no	greater	than	1x107	cells/mL	in	cryopreservation	media.	Cell	suspension	was	
transferred	 to	 a	 cryogenic	 vial	 (Corning;	 430487),	 appropriately	 labelled	 describing	 the	
donor	and	date,	and	placed	in	Mr	Frosty	(ThermoFisher,	USA;	5100-0001)	to	slowly	freeze	
for	24hrs	in	-80°C	freezer.	After	24hrs,	cryovials	were	transferred	to	liquid	nitrogen	storage	
and	maintained	at	-180°C	vapour	phase.	
Cells	were	quickly	thawed	by	warming	cryovial	 in	a	37°C	water	bath	until	a	tiny	frozen	cell	
crystal	remained.	Cells	were	transferred	to	37°C	RPMI	10%	FCS	to	a	total	volume	of	10mLs	in	
a	14mL	PP	 tube	and	centrifuged	at	300	x	g	 for	5mins.	The	supernatant	was	 removed	and	
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cells	resuspended	in	1mL	of	media.	Cells	were	counted	and	resuspended	to	an	appropriate	
concentration	in	media	to	be	used	for	the	experiment.	
2.3 Cell	counting	
2.3.1 Counting	of	viable	cells	by	flow	cytometry	
A	50μL	aliquot	of	cells	was	resuspended	in	PBS	to	a	total	volume	of	250mL.	The	sample	was	
loaded	on	the	Accuri	C6	(BD	Biosciences)	and	set	to	acquire	50μL	of	sample	with	a	medium	
flow	rate.	Leucocytes	were	identified	by	forward	and	side	scatter	profile.	Event	counts	were	
used	to	calculate	cell	concentration	using	the	formula:		
𝑐𝑒𝑙𝑙𝑠 𝑚𝐿 = 𝑡𝑜𝑡𝑎𝑙 𝑒𝑣𝑒𝑛𝑡𝑠 × 100 (𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟) 	
2.3.2 Counting	of	viable	cells	with	haemocytometer	
Cells	were	resuspended	in	1mL	of	PBS	and	a	10μL	aliquot	of	cell	suspension	was	diluted	with	
an	equal	 volume	of	Trypan	Blue	dye	 (Life	Technologies;	15250061).	A	10μL	aliquot	of	 cell	
suspension	was	 loaded	onto	 the	haemocytometer	 (Blau	Brand,	Germany;	 717805).	Viable	
cells	 were	 counted	 under	 40X	 magnification	 on	 an	 inverted	 light	 microscope	 (Olympus,	
Australia;	CKX41)	and	the	concentration	of	cells	was	calculated	using	the	formula:	
𝑐𝑒𝑙𝑙𝑠 𝑚𝐿 = 𝑡𝑜𝑡𝑎𝑙 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 16 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 × 2 (𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟)× 10! 	
2.4 Cytocentrifugation	of	cells	
Cells	were	 resuspended	 at	 2.5-5x105	 cells/mL	 in	 PBS.	 Cells	were	 centrifuged	 onto	 a	 glass	
slide	 (Livingstone,	 Australia;	 7105-PPA)	 using	 a	 Thermo	 Shandon	 Cytospin	 3	
(ThermoScientific,	USA;	8358-30-0001)	at	18	x	g	for	4mins.	After	centrifugation,	slides	were	
air	dried	before	further	experiment.		
2.5 Confocal	staining	and	microscopy	
Cells	were	seeded	on	to	10mm	round	cover	slip	(PLP,	Australia;	CS10100)	overnight	at	37°C	
for	16hrs	in	Complete	RPMI	10%	FCS	to	allow	cells	to	adhere	to	cover	slips.	After	16hrs,	the	
media	 was	 removed	 and	 cells	 were	 washed	 in	 warm	 PBS	 before	 fixation	 with	 4%	
paraformaldehyde	 (Sigma	Aldrich;	P6148)	 for	20mins	at	 room	temperature.	After	 fixation,	
the	cells	were	washed	in	warm	PBS	and	then	permeabilised	with	10%	BSA/10%	goat	serum	
41	
	
(ThermoFischer;	 10000C)/1%	 Triton-X	 (Sigma	 Aldrich;	 T8787)	 for	 30mins	 at	 room	
temperature.	 After	 permeabilisation,	 cells	 were	 washed	 with	 PBS	 and	 incubated	 with	
primary	mAb	 for	 30mins	 at	 room	 temperature.	 After	 primary	mAb	 incubation,	 cells	were	
washed	 in	PBS	and	 incubated	with	appropriate	secondary	mAb	to	detect	primary	mAb	for	
30mins	 at	 room	 temperature	 and	 protected	 from	 light.	 After	 secondary	 incubation,	 cells	
were	 again	 washed	 with	 PBS	 and	 a	 final	 concentration	 of	 18μM	 4ʹ,6-diamidino-2-
phenylindole	 (DAPI)	 (Life	 Technologies;	 D1306)	 was	 incubated	 for	 10mins	 at	 room	
temperature	and	protected	from	light.	Cells	were	washed	in	PBS	and	mounted	onto	Poly-L-
Lysine	slides	(Starfrost,	Germany;	G312P-G)	with	Fluoro-Gel	mounting	medium	(ProSciTech,	
Australia;	IM030)	and	allowed	set	overnight	at	room	temperature	and	protected	from	light.	
Slides	were	 imaged	 by	 confocal	microscopy	 (Leica,	 Australia;	 Leica	 TCS	 SP8	 X)	within	 one	
week	of	staining.	Image	analysis	was	performed	with	ImageJ	(Schindelin	et	al.,	2012).	
2.6 Multiparameter	flow	cytometry	and	FACS		
2.6.1 mAbs	used	for	multiparameter	flow	cytometry	and	FACS	
Each	 mAb	 saturation	 concentration	 was	 determined	 by	 titration	 before	 being	 used	
experimentally.	All	mAbs	were	stored	at	4°C	and	protected	from	light.	
mAb	 Fluorochrome	 Clone	 Isotype	 Supplier	
CD1c	 PerCP	EFluor710	 L161	 IgG1	 eBioscience	
CD3	
AF700	 SP34-2	 IgG1	 BD	Biosciences	
Pacific	Blue	 HIT3a	 IgG2a	 Biolegend	
CD4	 PerCP-Cy5.5	 RPA-T4	 IgG1	 BD	Biosciences	
CD8	
AlloPC	 SK1	 IgG1	 BD	Biosciences	
BV421	 RPA-T8	 IgG1	 BD	Biosciences	
CD11c	 AF700	 B-ly6	 IgG1	 BD	Biosciences	
CD16	 V500	 3G8	 IgG1	 BD	Biosciences	
CD14	
PE	 M5E2	 IgG2a	 BD	Biosciences	
PerCP-Cy5.5	 M5E2	 IgG2a	 BD	Biosciences	
PE-Cy7	 M5E2	 IgG2a	 BD	Biosciences	
V450	 M5E2	 IgG2a	 BD	Biosciences	
CD19	 PE	 HIB19	 IgG1	 BD	Biosciences	
Table	2.3	List	of	fluorescent	and	purified	mAbs	used	to	stain	cells	
42	
	
Pacific	Blue	 HIB19	 IgG1	 Biolegend	
CD20	
PE	 2H7	 IgG2b	 BD	Biosciences	
Pacific	Blue	 2H7	 IgG2b	 Biolegend	
CD40	 PE-Cy7	 5C3	 IgG1	 BD	Biosciences	
huCD45	 AlloPC-Cy7	 2D1	 IgG1	 BD	Biosciences	
muCD45	 PerCP-Cy5.5	 30-F11	 IgG2b	 BD	Biosciences	
CD54	 PE	 HA58	 IgG1	 BD	Biosciences	
CD56	 BV421	 B159	 IgG1	 BD	Biosciences	
CD80	 PE-Cy7	 L307.4	 IgG1	 BD	Biosciences	
CD83	 FITC	 HB15a	 IgG2b	 Beckman	Coulter	
CD86	 BV650	 IT2.2	 IgG2b	 Biolegend	
CD107a	 PE-Cy7	 H4A3	 IgG1	 BD	Biosciences	
CD141	 BV711	 1A4	 IgG1	 BD	Biosciences	
CD274	
PE-CF594	 MIH1	 IgG1	 BD	Biosciences	
PE-Cy7	 MIH1	 IgG1	 BD	Biosciences	
CD279	 BV786	 EH12.1	 IgG1	 BD	Biosciences	
CD304	 AlloPC	 AD5-17F6	 IgG1	 Miltenyi	Biotec	
CCR7	 PE	 150503	 IgG2a	 R&D	Systems	
hCMRF-56	 Biotin	 CMRF-56	 IgG4	 DendroCyte	
HLA-DR	
PE-Cy7	 L243	 IgG2	 BD	Biosciences	
AlloPC-Cy7	 L242	 IgG2	 BD	Biosciences	
AlloPC-H7	 L243	 IgG2	 BD	Biosciences	
IFN	gamma	 AF488	 B27	 IgG1	 BD	Biosciences	
Influenza	M1/HLA-
A2	complex	
AF488	 405H1.01	 IgG1	 Dendritics	
FMP	dextramer	
126-134	
PE	 N.A.	 N.A.	 Immudex	
WT1	dextramer	58-
66	
PE	 N.A.	 N.A.	 Immudex	
LYVE-1	 Purified	 223322	 IgG2a	 R&D	Systems	
WT1	 Purified	 6F-H2	 IgG1	 Dako	
AF;	alexafluor,	AlloPC;	allophycocyanin,	BV;	brilliant	violet,	Cy7;	cyanine7,	FITC;	fluorescein	isothiocyanate,	PE;	
phycoerythrin,	PerCP;	peridinin	chlorophyll.	
Streptavidin	 AF647	 (Life	 Technologies,	 S21374)	 was	 used	 to	 detect	 biotinylated	 mABs	
binding	 to	human	cells.	Goat	anti-mouse	 IgG	AF488	 (ThermoFisher,	A-11017)	was	used	 to	
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detect	 binding	 of	 mouse	 anti-human	 mAbs	 to	 human	 cells.	 Goat	 anti-rat	 IgG	 Texas	 Red	
(ThermoFisher,	 T6392)	 was	 used	 to	 detect	 rat	 anti-mouse	 mAbs.	 For	 defining	 flow	
cytometry	gates	and	measuring	expression	included	the	use	of	fluorescence	minus	one	and	
isotype	controls.	Flow	cytometers	were	compensated	before	data	acquisition.	
2.6.2 Multiparameter	flow	cytometry	
2.6.2.1 Cell	surface	staining	
A	 maximum	 of	 5x106	 cells	 were	 washed	 with	 FACS	 buffer	 in	 a	 5mL	 PP	 tube	 (Corning;	
352002)	 unless	 otherwise	 stated.	 Cells	 were	 resuspended	 to	 a	 final	 volume	 of	 50μL	 per	
sample	and	incubated	with	a	50μL	mAb	staining	mixture	that	comprised	of	mAbs	from	Table	
2.3.	Each	sample	was	incubated	for	30mins	at	4°C	in	the	dark.	After	staining,	samples	were	
washed	 twice	 with	 FACS	 buffer	 by	 centrifugation	 at	 500	 x	 g	 for	 5	mins	 in	 a	 refrigerated	
Allegra-X12R	 centrifuge.	 After	 final	 wash,	 the	 cells	 were	 resuspended	 in	 200μL	 of	 FACS	
buffer	and	stored	at	4°C	 in	 the	dark	until	 ready	 for	data	acquisition.	FACS	acquisition	was	
performed	on	the	day	of	staining	using	either	BD	Influx	(BD	Biosciences),	BD	Accuri	C6	or	BD	
LSR	Fortessa-X20	(BD	Biosciences)	flow	cytometers.	
2.6.2.2 Intracellular	cytokine	staining	for	antigen	specific	T	cell	immune	responses	
Intracellular	cytokines	were	detected	by	multiparameter	flow	cytometry.	Briefly,	cells	were	
harvested	in	5mL	PP	tubes	and	washed	with	PBS	before	resuspension	in	1mL	of	X-Vivo	15.	
Influenza	Matrix	 Protein	M1	 (FMP)58-66	 (Mimotopes,	 Australia)	 or	WT1126-134	 (Mimotopes)	
peptide	 was	 incubated	 with	 cells	 for	 6hrs	 at	 37°C.	 Both	 peptides	 were	 >95%	 purity,	
reconstituted	and	 stored	 following	 the	manufacturer’s	 recommendations.	 Brefeldin	A	 (BD	
Biosciences;	555029),	Monensin	(BD	Biosciences;	554724)	and	CD107a	were	added	for	the	
final	4hrs	incubation	following	manufacturer’s	instructions.	After	complete	incubation,	cells	
were	washed	 in	PBS	and	stained	with	Zombie	Aqua	viability	dye	(Biolegend,	USA;	423102)	
following	manufacturer’s	 instructions.	After	 Zombie	Aqua	viability	dye	 staining,	 cells	were	
washed	with	FACS	buffer	by	centrifugation	at	500	x	g	 for	5	mins	 in	a	 refrigerated	Allegra-
X12R	centrifuge.	Cells	were	stained	with	appropriate	cell	surface	mAbs	for	30mins	at	4°C	in	
the	 dark.	 Following	 cell	 surface	 staining,	 cells	 were	 washed	 with	 FACS	 buffer	 by	
centrifugation	 at	 500	 x	 g	 for	 5	mins	 in	 a	 refrigerated	 Allegra-X12R	 centrifuge.	 Cells	 were	
fixed	 and	 permeabilised	 using	 FoxP3	 Staining	 Buffer	 Set	 (eBioscience,	 USA;	 00-5523-00)	
following	 manufacturer’s	 instructions.	 After	 fixation	 and	 permeabilisation,	 cells	 were	
44	
	
stained	with	mAbs	for	detection	of	intracellular	cytokines	by	incubating	for	30mins	at	4°C	in	
the	dark.	Samples	were	resuspended	in	200μL	FACS	before	data	acquisition.	Samples	were	
stored	at	4°C	 in	the	dark	until	 ready	for	data	acquisition	using	compensated	BD	Influx,	BD	
Accuri	C6	or	BD	LSR	Fortessa-X20	flow	cytometers.	
2.6.2.3 Exclusion	of	dead	cells		
Viability	dyes	were	used	to	detect	live	cells	for	multiparameter	flow	cytometry	experiments.	
Loss	of	membrane	structure	is	an	indicator	of	cell	death.	Therefore	exclusion	of	dead	cells	
was	observed	by	the	inclusion	of	viability	dye	into	the	cell	cytoplasm.	Cells	were	incubated	
with	either	3μM	DAPI,	1.5μM	7-aminoactinomycin	D	(7AAD)	(Life	Technologies;	00-6993-50)	
or	1.5μM	propidium	iodide	(PI)	(Sigma	Aldrich;	P4170)	10mins	before	data	acquisition	for	all	
multiparameter	flow	cytometry	experiments	performed	on	unfixed	samples.		
2.6.3 Carboxyfluorescein	succinimidyl	ester	labelling	of	cells	
Cells	 were	 harvested	 and	 washed	 with	 sterile	 PBS.	 Following	 washing,	 cells	 were	
resuspended	to	1x107/mL	in	37°C	1%	FCS.	Carboxyfluorescein	succinimidyl	ester	(CFSE)	was	
added	to	a	final	concentration	of	1μM	and	incubated	for	7mins	at	37°C	protected	from	light.	
After	 incubation	 with	 CFSE,	 cells	 were	 washed	 three	 times	 with	 ice	 cold	 10%	 FCS	 and	
resuspended	to	an	appropriate	concentration.	
2.6.4 CellTrace	Violet	staining	
Cells	 were	 harvested	 and	 washed	 with	 sterile	 PBS.	 Following	 washing,	 cells	 were	
resuspended	at	 1x106/mL	 in	 37°C	1%FCS	 and	CellTrace	Violet	 (Life	 Technologies;	 C34571)	
was	added	to	a	 final	concentration	of	0.5μM	and	 incubated	 for	20mins	at	37°C	protected	
from	light.	After	incubation	with	CellTrace	Violet,	cells	were	washed	twice	with	ice	cold	10%	
FCS	and	resuspended	at	1x107/mL	in	RPMI	10%FCS.	
2.6.5 Fluorescent	activated	cell	sorting	
Following	 depletion	 of	 lineage+	 cells	 described	 in	 2.2.4,	 lineage-	 cells	 were	 stained	 with	
CD1c,	 CD3,	 CD14,	 CD16,	 CD19,	 CD20,	 CD56,	 CD304	 and	 HLA-DR	 fluorescently	 conjugated	
mAbs	 to	 identify	 CM,	 NCM,	 CD1c+	 and	 CD16+	 BDC	 populations	 by	 FACS.	 Cells	 were	
resuspended	to	1x107/mL	in	MACS	buffer	on	ice	prior	to	cell	sorting.	Cells	were	sorted	using	
a	BD	Influx	with	a	100μm	nozzle,	24psi	and	collected	in	to	1.5mL	eppendorf	tubes	containing	
MACS	buffer.	 Sorted	 cells	were	 greater	 than	95%	pure	 for	 all	 experiments	 and	 rested	 for	
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2hrs	on	ice	for	post	FACS	recovery	before	being	used	for	further	experiments.	
2.6.6 Flow	cytometry	data	analysis	
FCS	 version	 3.0	 files	were	 exported	 for	 data	 analysis	 performed	by	 FlowJo	 version	 10.0.6	
(FlowJo,	USA).	Flow	cytometry	data	was	compensated	before	FlowJo	analysis.	Spanning	tree	
progression	analysis	of	density-normalized	events	 (SPADE)	was	performed	using	Cytobank	
and	pre-processed	FCS	files	that	removed	cell	aggregates,	dead	cells	and	CD3-	CD19-	CD20-	
CD56-	HLA-DR+	cells	selection	 (Cytobank,	USA)	 (Kotecha	et	al.,	2010).	Results	were	 further	
processed	and	visualised	in	two-dimensional	space	by	viSNE	analysis	(Amir	el	et	al.,	2013).	
Hierarchical	 clustering	 was	 performed	 viSNE	 algorithm	 using	 R	 version	 3.31	 as	 described	
(Diggins	et	al.,	2015).	
2.7 IVT	mRNA	generation	and	RNA	isolation	
2.7.1 Transformed	bacterial	broth	cultures	
Transformed	DH5α	competent	cells	 (Life	Technologies;	18265017)	were	grown	in	LB	broth	
in	the	presence	of	100μg/mL	ampicillin	(Sigma	Aldrich;	A0166)	until	 log	phase	for	up	to	16	
hrs	in	a	37°C	shaking	incubator	at	180	revolutions	per	minute.	
2.7.2 Plasmid	isolation	from	transformed	bacteria	
Transformed	 DH5α	 competent	 cells	 were	 centrifuged	 to	 a	 cell	 pellet	 using	 a	 micro-
centrifuge	 (Hettich	 Lab	Technology,	Germany;	 521-0910)	 and	plasmid	was	extracted	 from	
transformed	 DH5α	 competent	 cells	 using	 Purelink	 Quick	 Plasmid	 MiniPrep	 Kit	 (Life	
Technologies;	 K210011)	 following	manufacturer’s	 instructions.	 The	 plasmid	was	 eluted	 in	
UltraPure	distilled	water	(Life	Technologies;	10977015)	and	stored	at	-20°C	until	ready	to	be	
used.	Purity	of	 the	plasmid	was	 routinely	assessed	by	measuring	 the	260:280nm	value	by	
spectrophotometry	(Beckman	Coulter;	A49421).	A	value	of	1.8	was	considered	pure.	
2.7.3 In	vitro	transcription	of	mRNA	
Separate	 FMP	 and	 Green	 Fluorescent	 Protein	 (GFP)	 full	 length	 coding	 sequences	 were	
cloned	into	pGEM4ZA64	and	provided	by	Professor	Eli	Gilboa	(Boczkowski	et	al.,	2000).	WT1	
full	 length	 coding	 sequence	 was	 cloned	 into	 pGEM4ZA64	 and	 provided	 by	 Professor	 Zwi	
Berneman	(Van	Driessche	et	al.,	2009).	Features	of	pGEM4ZA64	include:	a	T7	promoter	site	
for	 T7	 polymerase	 binding,	 a	 polyA	 tail	 for	 termination	 of	 in	 vivo	 transcription	 and	
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protection	 from	 enzymatic	 degradation,	 a	 single	 SpeI	 restriction	 site	 positioned	 after	 the	
polyA	 tail	 and	 ampicillin	 resistance	 gene.	 pGEM4ZA64	 containing	 the	 full	 length	 coding	
sequence	was	digested	with	SpeI	restriction	enzyme	(New	England	Biolabs,	USA;	R0133S)	in	
a	total	volume	of	200µL	for	16hrs	at	37°C		following	manufacturer’s	instructions.	Digestion	
was	 terminated	 following	 manufactuer’s	 instructions	 and	 linearisation	 was	 confirmed	 by	
1%w/v	agarose	(Invitrogen;	16500500)	gel	electrophoresis	set	to	80	volts	for	1hr.	DNA	was	
visualised	using	BIO-RAD	ChemiDoc	XRS+	Imaging	System	with	Image	Lab	Software	(Bio-Rad	
Laboratories,	USA;	1708265).	Plasmid	purity	was	assessed	by	260:280	nm	value	measured	
by	spectrophotometry.	A	value	of	1.8	was	considered	pure.		
A	 total	of	1µg	of	 linearised	pGEM4ZA64	containing	 full	 length	coding	protein	was	used	 to	
produce	IVT	mRNA	using	the	mMessage	mMachine	T7	Ultra	Kit	(Life	Technologies;	AM1345)	
following	 the	 manufacturer’s	 instructions.	 Briefly,	 linearised	 pGEM4ZA64	 containing	 full	
length	coding	sequence	was	incubated	for	3hrs	at	37°C	with	T7	polymerase	and	nucleotide	
triphosphates	 in	 the	 reaction	 buffer,	 with	 all	 reagents	 provided	 by	 the	 manufacturer.	
Following	IVT	mRNA	polymerization,	the	sample	was	incubated	with	DNase	provided	by	the	
manufacturer	 for	 30mins	 at	 37°C.	 IVT	mRNA	was	 precipitated	 by	 the	 addition	 of	 lithium	
chloride	 followed	 by	 two	 washes	 with	 100%	 molecular	 grade	 ethanol	 (Sigma	 Aldrich;	
E7023).	 IVT	mRNA	was	resuspended	in	UltraPure	distilled	water.	 IVT	mRNA	was	quantified	
by	spectrophotometer	from	measuring	the	optical	density	at	260nm.	IVT	mRNA	quality	was	
measured	with	260:280	ratio.	A	value	of	2.0	was	considered	pure.	Bioanalyzer	2000	(Agilent,	
USA;	5067-1511)	was	also	used	to	analyse	the	quality	of	IVT	mRNA.	After	production	of	IVT	
mRNA,	10μg	aliquots	of	GFP,	FMP	or	WT1	IVT	mRNA	were	stored	at	-20°C	for	a	maximum	of	
six	months	to	ensure	maximum	quality	of	IVT	mRNA.	
2.8 IVT	mRNA	transfection	of	primary	cells	
2.8.1 IVT	mRNA	transfection	of	hCMRF-56+	cells	
hCMRF-56+	immune	selected	cells	were	transfected	with	IVT	mRNA	as	previously	described	
(Fromm	 et	 al.,	 2016).	 Briefly,	 approximately	 1-2x106	 hCMRF-56+	 immune	 selected	 cells	
described	 in	 2.2.3	 were	 resuspended	 in	 100μL	 of	 room	 temperature	 P3	 nucleofection	
solution	with	 supplement	 1	 provided	 by	 the	manufacturer	 (Lonza;	 V4XP-3024).	A	 total	 of	
10μg	 of	 IVT	 mRNA	 was	 added	 to	 the	 cell	 suspension	 and	 transferred	 to	 Lonza	 4D	
nucleofection	cuvette	 (Lonza;	V4XP-3024).	For	mock	controls,	no	 IVT	mRNA	was	added	 to	
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the	 cell	 suspension	 before	 transfer	 to	 the	 nucleofection	 cuvette.	 Cells	 were	 transfected	
using	 the	optimally	determined	CU110	program.	 Immediately	 after	 transfection,	 400μL	of	
37°C	X-Vivo	15	was	added	to	the	cells	and	allowed	to	rest	at	37°C	5%	CO2	for	15-30	mins.	
After	resting,	the	cells	were	transferred	to	500μL	of	37°C	X-Vivo	15	for	further	downstream	
application.	
2.8.2 IVT	mRNA	transfection	of	monocyte-derived	dendritic	cells	
Mo-DC	were	transfected	with	IVT	mRNA	as	previously	described	(Fromm	et	al.,	2016).	After	
generation	of	Mo-DC	as	described	in	2.2.5,	approximately	1-2x106	cells	were	resuspended	in	
100μL	of	room	temperature	P3	nucleofection	solution	with	supplement	1	provided	by	the	
manufacturer.	 A	 total	 of	 10μg	 of	 IVT	 mRNA	 was	 added	 to	 the	 cell	 suspension	 and	
transferred	to	4D	nucleofection	cuvette.	For	mock	controls,	no	IVT	mRNA	was	added	to	the	
cell	 suspension	before	 transfer	 to	 the	nucleofection	 cuvette.	 Cells	were	 transfected	using	
the	optimally	determined	EH101	program.	 Immediately	after	nucleofection,	400μL	of	37°C	
X-Vivo	15	was	added	to	the	cuvette	and	the	cells	were	allowed	to	rest	at	37°C	5%	CO2	for	
15-30	 mins.	 After	 resting	 the	 cells	 were	 transferred	 to	 500μL	 of	 37°C	 X-Vivo	 15	 for	
downstream	application.	
2.9 Stimulation	of	hCMRF-56+	cells	
A	 total	 of	 1x106	 hCMRF-56+	 immune	 selected	 cells	were	 stimulated	with	 functional	 grade	
reagents	described	in	Table	2.4	for	2hrs	at	37°C	5%	CO2	in	X-Vivo	15.	Final	concentration	of	
reagents	used	for	hCMRF-56+	 immune	selected	cells	were	either	previously	established	by	
the	research	lab,	or	as	recommended	by	the	manufacturer.	After	2hrs	incubation,	cells	were	
washed	to	remove	excess	reagent	and	ready	for	downstream	application.	
Reagent	 Final	concentration	 Supplier	 Country	 Catalogue	number	
GM-CSF	 1000IU/mL	 Miltenyi	Biotec	 	 130-095-372	
PGE2	 100ng/mL	 Sigma	Aldrich	 	 P0409	
FLT3L	 10ng/mL	 Kindly	provided	by	Ken	Shortman	from	WEHI,	Australia	
IL-1β	 1.4x104IU/mL	 R&D	Systems	 	 201-LB-005	
IL-6	 5.5x103IU/mL	 R&D	Systems	 	 206-IL-010	
TNFα	 7.6x103/mL	 R&D	Systems	 	 210-TA-010	
anti-CD40	 1μg/mL	 Biolegend	 	 	
Table	2.4	Stimulation	conditions	for	hCMRF-56+	cells	
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Pam3CSK4	 300ng/mL	 Invivogen	 USA	 TLRL-PMS	
Resiquimod	 10μg/mL	 Invivogen	 	 TLRL-R848	
ATP	 0.5nM	 Invivogen	 	 TLRL-ATP	
Uric	acid	 200μg/mL	 Invivogen	 	 TLRL-MSU	
Poly(I:C)	 50μg/mL	 Sigma-Aldrich	 	 P1530	
LPS-EK	 50μg/mL	 Invivogen	 	 TLRL-EKLPS	
2.10 Generation	of	antigen	specific	T	cells	
GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	were	transfected	with	or	without	IVT	
mRNA	as	previously	described	in	2.8.1.	10	hCMRF-56-	immune	selected	cells	were	cultured	
with	1	autologous	HLA-A*0201+	hCMRF-56+	immune	selected	BDC	at	37°C	5%	CO2	in	X-Vivo	
15.	On	day	3,	cell	media	was	changed	to	Complete	RPMI	10%	AB	and	supplemented	with	
25IU/mL	 IL-2	 (Miltenyi	Biotec;	130-097-742),	400IU/mL	 IL-7	 (Miltenyi	Biotec;	130-093-937)	
and	80IU/mL	IL-15	(Miltenyi	Biotec;	130-093-955).	Media	was	replaced	with	Complete	RPMI	
10%	AB	supplemented	with	25IU/mL	IL-2	every	subsequent	2-3	days.	Cells	were	not	fed	IL-2	
up	to	48hrs	until	used	experimentally.		
For	 generation	 of	 antigen	 specific	 T	 cells	 used	 in	 antigen	 specific	 cytotoxicity	 assays,	 a	
method	 was	 adapted	 from	 Freeman	 et	 al.	 (2007)	 where	 lymphocytes	 underwent	 two	
additional	restimulations	with	autologous	PBMC.	On	day	7,	autologous	cryopreserved	PBMC	
were	 thawed	 in	RPMI	and	 treated	with	10μg/mL	Mitomycin	C	 (Sigma	Aldrich;	M4287)	 for	
1hr	at	37°C	5%	CO2.	After	 incubation	with	Mitomycin	C,	PBMC	were	washed	four	times	 in	
37°C	Complete	RPMI	10%FCS	followed	by	peptide	loading.	Mitomycin	C	treated	PBMC	were	
resuspended	 to	 1x106cells/mL	 in	 X-Vivo	 15	 with	 10μg/mL	MHC	 class	 I	 restricted	 peptide	
(FMP58-66,	WT1126-134	or	KLK411-19	(Mimotopes))	in	X-Vivo	15	for	1hr	at	room	temperature	in	
the	 dark.	 After	 peptide	 loading,	 Mitomycin	 C	 peptide	 loaded	 PBMC	 were	 washed	 with	
sterile	 PBS	 and	 10	 hCMRF-56-	 cells	 were	 co-cultured	with	 1	Mitomycin	 C	 peptide	 loaded	
PBMC	and	 incubated	at	37°C	5%	CO2	 in	Complete	RPMI	10%	AB.	Media	was	changed	and	
supplemented	with	 IL-2	 every	2-3	days.	 Cells	were	not	 fed	 IL-2	48	hrs	until	 usage	 in	 final	
experiment.	
2.11 Cell	migration	
2.11.1 In	vitro	chemotaxis	to	CCL21	
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hCMRF-56+	 immune	 selected	 cells	 were	 slowly	 loaded	 onto	 a	 5μm	 pore	 size	 and	 6.5mm	
diameter	transwell	insert	(Corning;	3421)	that	was	placed	onto	wells	containing	37°C	X-Vivo	
15	media	 in	 the	 presence	 or	 absence	 of	 100ng/mL	CCL21	 (Miltenyi	 Biotec;	 130-094-618).	
Wells	 containing	CCL21	measured	CCL21	active	 chemotaxis,	whereas	wells	without	CCL21	
measured	spontaneous	migration.	A	sample	of	cells	was	also	placed	in	to	a	5mL	PP	sterile	
tube	that	was	used	a	cell	count	control.	All	samples	were	incubated	for	4hrs	at	37°C	5%	CO2.	
Following	incubation,	transwell	inserts	were	carefully	removed	and	the	plate	was	placed	on	
ice	 for	 20mins	 before	 the	wells	were	washed	with	 cold	 FACS	 buffer	 to	 collect	 cells.	 Cells	
were	stained	with	CD14,	CD19,	CD20	and	hCMRF-56	from	Table	2.3	to	identify	hCMRF-56+	
cell	subsets.	CountBright	Absolute	Counting	Beads		(Life	Technologies;	C36950)	were	added	
immediately	 before	 multiparameter	 flow	 cytometry	 data	 acquisition	 to	 calculate	 the	
number	of	migrated	cells	using	the	formula:	
𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑣𝑒𝑛𝑡𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 × 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑏𝑒𝑎𝑑𝑠 𝑎𝑑𝑑𝑒𝑑	
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 =  (𝐴𝑐𝑡𝑖𝑣𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠)𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙  × 100	
2.11.2 In	vivo	migration	of	hCMRF-56+	BDC	or	Mo-DC	in	SCID	mice		
Five	 to	 seven	 week	 old	 SCID	 (Severe	 combined	 immunodeficient;	 C.B-17-Igh-1b-Prkdcscid)	
mice	 (Animal	 Resource	 Centre,	 Perth)	 were	 used	 for	 in	 vivo	 experiments	 (Fromm	 et	 al.,	
2016).	 Mice	 were	 acclimatised	 for	 seven	 days	 following	 receipt	 of	 delivery	 prior	 to	
experiments.	 SCID	mice	 were	 depleted	 of	 NK	 cells	 by	 intra-peritoneal	 injection	 of	 200μg	
anti-Asialo	GM-1	(Wako	Chemicals,	USA;	986-10001)	24hrs	prior	to	adoptive	cell	transfer	of	
hCMRF-56+	immune	selected	cells	or	Mo-DC.	SCID	mice	were	intra-dermally	injected	at	the	
tail	 base	 with	 either	 GM-CSF	 stimulated	 hCMRF-56+	 cells	 or	 cytokine	 matured	 Mo-DC.	
Inguinal	lymph	nodes	(LN)	were	collected	6hrs	after	adoptive	cell	transfer.	LN	were	treated	
with	Type	III	Collagenase	(Worthington	Biochemical	Corporation,	USA;	LS004180)	(Vremec,	
2010).	BDC	and	Mo-DC	were	 identified	by	multiparameter	flow	cytometry	as	murineCD45-	
CD45+	CD14-	CD19-	CD20-	hCMRF-56+.	CountBright	Absolute	Counting	Beads	were	used	 to	
calculate	BDC	or	Mo-DC	migration	using	the	previously	described	formula	in	section	2.11.1.	
The	recovery	of	migrated	cells	to	LN	was	calculated	using	the	formula:	
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𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =  (𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐵𝐷𝐶 𝑜𝑟 𝑀𝑜 − 𝐷𝐶 𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛)(𝑝𝑢𝑟𝑖𝑡𝑦 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 × 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠)	
2.11.3 Visualisation	of	hCMRF-56+	 immune	selected	cells	 chemotaxis	 in	explanted	
mouse	ear	lymphatics	
Chemotaxis	 of	 hCMRF-56+	 immune	 selected	 cells	 was	 visualised	 in	 SCID	 mouse	 ear	
lymphatics	 as	 previously	 described	 (Weber	 and	 Sixt,	 2013).	 Briefly,	 SCID	 mice	 ears	 were	
placed	 ventral	 side	 up	 with	 dorsal	 and	 ventral	 halves	 were	 pulled	 apart	 by	 carefully	
removing	outer	dermis	layer.	The	cartilage	free	ventral	ear	half	was	transferred	to	a	24	well	
plate	 (Falcon;	353047)	and	submerged	dermis	side	down	 in	Complete	RPMI	10%	FCS.	The	
ear	half	was	stained	with	rat	anti-mouse	LYVE-1	mAb	for	45mins	at	room	temperature.	After	
incubation,	the	supernatant	was	removed	from	ear	halves	and	were	carefully	washed	three	
times	with	PBS.	The	ear	halves	were	subsequently	submerged	in	Complete	RPMI	10%	FCS.	
Ear	halves	were	stained	with	goat	anti-rat	Texas	Red	(Assay	Matrix,	Australia;	3050-07)	for	
45mins	at	 room	temperature	and	protected	 from	 light.	After	 incubation,	 supernatant	was	
removed	 from	 ear	 halves	 and	 carefully	 washed	 three	 times	 with	 PBS.	 Ear	 halves	 were	
submerged	dermis	 side	down	 in	Complete	RPMI	10%	FCS.	GM-CSF	 stimulated	hCMRF-56+	
immune	 selected	 cells	 were	 labelled	with	 CFSE	 as	 described	 in	 2.6.3.	 GM-CSF	 stimulated	
hCMRF-56+	immune	selected	cells	were	loaded	onto	the	ear	half	and	incubated	for	4hrs	at	
37°C	 5%	 CO2.	 After	 migration	 of	 cells,	 ear	 halves	 were	 fixed	 with	 4%	 paraformaldehyde	
(Sigma	Aldrich;	P6148)	 for	4hrs	at	 room	temperature	and	protected	 from	 light.	Ears	were	
mounted	 onto	 Poly-L-Lysine	 slides	 with	 Fluoro-Gel	 mounting	 medium	 and	 imaged	 by	
confocal	microscopy	(Zeiss,	Germany;	ZEISS	LSM	510	META).	Image	analysis	was	performed	
with	ImageJ	(Schindelin	et	al.,	2012).	
2.12 Mixed	leucocyte	reaction	
One	way	mixed	leucocyte	reaction	(MLR)	was	prepared	by	co-cultured	irradiated	stimulating	
cells	 from	 three	 donors	 with	 responding	 cells	 stained	 with	 cell	 trace	 violet	 to	 measure	
proliferation.	 Stimulating	 cells	 were	 prepared	 from	 three	 pooled	 cryopreserved	 HLA-A2+	
healthy	 PBMC	 donors.	 Cryopreserved	 cells	 were	 thawed	 in	 Complete	 RPMI	 10%	 FCS	 and	
resuspended	 to	 5x106/mL	 in	 Complete	 RPMI	 10%	 FCS.	 Equal	 numbers	 of	 PBMC	 used	 as	
stimulators	were	transferred	to	a	14mL	tube	with	Complete	RPMI	10%FCS	added	to	10mLs.	
Cells	were	 irradiated	with	 25Gy	 (Precision	X-Ray,	USA;	 X-RAD	320).	After	 irradiation,	 cells	
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were	resuspended	to	4x106/mLs	in	Complete	RPMI	10%FCS.	Responding	cells	were	prepared	
from	PBMC	stained	with	CellTrace	Violet	as	previously	described	 in	2.6.4.	 Stimulating	and	
responding	 cells	were	 incubated	 for	5	days	at	37°C	5%	CO2	at	1	 stimulator:2.5	 responder	
cells.	Proliferation	was	measured	by	dilution	of	CellTrace	Violet	from	responding	CD4+	and	
CD8+	T	cell	subsets.	
2.13 Antigen	presentation	studies	
2.13.1 FMP58-66	HLA-A*0201	complex	presentation	
HLA-A*0201+	 hCMRF-56+	 immune	 selected	 cells	 or	Mo-DC	were	 transfected	with	 FMP	 or	
WT1	IVT	mRNA,	or	not	transfected.	After	transfection,	cells	were	incubated	for	either	2	or	
24hrs	 in	 X-Vivo	 15	media	 at	 37°C	 5%	 CO2.	 Expression	 of	 HLA-A*0201	 FMP58-66	 complexes	
were	 measured	 for	 both	 FMP	 and	WT1	 IVT	 mRNA	 transfected	 samples	 by	 staining	 with	
CD14,	CD19,	CD20,	hCMRF-56	and	 Influenza	M1/HLA-A2	complex	 for	30mins	at	4°C.	After	
staining,	cells	were	washed	with	FACS	buffer	and	7AAD	was	added	to	samples	before	data	
acquisition	on	BD	Accuri	C6.	Specific	FMP58-66	expression	at	2	and	24hrs	incubation	for	each	
cell	population	was	calculated	by:	
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐹𝑀𝑃!"!!! 𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑎𝑡𝑖𝑜𝑛=  𝐹𝑀𝑃 𝑠𝑎𝑚𝑝𝑙𝑒 𝐹𝑀𝑃!"!!! 𝑀𝐹𝐼 – 𝑊𝑇1 𝑠𝑎𝑚𝑝𝑙𝑒 𝐹𝑀𝑃!"!!! 𝑀𝐹𝐼 	
Relative	expression	at	24hrs	compared	to	2hrs	was	calculated	by:	
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 24ℎ𝑟/2ℎ𝑟 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 =  24 ℎ𝑟 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐹𝑀𝑃!"!!! 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛2 ℎ𝑟 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐹𝑀𝑃!"!!! 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛   × 100	
2.14 Calcein	cytotoxicity	
Specific	 cytotoxicity	was	measured	 using	 free	 calcein	 in	 culture	 supernatant	 from	 calcein	
labelled	 targets	 and	 antigen	 specific	 effector	 cells	 as	 previously	 described	 (Chung	 et	 al.,	
2014,	 Fromm	et	al.,	 2016,	 Lichtenfels	et	al.,	 1994).	Briefly,	 T2	 cells	 (American	Type	Tissue	
Culture,	USA:	CRL-1992)	used	as	target	cells	were	maintained	in	Complete	RPMI	10%	FCS	at	
37°C	 5%	 CO2	 and	 passaged	 the	 day	 before	 scheduled	 cytotoxicity	 assay.	 T2	 cells	 were	
harvested	and	loaded	either	with	10μg/mL	FMP58-66	peptide,	WT1126-134	peptide	or	10μg/mL	
KLK411-19	used	as	relevant	and	irrelevant	peptide	in	X-Vivo	15	for	1hr	at	room	temperature.	
After	peptide	loading,	T2	cells	were	washed	twice	in	RPMI	1%	FCS	and	labelled	with	25μM	
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Calcein-AM	 (Life	 Technologies;	 C1430)	 for	 30mins	 at	 37°C	 protected	 from	 the	 light.	 After	
Calcein-AM	labelling,	T2	cells	were	washed	twice	in	37°C	RPMI	1%	FCS	before	transferring	to	
96	well	U	bottom	plate.	Target	cells	were	combined	with	generated	antigen	specific	T	cells	
as	described	in	2.10	and	centrifuged	at	300	x	g	for	5mins	before	incubation	for	3hrs	at	37°C.	
In	addition,	separate	Calcein-AM	labelled	T2	cells	loaded	with	peptide	were	lysed	using	1%	
Triton-X	 to	obtain	maximum	 lysis	value.	After	 incubation,	 the	96	well	U	bottom	plate	was	
centrifuged	 at	 300	 x	 g	 for	 5mins	 and	 care	was	 taken	 to	 remove	 100μL	 of	 combined	 cell	
supernatant	 and	was	 transferred	 to	 a	 96	well	 clear	 bottom	 black	 plate	 (VWR,	 USA;	 734-
1612).	 Fluorescence	 emission	 was	measured	 from	 the	 harvested	 supernatant	 on	 EnSpire	
Multimode	 Plate	 Reader	 (Perkin	 Elmer,	 USA;	 2300-0000)	 at	 532nm.	 Antigen	 specific	 %	
cytotoxicity	was	calculated	using	the	formula:	
% 𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 = 𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 × 100	
2.15 Measurement	of	cytokine	production	
2.15.1 Cytometric	bead	array	
Cytokines	were	detected	in	supernatants	of	cultured	cells	either	by	Cytometric	Bead	Array	
flex	set	comprising	of	IL-6	(BD	Bioscience;	558276),	 IL-12p70	(BD	Biosciences;	558283)	and	
TNF	 (BD	Biosciences;	 560112).	 Alternatively,	 the	 13	plex	 LEGENDplex	 (Biolegend;	 740118)	
was	used.	Samples	that	used	the	Cytometric	Bead	Array	flex	set	were	performed	following	
the	 manufacturer’s	 instructions,	 whereas	 samples	 that	 used	 the	 LEGENDplex	 assay	 was	
performed	by	pre-diluting	the	supernatant	1:2,	then	following	manufacturer’s	instructions.	
After	 sample	 preparation,	 Cytometric	 Bead	 Array	 or	 LEGENDplex	 cytokine	 capture	 beads	
and	corresponding	detection	mAb	were	added	to	each	sample.	Samples	were	incubated	in	
the	dark	for	2hrs	at	room	temperature.	Following	the	incubation,	PE	detection	reagent	was	
added	 to	 each	 sample	 and	 incubated	 in	 the	 dark	 at	 room	 temperature	 for	 an	 additional	
30mins	 at	 room	 temperature.	 At	 the	 end	 of	 the	 incubation,	 each	 sample	was	washed	 in	
wash	buffer	and	supernatants	removed.	Additional	assay	buffer	was	added	to	before	data	
acquisition	 using	 a	 BD	Accuri	 C6	 or	 BD	 LSR	 Fortessa-X20.	 Cytometric	 Bead	 Array	 samples	
were	analysed	by	FCAP	Array	Software	version	1.0.1	(BD	Biosciences).	LEGENDplex	samples	
were	analysed	using	LEGENDplex	software	version	7.0	(Biolegend).	
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2.15.2 IFNγ	ELISA	
IFNγ	 was	 detected	 in	 cultured	 cells	 supernatants	 using	 a	 specific	 sandwich	 ELISA	 kit	
(Peprotech,	Germany;	900-K27)	following	manufacturer’s	instructions.	Briefly,	a	96	well	flat	
bottom	plate	(Sigma	Aldrich;	M9410)	was	coated	overnight	at	room	temperature	with	anti-
IFNγ	capture	antibody	provided	by	the	ELISA	kit.	Wells	were	washed	four	times	with	0.05%	
TWEEN	20	(Sigma	Aldrich;	P1379)	and	incubated	with	1%	BSA	for	1hr	at	room	temperature.	
After	1hr,	the	supernatant	was	removed	and	wells	were	washed	four	times.	Samples	were	
added	 to	 the	 wells	 and	 incubated	 for	 2hrs	 at	 room	 temperature.	 Following	 sample	
incubation,	 the	wells	were	washed	 four	 times	and	 the	detection	mAb	was	added	 to	each	
well	 for	 2hrs	 at	 room	 temperature.	 After	 incubation	with	 detection	mAb,	 the	wells	were	
washed	 four	 times	 and	 avidin-HRP	 conjugate	 was	 added	 to	 each	 well	 and	 incubated	 for	
30mins	 at	 room	 temperature.	 During	 this	 incubation,	 one	 tablet	 of	 o-Phenylenediamine	
(OPD)	(Sigma	Aldrich;	P9187)	was	prepared	following	the	manufacturer’s	instructions.	After	
incubation	with	avidin-HRP,	the	wells	was	washed	four	times	and	prepared	OPD	was	added	
to	 each	 well	 and	 incubated	 for	 30mins	 at	 room	 temperature	 in	 the	 dark	 following	 the	
manufacturer’s	 instructions.	 Colour	 change	 in	 each	 well	 was	 determined	 by	 reading	
absorbance	at	492nm	on	EnSpire	Multimode	Plate	Reader.	Unknown	concentrations	of	IFNγ	
were	interpolated	using	a	standard	curve	generated	from	known	concentrations.	
2.16 Statistical	analysis	
Statistical	 analysis	 was	 performed	 using	 Prism	 version	 7.0b	 (GraphPad,	 USA).	 Standard	
deviation	is	shown	unless	otherwise	stated.	Experiments	were	repeated	were	possible.	A	p	
value	<	0.05	was	considered	statistically	significant.	Only	statistically	significant	results	were	
displayed	 and	 indicated	 using	 symbols	 described	 in	 the	 relevant	 figure	 legend	 with	 the	
statistical	test	also	described	in	the	figure	legend.	Normality	was	assumed	due	to	the	use	of	
healthy	donor	blood	samples.	
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3 CHARACTERISATION	OF	hCMRF-56	
3.1 Introduction	
Cancer	 specific	 T	 cell	 and	 humoral	 immune	 responses	 have	 been	 generated	 from	Mo-DC	
using	different	antigen	loading	strategies	(De	Vries	et	al.,	2003,	Rosenblatt	et	al.,	2011,	Van	
Tendeloo	et	al.,	2010).	However,	 functional	differences	between	Mo-DC	and	BDC	are	now	
coming	 to	 light	 and	 the	use	of	Mo-DC	 and	BDC	 in	 clinical	 trials	was	 discussed	 in	 1.3.	 (De	
Vries	et	al.,	2003,	Dhodapkar	et	al.,	2001,	Fromm	et	al.,	2016).	The	paradigm	of	using	in	vitro	
manufactured	 Mo-DC	 is	 now	 shifting	 towards	 natural	 circulating	 BDC	 (Wimmers	 et	 al.,	
2014).	 The	 interest	 in	 the	use	of	BDC	has	prompted	a	number	of	different	approaches	 to	
harness	 their	 functions	 including	 Sipuleucel-T,	 pDc	 and	 CD1c+	 mDC	 immune	 selection	 to	
treat	 melanoma	 and	 prostate	 cancer	 (Kantoff	 et	 al.,	 2010,	 Prue	 et	 al.,	 2015,	 Tel	 et	 al.,	
2013a).		
BDC	 lack	 lineage	 cell	 surface	 makers	 and	 express	 HLA-DR	 (Dzionek	 et	 al.,	 2000).	 Studies	
detecting	 novel	 BDC	 surface	 molecules	 have	 identified	 CMRF-44	 and	 CMRF-56	 for	 the	
identification	 of	 APC,	 including	 BDC	 (Hock	 et	 al.,	 1999,	 Hock	 et	 al.,	 1994).	 The	 antigen	
detected	by	CMRF-56	is	95kDa	and	is	expressed	by	early	activated	APC,	including	CD1c+	BDC	
(Hock	 et	 al.,	 1999).	 CMRF-56	 expression	 is	 restricted	 to	 APC	 and	 provides	 a	 method	 to	
isolate	 a	 heterogeneous	 APC	 population	 without	 the	 need	 of	 culturing	 monocytes	 with	
cytokines	 (Ho	et	al.,	2002).	CMRF-56+	cells	 isolated	from	PBMC	are	more	stimulatory	than	
whole	 PBMC	 due	 to	 the	 enriched	 population	 of	 APC.	 This	 demonstrates	 the	 antigen	
presentation	 capability	 of	 this	 heterogeneous	 APC	 population	 compared	 to	 whole	 PBMC	
(Hock	et	al.,	1999).	This	chapter	examines	the	use	of	the	newly	engineered	hCMRF-56	as	a	
tool	 for	 BDC	 immune	 selection	while	 drawing	 comparisons	 to	 the	 previously	 used	mouse	
anti-human	CMRF-56.	The	cellular	constituents	of	hCMRF-56+	immune	selected	cells	will	be	
addressed	 in	 addition	 to	 the	 expression	 of	 activation	 and	 co-stimulatory	 molecules	 on	
hCMRF-56+	BDC.		
3.2 Results	
3.2.1 Generation	and	titration	of	biotinylated	hCMRF-56	
Moving	 forward	 in	 preparation	 for	 CMRF-56	 to	 be	 used	 in	 the	 clinic	 for	 BDC	 immune	
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therapy,	changes	were	previously	made	to	mouse	anti-human	CMRF-56	for	the	purpose	this	
research.	The	isotype	of	mouse	anti-human	CMRF-56	was	switched	from	IgG1	to	IgG4.	This	
was	done	by	splice	overlap	extension	PCR	(Fromm	et	al.,	2016).	Briefly,	human	B	cells	were	
incubated	in	the	presence	of	IL-4	and	CD40L	for	seven	days	before	PCR	amplification	of	IgG4	
VH	and	VL	constant	chains.	VH	and	VL	constant	chains	were	separately	cloned	 into	pCR2.1.	
Splice	 overlap	 extension	 PCR	with	 pCR2.1IgG4	 and	 pCR_CMRF56,	 containing	 the	 VH	 or	 VL	
constant	chains	of	mouse	anti-human	IgG1	CMRF-56	was	performed.	CMRF-56	IgG4	VH	was	
excised	and	 cloned	 into	dicistronic	pBudCE4.1	multiple	 cloning	 site	under	 EF1a	promoter.	
CMRF-56	IgG4	VL	was	excised	and	cloned	into	same	pBudCE4.1	under	CMV	multiple	cloning	
site.	 The	 final	 pBud	 containing	 chimeric	 CMRF-56	 IgG4	 VH	 and	 VL	 fragments	 was	 stably	
transfected	 into	 CHO	 cells	 where	 five	 clones	 were	 assessed	 for	 antibody	 production	 and	
viability.	One	 clone	was	 selected	 to	 establish	 a	master	 cell	 bank	 for	mAb	production.	 For	
biotinylation	 of	 GMP	 grade	 hCMRF-56	 IgG4,	 the	 supernatant	 from	 the	 master	 cell	 bank	
underwent	 protein	 G	 purification	 by	 Q-Gen	 Cell	 Therapeutics	 according	 to	 Therapeutics	
Goods	 Administration	 (TGA)	 requirements	 in	 a	 monitored	 clean	 room	 before	 completing	
biotinylation.		
To	confirm	the	binding	activity	of	hCMRF-56	for	multiparameter	flow	cytometry	purposes,	a	
single	titration	of	the	mAb	was	performed	and	was	compared	to	mouse	anti-human	CMRF-
56.	This	 single	 titration	purpose	was	 to	confirm	 the	binding	activity	of	hCMRF-56	and	not	
optimise	 immune	 selection.	 PBMC	 were	 incubated	 for	 14hrs	 at	 37°C	 5%	 CO2.	 After	
incubation,	 PBMC	 were	 labelled	 with	 CD3,	 CD14,	 CD19,	 CD20,	 CD56,	 HLA-DR	 and	 either	
mouse	 anti-human	 CMRF-56	 or	 hCMRF-56	 to	 identify	 APC	 populations	 that	 express	 the	
antigen	 detected	 by	 hCMRF-56.	 CD3	 and	 CD56	 were	 used	 to	 exclude	 T	 and	 NK	 cells.	
Streptavidin	AF647	was	used	to	detect	hCMRF-56	and	goat	anti-mouse	IgG	AF488	was	used	
to	detect	mouse	anti-human	CMRF-56.	Multiparameter	flow	cytometry	was	used	to	analyse	
the	 mouse	 anti-human	 CMRF-56	 MFI	 or	 hCMRF-56	 by	 B	 cells,	 BDC	 and	 monocyte	
populations.		
hCMRF-56	and	mouse	anti-human	CMRF-56	identified	multiple	APC	populations	including:	B	
cells,	BDC	and	monocytes.	Figure	3.1.A	shows	the	gating	strategy	to	measure	hCMRF-56	and	
mouse	anti-human	CMRF-56	on	B	cell,	BDC	and	monocyte	populations	 	
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Human	PBMC	were	incubated	14hrs	at	37°C	5%	CO2.	Following	14hrs	incubation,	cells	were	
harvested	 and	 stained	 with	 serially	 diluted	 hCMRF-56	 or	 mouse	 anti-human	 CMRF-56.	
Labelling	concentration	of	CMRF-56	mAb	used	 is	shown	 in	μg/mL.	Streptavidin	AF647	was	
used	as	 to	detect	hCMRF-56.	Goat	anti-mouse	 IgG	AF488	was	used	 to	detect	mouse	anti-
human	CMRF-56.	Cells	were	 stained	with	CD3	and	CD56	 to	exclude	T	and	NK	cells.	CD14,	
CD19,	 CD20	 and	 HLA-DR	 were	 included	 to	 identify	 B	 cells	 and	 monocytes.	 Remaining	
lineage-	 and	 HLA-DR+	 were	 identified	 as	 BDC.	A)	 Gating	 strategy	 used	 to	 identify	 B	 cells,	
monocytes	and	BDC	and	measure	CMRF-56	MFI.	B)	Results	of	hCMRF-56	titration	showing	
binding	 to	 monocytes	 and	 BDC	 n=1.	 C)	 Results	 of	 mouse	 anti-human	 CMRF-56	 titration	
showing	binding	to	BDC	and	B	cells	n=1.	
		 	
Figure	3.1	Titration	of	CMRF-56	on	14hrs	incubated	PBMC	identifying	hCMRF-56+	APC	
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.	Monocytes	displayed	the	highest	hCMRF-56	MFI	with	all	concentrations,	followed	by	BDC	
then	B	 cells	 (Figure	 3.1.B).	Whereas	 Figure	 3.1.C	 shows	mouse	 anti-human	CMRF-56	BDC	
showed	greatest	MFI	at	all	concentrations	followed	by	B	cells	and	monocytes.	The	hCMRF-
56	concentration	of	10μg/mL	provided	the	greatest	separation	in	MFI	between	all	hCMRF-
56+	 APC	 populations	 and	 was	 adopted	 as	 the	 concentration	 for	 multiparameter	 flow	
cytometry	 analysis.	 At	 10μg/mL	 of	 hCMRF-56,	 the	 MFI	 difference	 between	 BDC	 and	
monocytes	 was	 evident	 but	 the	 difference	 was	 not	 as	 great	 as	 lower	 hCMRF-56	
concentrations.	 The	 concentration	 of	 mouse	 anti-human	 that	 provided	 the	 greatest	
separation	of	populations	was	1.25μg/mL.		
3.2.2 hCMRF-56+	immune	selection	
To	 assess	 hCMRF-56+	 BDC	 immune	 selection,	 PBMC	 were	 isolated	 from	 approximately	
400mLs	 of	 whole	 blood	 and	 incubated	 for	 14hrs	 at	 37°C	 5%	 CO2.	 After	 the	 incubation	
period,	cells	were	harvested	and	stained	with	1.25μg/mL	hCMRF-56.	This	concentration	was	
previously	established	for	clinical	immune	selections	in	pre-clinical	studies	and	was	used	for	
all	hCMRF-56+	BDC	immune	selections	(Dr	R	Prue	2013,	personal	communication).	Following	
staining	 with	 hCMRF-56,	 PBMC	 were	 incubated	 with	 anti-biotin	 microbeads	 to	 allow	 for	
immune	 selection.	 Multiparameter	 flow	 cytometry	 was	 used	 to	 detect	 CMRF-56+	 cells	
including	B	 cells,	BDC	and	monocytes.	Values	assessed	by	multiparameter	 flow	cytometry	
were:	%	CMRF-56+	BDC	pre-immune	selection,	%	CMRF-56+	BDC	post	immune	selection,	%	
yield	immune	selected	CMRF-56+	cells	and	%	CMRF-56+	BDC	recovery.	
Results	from	Table	3.1	show	BDC	were	enriched	from	overnight	incubated	PBMC	by	hCMRF-
56	 immune	 selection	 that	 resulted	 in	 a	 46	 fold	 change.	 Previous	 published	 mouse	 anti-
human	CMRF-56	 immune	 selection	data	by	Vari	et	al.	 (2008)	 and	 Lopez	et	al.	 (2003)	was	
compared	 to	 hCMRF-56	 immune	 selections	 from	 this	 study.	Mouse	 anti-human	 CMRF-56	
biotin	 showed	 greater	 values	 for	 %	 CMRF-56+	 BDC	 and	 %	 CMRF-56+	 BDC	 recovery,	
respectively	28%	and	48%.	However,	hCMRF-56	immune	selections	showed	the	greatest	%	
yield	of	79%	(25-99%)	whilst	no	 increase	 in	%	recovery	of	CMRF-56+	BDC	was	observed.	A	
46X	 increase	 of	 BDC	 from	 starting	 14	 hrs	 incubated	 PBMC	 was	 observed	 as	 a	 result	 of	
hCMRF-56	 immune	 selection.	 Although	BDC	hCMRF-56+	 immune	 selection	 is	 greater	 than	
the	 39X	 increase	 using	 the	mouse	 anti-human	 CMRF-56,	 it	 is	 less	 than	 the	 70X	 increase	
using	the	mouse	anti-human	CMRF-56	biotin.		
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selection	
	
	
	
	
CMRF-56	immune	selection	
	 BDC	
immune	
selection	
fold	
change	
from	pre-
immune	
selection		
%	CMRF-
56+	BDC	 	
%	CMRF-56+	
BDC	
%	yield	of	
CMRF-56+	
cells	
%	CMRF-56+	
BDC	
recovery	
	
Fromm	&	
Papadimitrious	
et	al.	(2016)	
(hCMRF-56	
biotin)	
32	 0.4	(0.1-0.7)	 	
18.4	(6.1-
45)	 79	(25-99)	
43.9	(6.1-
153.9)	
	
46	
Prue	et	al.		
(hCMRF-56	
biotin)	
4	 1.2	(0.8-2.1)	 	
41.1	(33.6	-
56.5)	
95.0	(91.7-
98.2)	
32.0	(12.0-
44.8)	
	
40	
Vari	et	al.	(2008)	
(mouse	anti-
human	CMRF-56	
biotin)	
6	 0.4	(0.1)*	 	 28	(5)*	 72	(8)*	 48	4(4.9)*	
	
70	
Lopez	et	al.	
(2003)	
(mouse	anti-
human	CMRF-56)	
20	 0.7	(0.2-1.4)	 	 27	(6-65)	 55	(18-86)	 66	(21-91)	
	
39	
Mean	percentage	(range);	*,	standard	error	of	mean.	
3.2.3 hCMRF-56+	immune	selection	cellular	constituents	
To	 determine	 the	 overall	 constituents	 of	 hCMRF-56+	 immune	 selected	 cells,	 PBMC	 were	
incubated	for	14hrs	at	37°C	5%	CO2.	hCMRF-56+	cells	were	 immune	selected	as	previously	
described	 in	 3.2.2	 and	 multiparameter	 flow	 cytometry	 was	 used	 to	 identify	 human	
leucocyte	subpopulations,	in	particular	BDC	subsets.		
Results	in	Figure	3.2.A-C	show	hCMRF-56+	immune	selection	resulted	in	enrichment	of	BDC	
(30.6%),	B	cells	(34.9%)	and	monocytes	(27.9%)	of	all	leucocytes.	Minimal	T	cells	(2.3%)	and	
NK	 cells	 (1.8%)	 were	 hCMRF-56+	 immune	 selected.	 BDC	 were	 further	 analysed	 in	 Figure	
3.2.D	 to	 identify	 BDC	 subsets.	 CD1c+	 BDC	 were	 identified	 as	 the	 largest	 BDC	 subset	
comprising	59.1%	of	all	BDC.	CD141+	and	CD16+	BDC	respectively	comprised	6.6%	and	7.1%.		
Table	 3.1	 Summary	 of	 hCMRF-56	 immune	 selections	 and	 comparison	 to	 previous	 mouse	 anti-
human	CMRF-56	published	data	
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hCMRF-56	immune	selects	for	APC	including	B	cells,	BDC	and	monocytes.	BDC	subsets	including	CD1c+,	CD16+	and	CD141+	mDC	are	enriched	during	
hCMRF-56	immune	selection.	A)	hCMRF-56+	APC	are	detected	from	PBMC	incubated	for	14hrs.	hCMRF-56	immune	selection	resulted	in	enrichment	
of	APC	defined	as	HLA-DR+	and	hCMRF-56+.	B)	viSNE	analysis	 illustrates	expression	of	hCMRF-56,	HLA-DR,	CD11c,	CD1c,	CD141,	CD14,	CD16,	CD3,	
CD19	and	CD20	by	PBMC	incubated	for	14hrs	before	immune	selection	and	hCMRF-56	immune	selection.	Predominant	populations	observed	as	a	
result	of	hCMRF-56	immune	selection	include	B	cells,	monocytes,	CD1c+	and	CD141+	BDC.	C)	hCMRF-56+	immune	selection	results	in	enrichment	of	B	
cells,	BDC	and	monocytes.	Minimal	T	cells	and	NK	cells	were	hCMRF-56+	immune	selected.	D)	Analysis	of	BDC	subsets	showed	prevalence	of	CD1c+,	
CD141+	 and	CD16+	BDC	 subsets.	 The	predominant	BDC	 component	of	hCMRF-56+	 immune	 selected	 cells	was	CD1c+	mDC.	E)	 hCMRF-56+	 immune	
selection	results	in	the	enrichment	of	CD1c+	and	CD141+	BDC	subsets.	n=5	
Figure	3.2	hCMRF-56+	immune	selects	for	APC,	including	multiple	BDC	subsets	
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Minimal	 pDC	 (1.6%)	were	detected.	 Figure	3.2.E	 shows	a	 fold	 increase	of	 4.4X	CD1c+	 and	
1.5X	CD141+	BDC.	
3.2.4 hCMRF-56+	immune	selected	BDC	phenotype	
Specific	surface	molecules	on	APC	are	crucial	for	 immune	function	and	lacking	specific	cell	
surface	molecules	required	for	co-stimulation	may	impair	antigen	presentation	(Dolfi	et	al.,	
2011,	Kuipers	et	al.,	2006).	Activation	molecules	(CD54	and	CD83),	co-stimulatory	molecules	
(CD40,	CD80	and	CD86)	and	CCL21	chemokine	receptor	(CCR7)	were	measured	on	hCMRF-
56+	 immune	 selected	 BDC.	 The	 BDC	 phenotype	 was	 determined	 by	multiparameter	 flow	
cytometry	after	hCMRF-56+	immune	selection	and	after	20hrs	incubation	(Figure	3.3).	FMO	
and	isotype	controls	were	used	to	determine	the	%	positive	expression	on	BDC.	
Figure	 3.3A-B	 shows	 that	 after	 hCMRF-56+	 immune	 selection,	 BDC	 resemble	 a	 partially	
mature	 phenotype	 expressing	 high	 levels	 of	 CD54	 (91.3%)	 and	 CD83	 (85.9%).	 Moderate	
levels	 of	 CD40	 (41.9%),	 CD86	 (58.3%)	 and	 CCR7	 (72.6%)	 were	 expressed	 by	 BDC.	 Low	
expression	of	CD80	(1.8%)	was	detected.	Figure	3.3C-D	shows	high	CD54	expression	(86.7%)	
and	CD83	(74.6%)	were	again	detected	by	BDC	post	hCMRF-56+	immune	selection	and	20hrs	
incubation.	 Moderate	 levels	 of	 CD40	 (68.2%),	 CD86	 (59.8%)	 and	 CCR7	 (72.5%)	 were	
expressed	by	BDC	post	hCMRF-56+	immune	selection	and	20hrs	incubation.	CD80	expression	
remained	low	(5.7%)	by	BDC	after	hCMRF-56+	immune	selection	and	20hrs	incubation.	
3.2.5 Extended	hCMRF-56+	BDC	phenotypic	analysis	
The	10th	International	Human	Leucocyte	Differentiation	Antigen	(HLDA)	Workshop	was	held	
in	Wollongong,	New	South	Wales	1-2	December	2014.	The	primary	focus	of	this	workshop	
was	to	assign	new	CD	numbers	to	validated	mAbs	that	target	immune	cell	populations,	with	
an	emphasis	of	BDC	and	in	vitro	derived	DC	(Autenrieth	et	al.,	2015,	Clark	et	al.,	2016a,	Clark	
et	 al.,	 2016b,	 Gurka	 et	 al.,	 2015,	 Ohradanova-Repic	 et	 al.,	 2016).	 mAbs	 were	 generated	
against	a	specific	cell	surface	target	were	supplied	as	hybridoma	supernatant,	purified	mAb	
or	conjugated	to	fluorochromes	by	external	contributing	laboratories.	Binding	of	submitted	
mAbs	to	CD3-	CD14-	CD19-	CD20-	HLA-DR+	hCMRF-56+	BDC	was	examined	by	multiparameter	
flow	cytometry.	A	total	of	85	mAbs	were	submitted	as	part	of	the	HLDA10	workshop.	A	total	
of	60	mAbs	were	available	 for	 testing	 to	measure	 their	binding	 to	hCMRF-56+	BDC.	 Some	
mAb	targets	had	multiple	clones	submitted	to	the	workshop	for	validation.	
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hCMRF-56+	 immune	 selected	 BDC	 expression	 of	 activation	 and	 co-stimulatory	 surface	 molecules	 was	 assessed	 by	 multiparameter	 flow	
cytometry.	 These	 surface	markers	were	 examined	 due	 to	 their	 immune	 stimulatory	 role,	 or	 previously	 described	 to	 be	 of	 importance.	A)	
Expression	 of	 activation	 and	 co-stimulatory	 cell	 surface	molecules	 by	 immune	 selected	 hCMRF-56+	 BDC	 and	B)	 representative	 histograms	
displaying	 expression	 of	 activation	 and	 co-stimulatory	 cell	 surface	molecules	 after	 immune	 selection.	C)	 Expression	 of	 CD40,	 CD54,	 CD80,	
CD83,	CD86	and	CCR7	by	hCMRF-56+	immune	selected	BDC	incubated	for	20hrs	at	37°C	5%	CO2	and	D)	representative	histograms	displaying	
expression	of	activation	and	co-stimulatory	cell	surface	molecules	after	an	incubation.	Mean	%	positive	was	measured	by	isotype	control	or	
appropriate	FMO.	n=3	
Figure	3.3	Phenotype	of	hCMRF-56+	immune	selected	BDC	and	after	20hrs	incubation	
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To	examine	their	expression	by	hCMRF-56+	BDC,	PBMC	were	incubated	for	14hrs	at	37°C	5%	
CO2.	 After	 incubation,	 submitted	 mAbs	 were	 examined	 for	 their	 binding	 to	 hCMRF-56+	
BDC.hCMRF-56+	 BDC	 were	 defined	 as	 CD3-,	 CD14-,	 CD19-,	 CD20-,	 CD56-,	 HLA-DR+	 and	
hCMRF-56+.	Binding	patterns	of	HLDA10	mAbs	showed	either:	no	 staining,	bi-modal,	peak	
shift	or	 strong	peak	 shifts.	Binding	of	HLDA10	mAbs	 to	hCMRF-56+	BDC	was	 compared	 to	
freshly	 isolated	CD1c+	BDC	and	Mo-DC	completed	by	Clark	et	al.	 (2016)	 and	Ohradanova-
Repic	 et	 al.	 (2016),	 respectively.	 HLDA10	 Workshop	 provided	 a	 suitable	 opportunity	 to	
examine	 the	 phenotypic	 differences	 between	 BDC	 and	Mo-DC	 to	 expand	 the	 differences	
between	these	cell	populations.	
Table	 3.2	 shows	 a	 total	 of	 28	mAbs	 exhibited	 positive	 binding	 to	 hCMRF-56+	 BDC.	 These	
positive	mAbs	targeted	a	variety	of	cell	surface	molecules	including	C-type	lectins,	cytokine	
receptors,	immunoregulatory	molecules	and	previously	validated	CD	molecules.	Five	of	the	
mAbs	 exhibiting	 positivity	 by	 hCMRF-56+	 BDC	 were	 assigned	 CD	 numbers	 by	 the	 HLDA	
organising	committee	(Clark	et	al.,	2016a,	Clark	et	al.,	2016b).	Another	five	mAbs	displayed	
similar	reactivity	between	hCMRF-56+	BDC	and	freshly	isolated	CD1c+	BDC.	A	total	of	seven	
mAbs	 showed	 greater	 reactivity	with	 freshly	 isolated	CD1c+	 BDC	 compared	 to	 hCMRF-56+	
BDC.	A	total	of	14	mAbs	showed	greater	reactivity	with	hCMRF-56+	BDC	compared	to	freshly	
isolated	CD1c+	BDC.	hCMRF-56+	BDC	were	also	compared	 to	mature	Mo-DC	as	 these	cells	
resemble	 a	 mature	 APC.	 Three	 mAbs	 displayed	 similar	 binding	 to	 hCMRF-56+	 BDC	 and	
mature	Mo-DC.	Three	mAbs	displayed	greater	 reactivity	with	mature	Mo-DC	compared	to	
hCMRF-56+	 BDC.	 A	 total	 of	 11	 mAbs	 showed	 greater	 reactivity	 with	 hCMRF-56+	 BDC	
compared	to	mature	Mo-DC.	
	 	 	 hCMRF-56+	BDC	
	
Fresh	
CD1c	
BDC*	
	 Mo-DC**	
Test	
mAb	 Target	 	
%	
positive	 Reactivity	
	
	 Immature	 Mature	
10-08	 FAT1	Cadherin	 	 23.0	 +	-	 	 +/-	 	 n.d.	 n.d.	
10-13	 Clec4A	 CD367	 26.3	 +	-	 	 +	+	 	 99.4	 97.9	
10-17	 Clec12A	 	 33.7	 +	-	 	 +	 	 2.9	 7.3	
10-19	 LPAP	 	 29.0	 +	-	 	 -	 	 n.d.	 n.d.	
10-20	 Unknown	 	 99.0	 +	+	 	 NT	 	 n.d.	 n.d.	
10-23	 Calreticulin	 	 60.0	 +	-	 	 -	 	 n.d.	 n.d.	
10-24	 Tim3	 CD366	 14.0	 -	-	 	 +	+	 	 n.d.	 n.d.	
Table	 3.2	 Summary	 of	 positive	 HLDA10	 mAbs	 binding	 on	 hCMRF-56+	 BDC	 and	 comparison	 of	
positive	binding	to	freshly	isolated	CD1c+	BDC	and	Mo-DC	completed	by	other	studies	
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10-26	 CD1c	 	 76.6	 +	+	 	 +	+	 	 n.d.	 n.d.	
10-27	 Unknown	 	 98.8	 +	+	+	 	 NT	 	 n.d.	 n.d.	
10-33	 Unknown	 	 98.0	 +	+	+	 	 NT	 	 n.d.	 n.d.	
10-34	 CD101	 	 41.3	 +	+	 	 +	+	 	 2.0	 7.9	
10-41	 IL-13	RA2	 	 35.5	 +	-	 	 -	 	 n.d.	 n.d.	
10-43	 CD245	 	 98.8	 +	+	+	 	 +	 	 17.8	 81.9	
10-48	 CD245	 	 61.7	 +	-	 	 +	 	 n.d.	 n.d.	
10-51	 Clec12A	 CD371	 41.4	 +	-	 	 +	+	 	 3.7	 5.1	
10-53	 IL-1RACP	 	 94.4	 +	+	+	 	 +	 	 0.7	 1.2	
10-55	 Vimentin	 	 40.2	 +	-	 	 +	 	 n.d.	 n.d.	
10-61	 CD273	 	 22.9	 +	-	 	 -	 	 90.2	 99.9	
10-62	 GARP	 	 20.9	 +	-	 	 -	 	 n.d.	 n.d.	
10-68	 TSLP-R	 	 81.4	 +	+	 	 -	 	 0.2	 58.2	
10-69	 CMRF-56	 	 99.7	 +	+	+	 	 +	 	 12.5	 84.7	
10-70	 P2RX7	 	 98.1	 +	+	+	 	 +/-	 	 35.3	 99.3	
10-71	 DCIR	 	 85.1	 +	+	+	 	 +/-	 	 n.d.	 n.d.	
10-72	 Clec4A	 CD367	 35.2	 +	-	 	 +	 	 99.4	 97.9	
10-73	 Clec12A	 CD371	 49.6	 +	-	 	 +	+	 	 12.1	 12.1	
10-75	 Tim3	 	 77.6	 +	+	 	 +	+	 	 88.2	 18.9	
10-82	 CMRF-44	 	 100.0	 +	+	+	 	 -	 	 4.3	 55.3	
10-83	 DC-SIGN	like	 	 59.3	 +	-	 	 -	 	 89.1	 25.5	
10-84	 FDF03	 	 92.4	 +	+	+	 	 +/-	 	 1.6	 6.0	
+-,	 bi-modal	 peak;	 ++,	 peak	 shift;	 +++,	 strong	 peak	 shift;	 *,	 data	 adapted	 from	 results	
published	by	Clark	et	al.	 (2016);	 **,	data	adapted	 from	 results	published	by	Ohradanova-
Repic	et	al.	(2016);	n.d.,	no	data	
3.3 Discussion	
A	human	chimeric	CMRF-56	was	produced	by	splice	overlap	extension	PCR	to	 incorporate	
human	VH	and	VL	and	minimise	xenogeneic	reactive	components	of	the	mouse	anti-human	
mAb	(Fromm	et	al.,	2016).	In	addition,	the	isotype	of	mouse	anti-human	CMRF-56	mAb	was	
switched	from	mouse	IgG1	to	human	IgG4	to	reduce	ADCC	and	CDC	activity	in	patients	from	
residual	binding	of	hCMRF-56	mAb	to	administered	cells.	However,	confirmation	of	ADCC	or	
CDC	activity	by	hCMRF-56	was	not	part	of	this	research	and	remains	to	be	confirmed.	This	
should	be	 completed	before	 commencing	 any	 clinical	 studies.	 CHO	 cells	were	 transfected	
with	the	plasmid	construct	of	hCMRF-56	to	create	a	stable	transfected	master	cell	line.	The	
master	cell	line	is	to	ensure	reproducibility	for	producing	hCMRF-56	and	consistent	binding	
to	 target	 cells.	 Secreted	hCMRF-56	was	protein	G	purified	 in	 a	 TGA	approved	 clean	 room	
and	a	GMP	grade	hCMRF-56	that	can	be	used	with	human	patients	was	produced.	Finally,	
hCMRF-56	 was	 biotinylated	 to	 allow	 for	 immune	 selection	 using	 existing	 anti-biotin	
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magnetic	beads	 immune	selection	methods	and	 it	was	 this	product	 that	was	used	 for	my	
studies.	
Validation	of	hCMRF-56	was	performed	by	 titration	on	PBMC	 incubated	 for	14hrs	at	37°C	
5%	CO2	with	staining	patterns	compared	 to	mouse	anti-human	CMRF-56.	Like	 the	original	
mouse	anti-human	CMRF-56,	hCMRF-56	identified	three	APC	populations:	B	cells,	BDC	and	
monocytes	(Fromm	et	al.,	2016,	Hock	et	al.,	1999.	While	both	mAbs	bound	BDC,	differences	
in	binding	to	monocytes	and	B	cells	were	observed.	These	differences	may	be	due	to	isotype	
switching	 from	 IgG1	 to	 IgG4.	 Saturation	 of	 hCMRF-56	 was	 not	 observed	 as	 observed	 by	
multiparameter	 flow	 cytometry,	 which	 is	 similar	 to	 mouse	 anti-human	 CMRF-56.	 The	
optimal	 hCMRF-56	 concentration	 for	 multiparameter	 flow	 cytometry	 that	 provided	
separation	 of	 B	 cells,	 BDC	 and	 monocytes	 was	 10μg/mL.	 hCMRF-56+	 immune	 selections	
were	routinely	assessed	by	multiparameter	flow	cytometry	for	their	%	BDC	and	the	%	purity	
of	 the	 immune	 selection.	 The	%	 CMRF-56	 BDC	 and	%	 recovery	 BDC	were	 calculated	 and	
compared	 to	 previously	 published	 research	 using	 purified	 hybridoma	 supernatant	 or	
biotinylated	mouse	 anti-human	 CMRF-56	 {Lopez,	 2003	 #1093,	 Vari	 et	 al.,	 2008).	 As	 with	
previous	 CMRF-56	 mAbs,	 hCMRF-56	 immune	 selection	 enriches	 for	 APC	 including	 BDC.	
Comparison	 between	 this	 study	 and	 Prue	 et	 al.	 unpublished	 results	 indicate	 differences	
between	each	parameter	measured	 in	 Table	3.1	except	 for	 the	%	CMRF-56	BDC	 recovery	
and	 the	 BDC	 immune	 selection	 fold	 change	 from	 pre-immune	 selection.	 The	 recovery	 is	
calculated	based	on	the	number	of	BDC	before	and	after	immune	selection	expressed	as	a	
percentage.	The	 fold	change	calculates	 the	 fold	change	of	%	CMRF-56+	BDC	as	a	 result	of	
immune	 selection.	Despite	 Lopez	et	al.	 (2003)	using	 the	 greater	 concentration	of	 purified	
mouse	anti-human	CMRF-56	mAb	at	5μg/mL,	BDC	were	consistently	immune	selected	using	
1.25μg/mL	hCMRF-56	mAb.	It	was	observed	that	%	CMRF-56+	BDC	was	reduced	when	less	
hCMRF-56	 was	 used,	 compared	 to	 either	 mouse	 anti-human	 CMRF-56	 after	 immune	
selection.	 However,	 a	 greater	 fold	 increase	 in	 %	 CMRF-56+	 BDC	 enrichment	 from	 pre-
immune	 selection	 using	 1.25μg/mL	 hCMRF-56	 compared	 to	 5μg/mL	 mouse	 anti-human	
CMRF-56	by	Lopez	et	al.	(2003)	was	observed.	The	immune	selection	fold	change	was	not	as	
great	 as	 the	 70X	 enrichment	 observed	 by	 Vari	 et	 al.	 (2008)	 using	 the	mouse	 anti-human	
CMRF-56	biotin.	This	may	be	due	to	healthy	donor	variability.	Increasing	the	concentration	
of	 hCMRF-56	 for	 immune	 selection	may	 increase	 the	%	CMRF-56+	BDC	and	%	hCMRF-56+	
BDC	 recovery.	Both	biotinylated	CMRF-56	versions	 show	similar	%CMRF-56	BDC	 recovery,	
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indicating	 the	 biotinylation	 process	 may	 impact	 the	 BDC	 recovery.	 hCMRF-56+	 immune	
selection	 resulted	 in	 a	 4.4X	 increase	 in	CD1c+	BDC	and	1.5X	 increase	 in	CD141+	BDC.	 This	
increase	demonstrates	the	utility	to	enrich	for	a	heterogeneous	population	of	BDC,	using	a	
single	 step	 immune	 selection.	Potential	 applications	 for	hCMRF-56+	 immune	 selected	BDC	
include	basic	science	examining	mature	BDC	and	adoptive	DC	immune	therapy.	Depletion	of	
B	 cells	 and	 monocytes	 may	 improve	 the	 %	 hCMRF-56+	 BDC	 yield	 but	 in	 the	 interest	 of	
keeping	 this	 process	 a	 one-step	 immune	 selection	 that	 is	 to	 be	 simpler	 than	 CD1c+	 BDC	
isolation,	this	option	was	not	investigated.	In	this	study,	400	mLs	of	whole	blood	was	used	
for	enrichment	of	hCMRF-56+	cells.	In	the	CMRF-56+	cell	study	completed	and	published	by	
Prue	et	al.	(2015),	a	minimum	of	3x106	CMRF-56+	BDC	were	administered	into	the	patient.		
To	 achieve	 a	 similar	 result,	 1.6x1010	 PBMC	 will	 need	 to	 be	 harvested	 from	 the	 patient’s	
whole	 blood	 to	 isolate	 this	 number	 of	 hCMRF-56+	 immune	 selected	 BDC.	 To	 obtain	 this	
amount	of	PBMC	from	a	single	leukapheresis	will	be	possible	from	a	healthy	donor	(Wolf	et	
al.,	 2005).	Validation	 studies	will	need	 to	be	completed	using	diseased	patients	 to	ensure	
the	appropriate	hCMRF-56+	immune	selected	BDC	numbers	can	be	achieved.	
Monocytes	 and	 B	 cells	 express	 Fc	 receptors	 that	 bind	 to	 mAb	 Fc	 portion	 and	 therefore	
increase	 non-specific	mAb	 binding.	 IgG1	 strongly	 binds	 to	 all	 Fc	 receptors,	 whereas	 IgG4	
only	binds	 to	FcγRI,	FcγRIIA,	FcγRIIB,	FcγRIIC	and	FcγRIIIA	expressed	by	B	cells,	monocytes	
and	macrophages	(Bruhns	et	al.,	2009).	IgG4	binding	affinities	for	Fc	receptors	are	less	than	
IgG1	binding	affinities.	Therefore	it	is	speculated	that	Fc	receptor	engagement	by	hCMRF-56	
would	 be	 less	 compared	 to	mouse	 anti-human	 CMRF-56.	 This	would	 indicate	 Fc	 blocking	
would	not	 improve	 staining	of	hCMRF-56	and	eliminate	non-specific	binding	 compared	 to	
mouse	 anti-human	 CMRF-56.	 In	 addition	 to	 increasing	 mAb	 non-specific	 binding	 to	 Fc	
receptors,	cellular	activation	is	a	result	of	FcγRI,	FcγRIIA,	FcγRIIC	and	FcγRIIIA	binding	to	IgG.	
Binding	of	 IgG	to	FcγRIIB	results	 in	 inhibition	(Guilliams	et	al.,	2014).	 Immune	functions	of	
IgG	binding	to	these	receptors	are	being	investigated	for	their	role	in	immune	therapy	(Abes	
et	 al.,	 2009).	 Activating	 cells	 via	 Fc	 receptor	 engagement	 mediates	 phagocytosis	 of	
opsonised	 particles,	 ADCC	 and	 secretion	 of	 TNF.	 Whereas	 binding	 of	 FcγRIIB	 and	 an	
activating	 Fc	 receptor	 results	 in	 immunosuppressive	 functions	 and	 inhibiting	 effector	
functions.		
In	preparation	for	an	hCMRF-56+	automated	immune	selection,	the	AutoMACS	Pro	was	used	
69	
	
throughout	 this	 research	 to	 perform	 all	 immune	 selections.	 To	 perform	 the	 immune	
selection,	magnetic	anti-biotin	microbeads	bind	 to	cells	 labelled	with	biotinylated	hCMRF-
56.	 When	 cells	 that	 are	 labelled	 with	 hCMRF-56	 coupled	 with	 magnetic	 anti-biotin	
microbeads	are	passed	through	a	magnetic	column	where	they	are	retained	by	the	column.	
Cells	 not	 labelled	 with	 hCMRF-56	 coupled	 with	 magnetic	 anti-biotin	 microbeads	 are	
immediately	 eluted.	 This	 method	 automatically	 positively	 selects	 for	 hCMRF-56+	 cells	
performed	by	the	AutoMACS	Pro.	This	is	different	to	previous	studies	using	manual	CMRF-
56+	immune	selection	techniques	(Freeman	et	al.,	2007,	Lopez	et	al.,	2003).	The	use	of	the	
AutoMACS	Pro	was	chosen	to	simulate	the	automated	 immune	selection	process	using	an	
instrument	such	as	a	CliniMACS	(Miltenyi-Biotec).	The	CliniMACS	is	approved	for	performing	
clinical	 grade	 immune	 selections	 with	 the	 intent	 of	 being	 used	 for	 clinical	 applications.	
Clinical	 isolation	for	only	CD1c+	BDC	and	pDC	can	be	achieved	using	the	CliniMACS	due	to	
limitations	of	GMP	grade	reagents.	The	PosselD2	program	selected	 to	perform	AutoMACS	
PRO	 immune	 selections	 can	 be	 translated	 to	 a	 CliniMACS	 program.	 However,	 a	 direct	
comparison	of	immune	selections	between	the	AutoMACS	Pro	and	CliniMACS	programs	will	
need	to	be	validated	prior	to	any	future	clinical	studies.	Both	Vari	et	al.	(2008)	and	this	study	
used	 anti-biotin	 microbeads	 and	 not	 streptavidin	 microbeads	 in	 combination	 with	 a	
biotinylated	mAb	for	immune	selections.	The	use	of	anti-biotin	microbeads	has	been	shown	
to	 reduce	 non-specific	 binding	 by	 only	 binding	 to	 membrane	 bound	 biotin.	 Streptavidin	
microbeads	 bind	 to	 free	 and	 membrane	 bound	 biotin,	 therefore	 increasing	 non-specific	
immune	selection.	
A	 previous	 pre-clinical	 study	 using	 hCMRF-56	 identified	 1.25μg/mL	 as	 the	 optimal	
concentration	 for	 immune	 selection	 with	 anti-biotin	 microbeads.	 Following	 hCMRF-56+	
immune	selection,	multiparameter	 flow	cytometry	was	used	 to	determine	 the	hCMRF-56+	
APC	 constituents	 including	 B	 cells,	 BDC	 and	monocytes.	 These	 three	 cell	 populations	 are	
known	to	play	a	major	role	in	antigen	presentation	(Clark	et	al.,	2012,	Harvey	et	al.,	2014).	
Three	 functionally	 and	 phenotypically	 distinct	 subsets	 of	 mDC	 have	 been	 identified	 in	
humans	(Clark	et	al.,	2016b,	Fromm	et	al.,	2016,	Jongbloed	et	al.,	2010,	MacDonald	et	al.,	
2002).	 Similar	 cellular	 constituents	 were	 found	 between	 hCMRF-56+	 immune	 selection	
compared	to	mouse	anti-human	CMRF-56+	immune	selection	for	T	cells,	NK	cells,	BDC	and	
monocytes.	 Greater	 percentage	 of	 B	 cells	 was	 found	 from	 hCMRF-56+	 immune	 selection	
compared	 to	 mouse	 anti-human	 CMRF-56	 immune	 selection	 (Freeman	 et	 al.,	 2007).	 A	
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heterogeneous	population	of	hCMRF-56+	 immune	selected	BDC	was	observed,	detecting	a	
predominant	CD1c+	mDC	subset.	MacDonald	et	al.	(2002)	describes	the	frequency	of	CD1c+	
BDC	being	 18.6%	of	 lineage-	HLA-DR+	BDC.	 hCMRF-56+	 immune	 selection	 results	 in	 59.1%	
CD1c+	BDC.	The	hCMRF-56+	immune	selection	results	in	an	enrichment	of	CD141+	the	mDC	
subset.	This	subset	possesses	the	ability	to	cross	present	antigen,	generating	a	CD8+	T	cell	
response	from	exogenous	antigen	(Jongbloed	et	al.,	2010).	No	current	method	exists	for	the	
CliniMACS	immune	selection	of	CD141+	BDC.	Consistent	with	Freeman	et	al.	(2007)	minimal	
pDC	were	enriched	by	hCMRF-56+	immune	selection.	hCMRF-56	immune	selection	does	not	
require	incubation	of	five	to	seven	days	in	the	presence	of	cytokines	that	is	an	advantage	to	
differentiating	 Mo-DC,	 or	 multi-step	 immune	 selections	 for	 enriching	 CD1c+	 BDC.	 The	
presence	of	multiple	APC	populations,	 including	multiple	BDC	 subsets,	 is	 advantageous	 to	
other	Mo-DC	and	BDC	immune	therapies	that	rely	on	the	presence	of	one	type	of	cell.	BDC	
compared	 to	 pooled	 B	 cells	 and	 monocytes	 provide	 greater	 antigen	 presentation	 to	
autologous	 T	 cells	 (Fromm	 et	 al.,	 2016).	 They	 found	 BDC	 antigen	 presentation	 induced	
antigen	specific	T	cells,	thus	resulting	in	antigen	specific	lysis.	
BDC	are	 the	most	potent	APC	 (Manca	et	 al.,	 1994,	 Yoshimura	et	 al.,	 2001).	 Expression	of	
activation	and	co-stimulatory	molecules	is	important	for	immune	function	as	the	absence	of	
specific	 cell	 surface	 molecules	 impairs	 the	 stimulation	 of	 other	 immune	 cells,	 thereby	
potentially	 dampening	 the	 immune	 response.	 Freeman	 et	 al.	 (2007)	 examined	 the	
expression	 of	 CD40,	 CD80,	 CD83	 and	 CD86	 on	 mouse	 anti-human	 CMRF-56+	 immune	
selected	BDC.	They	found	low	expression	of	CD40,	moderate	expression	of	CD80	and	CD86	
and	high	expression	of	CD83.	In	this	study,	similar	results	were	found	with	CD83	and	CD86	
hCMRF-56+	immune	selected	BDC.	Differences	were	observed	in	CD40	and	CD80	expression	
levels	 between	 the	 different	 CMRF-56	 immune	 selection	methods.	 Freeman	 et	 al.	 (2007)	
found	 that	CD40	expression	was	 the	 least	on	BDC,	not	CD80	as	 found	 in	 this	 study.	CD40	
ligation	is	crucial	for	the	secretion	of	IL-12p70	by	BDC.	Expression	of	CD154	by	T	cells	is	the	
ligand	 for	CD40.	Although	both	 studies	 show	expression	of	CD40,	 the	 levels	of	expression	
are	 irrelevant	 as	 co-stimulation	 requires	 TCR	 engagement	 by	 MHC,	 followed	 by	 co-
stimulation	 molecule	 ligation.	 CD28	 is	 the	 ligand	 for	 both	 CD80	 and	 CD86,	 which	 are	
expressed	by	T	cells.	The	low	levels	of	CD80	may	not	be	able	to	successfully	bind	to	its	ligand	
on	T	cells.	However,	CD86	may	be	able	to	bind	to	the	same	ligand.	The	high	expression	of	
CD54	 and	 CD83	 indicate	 that	 hCMRF-56+	 BDC	 display	 an	 activated	 phenotype,	 a	
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requirement	for	reduced	capture	by	BDC,	and	present	antigen	(Aerts-Toegaert	et	al.,	2007,	
Sheikh	and	Jones,	2008,	Zhou	and	Tedder,	1995).	Sheikh	&	Jones	(2008)	describe	the	use	of	
CD54	 as	 a	 surrogate	marker	 for	 APC	 activation	 during	 Sipuleucel-T	 vaccination.	 This	 was	
later	adopted	as	a	marker	of	potency	for	Sipuleucel-T.	However	the	high	expression	of	CD54	
post	 hCMRF-56+	 immune	 selection	 suggests	 it	may	 not	 be	 a	 suitable	 surrogate	marker	 of	
BDC	 activation.	 Expression	 of	 CCR7	 mediates	 cell	 migration	 to	 CCL21,	 which	 is	 the	
chemokine	 secreted	 by	 lymphoid	 organs	 to	 attract	 immune	 cells	 (Nagira	 et	 al.,	 1997).	
Moderate	 expression	 of	 CD40	 and	 CD86	 co-stimulatory	 molecules	 might	 facilitate	 the	
potential	antigen	presentation	to	T	cells.		
The	ubiquitous	use	of	mAbs	extends	from	scientific	research	through	to	clinical	applications.	
Antibodies	 are	 widely	 used	 for	 research,	 disease	 diagnosis	 and	 monitoring.	 Laboratories	
experienced	 in	 tissue	 culture	 can	produce	of	mAbs	 for	 their	 research	purposes.	However,	
these	 mAbs	 produced	 in	 the	 laboratory	 have	 not	 undergone	 independent	 validation	 to	
confirm	their	specificity	and	often	cause	dispute	within	the	scientific	field	(Baker,	2015).	The	
Human	 Cell	 Differentiation	 Molecule	 Committee	 co-ordinate	 HLDA	 Workshops	 so	
independent	characterisation	of	mAbs	can	confirm	their	specificity.	Binding	of	 the	mAb	to	
the	 antigen	 is	 assessed	 on	 transfected	 cell	 lines	 and	 primary	 cells.	 If	 required,	 further	
assessment	is	performed	on	other	cell	 lines.	After	 independent	characterisation,	mAbs	are	
discussed	at	 the	HLDA	Workshop	and	may	be	assigned	a	CD	number.	A	 total	 of	 85	mAbs	
were	 submitted	 to	 the	 10th	 HLDA	Workshop	 with	 cell	 surface	 molecules	 responsible	 for	
immune	 regulation.	A	 total	of	 seven	mAbs	 from	 the	HLDA10	workshop	were	assigned	CD	
numbers.	 A	 cohort	 of	mAbs	 submitted	 as	 part	 of	 the	 HLDA	Workshop	was	 examined	 for	
their	ability	 to	bind	 to	hCMRF-56+	BDC.	Three	mAbs	 that	were	assigned	new	CD	numbers	
bound	to	hCMRF-56+	BDC.	They	are:	CD366	(Tim-3),	CD367	(Clec4A)	and	CD371	(Clec12A).	
1.	T	cell	 immunoglobulin	and	mucin	domain	3	 (Tim3),	or	CD366,	expression	was	originally	
identified	 on	 Th1	 but	 not	 Th2	 cells	 (Monney	 et	 al.,	 2002).	 Binding	 of	 galectin-9	 to	 Tim3	
negatively	 regulates	 Th1	 cell	 survival	 and	 cytokine	 production,	 such	 as	 IFNγ	 (Zhu	 et	 al.,	
2005).	Galectin-9	 induces	expression	activation	and	co-stimulatory	 cell	 surface	markers	of	
immature	Mo-DC.	Secretion	of	functional	IL-12	by	Mo-DC	also	increases	in	the	presence	of	
galectin-9	 (Dai	 et	 al.,	 2005).	 Mouse	 models	 have	 demonstrated	 expression	 of	 CD366	
increases	 in	the	presence	of	glaectin-9,	 in	addition	to	the	cell	counts	of	mature	splenic	DC	
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(Nagahara	 et	 al.,	 2008).	 Low	 expression	 of	 CD366	 by	 hCMRF-56+	 BDC	may	 indicate	 poor	
secretion	of	IL-12	without	any	additional	stimuli,	despite	possessing	an	activated	phenotype.	
Low	expression	of	CD366	by	hCMRF-56+	BDC	supports	the	finding	by	Clark	et	al.	(2016)	that	
show	high	CD366	expression	by	freshly	isolated	CD1c+	mDC	that	have	not	been	stimulated.	
Stimulation	of	hCMRF-56+	BDC	with	galectin-9	may	 increase	CD366	expression,	 in	addition	
to	 other	 activation	 and	 co-stimulatory	 cell	 surface	 molecules.	 Furthermore	 this	 may	
enhance	 antigen	 specific	 T	 cell	 immune	 responses	 by	 increasing	 the	 production	 of	 Th1	
cytokines.		
2.	CD367,	commonly	known	as	CLEC	domain	family	4	 (Clec4A),	was	first	described	on	APC	
and	 granulocytes	 (Bates	 et	 al.,	 1999).	 Expression	 of	 CD367	 by	 APC	 decreases	 upon	
stimulation	with	CD40L	and	LPS	whilst	remaining	high	on	freshly	isolated	APC,	including	BDC	
subsets	(Bates	et	al.,	1999,	Clark	et	al.,	2016b).	As	hCMRF-56+	BDC	contain	a	heterogeneous	
population	of	activated	BDC,	this	low	expression	supports	Clark	et	al.	(2016)	who	discussed	
high	expression	on	freshly	 isolated	CD1c+	BDC.	Recent	studies	examining	 internalisation	of	
CD367	 inhibited	 TLR8-mediated	 IL-12	 and	 TNF	 cytokine	 production	 by	 Mo-DC	 (Meyer-
Wentrup	et	al.,	 2009).	 TLR8	 is	mainly	expressed	by	CD16+	BDC	and	 the	 inhibition	of	 IL-12	
production	may	result	in	a	suppressed	Th1	response	(Lyakh	et	al.,	2008,	Piccioli	et	al.,	2007).	
This	 demonstrates	 that	 decreased	 expression	 of	 CD367	 on	 APC	 is	 essential	 to	 elicit	 an	
antigen	specific	T	cell	immune	response.	Low	expression	of	CD367	by	hCMF-56+	BDC	is	likely	
to	be	beneficial	as	this	demonstrates	BDC	activation	and	ability	to	initiate	a	T	cell	 immune	
response.	
3.	CD371	(Clec12A)	is	another	member	of	the	C-type	lectin	domain	family	expressed	by	all	
human	BDC	subsets	and	monocytes	(Lahoud	et	al.,	2009).	CD371	behaves	as	a	receptor	for	
dead	 cells	 by	 detecting	MSU	 (Monosodium	urate),	 a	 danger	 signal	 for	 cell	 death.	Using	 a	
GFP	reporter	cell	 line	transduced	with	hCLEC12A	(CD371)	and	transduced	cells	were	cross-
linked	with	mAbs.	As	expected,	dead	cells	and	MSU	cross-linked	CD371	measured	by	GFP,	
which	confirmed	CD371	 is	a	 receptor	 for	dead	cells.	 Intermediate	expression	of	CD371	by	
hCMRF-56+	BDC	show	the	potential	for	detecting	MSU	and	dead	cells.	The	ligation	of	CD371	
should	increase	the	activation	of	hCMRF-56+	BDC,	thus	creating	a	more	immune	stimulatory	
BDC.	However,	 the	expression	of	CD371	 is	 strong	on	 freshly	 isolated	BDC,	and	appears	 to	
have	 decreased	 after	 14hrs	 incubation	 on	 hCMRF-56+	 BDC	 (Clark	 et	 al.,	 2016b).	 This	
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demonstrates	 that	 as	 BDC	 become	 activated,	 CD371	 expression	 decreases	 further	
suggesting	a	role	associated	with	activated	BDC.	
The	remaining	20	mAbs	that	targeted	a	variety	of	cell	surface	molecules	including	cytokine	
receptors,	 C-type	 lectins	 and	 immune	 regulatory	molecules,	 displayed	 positive	 binding	 to	
hCMRF-56+	BDC,	although	no	CD	number	was	assigned	to	these	mAbs.	Although	these	mAbs	
were	not	validated,	some	positive	binding	to	hCMRF-56+	BDC	was	expected.	The	mAbs	10-
69	and	10-82	have	previously	been	shown	to	bind	to	activated	BDC.	The	target	for	10-26	is	
the	 CD1c	 surface	 molecule,	 which	 is	 expressed	 by	 the	 predominant	 hCMRF-56+	 BDC	
population.	Reduced	expression	of	CD367	is	characteristic	of	potent	APC	with	T	cell	priming	
ability.	 This	 ability	 is	 a	 crucial	 function	 of	 APC	 and	 demonstrates	 that	 Mo-DC	 may	 not	
process	and	present	antigen	to	T	cells	as	effective	as	BDC.	Expression	of	CD371	was	greatest	
on	 hCMRF-56+	 BDC	 and	 demonstrates	 a	 potential	 functional	 difference,	 removal	 of	 dead	
cells,	between	Mo-DC	and	BDC.	These	differences	are	important	due	to	the	extensive	use	of	
Mo-DC	 in	 clinical	 trials	 which	 show	 Mo-DC	 do	 not	 migrate	 from	 site	 of	 injection.	
Accumulation	of	dead	cells	would	occur	at	this	site	that	may	require	phagocytes	such	as	BDC	
to	remove	administered	Mo-DC.	
3.4 CONCLUSION	
Traditional	 DC	 based	 immune	 therapy	 utilises	 monocytes	 incubated	 in	 the	 presence	 of	
cytokines	 for	 up	 to	 seven	 days	 to	 manufacture	 Mo-DC.	 Stark	 molecular	 and	 functional	
differences	 between	Mo-Dc	 and	 BDC	 have	 reinvigorated	 interest	 in	 the	 use	 of	 BDC	 as	 a	
source	 of	 DC	 for	 immune	 therapies.	 hCMRF-56	 immune	 selection	 is	 a	 now	 a	 realistic	
alternative	to	isolate	BDC	without	the	need	of	a	seven	day	incubation,	nor	use	of	cytokines.	
hCMRF-56+	immune	selection	is	performed	in	a	single	step	after	PBMC	are	incubated	for	a	
short	period.	 I	have	demonstrated	that	hCMRF-56	 isolates	APC	 including:	B	cells,	BDC	and	
monocytes.	 Multiple	 BDC	 subsets	 are	 enriched	 including	 CD1c+	 BDC	 and	 the	 cross	
presenting	 CD141+	 BDC.	 Phenotypic	 differences	 between	 hCMRF-56+	 and	 freshly	 isolated	
CD1c+	 BDC	 were	 detected	 by	 multiparameter	 flow	 cytometry	 as	 part	 of	 the	 HLDA10	
workshop.	 The	 main	 difference	 between	 these	 BDC	 is	 that	 hCMRF-56+	 BDC	 are	 more	
activated	 than	 freshly	 isolated	 CD1c+	 BDC,	 as	 indicated	 by	 the	 positive	 expression	 of	 cell	
surface	 CD83	 (Hock	 et	 al.,	 1999).	 In	 addition,	 comparisons	 between	 hCMRF-56+	 BDC	 and	
Mo-DC	 were	 also	 detected	 by	 multiparameter	 flow	 cytometry	 from	 different	 testing	
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laboratories	 as	 part	 of	 the	 HLDA10	 workshop.	 These	 differences	 highlight	 potential	
functional	disparities	between	hCMRF-56+	BDC	and	Mo-DC.	Furthermore,	this	highlights	the	
potential	use	of	hCMRF-56+	immune	selected	cells	as	a	tool	to	isolate	APC,	including	CD1c+	
BDC,	as	a	second	generation	therapeutic	DC	vaccine.	 	
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4 IVT	mRNA	TRANSFECTED	hCMRF-56+	CELLS	GENERATE	ANTI-
CANCER	IMMUNE	RESPONSES	
4.1 Introduction	
Having	obtained	BDC	after	hCMRF-56+	 immune	 selection,	 stimulation	and	antigen	 loading	
strategies	need	to	be	addressed	for	effective	BDC	vaccination.	GM-CSF	was	 identified	as	a	
potent	cytokine	that	 induces	BMDC	maturation	and	stimulation	of	CD8+	T	cells	(Min	et	al.,	
2010).	 GM-CSF	 has	 been	 described	 to	 play	 a	 role	 in	 DC	 proliferation,	 survival	 and	
differentiation	 (van	 de	 Laar	 et	 al.,	 2012).	 Furthermore,	 generation	 of	 Mo-DC	 occurs	 by	
incubating	monocytes	with	GM-CSF	and	IL-4.	Stimulation	of	monocytes	with	GM-CSF	is	not	
sufficient	to	create	Mo-DC.	Incubation	of	CD14+	immune	selected	monocytes	with	GM-CSF	
still	display	expression	of	CD14	and	it	is	not	until	IL-4	is	introduced	that	CD14	expression	is	
decreased	(Ohradanova-Repic	et	al.,	2016,	Sallusto	and	Lanzavecchia,	1994).	Freeman	et	al.	
(2007)	 describe	 potent	 anti-cancer	 immune	 responses	 from	GM-CSF	 combined	with	 PGE2	
stimulation	of	mouse	anti-human	CMRF-56+	immune	selected	cells.	PGE2	has	been	shown	to	
be	crucial	for	 inducing	Mo-DC	CCR7	expression	and	chemotactic	migration	(De	Vries	et	al.,	
2003).	However,	suppression	of	T	cell	priming	by	Mo-DC	in	the	presence	of	PGE2	has	been	
observed	 (Muthuswamy	 et	 al.,	 2010).	 Furthermore,	 T	 cells	 incubated	 in	 the	 presence	 of	
PGE2	have	shown	a	decrease	in	CD25	that	suggests	a	decrease	in	T	cell	growth	(Rincon	et	al.,	
1988).	 Therefore	 a	 BDC	 stimulation	method	 that	 facilitates	 BDC	migration,	without	 PGE2,	
whilst	augmenting	T	cell	responses	needs	to	be	established.	
Multiple	 tumour	 antigen	 loading	 techniques	 exist	 including:	 in	 vivo	 and	 in	 vitro	 peptide	
loading,	and	tumour	cell	fusions.	Tumour	antigen	loading	by	IVT	mRNA	transfection	is	able	
to	generate	a	multi-epitope	response	without	HLA	restrictions,	which	is	usually	encountered	
by	traditional	peptide	loading	methods	(Van	Nuffel	et	al.,	2010).	Transfection	of	Mo-DC	with	
tumour	antigen	mRNA	has	been	used	to	generate	pre-clinical	data	and	also	used	in	Phase	I	
and	 II	 clinical	 trials	 where	 they	 have	 demonstrated	 the	 ability	 to	 drive	 patients	 into	
remission	(Bonehill	et	al.,	2009,	Michiels	et	al.,	2006,	Van	Nuffel	et	al.,	2012a,	Van	Tendeloo	
et	al.,	2010,	Wilgenhof	et	al.,	2016).	Transfection	efficiency	 is	dependent	on	cell	type	with	
non-proliferating	 cells	 such	 as	 BDC	 are	 hard	 to	 transfect.	 Nucleofection	 is	 a	 technology	
capable	 of	 transfecting	 difficult	 cell	 lines	 that	 delivers	 genetic	 material	 not	 only	 to	 the	
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cytoplasm	but	also	to	the	nucleus,	whilst	minimally	affecting	cell	viability.		
In	Chapter	 3,	 I	 demonstrated	 that	hCMRF-56	 is	 able	 to	 isolate	BDC	and	enrich	CD1c+	 and	
CD141+	 BDC	 subsets	 using	 a	 single	 step	 immune	 selection,	 negating	 the	 need	 to	
manufacture	 in	 vitro	 derived	 Mo-DC.	 The	 following	 chapter	 examines	 the	 effect	 of	 IVT	
mRNA	 transfection	 on	 hCMRF-56+	 immune	 selected	 cells	 and	 their	 ability	 to	 generate	
antigen	specific	T	cell	immune	responses	in	healthy	donors.	Multiparameter	flow	cytometry	
was	 used	 to	 assess	 the	 phenotype	 of	 transfected	 hCMRF-56+	 immune	 selected	 BDC	
measuring	 activation	 and	 co-stimulatory	 cell	 surface	 molecules.	 CCL21	 specific	 in	 vitro	
migration	 by	 hCMRF-56+	 immune	 selected	 cells	was	 assessed.	 Furthermore,	 trafficking	 of	
hCRMF-56+	 immune	 selected	 cells	 to	 draining	 lymph	 nodes	 and	 through	 mouse	 ear	
lymphatics	was	observed.	Antigen	specific	HLA-A*0201	complexes	from	hCMRF-56+	immune	
selected	cells	was	detected	by	multiparameter	flow	cytometry	and	compared	to	Mo-DC.	T	
cell	 activation	 was	 measure	 by	 IFNγ	 and	 CD107a	 production	 when	 exposed	 to	 antigen	
peptide.	Finally,	antigen	specific	T	cells	were	used	to	measure	antigen	specific	cytotoxicity	
by	loading	Calcein-AM	labelled	T2	cells	with	relevant	or	irrelevant	peptide.	
4.2 Results	
4.2.1 Production	of	 IVT	mRNA	 for	hCMRF-56+	 immune	 selected	 cells	 and	Mo-DC	
transfection	
GFP,	 FMP	 and	 WT1	 IVT	 mRNA	 were	 routinely	 produced	 for	 transfection	 of	 hCMRF-56+	
immune	selected	cells	and	Mo-DC.	Coding	sequences	for	GFP,	FMP	and	WT1	were	encoded	
in	pGEM4ZA64	with	the	WT1	coding	sequence	inserted	into	pGEM4ZA64	is	shown	in	Figure	
4.1.A.	As	a	measure	of	quality	control,	 IVT	mRNA	was	periodically	assessed	during	the	 IVT	
mRNA	 production	 process	 and	 at	 the	 completion	 of	 production	 with	 the	 Bioanalyzer	 as	
shown	in	Figure	4.1.B&C.	The	size	of	the	IVT	mRNA	transcript,	concentration	and	purity	was	
measured	with	the	Bioalayzer	and	compared	to	the	expected	size.	
4.2.2 Optimisation	of	IVT	mRNA	transfection	for	hCMRF-56+	immune	selected	cells	
and	Mo-DC	
Nucleofection	was	the	method	used	to	transfect	hCMRF-56+	immune	selected	cells	and	Mo-
DC	 with	 IVT	 mRNA.	 Nucleofection	 is	 an	 advancement	 on	 traditional	 electroporation	
technologies	that	delivers	genetic	material	to	the	cytoplasm	and	nucleus.	
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Production	of	IVT	mRNA	workflow	required	multiple	steps	to	ensure	sufficient	quantity	and	
quality	was	obtained.	A)	A	schematic	illustrating	full	length	coding	sequence	transcript	that	
was	previously	cloned	into	pGEM4ZA64.	Features	of	pGEM4ZA64	include:	T7	promoter	site,	
poly-A	 tail	 after	 3’	 untranslated	 region	 of	 protein	 transcript,	 SpeI	 restriction	 site	 directly	
after	 poly-A	 tail	 site	 for	 linearisation	 of	 pGEM4ZA64	 and	 ampicillin	 resistance	 gene.	 B)	
pGEM4ZA64/WT1	was	 linearised	 as	 described	with	 SpeI	 restriction	 enzyme.	 Samples	with	
and	 without	 SpeI	 restriction	 enzyme	 treatment	 were	 visualised	 by	 gel	 electrophoresis	 to	
confirm	size	and	linearisation	of	digested	sample.	L)	1Kb	Plus	DNA	ladder	(Life	Technologies;	
10787-018),	 1)	 Undigested	 supercoiled	 pGEM4ZA64/WT1	 and	 2)	 Linearised	
pGEM4ZA64/WT1	digested	with	SpeI	restriction	enzyme.	C)	An	example	of	WT1	IVT	mRNA	
assessed	by	Bioanalyzer	2000.		
	
Figure	4.1	Production	of	IVT	mRNA	
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This	 method	 is	 particularly	 useful	 with	 non-proliferating	 cells.	 However,	 nucleofection	
conditions	are	dependent	on	cell	 type	with	optimal	 conditions	need	 to	be	established	 for	
each	cell	type.	To	determine	the	optimal	IVT	mRNA	transfection	conditions,	1-2x106	hCMRF-
56+	 immune	 selected	 cells	 or	Mo-DC	were	 transfected	with	 10μg/mL	GFP	 IVT	mRNA	 and	
translation	 of	 GFP	 IVT	 mRNA	 was	 measured	 by	 multiparameter	 flow	 cytometry.	 Single	
stranded	 IVT	mRNA	was	 produced	 using	 linearised	 pGEM4ZA64	 inserted	with	 full	 protein	
coding	 sequence,	 including	 both	 5’	 and	 3’	 gene	 untranslated	 regions.	 T7	 polymerase	
promoter	site	was	situated	before	the	5’	untranslated	region	and	a	polyA	tail	was	 located	
directly	 after	 the	 3’	 untranslated	 region.	 hCMRF-56+	 immune	 selected	 cells	 or	 Mo-DC	
transfection	 conditions	 were	 tested	 using	 nucleofection	 reagents	 provided	 by	 the	
manufacturer.	Translation	of	GFP	mRNA	and	 transfection	 related	mortality	 for	hCMRF-56+	
immune	selected	cells	was	assessed	at	4,	24	and	48hrs	after	GFP	IVT	mRNA	transfection	and	
assessed	by	multiparameter	 flow	cytometry.	Transfection	 related	mortality	was	measured	
by	 loss	 of	 cell	 membrane	 integrity	 by	 excluding	 PI+	 cells	 after	 transfection	 with	 GFP	 IVT	
mRNA.	Transfection	efficiency	was	measured	by	%	GFP	expression	by	hCMRF-56+	 immune	
selected	cells	or	Mo-DC.	
Figure	 4.2.A	 shows	 IVT	 mRNA	 transfection	 conditions	 tested	 for	 hCMRF-56+	 immune	
selected	 cells	 and	 Mo-DC	 measuring	 cell	 transfection	 related	 mortality	 and	 %	 GFP	
expression.	 	 Two	 favourable	 IVT	mRNA	 transfection	programs	were	 identified	 for	hCMRF-
56+	 immune	 selected	BDC.	 Program	CL133	 showed	87.6%	GFP	expression	with	 11.5%	 cell	
death.	Program	CU110	 showed	82.0%	eGFP	expression	with	2.5%	cell	 death.	 Transfection	
program	CU110	showed	greater	viability	compared	to	CL133	and	CU110	was	selected	for	all	
future	 IVT	 mRNA	 transfection	 for	 hCMRF-56+	 immune	 selected	 cells.	 For	 Mo-DC,	 one	
transfection	 program	 was	 identified	 that	 gave	 comparable	 results	 to	 hCMRF+	 immune	
selected	 BDC	 in	 terms	 of	 IVT	 mRNA	 translation	 and	 viability.	 The	 transfection	 program	
EH101	 showed	 78.0%	 GFP	 expression	 with	 14.0%	 cell	 death.	 Despite	 having	 a	 larger	 cell	
death	 than	 IVT	 mRNA	 transfected	 hCMRF-56+	 immune	 selected	 cells,	 this	 program	 was	
selected	 for	 all	 future	 Mo-DC	 IVT	 mRNA	 transfections	 due	 to	 achieving	 similar	 GFP	
expression.	
Figure	 4.2.B	 displays	 GFP	 expression	 after	 4hrs	 by	 B	 cells	 was	 greater	 than	 monocytes,	
84.26%	and	77.63%	respectively.	
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hCMRF-56+	 immune	 selected	 cells	 or	Mo-DC	were	 transfected	with	 GFP	 IVT	mRNA	 using		
transfection	 conditions	 as	 recommended	 by	 the	 manufacturer.	 A)	 Transfection	 related	
mortality	and	%	GPF	expression	were	measured	4hrs	after	transfection	for	both	hCMRF-56+	
immune	 selected	 cells	 and	 Mo-DC.	 B)	 GFP	 expression	 by	 hCMRF-56+	 immune	 selected	
constituents,	including	BDC	subsets,	was	measured	by	multiparameter	flow	cytometry.	C)	%	
hCMRF-56+	immune	selected	cells	viability	was	measured	by	excluding	PI+	cells	at	4,	24	and	
48hrs	after	GFP	IVT	mRNA	transfection	using	CU110	transfection	conditions.	n=1	 	
Figure	4.2	Optimisation	of	IVT	mRNA	transfection	conditions	for	hCMRF-56+	immune	selected	cells	
and	Mo-DC	
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BDC	 subsets	GFP	expression	was	 variable	with	 the	CD141+	BDC	 (93.21%)	 showing	 greater	
GFP	expression	than	CD1c+	BDC	(75.43%).	CD141+	BDC	showed	the	greatest	GFP	expression	
for	 any	 immune	 cell	 despite	 their	 rarity.	Mo-DC	 transfected	with	 GFP	 IVT	mRNA	 showed	
73.9%	eGFP	expression,	which	is	similar	to	hCMRF-56+	immune	selected	CD1c+	BDC	subset	
and	hCMRF-56+	immune	selected	monocytes.	
Transfection	of	cells	with	IVT	mRNA	can	affect	viability	resulting	in	greater	cell	death	due	to	
the	 voltages	 applied	 when	 transfecting	 cells.	 However,	 viability	 of	 hCMRF-56+	 immune	
selected	cells	transfected	with	GFP	IVT	mRNA	was	greater	than	80%	as	seen	in	Figure	4.2.C.	
The	greatest	viability	observed	was	at	48hrs.		
4.2.3 Phenotype	of	IVT	mRNA	transfected	hCMRF-56+	BDC	
It	has	been	discussed	that	BDC	are	the	most	powerful	APC.	To	assess	the	effect	of	IVT	mRNA	
transfection	on	hCMRF+	 immune	selected	BDC	expression	of	activation	and	co-stimulatory	
cell	surface	molecules,	multiparameter	flow	cytometry	was	used	to	measure	the	expression	
of	 CD40,	 CD54,	 CD80,	 CD83,	 CD86	 and	 CCR7	 and	 compare	 the	 expression	 to	 hCMRF+	
immune	 selected	 BDC	 observed	 in	 0.	 hCMRF-56+	 immune	 selected	 cells	 were	 stimulated	
with	GM-CSF	for	2hrs	followed	with	transfection	in	the	presence	or	absence	(mock)	of	 IVT	
mRNA,	 or	 not	 transfected.	 After	 transfection,	 hCMRF-56+	 immune	 selected	 cells	 were	
incubated	 for	 20hrs	 for	 detection	 of	 IL-6,	 TNF	 and	 IL-12p70	 in	 cell	 culture	 supernatant.	
Multiparameter	flow	cytometry	was	used	to	measure	the	%	expression	of	activation	and	co-
stimulatory	cell	 surface	molecules.	Expression	of	 transfected	hCMRF-56+	 immune	selected	
BDC	was	compared	to	hCMRF-56+	immune	selected	BDC	that	were	incubated	for	20hrs.		
Figure	 4.3.A-B	 shows	GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 BDC	 incubated	 for	
20hrs	increased	expression	of	CD40	(94.5%),	CD83	(94.9%)	and	CD86	(90.9%).	Expression	of	
CD54	 (93.4%)	 and	 CCR7	 (70.0%)	 remained	 consistent.	 CD80	 expression	 was	 the	 lowest	
(27.3%).	 Figure	 4.3.C-D	 shows	 GM-CSF	 stimulated	 mock	 transfected	 hCMRF-56+	 immune	
selected	BDC	incubated	for	20hrs	with	high	expression	of	CD40	(96.2%),	CD54	(99.3%),	CD83	
(97.4%)	 and	 CD86	 (98.6%).	 Expression	 of	 CCR7	 (77.5%)	 remained	 consistent.	 CD80	
expression	was	the	lowest	(33.8%).	
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hCMRF-56+	 immune	 selected	 cells	 were	 stimulated	 with	 GM-CSF	 before	 transfection	 of	
hCMRF-56+	 immune	 selected	 BDC	 to	 observe	 differences	 in	 phenotype	 and	 cytokine	
secretion	 by	 multiparameter	 flow	 cytometry.	 Mean	 %	 positive	 ±SD	 expression	 and	
representative	 histograms	 of	 CD40,	 CD54,	 CD80,	 CD83,	 CD86	 and	 CCR7	 by	 GM-CSF	
stimulated	hCMRF-56+	immune	selected	BDC.	FMO	and	isotype	controls	for	detecting	CD40,	
CD54,	CD80,	CD83,	CD86	and	CCR7	positivity	were	used.		hCMRF-56+	immune	selected	cells	
A)	 stimulated	 with	 GM-CSF	 and	 B),	 mock	 transfection	 of	 GM-CSF	 stimulated	 hCMRF-56+	
immune	selected	cells	C)	and	D)	or	transfection	of	GM-CSF	stimulated	hCMRF-56+	immune	
selected	cells	with	FMP	IVT	mRNA	E)	and	F).	G)	Fold	changes	of	CD40,	CD54,	CD80,	CD83,	
CD86	and	CCR7	expression	from	hCMRF-56+	immune	selected	BDC	incubated	for	20hrs	as	a	
result	of	GM-CSF	stimulation,	with	or	without	IVT	mRNA	transfection.	Soluble	H)	IL-6,	I)	TNF	
and	 J)	 IL-12p70	was	 detected	 in	 supernatants	 of	 GM-CSF	 stimulated	 hCMRF-56+	 immune	
selected	cells	mock	or	IVT	mRNA	transfected	and	incubated	for	20hrs.	n=3.	
Figure	 4.3	 Effect	 of	 IVT	mRNA	 transfection	 on	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	
BDC	cell	surface	phenotype	and	cytokine	production	
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Figure	 4.3.E-F	 shows	 GM-CSF	 stimulated	 FMP	 IVT	mRNA	 transfected	 hCMRF-56+	 immune	
selected	 BDC	 incubated	 for	 20hrs	 increased	 expression	 of	 CD40	 (95.4%),	 CD54	 (98.3%),	
CD83	 (96.2%),	 CD86	 (98.8%)	 and	 CCR7	 (91.1%).	 Again,	 CD80	 expression	 was	 the	 lowest	
(55.3%).	 CD80	 expression	 showed	 the	 greatest	 expression	 increase	 from	 5.7%	 to	 27.3%	
between	 hCMRF-56+	 immune	 selected	 BDC	 incubated	 for	 20hrs	 and	 FMP	 IVT	 mRNA	
transfected	GM-CSF	stimulated	hCMRF-56+	immune	selected	BDC	samples.	This	resulted	in	a	
9.7X	 fold	 increase	 from	hCMRF-56+	 immune	 selected	BDC	 incubated	 for	20hrs	 to	GM-CSF	
stimulated	hCMRF-56+	immune	selected	BDC	transfected	with	FMP	IVT	mRNA	incubated	for	
20hrs	as	 shown	 in	Figure	4.3.G.	No	statistically	 significant	 increase	 for	CD40,	CD54,	CD83,	
CD86	and	CCR7	expression	was	observed	between	GM-CSF	stimulated	hCMRF-56+	immune	
selected	BDC	transfected	with	FMP	IVT	mRNA	or	mock,	or	no	transfection.	
The	null	 effect	of	 IVT	mRNA	 transfection	was	observed	by	GM-CSF	 stimulated	hCMRF-56+	
immune	selected	cells.	Cytokines	IL-6,	TNF	and	IL-12p70	were	measured	in	the	cell	culture	
supernatant.	 hCMRF-56+	 immune	 selected	 cells	 were	 stimulated	 with	 GM-CSF	 for	 2hrs	
before	 transfection	 with	 or	 without	 FMP	 IVT	 mRNA	 and	 incubation	 for	 20hrs.	 The	
supernatants	 from	 incubated	 cells	 were	 harvested	 and	 IL-6,	 IL-12p70	 and	 TNF	 were	
measured.	 In	 Figure	 4.3.H-I	 both	 IL-6	 and	 TNF	were	 detected	 following	mock	 or	 FMP	 IVT	
mRNA	transfection	from	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells.	No	IL-12p70	
was	detected	as	shown	in	Figure	4.3.J	by	any	sample.	No	statistical	difference	was	achieved	
for	TNF,	 IL-6	or	 IL-12p70	secretion	comparing	mock	transfection	to	 IVT	mRNA	transfection	
GM-CSF	stimulated	hCMRF-56+	immune	selected	cells.	
4.2.4 hCMRF-56+	immune	selected	cells	migration	studies	
Migration	 of	 hCMRF-56+	 immune	 selected	 cell	 was	 measured	 by:	 chemotaxis	 to	 CCL21,	
migration	through	transendothelial	mouse	ear	lymphatics,	and	to	draining	SCID	mice	lymph	
nodes.	In	vitro	chemotaxis	demonstrates	chemokine	dependent	migration.	However,	assays	
modelling	 chemokine	 dependent	 migration	 with	 human	 cells	 in	 animal	 models	 are	
uncommon.	 Therefore	 migration	 through	 mouse	 ear	 lymphatics	 and	 to	 draining	 lymph	
nodes	were	used	to	assess	in	vivo	BDC	migration	to	lymphoid	organs.	These	assays	were	all	
used	 to	 demonstrate	 superior	 hCMRF-56+	 immune	 selected	 BDC	 migration	 compared	 to	
other	hCMRF-56+	 immune	selected	APC	and	Mo-DC,	and	that	FMP	 IVT	mRNA	transfection	
does	 not	 affect	 chemotaxis.	 CCR7	 expression	 by	 hCMRF-56+	 BDC	 suggests	 they	 should	
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migrate	to	CCL21,	and	therefore	through	lymphatics	to	draining	lymph	node.	Whereas	low	
CCR7	expression	by	B	cells	and	monocytes	suggests	poor	chemotaxis	to	CCL21.		
4.2.4.1 in	vitro	chemotaxis	to	CCL21	
To	determine	 if	 IVT	mRNA	 transfection	 impairs	migration	of	 hCMRF-56+	 immune	 selected	
cells,	cell	culture	conditions	including:	unstimulated	or	stimulated	with	GM-CSF	followed	by	
no	 transfection,	 FMP	 IVT	mRNA	 transfection	 or	mock	 transfection	were	 tested	 for	 CCL21	
specific	 chemotaxis.	 hCMRF-56+	 immune	 selected	 cells	 from	 multiple	 conditions	 were	
loaded	on	to	a	5μm	pore	size	transwell	 insert	and	allowed	to	migrate	to	CCL21	for	4hrs	at	
37°C	 5%	 CO2.	 Migration	 of	 hCMRF-56+	 cells	 was	 enumerated	 by	 multiparameter	 flow	
cytometry	and	specific	migration	was	calculated.	Mean	%	CCL21	specific	migration	±SD	by	
hCMRF-56+	immune	selected	BDC	and	hCMRF-56+	immune	selected	B	cells	and	monocytes	
for	each	condition	were	calculated.	
Results	 in	Figure	4.4.A	 show	hCMRF-56+	 immune	selected	BDC	with	high	CCR7	expression	
and	suggests	migration	to	CCL21.	CCR7	expression	by	hCMRF-56+	 immune	selected	BDC	 is	
high	 after	 GM-CSF	 stimulation	 and	 low	 by	 hCMRF-56+	 immune	 selected	 B	 cells	 and	
monocytes.	 Low	 CCR7	 expression	 suggests	 poor	 migration	 to	 CCL21.	 Figure	 4.4.B	 results	
show	 hCMRF-56+	 immune	 selected	 BDC	 migrated	 to	 CCL21	 demonstrated	 by	 in	 vitro	
chemotaxis	assay.	Unstimulated	hCMRF-56+	immune	selected	BDC	or	stimulation	with	GM-
CSF	 resulted	 in	migration	 to	 CCL21,	 with	 respective	mean	 values	 of	 30.06%	 and	 20.87%.	
CCL21	 specific	 migration	 by	 mock	 or	 FMP	 IVT	 mRNA	 transfected	 hCMRF-56+	 immune	
selected	BDC	was	27.44%	and	24.93%,	respectively.	GM-CSF	stimulation	or	transfection	with	
or	 without	 IVT	 mRNA	 did	 not	 alter	 the	 ability	 of	 hCMRF-56+	 immune	 selected	 BDC	 to	
migrate	 to	 CCL21.	 Regardless	 of	 GM-CSF	 stimulation	 or	 transfection,	 hCMRF-56+	 immune	
selected	B	cells	and	monocytes	did	not	migrate	to	CCL21	as	effective	as	hCMRF-56+	immune	
selected	 BDC.	 Unstimulated	 hCMRF-56+	 immune	 selected	 B	 cells	 and	 monocytes	 or	
stimulated	with	GM-CSF	did	not	migrate	to	CCL21,	with	respective	mean	values	of	2.1%	and	
3.3%.	CCL21	specific	migration	by	mock	or	FMP	IVT	mRNA	transfected	hCMRF-56+	immune	
selected	 B	 cells	 and	 monocytes	 was	 5.6%	 and	 2.2%,	 respectively.	 Statistically	 significant	
differences	between	each	hCMRF-56+	immune	selected	BDC	condition	and	each	hCMRF-56+	
immune	selected	B	cells	and	monocytes	condition	were	observed	(p<0.01).	
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hCMRF-56+	 immune	 selected	 cells	 were:	 unstimulated	 or	 stimulated	 with	 GM-CSF	 were	
transfected	with	or	without	FMP	IVT	mRNA.	Cells	were	loaded	on	to	a	5μm	transwell	insert	
and	allowed	to	migrate	to	CCL21	for	4hrs.	After	4hrs,	the	cells	were	harvested	and	absolute	
counts	 of	 hCMRF-56+	 immune	 cell	 populations	 were	 determined.	 The	 %	 CCL21	 specific	
migration	 was	 calculated	 and	 mean	 values	 shown.	 A)	 CCR7	 expression	 for	 GM-CSF	
stimulated	 hCMRF-56+	 immune	 selected	 cells	 shows	 high	 expression	 on	 BDC,	 and	 low	
expression	by	B	cells	and	monocytes.	B)	hCMRF-56+	immune	selected	BDC	regardless	of	GM-
CSF	 stimulation,	 or	 transfection	 with	 or	 without	 IVT	 mRNA	 migrate	 to	 CCL21	 at	 similar	
levels.	 Whereas	 hCMRF-56+	 immune	 selected	 B	 cells	 and	 monocytes	 do	 not	 migrate	 to	
CCL21,	 regardless	 of	 GM-CSF	 stimulation	 or	 transfection	 with	 or	 without	 mRNA.	 n=4,	
statistics	were	performed	using	one-way	ANOVA	with	Dunnett’s	multiple	comparison	test,	
**	p<0.01.	
Figure	4.4	in	vitro	migration	of	hCMRF-56+	immune	selected	cells	to	CCL21	
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4.2.4.2 in	 vivo	 migration	 of	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 or	
cytokine	matured	Mo-DC	to	SCID	mice	inguinal	lymph	nodes	
It	was	previously	demonstrated	in	4.2.4.1	that	transfection	does	not	affect	in	vitro	migration	
of	hCMRF-56+	 immune	selected	BDC	to	CCL21,	and	BDC	are	more	efficient	at	migrating	to	
CCL21	 than	 B	 cells	 and	 monocytes.	 Expanding	 on	 this	 knowledge,	 migration	 of	 GM-CSF	
stimulated	hCMRF-56+	immune	selected	BDC	was	compared	to	cytokine	matured	Mo-DC	to	
the	draining	lymph	nodes	in	a	SCID	mouse.	Poor	Mo-DC	migration	to	draining	lymph	nodes	
has	 been	 observed	 in	 clinical	 studies	 with	 research	 indicating	 Mo-DC	 and	 cell	 number	
affecting	in	vivo	migration.	However,	no	comparison	between	hCMRF-56+	immune	selected	
cells	 and	 Mo-DC	 has	 been	 made	 in	 pre-clinical	 or	 clinical	 studies.	 In	 preparation	 for	
examining	 in	 vivo	 migration	 of	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 to	
inguinal	 lymph	 nodes,	 a	 pilot	 study	 was	 conducted	 to	 monitor	 the	 in	 vitro	 migration	 of	
hCMRF-56+	 immune	 selected	 cells	 to	 mouse	 CCL19.	 Migration	 of	 GM-CSF	 stimulated	
hCMRF-56+	 immune	 selected	 cells	 was	 compared	 to	 cytokine	 matured	 Mo-DC	 to	 the	
draining	lymph	nodes	in	a	SCID	mouse.	
In	Figure	4.5.A,	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	were	loaded	on	to	a	
5μm	 pore	 size	 transwell	 insert	 and	 allowed	 to	 migrate	 to	 mouse	 CCL19	 for	 4hrs.	 The	 %	
mouse	CCL19	specific	migration	±SD	by	hCMRF-56+	 immune	selected	BDC	and	hCMRF-56+	
immune	 selected	 B	 cells	 and	 monocytes	 were	 calculated.	 The	 %	 mouse	 CCL19	 specific	
migration	 by	GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 BDC	was	 94.8%	 and	 the	%	
mouse	CCL19	specific	migration	by	GM-CSF	stimulated	hCMRF-56+	immune	selected	B	cells	
and	monocytes	was	16.1%.	This	result	again	supports	the	finding	 in	4.2.4.1	demonstrating	
greater	CCL21	specific	migration	by	hCMRF-56+	immune	selected	BDC	compared	to	hCMRF-
56+	immune	selected	B	cells	and	monocytes.	After	migration	of	GM-CSF	stimulated	hCMRF-
56+	immune	selected	cells	to	mouse	CCL19	was	confirmed,	migration	of	GM-CSF	stimulated	
hCMRF-56+	immune	selected	cells	or	cytokine	matured	Mo-DC	to	inguinal	lymph	nodes	was	
examined.	 Unpaired	 hCMRF-56+	 immune	 selected	 cells	 or	 cytokine	matured	Mo-DC	were	
i.d.	administered	 into	tail	base	of	a	SCID	mouse	and	inguinal	 lymph	nodes	were	harvested	
and	 digested	 after	 6hrs.	 Migration	 of	 hCMRF-56+	 immune	 selected	 cells	 or	 Mo-DC	 to	
inguinal	lymph	nodes	was	detected	by	multiparameter	flow	cytometry.		
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A)	Mouse	CCL19	specific	migration	by	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	
was	assessed	 in	vitro	by	 loading	cells	on	to	a	5μm	transwell	 insert	and	allowed	to	migrate	
for	4hrs,	n=1.	B)	GM-CSF	stimulated	hCMRF-56+	immune	selected	BDC	or	cytokine	cocktail	
matured	Mo-DC	were	 i.d.	administered	 in	 the	 tail	base	of	a	SCID	mouse.	After	6hrs,	mice	
were	euthanised	and	inguinal	 lymph	nodes	were	harvested	and	collagenase	digested.	BDC	
or	Mo-DC	were	identified	and	enumerated	by	hCMRF-56+	expression	in	addition	to	mouse	
CD45-,	CD14-,	CD19-,	CD20-	and	CD45+	by	multiparameter	flow	cytometry.	C)	%	cell	recovery	
from	 inguinal	 lymph	node	was	calculated	 for	cytokine	cocktail	matured	Mo-DC	 (n=	9)	and	
GM-CSF	stimulated	hCMRF-56+	immune	selected	BDC	(n=7).	 	
Figure	4.5	 in	vivo	migration	of	GM-CSF	 stimulated	hCMRF-56+	 immune	selected	BDC	or	 cytokine	
cocktail	matured	Mo-DC	
92	
	
Lymph	nodes	were	stained	with	mouse	CD45,	CD14,	CD19,	CD20,	CD45,	hCMRF-56	and	HLA-
DR.	Mean	%	cell	recovery	±SD	was	calculated	from	number	of	cells	i.d	administered	into	the	
mouse.	
Figure	 4.5.B	 shows	 hCMRF-56	 was	 used	 to	 detect	 both	Mo-DC	 and	 BDC	 cell	 populations	
when	used	 in	conjunction	with	mouse	CD45-	CD14+	CD19+	CD20+	CD45+.	Similar	 to	4.2.4.1	
and	previous	mouse	CCL19	specific	 in	vitro	migration	result,	B	cells	and	monocytes	did	not	
migrate	 to	 SCID	 mice	 inguinal	 lymph	 nodes	 when	 administered	 with	 GM-CSF	 stimulated	
hCMRF-56+	 immune	selected	cells.	A	timepoint	of	6hrs	was	selected	for	comparing	Mo-DC	
and	 BDC	migration	 to	 inguinal	 lymph	 nodes	 based	 of	 the	 in	 vitro	 chemotaxis	 data.	 After	
6hrs,	Figure	4.5.C	 shows	 the	mean	%	cell	 recovery	 from	 inguinal	 lymph	node	 for	 cytokine	
cocktail	 matured	 Mo-DC	 and	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 BDC	 was	
0.22%	and	0.38%,	respectively.	This	result	failed	to	reach	statistical	significance.	No	hCMRF-
56+	 immune	selected	B	cells	and	monocytes	were	detected	 in	mice	 i.d.	administered	with	
hCMRF-56+	immune	selected	cells.	
4.2.4.3 hCMRF-56+	immune	selected	BDC	traffic	through	mouse	lymphatics	
Poor	hCMRF-56+	immune	selected	BDC	and	Mo-DC	migration	to	SCID	mouse	inguinal	lymph	
nodes	 was	 observed	 in	 4.2.4.2.	 To	 determine	 if	 poor	 recovery	 of	 hCMRF-56+	 immune	
selected	BDC	and	Mo-DC	was	due	to	poor	migration	from	site	of	administration	or	viability	
in	a	 live	mouse	model,	trafficking	of	GM-CSF	stimulated	hCMRF-56+	 immune	selected	cells	
was	observed	through	SCID	mice	lymphatic	vessels.	GM-CSF	stimulated	hCMRF-56+	immune	
selected	 cells	were	 labelled	with	CFSE	before	 loading	on	 to	 split	mouse	ears	 stained	with	
LYVE-1	to	visualise	endothelial	lymphatic	vessels	by	microscopy.	GM-CSF	stimulated	hCMRF-
56+	immune	selected	cells	were	allowed	to	migrate	through	split	ears	for	2hr	or	4hrs	before	
PFA	 fixation	 and	 confocal	microscopy	 to	 observe	 co-localised	 cells	 and	 LYVE-1+	 lymphatic	
vessels.	Figure	4.6	shows	hCMRF-56+	immune	selected	cells	labelled	with	CFSE	co-localised	
with	LYVE-1+	lymphatic	vessels.	The	lack	of	CD14,	CD19	and	CD20	staining	to	identify	hCMF-
56+	 immune	 selected	 B	 cells,	 BDC	 and	monocytes	made	 it	 difficult	 to	 identify	 hCMRF-56+	
immune	selected	BDC	migrating	through	lymphatic	vessels.	Despite	the	difficulty	identifying	
specific	 hCMRF-56+	 BDC,	 some	 hCMRF-56+	 immune	 selected	 BDC	 were	 co-localised	 with	
lymphatic	vessels	based	on	morphological	analysis	from	an	experienced	haematologist	and	
microscopy	technician.		
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20X	confocal	microscopy	of	hCMRF-56+	 immune	selected	cells	 stimulated	with	GM-CSF	and	 labelled	with	CFSE	before	 loaded	onto	split	ear	
from	SCID	mice.	Split	ear	was	stained	with	rat	anti-mouse	LYVE-1	and	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	were	allowed	to	
migrate	 through	mouse	ear	 lymphatics	 for	A)	2	hrs	or	B)	4hrs	at	37°C.	After	 incubation,	ears	were	 fixed	with	4%	PFA	and	mounted	before	
confocal	microscopy.	Z	stack	analysis	revealed	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	migrating	through	mouse	ear	lymphatics.	
n=2.	
Figure	4.6	in	vivo	tracking	of	CFSE	labelled	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	through	mouse	ear	lymphatics	
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It	was	difficult	 to	enumerate	and	calculate	 the	number	of	migrated	cells	and	 I	decided	 to	
investigate	other	models	to	observe	hCMRF-56+	BDC	migration.	
4.2.5 FMP	IVT	mRNA	antigen	processing	and	presentation	
The	 ability	 for	 hCMRF-56+	 immune	 selected	 cells	 and	Mo-DC	 to	 translate	 IVT	mRNA	 and	
present	specific	FMP58-66	antigen	was	measured	by	multiparameter	flow	cytometry.	hCMRF-
56+	 immune	selected	cells	or	Mo-DC	were	 transfected	with	FMP	or	WT1	 IVT	mRNA.	After	
IVT	mRNA	transfection,	cells	were	incubated	for	2,	4	and	24hrs	and	expression	of	FMP58-66	
HLA-A*0201	 complexes	 were	 detected	 by	 multiparameter	 flow	 cytometry	 for	 samples	
transfected	 with	 FMP	 IVT-mRA	 or	WT1	 IVT	mRNA.	 Specific	 FMP58-66	 HLA-A*0201	 antigen	
presentation	and	relative	FMP58-66	HLA-A*0201	antigen	presentation	were	calculated.	
Figure	 4.7.A	 shows	 relative	 FMP58-66	 HLA-A*0201	 antigen	 presentation	 (fold	 increase	 at	
24hrs/2hrs)	 by	 hCMRF-56+	 immune	 selected	 BDC	 and	Mo-DC.	 A	 higher	 the	 value	 for	 this	
ratio	 indicates	 greater	 FMP58-66	HLA-A*0201	 complex	presentation.	Relative	 FMP58-66	HLA-
A*0201	presentation	(fold	increase	at	24hrs/2hrs)	by	hCMRF-56+	immune	selected	BDC	and	
Mo-DC	 was	 194.40%	 and	 57.28%,	 respectively.	 FMP	 IVT	 mRNA	 transfected	 hCMRF-56+	
immune	 selected	 BDC	 antigen	 presentation	 result	 is	 3.39	 greater	 than	 FMP	 IVT	 mRNA	
transfected	 Mo-DC.	 No	 statistically	 significant	 difference	 in	 relative	 presentation	 (fold	
increase	at	24hrs/2hrs)	by	hCMRF-56+	immune	selected	BDC	and	Mo-DC	was	observed.		
Figure	4.7.B	shows	efficient	GFP	IVT	mRNA	transfection	by	the	enriched	hCMRF-56+	immune	
selected	 BDC	 subsets,	 CD1c+	 and	 CD141+,	 and	Mo-DC.	 Figure	 4.7.C	 illustrates	 hCMRF-56+	
immune	 selected	 BDC	 are	 greatest	 at	 presenting	 FMP58-66	 HLA-A*0201	 complexes	 at	 2,	 4	
and	 24hrs	 compared	 to	 hCMRF-56+	 immune	 selected	 B	 cells	 and	monocytes.	 hCMRF-56+	
immune	selected	B	cells	present	FMP58-66	HLA-A*0201	complexes	at	2hrs	that	decreased	at	
4hrs	and	this	remained	low	until	24hrs.	hCMRF-56+	immune	selected	monocytes	presented	
FMP58-66	 HLA-A*0201	 complexes	 at	 2hrs	 and	 remained	 constant	 until	 4hrs.	 FMP58-66	 HLA-
A*0201	 complex	 presentation	 declined	 until	 24hrs.	 This	 result	 is	 consistent	 with	
presentation	of	FMP58-66	HLA-A*0201	complexes	Mo-DC	as	observed	in	Figure	4.7.A.		
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Multiparameter	 flow	 cytometry	was	used	 for	 the	detection	of	 hCMRF-56+	 immune	 selected	 cells	HLA-A*0201	 FMP58-66	 complexes	2,	 4	 and	
24hrs	post	FMP	IVT	mRNA	transfection.	hCMRF-56+	immune	selected	cells	or	Mo-DC	were	transfected	with	FMP	IVT	mRNA	or	WT1	IVT	mRNA.	
The	ΔMFI	was	calculated	to	detect	specific	HLA-A*0201	FMP58-66	complexes	on	FMP	IVT	mRNA	transfected	cells.		A	FMO	control	for	detecting	
HLA-A*0201	FMP58-66	complexes	positivity	was	used.	A)	hCMRF-56+	immune	selected	BDC	and	Mo-DC	demonstrated	different	relative	FMP58-66	
HLA-A*0201	 complex	 presentation	measured	 at	 2	 and	 24hrs	 expression.	B)	 GFP	 IVT	mRNA	 transfected	 hCMRF-56+	 CD141+	 and	CD1c+	 BDC	
subsets	show	GFP	expression	at	4hrs.		Mo-DC	transfected	with	GFP	IVT	mRNA	show	comparable	GFP	expression	to	GFP	IVT	mRNA	transfected	
hCMRF-56+	CD1c+	BDC.	C)	hCMRF-56+	immune	selected	cells	present	different	HLA-A*0201	FMP58-66	complex	presentation	kinetics	over	24hrs,	
mean	±	SD.	D)	hCMRF-56+	immune	selected	CD1c+	and	CD141+	BDC	subsets	show	similar	kinetics	over	24hrs,	mean	±	SD.	CD141+	BDC	showed	
greater	FMP58-66	HLA-A*0201	complexes.	n=3-6.	
Figure	4.7	Detection	of	hCMRF-56+	immune	selected	cells	HLA-A*0201	FMP58-66	complexes	by	multiparameter	flow	cytometry	
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hCMRF-56+	immune	selected	BDC	include	both	CD1c+	and	CD141+	BDC	subsets	that	showed	
an	 increase	 in	 FMP58-66	HLA-A*0201	 complex	presentation	 from	2	 to	4hrs	 in	 Figure	4.7.D.	
This	increase	in	FMP58-66	HLA-A*0201	antigen	presentation	remains	consistently	high	up	to	
24hrs.	
4.2.6 IVT	mRNA	transfected	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	
generate	polyfunctional	T	cell	responses	
To	ensure	IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells	initiate	antigen	specific	
T	 cell	 responses,	 hCMRF-56+	 immune	 selected	 cells	 were	 stimulated	 with	 GM-CSF	 and	
transfected	with	FMP	IVT	mRNA	or	mock	transfected.	Transfected	cells	were	incubated	for	
seven	days	with	autologous	hCMRF-56-	immune	selected	cells	at	a	10:1	hCMRF-56-:hCMRF-
56+	BDC.	During	the	incubation	period,	cells	were	supplemented	with	IL-2,	IL-7	and	IL-15.	On	
day	seven,	the	cells	were	harvested	and	incubated	with	FMP58-66	peptide	before	intracellular	
staining	to	detect	IFNγ	and	CD107a	for	CD4+	and	CD8+	T	cell	subsets	by	multiparameter	flow	
cytometry	
Figure	 4.8.A	 shows	 a	 representative	 FACS	 plot	 displaying	 intracellular	 IFNγ	 production	 by	
CD8+	 T	 cells	 expanded	 by	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 mock	
transfected	 or	 FMP	 IVT	mRNA	 before	 FMP58-66	 peptide	 restimulation.	 Figure	 4.8.B	 shows	
IFNγ	production	by	CD4+	and	CD8+	T	cells	when	incubated	with	mock	transfected	or	FMP	IVT	
mRNA	 transfected	GM-CSF	 stimulated	hCMRF-56+	 immune	 selected	 cells.	 IFNγ	production	
by	CD4+	and	CD8+	T	cells	was	statistically	significantly	greater	(p<0.05)	when	incubated	with	
FMP	IVT	mRNA	transfected	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	compared	
to	mock	transfected	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells.	
To	measure	the	ability	of	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	to	prime	a	T	
cell	immune	response	to	a	leukemic	antigen	in	healthy	donors,	hCMRF-56+	immune	selected	
cells	 were	 stimulated	 with	 GM-CSF	 and	 mock	 transfected	 or	 transfected	 with	 WT1	 IVT	
mRNA.	Transfected	cells	were	incubated	for	seven	days	with	autologous	hCMRF-56-	immune	
selected	 cells	 at	 a	 hCMRF-56-:hCMRF-56+	BDC	of	 10:1.	During	 the	 incubation	period,	 cells	
were	 supplemented	 with	 IL-2,	 IL-7	 and	 IL-15.	 On	 day	 seven,	 cells	 were	 harvested	 and	
incubated	with	WT1126-134	peptide	before	 intracellular	 staining	 to	detect	 IFNγ	and	CD107a	
expression	on	both	CD4+	and	CD8+	T	cell	subsets	by	multiparameter	flow	cytometry.	
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Figure	 4.8.C	 shows	 a	 representative	 FACS	 plot	 displaying	 intracellular	 IFNγ	 production	 by	
CD8+	 T	 cells	 incubated	 with	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 mock	
transfected	or	WT1	IVT	mRNA	before	WT1126-134	peptide	restimulation.	Figure	4.8.D	shows	
IFNγ	production	by	CD4+	and	CD8+	T	cells	when	incubated	with	mock	transfected	or	FMP	IVT	
mRNA	 transfected	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells.	 No	 significant	
increase	 in	 intracellular	 IFNγ	 after	 transfected	 hCMRF-56+	 immune	 selected	 cells	 were	
peptide	 restimulated	 was	 detected	 by	 CD4+	 and	 CD8+	 T	 cells.	 Figure	 4.8.E	 shows	 a	
representative	FACS	plot	displaying	cell	degranulation	measured	by	CD107a	expression	by	
CD8+	 T	 cells	 incubated	 with	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 mock	
transfected	or	WT1	 IVT	mRNA.	Figure	4.8.F	shows	CD107a	expression	by	CD4+	and	CD8+	T	
cells	 when	 incubated	 with	 mock	 transfected	 or	 FMP	 IVT	 mRNA	 transfected	 GM-CSF	
stimulated	 hCMRF-56+	 immune	 selected	 cells.	 Statistically	 greater	 (p<0.05)	 CD107a	
expression	was	 observed	 by	 CD4+	 and	 CD8+	 T	 cells	when	 incubated	with	WT1	 IVT	mRNA	
transfected	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 compared	 to	 mock	
transfected	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells.	
WT1126-134+	T	cells	were	generated	 from	HLA-A*0201	healthy	donors	 to	measure	cytotoxic	
activity.	 hCMRF-56+	 immune	 selected	 cells	were	 stimulated	with	GM-CSF	 and	 transfected	
with	WT1	IVT	mRNA	and	cultured	for	21	days	with	a	10:1	hCMRF-56-:hCMRF-56+	BDC.	Cells	
were	supplemented	with	IL-2,	IL-7	and	IL-15	during	the	21	days.	Cells	were	stimulated	with	
autologous	Mitomycin	 C	 treated	 PBMC	 loaded	 with	WT1126-134	 peptide	 every	 seven	 days	
with	two	restimulations	following	the	same	method.	WT1126-134+	CD8+	T	cells	were	detected	
by	multiparameter	flow	cytometry	in	fresh	peripheral	blood	and	after	21	day	expansion	with	
WT1	 IVT	mRNA	hCMRF-56+	 immune	 selected	 cells.	 Cytotoxicity	was	measured	by	Calcein-
AM	 labelled	 T2	 target	 cells	 loaded	with	 relevant	WT1126-134	 or	 KLK411-19	 (control)	 peptide.	
Generated	WT1126-134+	T	cells	and	T2	target	cells	were	incubated	at	a	effector:target	of	50:1	
for	3hrs.	Calcein-AM	released	from	dying	cells	was	measured	in	cell	culture	supernatant	by	
spectroscopy	and	specific	cytotoxicity	calculated	for	WT1126-134	or	KLK411-19	peptide	 loaded	
T2	cells.	The	mean	detection	of	WT1126-134	CD8+	T	cells	measured	by	WT1126-134	dextramer	
found	in	PBMC	pre-expansion	and	post-expansion	was	0.16%	and	0.64%,	respectively.	This	
was	 a	 four	 fold	 expansion	 of	 WT1126-134	 CD8+	 T	 cells.	 The	 mean	 specific	 cytotoxicity	 for	
KLK411-19	and	WT1126-134	loaded	T2	cells	was	6.59%	and	25.79%,	respectively.		
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GM-CSF	 stimulated	hCMRF-56+	 immune	 selected	cells	were	 transfected	with	FMP	or	WT1	
IVT	mRNA,	 or	mock.	 Transfected	 cells	were	 cultured	with	 autologous	 hCMRF-56-	 immune	
selected	 cells	 and	 supplemented	 with	 IL-2,	 IL7	 and	 IL-15	 for	 seven	 days	 before	 re-
stimulation	with	FMP58-66	peptide	or	WT1126-134.	Intracellular	IFNγ	or	CD107a	production	by	
CD4+	and	CD8+	CD3+	T	cells	was	measured	by	multiparameter	flow	cytometry.	FMO	controls	
for	 detecting	 intracellular	 IFNγ,	 CD107a,	 or	 WT1126-134	 positivity	 were	 used.	 A)	
Representative	 flow	 cytometry	 plot	 showing	 intracellular	 IFNγ	 expression	 by	 CD3+	 T	 cells	
after	 incubation	with	mock	transfected	or	FMP	IVT	mRNA	transfected	hCMRF-56+	 immune	
selected	cells.	B)	Intracellular	IFNγ	expression	by	CD4+	and	CD8+	CD3+	T	cells	after	incubation	
with	mock	transfected	or	FMP	IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells.	C)	
Representative	flow	cytometry	plots	showing	intracellular	IFNγ.	D)	Intracellular	IFNγ	by	CD4+	
and	CD8+	T	cells.	E)	CD107a	expression	by	CD3+	cells	after	incubation	with	mock	transfected	
or	WT1	IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells.	 F)	CD107a	expression	by	
CD4+	and	CD8+	T	cells	after	incubation	with	mock	transfected	or	WT1	IVT	mRNA	transfected	
hCMRF-56+	immune	selected	cells.	G)	Representative	flow	cytometry	plots	showing	WT1126-
134
+	 CD8+	 T	 cells	 pre	 and	 post	 21	 days	 expansion.	 H)	 Three	 experimental	 repeats	 for	
expanding	WT1126-134+	CD8+	T	cells.	I)	Expanded	WT1126-134	T	cells	were	cultured	with	calcein	
labelled	T2	cells	loaded	with	WT1126-134	or	KLK411-19	(control)	peptide	at	an	effector:target	of	
50:1	to	measure	antigen	specific	cytotoxicity.	n=3-7,	statistics	generated	using	one-sided	t	
test,	*	p<0.05.	
Figure	4.8	 IVT	mRNA	transfected	GM-CSF	stimulated	hCMRF-56+	 immune	selected	cells	generate	
autologous	polyfunctional	T	cells	
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4.3 Discussion	
Tumour	cell	lysate,	peptide	pulsing	or	Mo-DC-tumour	cell	hybrids	are	methods	to	load	Mo-
DC	 with	 tumour	 antigens	 that	 have	 demonstrated	 clinical	 efficacy	 to	 generate	 immune	
responses	against	haematological	malignancies	and	solid	tumours	(Fadul	et	al.,	2011,	Narita	
et	 al.,	 2015,	 Rosenblatt	 et	 al.,	 2011).	 A	 novel	 method	 to	 generate	 anti-cancer	 immune	
responses	 is	 transfection	of	Mo-DC	with	tumour	antigen	mRNA	(Michiels	et	al.,	2006,	Van	
Nuffel	et	al.,	2012a,	Van	Nuffel	et	al.,	2012b,	Van	Tendeloo	et	al.,	2010).	mRNA	transfection	
has	several	advantages	to	traditional	peptide	antigen	loading	methods.	The	whole	tumour	
antigen	 mRNA	 is	 translated	 and	 presented	 by	 MHC	 class	 I	 and	 II,	 both	 tumour	 antigen	
specific	CD4+	and	CD8+	T	cell	responses	are	generated	(Aarntzen	et	al.,	2013a,	Bonehill	et	al.,	
2004,	 Bonehill	 et	 al.,	 2003,	 Van	 Nuffel	 et	 al.,	 2012a).	 Combining	 CD4+	 and	 CD8+	 T	 cell	
responses	has	been	described	to	enhance	potent	cytotoxic	T	cell	responses	(Bonehill	et	al.,	
2005,	Hoyer	et	al.,	2014,	Van	Nuffel	et	al.,	2012a).	Priming	an	antigen-specific	CD4+	T	cell	
response	induces,	in	particular	IFNγ	secreting	T	cells,	induce	long-lasting	anti-cancer	CD8+	T	
cell	 responses	 (Bonehill	 et	 al.,	 2005).	 This	 research	 is	 the	 first	 study	 of	 primary	 BDC	 that	
have	 been	 transfected	 with	 tumour	 antigen	 mRNA	 to	 create	 an	 in	 vitro	 antigen	 specific	
immune	response.		
Van	Tendeloo	et	al.	 (2010)	 reported	the	use	of	Mo-DC	transfected	with	WT1	mRNA	as	an	
immune	therapy	for	the	treatment	of	AML	after	consolidation	chemotherapy.	A	total	of	10	
patients	 were	 recruited	 for	 this	 Phase	 I/II	 trial	 and	 a	 total	 of	 5/10	 patients	 achieved	
molecular	 complete	 remission,	with	 two	 of	 these	 patients	 relapsing.	Given	 the	 responses	
from	 this	 study,	 it	 was	 hypothesised	 that	 a	 more	 superior	 APC	 transfected	 with	 tumour	
antigen	mRNA	will	create	more	favourable	patient	outcomes	compared	to	Mo-DC.	hCMRF-
56	is	an	alternative	to	generating	Mo-DC	that	has	shown	to	immune	select	for	primary	APC	
including	 B	 cells,	 BDC	 and	 monocytes.	 A	 heterogeneous	 population	 of	 BDC	 are	 immune	
selected	with	CD1c+	BDC	comprising	of	the	predominant	BDC	population.	Whilst	it	 is	know	
that	BDC	subsets	have	been	described	to	play	different	roles	in	the	immune	system,	no	one	
specific	BDC	subset	has	been	agreed	to	be	the	most	beneficial	BDC.	TLR	stimulation	of	CD1c+	
BDC	 with	 R848	 secretes	 large	 amounts	 of	 IL-12p70	 compared	 to	 CD141+	 mDC	 and	 pDC	
(Nizzoli	et	al.,	2013).	Secretion	of	IL-12p70	was	further	shown	to	support	CD4+	T	cells	to	help	
prime	 CD8+	 T	 cells.	 TLR9	 stimulation	 of	 pDC	 results	 in	 the	 production	 of	 IFN	 subtypes	
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including	 IFNα,	 IFNβ,	 IFNο	 and	 IFNλ	 (Coccia	 et	 al.,	 2004).	 These	 IFN	 subtypes	 have	 been	
shown	 to	 crucial	 for	 inhibiting	 viral	 replication,	 with	 further	 potential	 uses	 for	 treating	
autoimmunity	and	cancer	therapy	(Donnelly	and	Kotenko,	2010,	Hagberg	et	al.,	2011).	
Optimised	 IVT	 mRNA	 transfected	 hCMRF-56+	 immune	 selected	 cells	 and	 Mo-DC	 confirm	
efficient	 GFP	 expression	 and	 good	 viability	 4hrs	 after	 IVT	mRNA	 transfection,	 until	 24hrs	
post	 transfection	 with	 Mo-DC	 and	 48hrs	 with	 hCMRF-56+	 immune	 selected	 cells	 post	
transfection.	 There	 was	 variation	 in	 GFP	 expression	 among	 GFP	 IVT	 mRNA	 transfected	
hCMRF-56+	immune	selected	cells.	All	hCRMF-56+	immune	selected	cells	showed	>75%	GFP	
expression	4hrs	after	transfection.	The	greatest	GFP	expression	was	observed	with	CD141+	
BDC	 subset,	 followed	 by	 B	 cells.	 Interestingly,	 the	 CD1c+	 BDC	 showed	 the	 lowest	 GFP	
expression.	 Kinetic	 studies	 show	 >80%	 of	 cells	 transfected	with	 GFP	 IVT	mRNA	 remained	
viable	after	transfection	up	to	48hrs.	This	was	important	to	ensure	efficient	antigen	delivery	
to	 T	 cells.	 Furthermore,	 administration	 of	 IVT	 mRNA	 transfected	 hCMRF-56+	 immune	
selected	 cells	 into	 patients	 requires	 viable	 cells	 for	 antigen	 presentation	 and	 T	 cell	 co-
stimulation.	
Previous	 research	 has	 demonstrated	 that	 phagocytosis	 of	 necrotic	 cells	 by	 Mo-DC	 has	
shown	 to	 induce	 expression	 of	 CD40,	 CD83	 and	 CD86	 (Sauter	 et	 al.,	 2000).	 Conversely,	
previous	studies	have	demonstrated	APC	secrete	IL-10	and	suppress	IL-12	with	phagocytosis	
of	 apoptotic	 cells	 (Pinzon-Charry	 et	 al.,	 2013,	 Voll	 et	 al.,	 1997).	 These	 combined	 factors	
suggest	the	ingestion	of	necrotic	cells	may	assist	with	antigen	presentation	to	T	cells	by	BDC	
and	other	APC.	Whereas	the	APC	ingestion	of	apoptotic	cells	may	suppress	T	cell	functions	
and	induce	tolerance.	Therefore	the	adoptive	transfer	of	IVT	mRNA	transfected	hCMRF-56+	
immune	 selected	 cells	 containing	 both	 necrotic	 and	 viable	 cells	 may	 enhance	 the	 T	 cell	
immune	 response.	 Mo-DC	 showed	 73.9%	 GFP	 expression	 4hrs	 after	 transfection.	 The	
previously	 described	use	 of	mRNA	 loaded	Mo-DC	by	Van	 Tendeloo	et	 al.	 (2010)	 confirms	
that	Mo-DC	can	be	efficiently	transfected.	Viability	of	Mo-DC	has	previously	shown	not	to	be	
affected	by	mRNA	electroporation	(Van	Driessche	et	al.,	2009).	This	result	is	consistent	with	
IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells	and	Mo-DC.	IVT	mRNA	transfection	
of	hCMRF-56+	 immune	selected	cells	 to	 initiate	a	WT1	specific	 response	has	only	 recently	
been	reported	(Fromm	et	al.,	2016).			
As	previously	discussed,	hCMRF-56+	 immune	selection	results	 in	the	enrichment	of	B	cells,	
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BDC	and	monocytes.	After	transfection	of	hCMRF-56+	 immune	selected	cells	with	FMP	IVT	
mRNA,	 the	 FMP58-66	 antigen	 presentation	 kinetics	 was	 detected	 by	 multiparameter	 flow	
cytometry	on	all	hCMRF-56+	subsets.	B	cells	showed	reduced	FMP58-66	antigen	HLA-A*0201	
complexes	 between	 2	 and	 4hrs,	 with	 maintained	 minimal	 presentation	 up	 to	 24hrs.	
Detection	of	FMP58-66	HLA-A*0201	complexes	on	hCMRF-56+	monocytes	by	multiparameter	
flow	cytometry	shows	antigen	presentation	steadily	decreases	over	24hrs.	hCMRF-56+	BDC	
show	an	increase	 in	FMP58-66	HLA-A*0201	complex	presentation	between	2	and	4hrs,	with	
sustained	presentation	up	to	24hrs.	This	pattern	of	antigen	presentation	was	observed	for	
both	 CD1c+	 and	 CD141+	 BDC	 subsets.	 The	 CD141+	 BDC	 subset	 displayed	 greatest	 eGFP	
expression	and	FMP58-66	HLA-A*0201	complexes	after	transfection	with	either	eGFP	or	FMP	
IVT	 mRNA.	 Translation	 of	 IVT	 mRNA	 by	 CD141+	 BDC	 may	 be	 due	 to	 the	 expression	 of	
cytoplasmic	 PRR	 such	 as	 RIG-I	 and	MDA5	may	 assist	 with	mRNA	 antigen	 processing	 and	
presentation	(Kato	et	al.,	2006,	Yoneyama	et	al.,	2004).	Whilst	CD141+	BDC	do	not	express	
RIG-I,	MDA5	 has	 not	 been	 characterised	 in	 CD141+	 BDC	 or	murine	 CD8+DC	 (Luber	 et	 al.,	
2010).	 TLR3	 expression	 is	 also	 greater	 with	 CD141+	 BDC	 compared	 to	 CD1c+	 BDC	
(Alexopoulou	 et	 al.,	 2001,	 Jongbloed	 et	 al.,	 2010).	 Although	 beyond	 the	 scope	 of	 this	
research,	 it	 would	 be	 beneficial	 to	 determine	 IVT	 mRNA	 motifs	 that	 allow	 efficient	
translation	 by	 BDC	 subsets	 and	 which	 BDC	 subset	 is	 more	 efficient	 at	 processing	 and	
presenting	 antigen	 after	mRNA	 transfection.	 eGFP	 IVT	mRNA	 transfected	Mo-DC	 showed	
comparable	expression	 to	hCMRF-56+	 immune	 selected	monocytes	 transfected	with	eGFP	
mRNA.	These	patterns	of	antigen	presentation	by	hCMRF-56+	immune	selected	cells	subsets	
demonstrate	 that	 BDC	 are	more	 efficient	 at	 translating	 IVT	mRNA	 and	 presenting	MHC	 I	
antigen	 over	 a	 sustained	 period	 of	 time	 than	 B	 cells	 and	 monocytes.	 Each	 of	 the	 cells	
displays	 different	 antigen	 presentation	 kinetics	 and	 these	 kinetics	 need	 to	 be	 considered	
when	preparing	a	clinical	therapeutic	vaccination	to	ensure	maximum	antigen	delivery	to	T	
cells	 as	 this	has	potential	 implications	when	administering	 the	mRNA	 transfected	hCMRF-
56+	 immune	 selected	 vaccine	 in	 to	 the	 patient.	 If	 the	 delivery	 of	 the	 vaccine	 is	 to	 be	
administered	later,	the	antigen	presentation	may	be	solely	reliant	on	BDC.	However,	if	the	
vaccine	 is	 administered	 as	 early	 as	 2hrs	 after	mRNA	 transfection,	 all	 hCMRF-56+	 immune	
selected	constituents	will	be	able	to	present	antigen	to	initiate	an	antigen	specific	immune	
response.	Therefore,	the	cell	therapy	manufacturing	facility	location	needs	to	be	considered	
to	 ensure	 administration	 of	 the	 transfected	 hCMRF-56+	 immune	 selected	 cells	 into	 the	
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patient	at	an	appropriate	time.	
Comparison	 of	 FMP58-66	 HLA-A*0201	 complex	 presentation	 between	 FMP	 IVT	 mRNA	
transfected	hCMRF-56+	 BDC	 and	Mo-DC	 showed	Mo-DC	did	 not	 display	 as	many	 FMP58-66	
HLA-A*0201	complexes	compared	to	hCMRF-56+	immune	selected	BDC,	although	two	Mo-
DC	 outliers	 may	 have	 influenced	 any	 significant	 results.	 Mo-DC	 displayed	 a	 decline	 in	
antigen	presentation	over	24hrs	whereas	hCMRF-56+	immune	selected	BDC	showed	stable	
antigen	 presentation.	 High	 levels	 of	 proteases	 have	 been	 reported	 in	Mo-DC,	 particularly	
with	immature	Mo-DC	(McCurley	and	Mellman,	2010).	Despite	this	study	comparing	Mo-DC	
and	 CD34+	 derived	 dendritic	 cells,	 high	 levels	 of	 proteases	 will	 affect	 mRNA	 antigen	
translation	 and	 MHC	 presentation.	 This	 suggests	 tumour	 antigen	 loading	 by	 mRNA	
transfection	 is	 sensitive	 to	 proteases	 and	 efficient	 translation	 is	 essential	 to	 ensure	
maximum	 antigen	 delivery.	 Kinetics	 of	 antigen	 presentation	 is	 crucial	 for	 Mo-DC	 clinical	
trials	 with	 early	 administration	 suggesting	 a	 more	 favourable	 patient	 outcome.	 This	 will	
ensure	efficient	in	vivo	antigen	presentation.	
The	 expression	 of	 hCMRF-56+	 BDC	 activation	 and	 co-stimulatory	 surface	 molecules	 was	
measured	after	GM-CSF	stimulation.	GM-CSF	is	a	haematopoietic	growth	factor	is	secreted	
by	many	 cells	 and	 has	 effects	 on	 leucocytes,	 including	 BDC	maturation	 (Shi	 et	 al.,	 2006,	
Ushach	and	Zlotnik,	2016).	Previous	studies	reported	the	induction	of	potent	anti-myeloma	
cytotoxic	T	cell	immune	responses	after	GM-CSF	stimulation	of	CMRF-56+	immune	selected	
cells	able	to	elicit	cytotoxic	function	(Freeman	et	al.,	2007).	To	determine	the	effect	of	IVT	
mRNA	 transfection	 on	 hMCRF-56+	 immune	 selected	 BDC	 phenotype,	 the	 expression	 of	
activation	 and	 co-stimulatory	 surface	 was	 measured	 after	 GM-CSF	 stimulation,	 and	
transfection	with	or	without	 IVT	mRNA.	These	BDC	cell	 surface	markers	are	 important	 for	
BDC	 interaction	 with	 T	 cells.	 GM-CSF	 stimulation	 of	 hCMRF-56+	 immune	 selected	 BDC	
showed	 consistent	 high	 surface	 expression	 for	 CD40,	 CD54,	 CD83	 and	 CD86	 after	 20hrs	
compared	to	hCMRF-56+	immune	selected	BDC.	The	surface	expression	increased	with	GM-
CSF	stimulation,	and	further	increased	to	its	highest	surface	expression	with	the	addition	of	
IVT	mRNA	transfection	 to	GM-CSF	stimulation.	The	expression	of	CD80	can	be	 induced	by	
TLR3	 stimulation	 in	 renal	 podocytes	 (Shimada	 et	 al.,	 2012).	 TLR3	 responds	 to	 dsRNA.	
Multiple	studies	have	described	TLR3	expression	by:	Mo-DC,	CD1c+	and	CD141+	BDC	subsets,	
reporting	their	response	to	TLR3	agonists	such	as	Poly(I:C)	(Jongbloed	et	al.,	2010,	Muzio	et	
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al.,	 2000).	 However,	 production	 of	 IVT	mRNA	 results	 in	 single	 stranded	 RNA,	 not	 double	
stranded	RNA	as	with	Poly(I:C).	Detection	of	single	stranded	RNA	from	vesicular	stomatitis	
virus	by	TLR7	has	been	shown	to	produce	IL-12	and	IFNα	(Lund	et	al.,	2004).	Piccioli	et	al.	
(2007)	 describe	 TLR7	mRNA	expression	was	 greatest	with	 CD16+	 BDC	 compared	 to	 CD1c+	
and	CD141+	BDC	subsets.	A	structural	change	 in	 the	single	stranded	RNA	 incorporating	an	
internal	 loop/bulge	has	 been	described	 to	be	 a	 TLR3	 agonist,	which	 also	 resulted	 in	 IFNα	
production	 (Tatematsu	et	 al.,	 2013).	 It	 is	 possible	 that	 IVT	mRNA	may	 include	an	 internal	
loop	and	thus	stimulating	TLR3.	Therefore	transfection	of	hCMRF-56+	immune	selected	BDC	
with	IVT	mRNA	may	act	as	an	agonist	for	TLR7.	 If	the	IVT	mRNA	contains	an	internal	 loop,	
this	may	further	stimulate	TLR3.	Stimulation	of	both	TLR3	and	TLR7	may	suggest	a	possible	
explanation	for	the	increase	in	CD80	expression.		
GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 were	 examined	 for	 their	 ability	 to	
secrete	TNF,	IL-6	and	IL-12p70	after	transfection,	and	also	determine	if	transfection	with	IVT	
mRNA	behaves	as	an	agonist	whereby	increased	TNF,	IL-6	and	IL-12p70	levels	compared	to	
mock	transfection.	No	difference	in	TNF	and	IL-12p70	secretion	was	observed	after	GM-CSF	
stimulated	hCMRF-56+	immune	selected	were	transfected	with	or	without	mRNA.	However,	
an	increase	in	IL-6	secretion	was	detected	in	samples	transfected	with	IVT	mRNA	compared	
to	mock	transfection.	TNF	is	a	pro-inflammatory	cytokine	that	is	produced	by	immune	cells	
in	response	to	inflammation	(Zelova	and	Hosek,	2013).	TNF	was	detected	in	the	supernatant	
of	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	regardless	of	the	transfection	with	
or	 without	 IVT	 mRNA.	 There	 was	 no	 difference	 in	 the	 amount	 of	 TNF	 between	 GM-CSF	
stimulated	hCMRF-56+	immune	selected	cells	and	if	they	were	transfected	with	or	without	
IVT	mRNA.	Mo-DC	stimulated	with	the	addition	of	Poly(I:C)	increases	the	production	of	TNF	
that	is	as	a	result	of	TLR3	stimulation	(Hardy	et	al.,	2009).	Autocrine	TNF	is	secreted	by	Mo-
DC	to	support	cell	survival.	This	was	demonstrated	by	Poly(I:C)	and	TNF	stimulation	of	Mo-
DC	that	improved	Mo-DC	viability	(Lehner	et	al.,	2012).	Therefore	the	presence	of	TNF	may	
play	an	important	role	in	promoting	the	survival	of	GM-CSF	stimulated	hCMRF-56+	immune	
selected	cells.	
No	significant	 increase	of	 IL-6	was	observed	when	GM-CSF	stimulated	hCMRF-56+	 immune	
selected	cells	were	transfected	with	IVT	mRNA	compared	to	mock	transfection.	Soluble	IL-6	
is	 an	 inflammatory	 cytokine	 that	 is	 secreted	 by	 APC	 such	 as	 B	 cells,	monocytes	 and	 BDC	
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(Kamimura	 et	 al.,	 2003).	 An	 increase	 in	 IL-6	 secretion	 by	 GM-CSF	 stimulated	 hCMRF-56+	
immune	 selected	 cells	 transfected	with	 IVT	mRNA	may	 be	 attributed	 to	MDA5	 signalling.	
Kato	et	al.	(2006)	investigated	the	effect	of	inducing	IL-6	production	via	the	MDA5	receptor	
in	response	to	the	single	stranded	virus,	EMCV.	Single	stranded	IVT	mRNA	may	behave	in	a	
similar	manner	to	EMCV	and	binding	to	the	MDA5	receptor.	Binding	of	single	stranded	IVT	
mRNA	 would	 therefore	 increase	 IL-6	 production	 by	 IVT	 mRNA	 transfected	 hCMRF-56+	
immune	selected	cells.	However,	the	presence	of	MDA5	would	need	to	first	be	established.	
The	 cytokine	 IL-12p70	 is	 the	 active	 functional	 heterodimer	 of	 IL-12p35	 and	 IL-12p4	
(Trinchieri,	1994,	Trinchieri,	1995).	Transfection	with	or	without	IVT	mRNA	does	not	affect	
the	secretion	of	IL-12p70	by	hCMRF-56+	immune	selected	cells	stimulated	with	GM-CSF.	IL-
12p70	 is	 secreted	by	BDC	upon	CD40	 ligation	and	 is	 responsible	 for	 the	differentiation	of	
naïve	T	cells	 to	Th1	cells	 (Heufler	et	al.,	1996,	Koch	et	al.,	1996).	Furthermore,	CD1c+	BDC	
secretes	 IL-12p70	when	 TLR3	 is	 stimulated	with	 Poly(I:C),	 and	 not	 Resiquimod	which	 is	 a	
TLR7	 agonist	 (Sittig	 et	 al.,	 2016).	Whilst	 it	 is	 hypothesised	 that	 single	 stranded	 IVT	mRNA	
may	 behave	 as	 an	 agonist	 for	 TLR3	 or	 TLR7,	 just	 as	 their	 respective	 agonists	 Poly(I:C)	 or	
Resiquimod,	there	was	no	IL-12p70	detected	by	any	transfected	sample	in	the	presence	or	
absence	 of	 IVT	mRNA	 confirming	 the	 findings	 by	 Sittig	 et	 al.	 (2016).	 Differences	 in	 TLR3	
expression	were	detected	between	CD1c+	and	CD141+	BDC	subsets,	whilst	no	differences	in	
TLR7/8	mRNA	expression	were	detected	between	these	BDC	subsets	(Piccioli	et	al.,	2007).	
This	suggests	that	stimulation	of	TLR3	for	hCMRF-56+	BDC	might	be	beneficial	for	enhancing	
BDC	activation	levels,	thus	creating	a	stronger	T	cell	response	due	to	the	increased	IL-12p70	
(Nizzoli	 et	al.,	 2013).	However,	 Sittig	et	al.	 (2016)	demonstrate	 the	potency	of	CD1c+	BDC	
stimulated	with	 Resiquimod	 to	 prime	 CD4+	 T	 cells	 compared	 to	 other	 agonists,	 including	
Poly(I:C),	irrespective	of	the	presence	of	IL-12p70.	It	is	important	to	note	that	generation	of	
mature	 Mo-DC	 with	 PGE2	 in	 the	 absence	 of	 IL-12p70	 favour	 a	 Th2	 T	 cell	 response,	 and	
inhibits	 the	 differentiation	 a	 Th1	 response	 (Ebner	 et	 al.,	 2001,	 Kalinski	 et	 al.,	 1997).	 As	
previously	 described,	 the	 culture	 of	Mo-DC	with	 PGE2	 usually	 occurs	 in	 the	 clinic	 for	 the	
maturation	of	Mo-DC.	Therefore	T	cell	 immune	 responses	generated	 from	antigen	 loaded	
Mo-DC	matured	with	PGE2	may	be	biased	to	a	Th2	response.	
An	 In	 vitro	 chemotactic	 assay	 was	 used	 to	 confirm	 hCMRF-56+	 immune	 selected	 cells	
migration	to	CCL21	was	not	affected	by	IVT	mRNA	transfection.	Both	CCL19	and	CCL21	are	
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ligands	to	CCR7,	and	are	responsible	for	immune	cells	migrating	to	and	within	lymph	nodes	
(Forster	et	al.,	2008,	Ricart	et	al.,	2011).	CCR7	knock	out	studies	show	a	lack	of	lymph	node	B	
cell	 follicles	 in	 addition	 to	 irregular	 B	 and	 T	 cell	 composition	 (Forster	 et	 al.,	 1999).	
Furthermore,	lymph	nodes	are	the	site	for	both	naïve	and	memory	T	cells,	which	are	ready	
to	 initiate	 a	 T	 cell	 mediated	 immune	 response.	 Significantly	 less	migration	 to	 CCL21	was	
observed	 by	 transfected	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 B	 cells	 and	
monocytes.	This	supports	the	low	CCR7	expression	after	GM-CSF	stimulation	by	hCMRF-56+	
immune	 selected	 B	 cells	 and	 monocytes.	 Surface	 expression	 of	 CCR7	 was	 detected	 by	
hCMRF-56+	 immune	 selected	 BDC	 directly	 after	 enrichment.	 CCR7	 expression	 by	 GM-CSF	
stimulated	hCMRF-56+	immune	selected	BDC	is	not	affected	by	IVT	mRNA	transfection	and	
is	therefore	it	is	hypothesised	that	 in	vitro	chemotaxis	to	CCL21	will	not	be	affected	by	IVT	
mRNA	transfection.	CCR7	expression	is	one	of	the	factors	that	determines	BDC	migration	to	
CCL21.	Other	factors	that	influence	in	vivo	and	in	vitro	migration	include	the	number	of	cells	
administered	 and	 pre-injection	 with	 inflammatory	 cytokines	 before	 administering	 BDC	
(Aarntzen	 et	 al.,	 2013b,	 MartIn-Fontecha	 et	 al.,	 2003).	 A	 cell	 number	 of	 5x106	 or	 less	
administered	 cells	 was	 shown	 to	 improve	 migration	 efficacy	 to	 draining	 lymph	 nodes	
tracked	by	111In	labelled	pDC.	As	a	smaller	number	of	hCMRF-56+	immune	selected	cells	are	
obtained	 from	 a	 blood	 sample	 compared	 to	 in	 vitro	 generation	 of	 Mo-DC,	 research	 by	
Aarntzen	et	al.	(2013)	would	support	the	use	of	a	reduced	quantity	of	hCMRF-56+	immune	
selected	 cells	 compared	 to	 Mo-DC	 as	 a	 large	 number	 of	 cells	 would	 not	 be	 required	 to	
migrate	to	draining	lymph	nodes.	Transfection	with	or	without	IVT	mRNA	did	not	impair	the	
migration	 of	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 BDC.	 Interestingly,	 hCMRF-
56+	immune	selected	BDC	migrated	as	effectively	as	GM-CSF	stimulated	hCMRF-56+	immune	
selected	 cells.	 This	 supports	 the	 expression	 of	 CD40,	 CD54,	 CD80,	 CD83	 and	 CD86	 cell	
surface	molecules	indicating	BDC	activation.		
As	 it	 was	 found	 that	 transfection	 with	 or	 without	 IVT	 mRNA	 does	 not	 affect	 in	 vitro	
chemotaxis	 to	 CCL21	 for	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 BDC,	 it	 was	
further	 investigated	 to	determine	 if	GM-CSF	 stimulated	hCMRF-56+	 immune	 selected	BDC	
migrate	more	efficiently	 that	 cytokine	matured	Mo-DC	 to	draining	 lymph	nodes	 in	a	 SCID	
mouse.	Mo-DC	were	matured	with	a	combination	of	cytokines	including:	IL-1β,	IL-6,	TNF	and	
PGE2.	 GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 or	 cytokine	 matured	Mo-DC	
were	i.d.	administered	into	the	tail	base	of	a	SCID	mouse	to	enumerate	cells	migrated	to	the	
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draining	 lymph	 nodes	 and	 establish	 which	 cell	 is	more	migratory.	 As	 with	 in	 vitro	 CCL21	
chemotaxis	studies,	no	migration	of	GM-CSF	stimulated	hCMRF-56+	immune	selected	B	cells	
and	monocytes	were	detected	in	the	draining	lymph	nodes.	The	only	population	of	GM-CSF	
stimulated	hCMRF-56+	 immune	selected	cells	detected	in	draining	lymph	nodes	were	BDC.	
This	result	is	consistent	with	in	vitro	CCL21	chemotaxis	transwell	studies	where	hCMRF-56+	
immune	 selected	 BDC	 displayed	 greater	 migration	 than	 co-immune	 selected	 B	 cells	 and	
monocytes.	 When	 cytokine	 matured	Mo-DC	 were	 administered	 into	 a	 SCID	 mouse,	 cells	
were	detected	but	to	a	lesser	amount	than	GM-CSF	stimulated	hCMRF-56+	immune	selected	
BDC,	 although	 two	potential	Mo-DC	and	BDC	outliers	may	have	prevented	any	 significant	
results.	
Clinical	 studies	 examining	 the	 migration	 of	 cytokine	 matured	 Mo-DC	 from	 site	 of	
administration	to	draining	lymph	nodes	describe	low	numbers	of	migrated	cells	to	draining	
lymph	nodes	with	these	studies	investigating	how	the	migration	time,	level	of	activation	and	
number	of	administered	cells	affects	Mo-DC	migration	to	draining	lymph	nodes	(Aarntzen	et	
al.,	 2013b,	 De	 Vries	 et	 al.,	 2003).	 Mo-DC	 consistently	 did	 not	 migrate	 from	 the	 site	 of	
injection	 to	 draining	 lymph	 nodes	 in	 all	 of	 these	 studies.	 It	 was	 therefore	 predicted	 that	
cytokine	 matured	 Mo-DC	 would	 not	 migrate	 to	 draining	 lymph	 nodes	 in	 a	 SCID	 mouse.	
Despite	 the	 encouraging	 result	 that	 demonstrates	 the	 favourable	 migration	 of	 GM-CSF	
stimulated	 hCMRF-56+	 immune	 selected	 cells	 compared	 to	 cytokine	matured	Mo-DC,	 this	
result	 failed	 to	 reach	significance.	Working	with	a	non-human	model	has	complications	 in	
mimicking	 the	 human	 immune	 system	 and	 the	 lack	 of	 migration	 by	 GM-CSF	 stimulated	
hCMRF-56+	immune	selected	BDC	may	be	due	to	an	incompatible	model	system,	or	the	fact	
that	GM-CSF	stimulated	hCMRF-56+	immune	selected	BDC	do	not	migrate.	However	as	GM-
CSF	stimulated	hCMRF-56+	immune	selected	BDC	did	effectively	migrate	to	CCL21	in	vitro,	it	
would	be	assumed	that	these	cells	would	effectively	migrate	to	draining	lymph	nodes.	When	
examining	 the	migration	of	GM-CSF	stimulated	hCMRF-56+	 immune	selected	cells	 labelled	
with	CFSE	 through	mouse	 lymphatics,	 identification	of	CFSE	 labelled	cells	 through	LYVE-1+	
lymphatics	was	required	to	correctly	identify	cells	travelling	through	the	lymphatics.	It	was	
difficult	 to	 identify	 specific	 hCMRF-56+	 cell	 subsets	 due	 the	 limitations	 of	 confocal	
microscopy	 that	 required	 the	 prelabelling	 of	 hCMRF-56+	 immune	 selected	 cells	 with	 a	
fluorescent	dye.	Morphological	analysis	of	the	cells	was	used	to	distinguish	hCMRF-56+	cell	
subsets.	This	proved	challenging	due	to	the	lack	of	fluorescent	staining	to	exclude	hCMRF-
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56+	immune	selected	B	cells	and	monocytes	migrating	through	lymphatics.	To	only	observe	
hCMRF-56+	immune	selected	BDC	migration	through	lymphatics,	B	cells	and	monocytes	can	
be	 depleted	 prior	 to	 hCMRF-56+	 immune	 selection.	 An	 alternative	method	would	 rely	 on	
FACS	 to	 isolate	 individual	 subsets	 of	 hCMRF-56+	 immune	 selected	 B	 cells,	 BDC	 and	
monocytes	 to	 study	 their	ability	 to	migrate	 through	mouse	 lymphatics.	However,	 this	and	
further	migration	 studies	were	 abandoned	 to	 allow	 for	 a	 future	 pre-clinical	 studies	 to	 be	
developed.	
Freeman	et	al.	 (2007)	previously	compared	the	migration	of	mouse	anti-human	CMRF-56+	
immune	selected	cells	stimulated	with	either:	GM-CSF,	PGE2,	GM-CSF	combined	with	PGE2	
or	a	cytokine	cocktail	containing	 IL-1β,	 IL-6,	TNF	and	PGE2.	They	 found	that	stimulation	of	
CMRF-56+	immune	selected	cells	with	GM-CSF	combined	with	PGE2	resulted	in	greatest	BDC	
in	 vitro	 chemotaxis	 to	CCL21.	Variable	migration	of	Mo-DC	has	been	observed	with	 some	
authors	describing	the	requirement	of	PGE2	to	ensure	migration	to	CCL21	or	draining	lymph	
nodes	(Allaire	et	al.,	2013,	De	Vries	et	al.,	2003).	When	GM-CSF	and	PGE2	stimulated	CMRF-
56+	 BDC	 were	 compared	 to	 cytokine	 cocktail	 matured	 Mo-DC	 in	 an	 in	 vitro	 transwell	
chemotaxis	assay,	BDC	outperformed	Mo-DC	in	their	ability	to	migrate	to	CCL21	(Freeman	
et	al.,	2007).	Both	stimulation	conditions	included	PGE2,	therefore	the	effect	of	the	inclusion	
of	PGE2	to	migration	cannot	be	compared	between	these	two	cells.	Despite	this,	CMRF-56+	
immune	selected	cells	stimulated	with	GM-CSF	without	PGE2	was	found	to	be	sufficient	 in	
inducing	migration	of	CMRF-56+	BDC	to	CCL21	(Freeman	et	al.,	2007,	Fromm	et	al.,	2011).	In	
this	 study,	 GM-CSF	 stimulated	 hCMRF-56+	 BDC	 outperformed	 Mo-DC	 matured	 with	
cytokines,	 including	 PGE2,	 in	 their	 ability	 to	 migrate	 to	 draining	 lymph	 nodes	 in	 a	 SCID	
mouse.	 In	 both	 in	 vitro	 chemotaxis	 and	 in	 vivo	 SCID	mouse	migration	 assays,	 hCMRF-56+	
immune	 selected	 B	 cells	 and	 monocytes	 did	 not	 migrate	 as	 effectively	 as	 hCMRF-56+	
immune	selected	BDC.	
GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	transfected	with	FMP	IVT	mRNA	were	
able	 to	 stimulate	 a	 CD4+	 and	 CD8+	 T	 cell	 response.	 This	 was	 measured	 by	 comparing	
intracellular	 IFNγ	production	between	CD4+	and	CD8+	T	cells	after	antigen	presentation	by	
hCMRF-56+	 immune	 selected	 cells	 transfected	with	 FMP	 IVT	mRNA,	or	mock	 transfection.	
hCMRF-56+	immune	selected	cells	transfected	with	FMP	IVT	mRNA	resulted	in	a	significant	
increase	 in	 intracellular	 IFNγ	 from	 CD4+	 and	 CD8+	 T	 cells	 compared	 to	 mock	 transfected	
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hCMRF-56+	 immune	 selected	 cells	 stimulated	 with	 GM-CSF.	 Restimulation	 with	 FMP58-66	
peptide	is	considered	to	be	HLA-A*0201	restricted.	However	an	antigen	specific	CD4+	T	cell	
immune	 response	 was	 detected	 after	 restimulation	 with	 FMP58-66	 peptide.	 A	 CD4+	 T	 cell	
immune	 response	 from	 a	 self	 antigen	 cryptic	 epitope	 can	 be	 detected	 when	 there	 is	 an	
increase	in	extracellular	antigen	concentration	(Warnock	and	Goodacre,	1997).	MHC	class	II	
restriction	would	have	to	be	confirmed	by	screening	every	donor,	which	was	not	part	of	this	
research.	 It	 is	predicted	 the	CD4+	T	 cell	 response	would	be	highly	 inconsistent	due	 to	 the	
MHC	class	 II	genetic	diversity	of	the	donors.	However,	 it	may	still	be	possible	to	achieve	a	
CD4+	 T	 cell	 immune	 response	 from	 the	 HLA-A*0201	 restricted	 peptide.	 The	 significant	
increase	 in	 CD4+	 and	 CD8+	 T	 cell	 intracellular	 IFNγ	 response	 may	 be	 due	 to	 the	 recall	
response	provided	by	the	 frequency	of	precursor	FMP	T	cells.	Therefore	repeated	antigen	
exposure	 may	 enhance	 T	 cell	 proliferation	 that	 possess	 an	 affinity	 for	 the	 antigen.	
Importantly	there	was	no	detrimental	effect	observed	by	hCMRF-56+	immune	selected	cells	
from	 IVT	mRNA	 transfection	 as	 an	 antigen	 specific	 immune	 response	was	 detected	 from	
FMP	IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells.		
It	proved	more	challenging	to	detect	CD8+	T	cell	intracellular	IFNγ	after	GM-CSF	stimulated	
WT1	IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells	were	incubated	with	hCMRF-
56-	 immune	selected	cells.	Although	WT1	 is	a	 self	 antigen	 in	healthy	 individuals,	 the	WT1	
antigen	 can	 become	 overexpressed	 in	 AML	 and	 solid	 tumours	 such	 as	 colorectal,	
endometrial	and	breast	 cancers	 (Nakatsuka	et	al.,	2006,	Ostergaard	et	al.,	2004,	Qi	et	al.,	
2015).	 T	 cells	 with	 a	 high	 affinity	 for	 self	 antigens,	 such	 as	 WT1,	 are	 rapidly	 deleted	 to	
minimise	autoimmunity	in	healthy	patients.	Therefore	the	frequency	of	WT1	CD8+	T	cells	is	
low	in	healthy	donors	(Schmied	et	al.,	2015,	van	den	Ancker	et	al.,	2013).	This	explains	why	
small	amounts	of	intracellular	IFNγ	were	detected	from	CD4+	and	CD8+	T	cells	cultured	with	
WT1	IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells.	Due	to	the	small	amounts	of	
intracellular	 IFNγ,	 CD107a	was	 also	 included	 as	 an	 additional	marker	 of	 T	 cell	 activation.	
CD107a	also	 known	as	 lysosome	associated	membrane	protein	1	 (LAMP-1)	 is	 a	marker	of	
cellular	degranulation.	A	T	cell	undergoes	degranulation	due	to	the	production	of	cytolysis	
lysosomes,	 followed	with	 these	 lysosomes	 being	 transported	 to	 the	 surface	 (Aktas	 et	 al.,	
2009).	 A	 significant	 difference	 of	 CD107a	 was	 detected	 between	 CD4+	 and	 CD8+	 T	 cells	
cultured	with	autologous	hCMRF-56+	immune	selected	cells	transfected	with	WT1	IVT	mRNA	
or	mock	transfected.	The	amount	of	CD107a	was	greater	than	the	amount	of	IFNγ.	CD107a	
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may	prove	 to	be	 important	 for	detecting	 low	 frequency	 low	affinity	antigen	specific	T	cell	
responses	in	future	clinical	studies.	Other	markers	that	demonstrate	T	cell	responses	include	
IL-2,	TNF,	CD137	and	CD154	 (Bacher	and	Scheffold,	2013,	Precopio	et	al.,	2007).	Cytokine	
production	and	phenotype	of	cells	determine	the	classification	of	cells.	Although	the	T	cells	
were	 not	 phenotyped,	 other	 T	 cell	 activation	 markers	 such	 as	 CD45RA,	 CD45RO,	 CD62L,	
CD95	and	CCR7	in	conjunction	with	the	cytokine	profile	will	classify	the	T	cells	(Mahnke	et	
al.,	2013).	It	has	been	described	that	T	memory	stem	cells	are	beneficial	for	an	anti-cancer	
immune	 response	 as	 they	 possess	 potent	 effector	 functions	 and	 a	 strong	 ability	 to	
proliferate	(Gattinoni	et	al.,	2011,	Klebanoff	et	al.,	2012).	
Transfection	 of	 hCMRF-56+	 immune	 selected	 cells	 with	 IVT	 mRNA	 antigen	 provides	 the	
opportunity	 to	 deliver	 the	whole	 tumour	 antigen,	 including	 other	 potential	 epitopes	 that	
may	be	recognized	by	both	CD4+	and	CD8+	T	cells.	When	the	IVT	mRNA	transfected	hCMRF-
56+	 immune	 selected	 cells	 are	 cultured	 with	 autologous	 T	 cells,	 multiple	 antigen	 HLA	
epitopes	 may	 be	 presented	 to	 the	 T	 cell.	 This	 is	 in	 contrast	 to	 peptide	 loading	 which	
presents	a	specific	single	HLA	epitope.	The	HLA-A*0201	restricted	epitope	was	used	at	the	
end	 a	 week	 to	 restimulate	 antigen	 specific	 T	 cells	 and	 measure	 their	 IFNγ	 or	 CD107a	
response.	This	method	does	not	take	 in	to	consideration	the	other	potential	HLA	epitopes	
presented	to	T	cells,	after	generating	a	multi-epitope	T	cell	immune	response.	
To	measure	antigen	specific	cytotoxicity,	hCMRF-56+	immune	selected	cells	were	stimulated	
with	 GM-CSF	 followed	 transfection	 with	 WT1	 IVT	 mRNA	 and	 incubated	 with	 autologous	
hCMRF-56-	 immune	 selected	 cells	 for	 three	 weeks.	 On	 the	 third	 week,	 expanded	 T	 cells	
were	 used	 as	 effector	 cells	 in	 a	 cytotoxicity	 assay.	 T2	 cells	 loaded	 with	 the	 HLA-A*0201	
WT1126-134	peptide	were	labelled	with	calcein-AM	and	used	as	target	cells.	Loading	T2	cells	
with	 this	peptide	allows	WT1126-134+	CD8+	T	cells	 to	engage	 in	antigen	specific	cytotoxicity.	
However,	 as	 this	 method	 to	 detect	 cytotoxicity	 measures	 all	 target	 cell	 death,	 including	
antigen	specific	cell	death,	care	must	be	taken	to	minimise	spontaneous	target	cell	death	as	
the	antigen	specific	cell	death	may	be	masked	by	the	spontaneous	cell	death.	Although	low	
levels	of	WT1	specific	IFNγ	and	CD107a	production	was	observed	by	T	cells	after	seven	days,	
it	 may	 be	 possible	 that	 these	 low	 levels	 of	 IFNγ	 and	 CD107a	 are	 sufficient	 as	 they	 will	
ultimately	 affect	 in	 vivo	 cytotoxicity	 as	 these	 are	 two	 cytokines	 responsible	 for	 tumour	
suppression	 (Aktas	 et	 al.,	 2009,	 Kaplan	 et	 al.,	 1998).	 Observing	 an	 increase	 in	 IFNγ	 and	
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CD107a	production	may	result	in	faster	tumour	regression.	
mRNA	transfection	of	APC	with	the	whole	TAA	produces	both	CD4+	and	CD8+	T	cell	immune	
responses.	However,	 the	method	used	 throughout	 this	 research	was	 to	 specifically	detect	
CD8+	T	cell	response.	The	generation	of	a	multiple	epitope	immune	response,	including	the	
CD4+	T	cell	 immune	response,	 is	beyond	the	scope	of	this	project	and	will	be	examined	 in	
preparation	for	future	clinical	research.	
The	MHC	antigen	binding	affinity	to	self-antigens	are	variable	(Yu	et	al.,	2004).	To	improve	
the	 immune	 response,	 modifications	 to	 the	 peptide:MHC	 interaction	 or	 the	 TCR	 are	
investigated	as	immune	therapies	(Borbulevych	et	al.,	2010,	Zhao	et	al.,	2015).	Such	changes	
include	 improvements	 to	 the	 binding	 affinity	 of	 the	 TCR	 for	 the	 peptide	 and	 specificity.	
These	 improvements	 to	TCR	binding	affinities	by	genetic	modification	have	demonstrated	
promising	clinical	efficacy	(Kuball	et	al.,	2009).	At	the	present	time,	genetic	modifications	to	
T	 cells	 containing	 improved	 TCR	 binding	 affinities	 have	 proven	 successful	 with	
haematological	malignancies	such	as	CD19+	blood	cancers	(Grupp	et	al.,	2013,	Kalos	et	al.,	
2011).	 However,	 the	 treatment	 of	 solid	 tumours	 is	 yet	 to	 reach	 the	 same	 efficacy	 as	
haematological	malignancies	with	genetically	improved	T	cells	(Kershaw	et	al.,	2006,	Lamers	
et	al.,	2006).	
4.4 Conclusion	
The	novel	TAA	loading	method	of	IVT	mRNA	transfection	was	examined	for	any	detrimental	
effects	from	IVT	mRNA	transfection	to	hCMRF	-56+	immune	selected	cells,	in	particular	BDC.	
IVT	 mRNA	 transfection	 did	 not	 affect	 the	 phenotype	 of	 GM-CSF	 stimulated	 hCMRF-56+	
immune	 selected	 BDC,	 although	 a	 higher	 CD80	 expression	 was	 observed.	 GM-CSF	
stimulated	IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells	still	secreted	cytokine,	
with	a	higher	concentration	of	 IL-6	detected	after	 transfection	with	 IVT	mRNA.	 IVT	mRNA	
did	not	affect	the	migration	of	hCMRF-56+	immune	selected	BDC	to	CCL21	or	draining	lymph	
nodes.	 Minimal	 migration	 of	 hCMRF-56+	 immune	 selected	 B	 cells	 and	 monocytes	 was	
observed	to	CCL21	or	draining	lymph	nodes.	Kinetic	analysis	of	hCMRF-56+	immune	selected	
cells	show	hCMRF-56+	BDC	present	FMP	antigen	for	a	 longer	period	of	 time,	compared	to	
other	 hCMRF-56+	 immune	 selected	 cells	 after	 IVT	mRNA	 transfection.	 This	 also	 held	 true	
when	GM-CSF	stimulated	hCMRF-56+	BDC	were	compared	to	cytokine	matured	Mo-DC.	GM-
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CSF	 stimulated	 IVT	 mRNA	 transfected	 hCMRF-56+	 immune	 selected	 cells	 were	 able	 to	
stimulate	an	antigen	specific	T	cell	response	in	healthy	donors,	for	both	viral	and	leukemic	
antigens.	 This	 was	 measured	 by:	 T	 cell	 activation,	 cytotoxicity	 and	 antigen	 specific	
proliferation.	It	was	often	found	that	low	amounts	of	expanded	viral	and	leukemic	antigen	
specific	T	cells	were	detected	throughout	this	research	when	using	healthy	donors.	Whilst	
these	amounts	are	low,	the	results	from	this	research	demonstrate	the	ability	of	IVT	mRNA	
transfected	hCMRF-56+	 immune	 selected	 cells	 to	 initiate	antigen	 specific	 T	 cell	 responses.	
This	 illustrates	 the	 importance	 to	 test	 the	 feasibility	 of	 IVT	mRNA	 transfected	hCMRF-56+	
immune	 selected	 cells	 from	 AML	 patient	 material	 and	 further	 expanding	 the	 testing	 to	
detect	antigen	specific	CD4+	T	cell	responses.	 	
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5 ENHANCEMENTS	TO	WT1	IVT	mRNA	TRANSFECTED	hCMRF-56+	
CELLS	IMMUNE	THERAPY	
5.1 Introduction	
Recent	advances	in	cancer	immune	therapy	were	described	in	1.2.	An	immune	therapeutic	
option	 for	 the	 treating	melanoma	 patients	 is	 the	 inhibition	 of	 an	 immune	 regulatory	 cell	
surface	 molecule,	 PD-1,	 binding	 to	 its	 ligand	 by	 Nivolumab	 (Brahmer	 et	 al.,	 2010).	 PD-1	
expression	 by	 CD8+	 T	 cells	 is	 upregulated	 following	 chronic	 TCR	 engagement,	 or	 even	
persistent	antigenic	stimulation	by	APC	(Day	et	al.,	2006,	Freeman	et	al.,	2006).	Furthermore	
the	 expression	 of	 PD-1	 is	 enhanced	 by	 the	 presence	 of	 IL-2,	 IL-7	 and	 IL-15	 (Kinter	 et	 al.,	
2008).	In	situations	where	PD-1	interacts	with	PD-L1	or	PD-L2,	chronically	activated	PD-1+	T	
cells	do	not	undergo	proliferation	nor	secrete	TNF,	IFNγ	and	IL-2	(Butte	et	al.,	2007,	Carter	
et	al.,	2002,	Wei	et	al.,	2013).	This	renders	chronically	activated	T	cells	as	non-responsive	in	
the	TME	and	permit	tumour	progression	(Benci	et	al.,	2016).	Inhibiting	ligation	of	PD-1	to	its	
ligands	 with	 Nivolumab	 reinitiates	 cytotoxic	 effector	 T	 cell	 functions	 resulting	 in	
proliferation	and	increased	IFNγ	production	from	chronically	activated	T	cells	(Wang	et	al.,	
2014).	The	use	of	Nivolumab	with	WT1	IVT	mRNA	transfected	hCMRF-56+	immune	selected	
cells	was	examined	to	determine	if	an	enhancement	of	WT1	specific	T	cell	immune	response	
was	observed.	Nivolumab	was	selected	to	inhibit	interactions	between	PD-1	and	its	ligands	
as	it	has	demonstrated	enhanced	T	cell	immune	response	in	clinical	studies	(Johnson	et	al.,	
2015,	Raedler,	2015,	Wang	et	al.,	2014).	I	set	out	to	determine	if	Nivolumab	interacted	with	
hCMRF-56+	immune	selected	cells	and	T	cells	by	reinvigorating	chronically	activated	PD-1+	T	
cells	to	produce	more	CD107a	and	cytotoxic	function.	
Alternative	stimulation	conditions	with	the	use	of	clinically	compatible	reagents	were	also	
examined	 to	 enhance	 the	 expression	 of	 CD80	 by	 hCMRF-56+	 immune	 selected	 BDC.	 As	 it	
was	established	in	4.2.3	that	the	expression	of	CD80	was	the	least	expressed	activation	and	
co-stimulatory	cell	surface	molecule,	CD80	expression	by	GM-CSF	stimulation	was	used	as	a	
baseline.	 Clinically	 compatible	 reagents	 that	 demonstrated	 encouraging	 results	 were	
combined	 with	 GM-CSF	 to	 again	 measure	 expression	 of	 CD80.	 Secreted	 cytokines	 were	
measured	after	stimulation	with	single	or	combination	reagents	to	determine	if	alternative	
clinically	 suitable	 stimulation	 method	 can	 influence	 the	 cytokine	 profile	 of	 stimulated	
hCMRF-56+	immune	selected	cells.	Lastly,	these	two	enhancements	will	provide	preliminary	
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data	to	establish	if	GM-CSF	stimulated	IVT	mRNA	transfected	hCMRF-56+	immune	selected	
cells	or	the	addition	of	checkpoint	inhibitor,	such	as	Nivolumab,	can	be	used	to	augment	an	
antigen	specific	immune	response	and	justify	the	use	in	a	clinical	trial.	
5.2 Results	
5.2.1 PD-L1	expression	on	hCMRF-56+	cell	subsets	
Chronically	activated	T	 cells	express	PD-1	 that	binds	 to	 its	 ligands:	PD-L1	and	PD-L2.	 Solid	
tumour	cells	express	PD-L1,	which	provides	a	mechanism	for	immune	evasion	(Juneja	et	al.,	
2017).	The	therapeutic	mAb	Nivolumab	binds	to	PD-1,	blocking	the	 ligation	between	PD-1	
and	 PD-L1	 (CD274)	 or	 PD-L2	 (CD273).	 To	 determine	 if	 BDC	 expressed	 CD274,	 I	 utilised	
hCMRF-56+	 immune	 selected	 cells	 and	measured	%	 CD274	 expression	 by	multiparameter	
flow	cytometry.	
	hCMRF-56+	 cells	 were	 immune	 selected	 and	 %	 CD274	 expression	 was	 measured	 by	
multiparameter	 flow	 cytometry	 as	 shown	 in	 Figure	 5.1.A	 and	 Figure	 5.1.B.	 CD16+	 BDC	
displayed	 the	 highest	%	 CD274	 expression	 (89.6%),	 followed	 closely	 by	 CD14+	monocytes	
and	 CD141+	 BDC	 both	 with	 87.6%	 CD274	 expression.	 CD1c+	 BDC	 showed	 79.2%	 CD274	
expression.	 Lastly,	B	 cells	 showed	44.5%	CD274	expression.	 This	data	 suggests	Nivolumab	
may	 be	 used	 to	 block	 the	 interaction	 between	 PD-1+	 T	 cells	 and	 hCMRF-56+	 immune	
selected	cells.	
5.2.2 Titration	of	Nivolumab	on	T	cells	subsets	
To	ascertain	 if	Nivolumab	binds	 to	T	cells	 in	healthy	donors,	a	 titration	of	Nivolumab	was	
performed	on	healthy	donor	CD8+	T	cells	subsets.	PBMC	were	isolated	and	incubated	with	
serially	 diluted	 Nivolumab	 followed	 with	 detection	 of	 Nivolumab	 by	 goat	 anti-human	
secondary	 antibody.	 Finally,	 cells	 were	 incubated	 with	 CD3,	 CD8	 and	 CD45RO	 and	
multiparameter	flow	cytometry	was	used	to	detect	T	cell	subsets.	The	T	cell	subsets	include	
CD45ROhi;	effector	memory	T	cells,	CD45ROlo;	resting	T	cells	and	CD45-;	naïve	T	cells.		
In	Figure	5.2.A	the	CD45ROhi	CD8+	T	cells	showed	the	greatest	binding	of	Nivolumab.	A	dose	
dependent	 response	was	 observed	 for	 Nivolumab	 binding	 showing	 decreased	 Nivolumab	
binding	when	reducing	the	concentration.	CD45ROlo	CD8+	T	cells	also	displayed	a	decrease	in	
Nivolumab	binding	that	also	decreased	in	a	dose	dependent	manner.	CD45RO-	CD8+	T	cells	
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showed	minimal	binding	of	Nivolumab	at	all	concentrations.	No	dose	dependent	response	
was	observed.	The	optimal	saturating	concentration	of	Nivolumab	binding	to	CD45ROhi	and	
CD45ROlo	CD8+	T	cell	populations	was	found	to	be	20μg/mL.	
Figure	5.2.B	shows	representative	histograms	of	Nivolumab	binding	at	the	20μg/mL	optimal	
concentration	 for	 CD45ROhi,	 CD45ROlo	 and	 CD45RO-	 CD8+	 T	 cells.	 Minimal	 binding	 of	
Nivolumab	at	the	optimal	saturating	concentration	was	observed	for	CD45RO-	CD8+	T	cells	
and	 showed	 consistent	 negative	 binding	 of	 Nivolumab.	 The	 optimal	 Nivolumab	
concentration	 for	 both	 CD45ROhi	 and	 CD45ROlo	 CD8+	T	 cell	 populations	 was	 found	 to	 be	
20μg/mL.	 This	 concentration	 of	 Nivolumab	 was	 used	 for	 all	 further	 in	 vitro	 T	 cell	
experiments.	
5.2.3 Late	addition	of	Nivolumab	in	an	MLR	increases	CD8+	T	cell	proliferation	but	
not	IFNγ	production	
In	 order	 to	 determine	 the	 effect	 of	 Nivolumab	 on	 the	 quality	 of	 developing	 an	 immune	
response,	a	one-way	MLR	to	test	both	proliferation	and	IFNγ	response	was	utilised.	The	MLR	
was	 designed	 to	 add	 Nivolumab	 at	 different	 days.	 Irradiated	 stimulating	 cells	 were	
incubated	 with	 responding	 T	 cells	 labelled	 with	 CTV.	 Three	 cryopreserved	 donors	 were	
pooled	 to	 form	 stimulating	 cells	 and	 were	 incubated	 at	 a	 responder:stimulator	 of	 2.5:1.	
Nivolumab	was	added	on	either:	day	1,	day	2,	day	3,	day	4	or	on	day	5.	After	five	days	the	
supernatant	was	collected	to	detect	IFNγ	by	ELISA	and	the	cells	were	harvested	to	measure	
proliferation	of	CD4+	and	CD8+	T	cells.	
Figure	5.3.A,C,E	shows	proliferation	was	only	observed	for	responding	CD4+	and	CD8+	T	cell	
subsets	 when	 incubated	 with	 stimulators.	 A	 significant	 difference	 in	 proliferation	 was	
observed	 for	 CD3+	 T	 cells	when	Nivolumab	was	 added	 on	 day	 4	 compared	 to	Nivolumab	
added	on	day	5	(p<0.05).	The	mean	%	CTV+	T	cells	for	days	1,	2	and	4	was	8.7,	8.3	and	7.7,	
respectively.	 A	 significant	 difference	 in	 proliferation	 was	 only	 observed	 for	 CD8+	 T	 cells	
when	Nivolumab	was	added	on	the	fourth	day	compared	to	Nivolumab	added	on	day	five	
(p<0.05).	No	difference	in	proliferation	was	observed	for	CD4+	T	cells	when	Nivolumab	was	
added	at	any	time	(p>0.05).		
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To	 establish	 the	 potential	 use	 of	 Nivolumab	 in	 enhancing	 antigen	 specific	 T	 cell	 immune	
responses,	PBMC	were	incubated	for	16	hrs.	Following	overnight	incubation	of	PBMC,	they	
were	 stained	with:	hCMRF-56,	CD1c,	CD3,	CD14,	CD16,	CD19,	CD20,	CD56,	CD141,	CD274	
and	 HLA-DR	 to	 identify	 hCMRF-56+	 immune	 cell	 populations	 and	 measure	 expression	 of	
CD274	by	multiparameter	flow	cytometry.	A	FMO	control	for	detecting	CD274	positivity	was	
used.	 A)	 Representative	 histograms	 displaying	 CD274	 expression	 on	 hCMRF-56+	 immune	
selected	cells.	B)	Mean%	expression	of	CD274	by	hCMRF-56+	immune	selected	cells.	n=3.	
	 	
Figure	5.1	CD274	expression	on	hCMRF-56+	immune	cell	populations	
120	
	
	
	
	
	
	
121	
	
	
	
	
	
	
	
To	measure	 the	binding	of	Nivolumab	 to	T	 cell	 subsets,	PBMC	 incubated	 for	16	hrs.	After	
incubation,	 PBMC	 were	 stained	 with	 serially	 diluted	 Nivolumab	 followed	 with	 goat	 anti-
human	AF488.	A	FMO	control	for	detecting	Nivolumab	binding	was	used.	PBMC	were	finally	
stained	with	CD3,	CD8	and	CD45RO	to	identify	memory,	resting	and	naïve	T	cell	populations.	
A)	 Binding	 of	 Nivolumab	 CD45hi,	 CD45ROlo	 and	 CD45RO-	 CD8+	 T	 cells	 at	 different	
concentrations.	The	optimal	Nivolumab	concentration	for	binding	to	CD45hi,	CD45ROlo	and	
CD45RO-	 CD8+	 T	 cells	 was	 found	 to	 be	 20μg/mL	B)	 Representative	 histograms	 displaying	
Nivolumab	binding	to	CD45hi,	CD45ROlo	and	CD45RO-	CD8+	T	cells.	n=1.	
	 	
Figure	5.2	Titration	of	Nivolumab	on	T	cell	subsets	
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The	 amount	 of	 IFNγ	 produced	 by	 the	 one-way	 MLR	 containing	 both	 stimulating	 and	
responding	 cells	 with	 Nivolumab	 added	 on	 day	 one,	 two,	 three,	 four,	 five	 or	 without	
Nivolumab	 was	 7.8ng/mL,	 7.8ng/mL,	 8.8ng/mL,	 8.1ng/mL,	 8.1ng/mL	 and	 7.8ng/mL,	
respectively	are	 shown	 in	Figure	5.4.	The	addition	of	Nivolumab	did	not	 significantly	alter	
the	 capacity	 of	 the	 one-way	 MLR	 to	 produce	 IFNγ	 irrespective	 of	 when	 Nivolumab	 was	
added	(p>0.05).	The	values	 for	 IFNγ	produced	by	the	one-way	MLR	containing	responding	
cells	only	with	Nivolumab	added	on	day	one,	 two,	 three,	 four,	 five	or	without	Nivolumab	
was	1.4ng/mL,	1.4ng/mL,	1.3ng/mL,	1.2ng/mL,	1.6ng/mL	and	1.8ng/mL,	respectively.		
5.2.4 Nivolumab	does	not	affect	the	quality	of	T	cell	responses	after	priming	with	
viral	or	tumour	antigen	IVT	mRNA	transfected	hCMRF-56+	immune	selected	
cells	
In	order	to	determine	how	Nivolumab	affected	the	quality	of	T	cell	responses	after	priming	
with	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	transfected	with	FMP	or	WT1	IVT	
mRNA,	FMP58-66	CD8+	T	cell	expansion	and	degranulation	was	measured	after	seven	days	by	
expression	of	CD107a	for	CD4+	and	CD8+	T	cells	by	multiparameter	flow	cytometry.	Briefly,	
hCMRF-56+	immune	selected	cells	were	stimulated	with	GM-CSF	and	transfected	with	FMP	
or	WT1	 IVT	mRNA.	After	 transfection,	 autologous	hCMRF-56-	 immune	 selected	 cells	were	
cultured	 at	 a	 hCMRF-56+	 BDC:hCMRF-56-	 cell	 of	 10:1	 in	 the	 presence	 or	 absence	 of	
Nivolumab.	Cells	were	 supplemented	with	 IL-2,	 IL-7	and	 IL-15	 throughout	 the	 seven	days.	
On	 day	 seven,	 CD107a	 expression	 on	 CD4+	 and	 CD8+	 T	 cell	 subsets	 was	 detected	 by	
multiparameter	 flow	cytometry	after	 restimulation	with	FMP58-66	or	WT1126-134	peptide.	 In	
addition	to	measuring	CD107a	expression,	FMP58-66	or	WT1126-134	specific	CD8+	T	cells	were	
detected	for	samples	incubated	in	the	presence	or	absence	of	Nivolumab.	Figure	5.5	shows	
the	expansion	of	FMP58-66	CD8+	T	 cells	and	 the	expression	of	CD107a	by	CD4+	and	CD8+	T	
cells	when	 incubated	 in	 the	presence	or	absence	of	Nivolumab.	Figure	5.5.A	 supports	 the	
mean	 expansion	 of	%	 FMP58-66	 CD8+	 T	 cells	was	 0.48	 and	 0.51	 incubated	with	 or	without	
Nivolumab,	respectively.	
123	
	
	 	
124	
	
	
	
	
MLR	containing	Nivolumab	added	on	either	day	1,	day	2,	day	3,	day	4	or	day	5	was	used	to	measure	CD4+	and	CD8+	T	cell	proliferation.	MLR	
either	contained	stimulating	cells:responding	cells,	or	only	responding	cells.	Responding	cells	were	labelled	with	CTV	to	measure	proliferation	
and	multiparameter	flow	cytometry	was	used	to	measure	proliferation	of	T	cell	subsets.	A)	Observed	proliferation	from	T	cells	shown	as	mean	
%	CTV+	for	T	cells	when	Nivolumab	was	added	at	day	1,	day	2,	day	3,	day	4,	day	5	or	without	Nivolumab	with	B)	representative	FACS	plots.	C)	
Observed	proliferation	from	T	cells	shown	as	mean	%	CTV+	for	CD4+	T	cells	when	Nivolumab	was	added	at	day	1,	day	2,	day	3,	day	4,	day	5	or	
without	Nivolumab	with	D)	 representative	FACS	plots.	 	E)	Observed	proliferation	from	T	cells	shown	as	mean	%	CTV+	for	CD8+	T	cells	when	
Nivolumab	was	added	at	day	1,	day	2,	day	3,	day	4,	day	5	or	without	Nivolumab	with	F)	representative	FACS	plots.	Statistics	generated	using	
one-way	ANOVA.	*,	p<0.05.	n=3	
	
Figure	5.3	Nivolumab	increases	CD8+	T	cell	proliferation	when	added	close	to	completion	of	MLR	experiment	
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One-way	MLR	with	Nivolumab	added	on	either:	day	1,	day	2,	day	3,	day	4	or	day	5	were	
prepared.	After	day	5,	the	supernatant	from	the	MLR	that	contained	either	stimulating	and	
responding	cells,	or	only	responding	cells	was	harvested.	ELISA	from	the	prepared	one-way	
MLR	detected	secreted	IFNγ	in	the	harvested	supernatants.	n=3	
	 	
Figure	5.4	Nivolumab	does	not	increase	production	of	IFNγ	detected	from	MLR	supernatants	
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No	difference	 in	 expansion	of	%	 FMP58-66	CD8+	 T	 cells	when	 incubated	 in	 the	presence	or	
absence	 of	 Nivolumab	 (p>0.05).	 Figure	 5.5.B	 and	 Figure	 5.5.C	 show	 the	mean	%	 CD107a	
expression	by	CD4+	T	cells	incubated	in	the	presence	or	absence	of	Nivolumab	was	4.73	and	
4.54,	respectively.	The	mean	%	CD107a	expression	by	CD8+	T	cells	incubated	in	the	presence	
or	 absence	 of	 Nivolumab	 was	 1.01	 and	 0.80,	 respectively.	 No	 difference	 in	 %	 CD107a	
expression	 by	 CD4+	 and	 CD8+	 T	 cells	 when	 incubated	 in	 the	 presence	 or	 absence	 of	
Nivolumab	(p>0.05).	
In	Figure	5.6,	the	expansion	of	%	WT1126-134	CD8+	T	cells	and	expression	of	CD107a	by	CD4+	
and	CD8+	T	cells	when	incubated	in	the	presence	or	absence	of	Nivolumab	was	measured	by	
multiparameter	parameter	flow	cytometry.	Figure	5.6.A	demonstrates	the	mean	expansion	
of	 %	 WT1126-134	 CD8+	 T	 cells	 was	 0.29	 and	 0.48	 incubated	 with	 or	 without	 Nivolumab,	
respectively.	The	prevalence	of	WT1126-134	CD8+	T	cells	 is	not	 increased	when	 incubated	 in	
the	 presence	 of	 Nivolumab	 (p>0.05).	 The	 mean	 %	 CD107a	 expression	 by	 CD4+	 T	 cells	
incubated	 in	 the	 presence	 or	 absence	 of	Nivolumab	was	 9.73	 and	 7.91,	 respectively.	 The	
mean	 %	 CD107a	 expression	 by	 CD8+	 T	 cells	 incubated	 in	 the	 presence	 or	 absence	 of	
Nivolumab	was	1.65	and	1.13,	respectively.	There	was	no	difference	in	CD107a	expression	
by	 CD4+	 and	 CD8+	 T	 cells	 when	 incubated	 with	 Nivolumab	 when	 compared	 to	 T	 cells	
incubated	without	Nivolumab	(p>0.05).		
5.2.5 Nivolumab	 does	 not	 enhance	 the	 expansion	 WT1126-134	 T	 cells	 and	 their	
cytotoxic	potential	
To	 assess	 the	 cytotoxicity	 of	 expanded	 WT1126-134	 T	 cells	 that	 were	 incubated	 in	 the	
presence	or	absence	of	Nivolumab,	a	21	days	T	cell	expansion	was	conducted	 to	obtain	a	
large	quantity	of	cells.	After	 the	21	days,	 the	expanded	cells	were	 incubated	with	T2	cells	
loaded	with	WT1126-134	peptide	or	LNCaP	cell	 line	 to	measure	antigen	specific	cytotoxicity.	
Briefly,	 hCMRF-56+	 immune	 selected	 cells	 were	 stimulated	 with	 GM-CSF	 followed	 by	
transfection	with	WT1	IVT	mRNA.	Following	transfection,	cells	were	incubated	with	hCMRF-
56-	 immune	 selected	 cells	 at	 a	 hCMRF-56+	 BDC:hCMRF-56-	 cell	 of	 10:1.	 Cells	 were	
supplemented	with	IL-2,	IL-7	and	IL-15	during	the	21	days	incubation	and	restimulated	every	
seven	days	with	autologous	mitomycin	C	 treated	PBMC	pulsed	with	WT1126-134	peptide.	A	
mitomycin	C	treated	WT1126-134	peptide	pulsed	PBMC:responder	of	10:1	was	used.			
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GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 were	 transfected	 with	 FMP	 IVT	
mRNA.	Transfected	cells	were	incubated	with	autologous	hCMRF-56-	immune	selected	cells	
in	the	presence	or	absence	of	Nivolumab	and	supplemented	with	IL-2,	IL-7	and	IL-15.	After	
seven	days	the	cells	were	harvested	and	stimulated	with	FMP58-66	peptide.	FMO	controls	for	
detecting	FMP58-66	and	CD107a	positivity	were	used.	A)	FMP58-66+	CD8+	T	cells	expanded	in	
the	presence	or	absence	of	Nivolumab.	B)	Dot	plots	illustrating	FMP58-66+	CD8+	of	total	CD3+	
T	cells.	CD4+	C)	and	CD8+	E)	T	cells	expressing	CD107a	incubated	in	the	presence	or	absence	
of	Nivolumab.	Representative	dot	plots	from	CD4+	D)	and	CD8+	F)	T	cells	illustrating	CD107a	
expression.	n=4	
	 	
Figure	5.5	FMP	IVT	mRNA	transfected	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	in	the	
presence	of	Nivolumab	does	not	enhance	cytotoxic	granulation	from	autologous	lymphocytes	
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GM-CSF	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 were	 transfected	 with	 WT1	 IVT	
mRNA.	Transfected	cells	were	incubated	with	autologous	hCMRF-56-	immune	selected	cells	
in	the	presence	or	absence	of	Nivolumab	and	supplemented	with	IL-2,	IL-7	and	IL-15.	After	
seven	days	the	cells	were	harvested	and	stimulated	with	WT1126-134	peptide.	FMO	controls	
for	 detecting	 WT1126-134	 and	 CD107a	 positivity	 were	 used.	 A)	 WT1126-134+	 CD8+	 T	 cells	
expanded	in	the	presence	or	absence	of	Nivolumab.	B)	Dot	plots	illustrating	FMP58-66+	CD8+	
T	 cells.	 C)	 CD4+	 and	 E)	 CD8+	 T	 cell	 expression	 of	 CD107a	 incubated	 in	 the	 presence	 or	
absence	of	Nivolumab.	D)	and	F)	Dot	plots	illustrating	CD107a	expression	by	CD4+	or	CD8+	T	
cells.	n=3	
Figure	5.6	WT1	IVT	mRNA	transfected	GM-CSF	stimulated	hCMRF-56+	immune	selected	cells	in	the	
presence	of	Nivolumab	does	not	enhance	cytotoxic	granulation	from	autologous	lymphocytes	
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GM-CSF	stimulated	WT1	IVT	mRNA	transfected	hCMRF-56+	immune	selected	cells	were	incubated	
with	autologous	hCMRF-56-	cells	in	the	presence	or	absence	of	Nivolumab.	Transfected	cells	were	
expanded	 for	 21	 days	 and	 supplement	 with	 IL-2,	 IL-7	 and	 IL-15.	 Nivolumab	 was	 added	 at	 the	
beginning	 of	 the	 incubation	 and	 on	 days	 7	 and	 14.	 Effector	 cells	 were	 restimulated	 with	
autologous	mitomycin	C	treated	PBMC	pulsed	with	WT1126-134	peptide	every	seven	days.	Antigen	
specific	cytotoxicity	was	measured	on	day	21	to	Calcein-AM	labelled	T2	cells	loaded	with	WT1126-
134	peptide	or	Calcein-AM	labelled	LNCaP	cell	line	A)	Effector	cell	counts	at	days	0,	7	and	14	in	the	
presence	or	absence	of	Nivolumab.	%	Specific	cytotoxicity	of	expanded	WT1126-134	T	cells	cultured	
in	the	in	the	presence	or	absence	of	Nivolumab	against	B)	Calcein-AM	labelled	T2	cells	loaded	with	
WT1126-134	 or	 C)	 Calcein-AM	 labelled	 LNCaP	 cells	 both	 at	 an	 effector:target	 of	 50:1.	 D)	 WT1	
expression	 in	 LNCaP	 cells	was	 observed	 by	 immunohistochemical	 staining	 of	 paraformaldehyde	
fixed	 cells	 adhered	 to	 coverslips.	 Cells	were	 counterstained	with	 DAPI	 for	 nuclear	 visualisation.	
WT1,	green;	DAPI,	blue;	a	scale	bar	of	20μm	is	shown.	n=3	
Figure	5.7	Expanded	WT1126-134	T	cells	 incubated	with	Nivolumab	show	the	same	cytotoxicity	to	T2	cells	
loaded	with	WT1126-134	peptide	or	LNCaP	cell	line	as	expanded	WT1126-134	T	cells	without	Nivolumab	
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Nivolumab	was	added	at	the	beginning	of	the	incubation	and	every	seven	days	until	day	21.	
On	 Day	 21,	 the	 expanded	 cells	 were	 measured	 for	 %	WT1126-134	 specific	 CD8+	 T	 cells	 by	
multiparameter	flow	cytometry.	The	%	specific	cytotoxicity	was	measured	with	Calcein-AM	
labelled	T2	 cells	 loaded	with	WT1126-134	 peptide	and	Calcein-AM	 labelled	WT1+	 LNCaP	 cell	
line.	Cell	counts	at	days	of	restimulation	with	autologous	mitomycin	C	treated	PBMC	pulsed	
with	WT1126-134	peptide	showed	no	difference	in	the	number	of	effector	cells	regardless	of	
the	 presence	or	 absence	of	Nivolumab	 as	 seen	 in	 Figure	 5.7.A	 (p>0.05).	 The	 greatest	 cell	
count	for	effector	cells	was	observed	on	day	14	of	the	expansion.	The	mean	cell	count	on	
day	14	for	effector	cells	incubated	with	Nivolumab	was	6.0x106	cells,	and	the	mean	cell	for	
effector	 cells	 incubated	 without	 Nivolumab	 was	 5.3x106.	 Figure	 5.7.B	 demonstrates	 no	
difference	 in	 the	mean	%	 specific	 cytotoxicity	 for	 T2	 cells	 loaded	with	WT1126-134	 peptide	
with	WT1	specific	T	cells	expanded	in	the	presence	or	absence	of	Nivolumab	was	51.3	and	
48.0,	respectively	(p>0.05).	
No	difference	in	the	%	specific	cytotoxicity	of	a	WT1+	cell	line,	LNCaP	cells	were	labelled	with	
Calcein-AM	and	 incubated	with	expanded	WT1126-134	T	cells	 in	 the	presence	or	absence	of	
Nivolumab.	The	mean	values	for	LNCaP	%	specific	cytotoxicity	was	43.0	and	42.8	for	T	cells	
expanded	 in	 the	presence	or	absence	of	Nivolumab,	 respectively	 (p>0.05).	To	confirm	the	
expression	of	WT1	by	LNCaP	cells,	the	cells	were	seeded	onto	coverslips	followed	by	fixation	
and	permeabilisation,	then	staining	with	WT1	and	DAPI.	Figure	5.7.D	shows	LNCaP	cells	with	
dim	intracellular	WT1	staining.		
5.2.6 Stimulation	of	hCMRF-56+	immune	selected	BDC	
5.2.6.1 CD80	expression	
CD80	was	previously	 identified	as	a	potential	biomarker	 to	measure	activation	of	hCMRF-
56+	 immune	 selected	 BDC	 after	 transfection	 with	 IVT	 mRNA	 in	 4.2.3.	 It	 was	 found	 that	
hCMRF-56+	 immune	 selected	 BDC	 had	 low	 expression	 levels	 of	 CD80	 while	 other	 co-
stimulatory	molecules	including,	CD40	and	CD86,	were	highly	expressed	following	overnight	
incubation	described	in	Figure	3.3	and	Figure	4.3.	To	induce	further	levels	of	activation	for	
hCMRF-56+	 immune	 selected	 BDC,	 a	 range	 of	 clinically	 available	 cytokines	 and	 PRR	were	
used	 to	 optimise	 activation	 measured	 by	 CD80	 expression	 for	 the	 hCMRF-56+	 immune	
selected	BDC.	
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hCMRF-56+	 immune	selected	cells	were	stimulated	 for	2hrs	with	either:	A)	GM-CSF,	 IL-1β,	
Pam3CSK4,	anti-CD40,	PGE2,	FLT3L,	IL-6,	TNF,	Resiquimod,	ATP,	Uric	acid,	Poly(I:C)	or	LPS	to	
measure	expression	of	CD80	by	hCMRF-56+	 immune	selected	BDC.	Mean	CD80	expression	
by	 hCMRF-56+	 immune	 selected	 BDC	 is	 displayed	 for	 each	 stimulation	 reagent.	 B)	
Histograms	for	CD80	expression	by	hCMRF-56+	immune	selected	BDC	after	stimulation	with	
GM-CSF,	IL-1β,	Pam3CSK4	and	anti-CD40	compared	to	GM-CSF	stimulation.	An	FMO	control	
for	detecting	CD80	positivity	was	used.	hCMRF-56+	 immune	selected	cells	were	stimulated	
for	2hrs	with	either:	C)	GM-CSF	&	 IL-1β,	GM-CSF	&	Pam3CSK4	or	GM-CSF	&	anti-CD40	 to	
measure	expression	of	CD80	by	hCMRF-56+	 immune	selected	BDC.	Mean	CD80	expression	
by	 hCMRF-56+	 immune	 selected	 BDC	 is	 displayed	 for	 each	 stimulation	 reagent.	 D)	
Histograms	for	CD80	expression	by	hCMRF-56+	immune	selected	BDC	after	stimulation	with	
GM-CSF	 &	 IL-1β,	 GM-CSF	 &	 Pam3CSK4	 or	 GM-CSF	 &	 anti-CD40.	 An	 FMO	 control	 for	
detecting	CD80	positivity	was	used.	n=3.	
	
	 	
Figure	 5.8	 Stimulation	 of	 hCMRF-56+	 immune	 selected	 cells	 with	 clinically	 available	 reagents	
measuring	CD80	expression	by	hCMRF-56+	BDC		
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hCMRF-56+	 immune	 selected	 cells	 were	 isolated	 from	 PBMC	 and	 incubated	with	 a	 single	
stimulating	reagent,	or	in	combination	described	in	Table	2.4	for	2hrs	incubation.	After	the	
2hrs,	the	cells	were	washed	to	remove	excess	reagent	and	then	incubated	for	an	additional	
20hrs.	After	20hrs,	CD80	expression	was	examined	on	hCMRF-56+	immune	selected	BDC	by	
multiparameter	flow	cytometry.	
The	mean	CD80	expression	by	hCMRF-56+	immune	selected	BDC	increased	when	stimulating	
with	 IL-1β	 (47.9%),	 Pam3CSK4	 (47.6%)	 and	 anti-CD40	 (28.0%)	 compared	 to	 GM-CSF	
stimulation	as	seen	 in	Figure	5.8.A.	Stimulating	reagents	that	did	not	 increase	mean	CD80	
expression	 for	 hCMRF-56+	 immune	 selected	 cells	 were	 PGE2	 (12.0%),	 FLT3L	 (14.3%),	 IL-6	
(22.5%),	 Resiquimod	 (13.4%),	 ATP	 (19.1%),	 uric	 acid	 (14.6%)	 and	 Poly(I:C)	 (21.7%).	 It	was	
noted	that	stimulation	with	ATP	was	a	potent	stimulator	and	thus	resulted	in	poor	viability	
for	hCMRF-56+	immune	selected	cells	as	observed	by	microscopy	(data	not	shown).	In	Figure	
5.8.C	GM-CSF	was	 combined	with	 either:	 IL-1β,	 Pam3CSK4	and	 anti-CD40	 to	measure	 the	
expression	of	CD80	by	hCMRF-56+	 immune	selected	BDC.	The	mean	CD80	expression	GM-
CSF	stimulation	in	combination	with	IL-1β,	Pam3CSK4	and	anti-CD40	was	42.8%,	49.3%	and	
27.1%,	respectively.	There	was	no	significant	increase	in	CD80	expression	when	comparing	
single	stimulation	to	combination	stimulation	(p>0.05).	
5.2.6.2 Cytokine	secretion		
To	observe	any	differences	in	the	production	of	cytokines	by	hCMRF+	immune	selected	cells	
after	 stimulation,	 supernatants	 from	 stimulated	 hCMRF-56+	 immune	 selected	 cells	 were	
collected.	Stimulation	conditions	included	GM-CSF,	IL-1β,	Pam3CSK4,	anti-CD40,	GM-CSF	&	
IL-1β,	 GM-CSF	 &	 Pam3CSK4	 or	 GM-CSF	 &	 anti-CD40.	 Amounts	 of	 IL-1β,	 IFNα,	 IFNγ,	 TNF,	
CCL2,	IL-6,	IL-8,	IL-10,	Il-12p70,	IL-18,	IL-23	and	IL-33	were	quantified	by	CBA	and	shown	in	
Figure	5.9.A-L.	
There	was	a	 statistically	 significant	 increase	 in	TNF	 (2898pg/mL),	CCL2	 (42138pg/mL),	 IL-6	
(13578pg/mL)	 and	 IL-10	 (1380pg/mL)	 secretion	 when	 hCMRF-56+	 immune	 selected	 cells	
were	 stimulated	 with	 Pam3CSK4	 when	 compared	 to	 GM-CSF	 stimulation	 (p<0.05).	 No	
difference	in	amounts	of	IFNα,	IFNγ,	TNF,	CCL2,	IL-6,	IL-8,	IL-10,	IL-12p70,	IL-18,	IL-23	and	IL-
33	were	detected	in	the	supernatant	of	hCMRF-56+	immune	selected	cells	stimulated	with	a	
range	of	reagents	as	seen	in	Figure	5.9.B-L.	
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hCMRF-56+	 immune	selected	cells	were	stimulated	with	either:	nil,	GM-CSF,	anti-CD40,	 IL-
1β,	Pam3CSK4	or	in	combination	with	GM-CSF	for	2hrs	at	37C	5%	CO2.	After	2hrs,	the	cells	
were	washed	and	 incubated	 for	 an	 additional	 20hrs	 at	 37C	5%	CO2.	A)	 –	L)	 Supernatants	
were	analysed	for	the	detection	of	the	following	cytokines:	IL-1β,	IFNα,	IFNγ,	TNF,	CCL2,	IL-
6,	IL-8,	IL-10,	IL-12p70,	IL-18,	IL-23	and	IL-33	by	CBA.	When	appropriate,	a	solid	line	through	
the	plot	indicates	the	minimum	detection	limit	of	the	CBA	for	that	specific	cytokine.	Mean	±	
SD	 concentration	 of	 cytokines	 as	 described.	 Statistics	 were	 generated	 comparing	 mean	
cytokine	concentration	of	 stimulated	hCMRF-56+	 immune	selected	cells	 compared	 to	GM-
CSF	stimulated	hCMRF-56+	immune	selected	cells	using	one-way	ANOVA	test.	*,	p<0.05;	**,	
p<	0.01;	***,	p<0.001.	n=3	
	 	
Figure	5.9	Cytokine	secretion	from	stimulated	hCMRF-56+	immune	selected	cells	
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There	was	a	 significant	 increase	 in	 IL-1β	secretion	after	hCMRF-56+	 immune	selected	cells	
were	 stimulated	with IL-1β	and	GM-CSF	combined	with	 IL-1β	when	compared	 to	GM-CSF	
stimulation	as	shown	in	Figure	5.9.A.	However,	the	detection	of	IL-1β	may	be	due	to	excess	
IL-1β	used	for	stimulation.	A	statistically	significant	amount	of	TNF	and	IL-10	was	detected	
after	hCMRF-56+	immune	selected	cells	were	stimulated	with	IL-1β	when	compared	to	GM-
CSF	stimulation	Figure	5.9.D.	and	H.	Combined	GM-CF	and	Pam3CSK4	stimulation	resulted	
in	 statistically	 significant	 increases	 in	 CCL2	 and	 IL-10	 secretion	 when	 compared	 GM-CSF	
stimulation	Figure	5.9.E.	and	H.	Furthermore,	GM-CSF	combined	with	IL-1β	stimulation	also	
resulted	 in	 statistically	 significant	 increase	 in	 IL-10	 secretion	 compared	 to	 GM-CSF	
stimulation	Figure	5.9.H.		
5.3 Discussion	
T	cells	that	have	undergone	chronic	activation	by	repeated	TCR	engagement	express	the	PD-
1	surface	receptor	(Day	et	al.,	2006).	Upon	TCR	engagement	by	T	cells	and	PD-1	binding	to	
its	 ligand	 expressed	 by	 other	 immune	 cells	 or	 tumour	 cells,	 T	 cells	 fail	 to	 proliferate	 and	
secrete	IL-2	(Kuipers	et	al.,	2006).	T	cell	subsets	express	varying	levels	of	PD-1.	Naïve	T	cells	
do	 not	 express	 PD-1	whereas	 activated	memory	 T	 cells	 do	 express	 PD-1,	 which	 supports	
chronic	 TCR	engagement	 (Wang	et	 al.,	 2014).	Although	using	PD-1	blockade	with	an	 IgG1	
mAb,	 Pembrolizumab	 has	 been	 shown	 to	 expand	 memory	 CD4+	 and	 CD8+	 T	 cells	 in	
metastatic	melanoma	patients	(Ribas	et	al.,	2016).	In	this	study,	memory	CD8+	T	cells	were	
the	major	T	cell	subset	expanded	in	patients	thus	demonstrating	the	ability	of	PD-1	blockade	
to	 expand	 T	 cells	 with	 the	 ability	 to	 provide	 protective	 CD4+	 and	 CD8+	 T	 cell	 immune	
responses	(Farber	et	al.,	2014).		
Nivolumab	is	an	IgG4	mAb	that	is	approved	by	the	FDA	for	the	treatment	of	treat	melanoma	
and	 renal	 cell	 carcinoma,	 with	 many	 other	 clinical	 trials	 underway	 to	 demonstrate	 the	
efficacy	treating	other	cancers	(Nguyen	and	Ohashi,	2015).	To	test	whether	Nivolumab	may	
interrupt	 T	 cell	 and	 hCMRF-56+	 immune	 selected	 cells	 signalling,	 PD-L1	 expression	 was	
confirmed	 for	 hCMRF-56+	 immune	 selected	 cells	 by	multiparameter	 flow	 cytometry.	 APC	
and	tumour	cells	both	express	PD-L1,	whereas	expression	of	PD-L2	 is	more	restricted	only	
found	on	immune	cells	(Brown	et	al.,	2003,	Latchman	et	al.,	2001).	Blocking	PD-1	and	PD-L1	
and	 PD-L2	 interactions	 enables	 chronically	 activated	 T	 cells	 to	 restore	 effector	 immune	
function	 by	 producing	 reinvigorating	 cytokine	 production	 and	 proliferate.	 PD-L1	 was	
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detected	on	the	surface	of	all	hCMRF-56+	immune	selected	constituents	including	the	BDC	
subsets.	B	cells	displayed	the	lowest	PD-L1	expression,	while	monocytes,	CD1c+	BDC,	CD141+	
BDC	and	CD16+	BDC	showed	high	levels	of	PD-L1	expression.	Several	studies	have	explored	
the	expression	strength	of	PD-1	and	PD-L1	or	PD-L2	and	the	impact	on	T	cell	function.	One	
study	found	that	murine	splenic	and	bone	marrow	APC	display	varying	expression	levels	of	
PD-L1	(Blackburn	et	al.,	2010).	Cell	cultures	from	this	study	with	PD-L1hi	APC	and	PD-1hi	CD8+	
T	 cells	 increased	CD8+	 T	 cell	 death.	However,	 the	 combination	of	 PD-L1lo	 APC	with	 PD-1hi	
CD8+	T	cells	promoted	T	cell	survival.	The	intermediate	to	high	PD-L1	expression	of	hCMRF-
56+	immune	selected	cells	may	demonstrate	the	value	of	Nivolumab	inhibiting	PD-1	to	PD-
L1	 to	 boost	 an	 antigen	 specific	 immune	 response.	 Another	 study	 used	 PD-1	 mRNA	
transfected	 purified	 CD8+	 T	 cells	 to	 measure	 the	 effector	 T	 cell	 function	 with	 low,	
intermediate	or	high	surface	PD-1	expression	when	incubated	with	artificial	APC	(Wei	et	al.,	
2013).	Artificial	APC	were	generated	from	K562	cells	lentiviral	transduced	with	PD-L1	mRNA	
to	 express	 high	 levels	 of	 PD-L1.	 High	 levels	 of	 PD-1	 expression	 blocked	 all	 T	 cell	 effector	
functions	 including	 cytokine	 secretion,	 proliferation	 and	 calcium	 flux.	 Intermediate	 PD-1	
expression,	similar	to	expression	found	on	activated	peripheral	blood	T	cells,	reduced	T	cells	
effector	 function.	Furthermore	Wei	et	al.	 (2013)	demonstrate	that	only	 intermediate	PD-1	
expressing	CD8+	T	cells	are	sensitive	to	PD-L1	mediated	inhibition	of	cytotoxicity.	Therefore,	
complete	 blocking	 of	 PD-1	 by	 Nivolumab	 is	 required	 to	 ensure	 maximum	 effector	 T	 cell	
function.	It	has	never	been	examined	if	the	overnight	incubation	of	PBMC	upregulates	T	cell	
surface	molecules	such	as	PD-1.	Serial	dilutions	of	Nivolumab	were	used	to	determine	the	
optimal	 concentration	 for	 use	 with	 in	 vitro	 experiments.	 A	 saturating	 concentration	 of	
20μg/mL	 was	 established.	 Whilst	 it	 was	 unsurprising	 that	 the	 20μg/mL	 concentration	 of	
Nivolumab	 was	 optimal	 for	 saturating	 memory	 T	 cell	 as	 Wang	 et	 al.	 (2014)	 reported	 a	
20μg/mL	saturating	concentration	for	freshly	isolated	memory	T	cells.	However,	this	result	
was	 still	 required	 as	 PBMC	 incubation	may	 activate	 effector	 and	naïve	 T	 cell	 subsets	 in	 a	
similar	manner	as	overnight	 incubation	 induces	the	expression	of	 the	antigen	detected	by	
CMRF-56	 (Lopez	 et	 al.,	 2003).	 Adverse	 events	 associated	 with	 Nivolumab	 include	 colitis,	
immune	mediated	 thyroiditis	 and	 immune	mediated	 nephritis	 (Raedler,	 2015).	 Increasing	
the	dose	of	Nivolumab	administered	into	the	patient	may	increase	the	prevalence	of	these	
adverse	events.	The	combination	of	BDC	vaccination	and	Nivolumab	may	allow	a	lower	dose	
of	Nivolumab	to	initiate	an	antigen	specific	immune	response.	This	may	reduce	the	number	
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of	adverse	events	and	toxicities	associated	with	treating	patients	with	Nivolumab.	However,	
this	will	need	to	be	confirmed.		
Five	 day	 MLR	 experiments	 with	 Nivolumab	 added	 on	 different	 days	 were	 performed	 to	
observe	 the	 increase	 in	 proliferation	 by	 CD4+	 and	 CD8+	 T	 cell	 subsets.	 Responding	 cells	
without	the	presence	of	stimulating	cells	 found	that	Nivolumab	added	on	any	day	did	not	
expand	 responding	 T	 cells.	 The	 lack	 of	 engagement	 by	 TCR	 would	 not	 facilitate	 the	
proliferation	of	T	cells,	even	when	Nivolumab	 is	present.	 	When	Nivolumab	was	added	on	
days	one	or	two	in	the	five	day	MLR,	a	significant	 increase	in	CD4+	T	cell	proliferation	was	
observed.	This	result	supports	previously	published	data	that	shows	CD4+	T	cells	proliferate	
more	readily	than	CD8+	T	cells	in	the	presence	of	Nivolumab	(Malm	et	al.,	2015).	There	was	
no	 increase	 in	CD8+	 T	 cell	 proliferation	 at	 any	 time	point.	 The	presence	of	 CD4+	 T	 cells	 is	
important	 to	 achieving	 an	 efficient	 tumour	 antigen	 cytotoxic	 response	 by	 inducing	 IFNγ	
production	 in	 the	 tumour	microenvironment,	while	enhancing	 cytotoxic	activity	of	CD8+	T	
cells	(Matsuzaki	et	al.,	2015).	Secretion	of	IFNγ	by	lymphocytes	has	been	shown	to	increase	
PD-L1	expression	by	tumour	cells	and	APC	(Abiko	et	al.,	2015,	Loke	and	Allison,	2003,	Martin	
et	al.,	2015).	The	upregulation	of	PD-L1	or	PD-L2	by	tumour	cells	demonstrates	the	potential	
efficacy	 of	 Nivolumab	 by	 inhibiting	 ligation	 of	 PD-1	 to	 PD-L1	 or	 PD-L2	 and	 maximising	
tumour	cell	cytolysis.	Detection	of	soluble	IFNγ	was	detected	in	the	supernatants	of	the	five-
day	MLR	experiments	with	Nivolumab	added	at	each	described	day.	No	difference	in	soluble	
IFNγ	 was	 detected	 when	 Nivolumab	 was	 added	 at	 different	 days.	 Greater	 cytokine	
production	 by	 MLR	 containing	 stimulating	 and	 responding	 cells	 compared	 to	 only	
responding	 cells	 was	 expected	 and	 observed.	 Performing	MLR	 experiments	 with	 purified	
CD4+	 and	 CD8+	 T	 cells	 may	 further	 establish	 if	 there	 is	 a	 significant	 difference	 in	 IFNγ	
production	 or	 proliferation	 when	 Nivolumab	 is	 added	 at	 different	 days.	 Furthermore,	
Nivolumab	was	only	added	once	during	the	five	days.	Performing	this	in	vitro	five	day	MLR	
would	provide	insight	to	the	required	dose	and	how	long	it	 is	Nivolumab	is	required	to	be	
present	in	the	system	for	proliferation	of	CD8+	T	cells.		
The	data	generated	from	this	research	demonstrates	that	Nivolumab	inhibition	between	IVT	
mRNA	transfected	hCMRF-56+	immune	selected	cells	and	hCMRF-56-	immune	selected	cells	
does	not	enhance	the	 in	vitro	generation	of	antigen	specific	CD8+	T	cells	when	used	in	the	
ways	described.	This	is	not	to	say	this	combination	theory	is	ineffective,	but	further	research	
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is	 required.	This	 includes	 investigating	 the	Nivolumab	 interaction	between	effector	T	 cells	
and	 target	 tumour	 cells.	 It	 has	been	previously	described	by	Van	Nuffel	et	al.	 (2012)	 that	
transfection	of	APC	with	tumour	antigen	IVT	mRNA	results	in	antigen	presentation	by	both	
MHC	class	I	and	II.	With	the	significant	increase	in	CD4+	proliferation	when	Nivolumab	was	
added	on	days	one	and	two	in	MLR,	it	would	be	worthwhile	investigating	the	expansion	of	
antigen	specific	CD4+	T	cells	in	the	presence	of	Nivolumab	after	transfection	of	hCMRF-56+	
immune	 selected	 cells	 with	 tumour	 antigen	 IVT	 mRNA.	 This	 may	 lead	 to	 an	 increase	 in	
antigen	 specific	 CD4+	 T	 cells.	 No	 difference	 in	 the	 generation	 of	 FMP	 and	WT1	 specific	 T	
cells,	 in	 addition	 to	 the	 degranulation	 of	 CD4+	 and	 CD8+	 T	 cells	 measured	 by	 CD107a	
expression	 was	 observed	 after	 hCMRF-56+	 immune	 selected	 cells	 were	 transfected	 IVT	
mRNA	with	and	without	Nivolumab.		
Previous	 published	 data	 examined	 the	 kinetics	 of	 secreted	 cytokines	 by	 purified	 T	 cells	
stimulated	by	melanoma	peptide	in	the	presence	of	Nivolumab	or	an	isotype	control	(Wong	
et	al.,	2007).	The	authors	of	this	study	found	the	amount	of	 IL-5,	 IL-10,	 IL-13,	GM-CSF	and	
IFNγ	was	 increased	after	administration	of	Nivolumab	during	the	time	course.	Wong	et	al.	
(2007)	 also	 reported	 a	 difference	 in	 TNF	 secretion	 by	 purified	 T	 cells	 stimulated	 by	
melanoma	peptide	in	the	presence	of	Nivolumab,	but	this	difference	was	not	observed	after	
day	four.		
The	 study	 by	 Wong	 et	 al.	 (2007)	 also	 showed	 variable	 T	 cell	 CD107a	 expression	 after	
restimulation	with	melanoma	target	cells	in	the	presence	of	Nivolumab	and	Mo-DC.	Results	
from	 my	 research	 would	 indicate	 CD4+	 and	 CD8+	 T	 cell	 subsets	 would	 provide	 similar	
CD107a	expression	regardless	of	the	presence	or	absence	of	Nivolumab.	However,	this	was	
not	witnessed	by	Wong	et	al.	 (2007)	and	a	difference	 in	degranulation	was	observed.	The	
lack	of	CD107a	difference	by	samples	incubated	with	Nivolumab	may	be	due	to	a	number	of	
factors	 including	 the	 disease	 state	 of	 the	 recruited	 donors,	 expression	 of	 CD274	 by	 APC,	
selected	tumour	antigen,	peptide	sequence	of	 restimulators	and	method	of	 restimulation.	
Optimisation	of	 restimulation	method	may	 include	performing	11	day	expansions	 such	as	
described	by	Wong	et	al.	 (2007).	Detection	of	other	 intracellular	cytokines	such	as	IL-5,	 IL-
10,	IL-13,	GM-CSF	and	TNF	may	assist	with	observing	a	functional	difference	when	T	cells	are	
incubated	with	 Nivolumab.	 Furthermore,	 this	 study	 showed	 no	 difference	 in	 effector	 cell	
counts	between	samples	 incubated	 in	the	presence	or	absence	of	Nivolumab	for	up	to	21	
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days.	Interestingly,	an	increase	in	absolute	effector	cells	counts	was	observed	after	the	first	
stimulation	with	autologous	mitomycin	C	 treated	PBMC	 loaded	with	WT1126-134	peptide.	 It	
would	 be	 ideal	 to	 restimulate	 expanding	 effector	 cells	 with	 WT1	 IVT	 mRNA	 transfected	
hCMRF-56+	 immune	 selected	 cells	 as	 this	method	would	provide	multiple	 tumour	antigen	
epitopes	to	both	CD4+	and	CD8+	T	cells.	This	 restimulation	method	may	end	up	 increasing	
antigen	specific	CD4+	and	CD8+	T	cells.	The	%	specific	cytotoxicity	was	not	affected	by	the	
addition	of	Nivolumab	at	each	effector	cell	restimulation.	This	data	confirms	that	the	initial	
interaction	 between	 IVT	 mRNA	 transfected	 hCMRF-56+	 immune	 selected	 cells	 and	
autologous	hCMRF-56-	immune	selected	cells	does	not	increase	the	antigen	specific	CD8+	T	
cells	with	 the	 addition	 of	Nivolumab.	Only	 the	 inhibition	 between	 T	 cells	 and	 hCMRF-56+	
immune	 selected	 cells	 by	 Nivolumab	 was	 investigated	 in	 this	 research.	 The	 addition	 of	
Nivolumab	 during	 the	 cytotoxicity	 assay	 may	 be	 a	 more	 suitable	 method	 to	 assess	
Nivolumab	associated	cytotoxicity	between	T	cells	and	tumour	cells.	The	expression	of	PD-
L1	is	often	used	as	a	prognostic	marker	for	solid	tumours	and	expression	is	often	confirmed	
before	commencing	treatment	with	Nivolumab	(Brahmer	et	al.,	2010,	Sorensen	et	al.,	2016,	
Zhou	et	al.,	2015).	PD-L1	 is	upregulated	by	 IFNγ	that	 is	secreted	by	activated	T	cells.	PD-1	
and	PD-L1	interactions	provide	a	method	for	immune	evasion	from	CD8+	T	cells	and	tumour	
growth	(Abiko	et	al.,	2015,	 Juneja	et	al.,	2017).	 Inhibiting	PD-1+	T	cells	and	PD-L1+	tumour	
interactions	 would	 support	 the	 hypothesis	 that	 Nivolumab	 plays	 a	 role	 in	 cytotoxicity.	
Recent	studies	have	observed	that	lack	of	PD-L1	expression	by	tumour	cells	delays	tumour	
growth	(Kleinovink	et	al.,	2017).	This	supports	this	research	that	suggests	PD-L1	expression	
by	tumour	cells	and	not	immune	cells	are	important	for	anti-PD-1	therapy.	
PD-L2	 expression	 is	 restricted	 to	 APC	 and	 other	 immune	 cells	 (Shin	 et	 al.,	 2005).	 As	 my	
research	 has	 demonstrated	 that	 inhibiting	 interactions	 between	 hCMRF-56+	 immune	
selected	cells	and	hCMRF-56-	immune	selected	cells	does	not	result	in	an	increase	in	T	cell	
degranulation	 or	 expansion	 of	 antigen	 specific	 T	 cells,	 it	 should	 be	 questioned	 if	 mAbs	
binding	to	PD-L2	would	provide	any	clinical	benefit.	However,	the	level	of	expression	for	PD-
1,	PD-L1	or	PD-L2	 is	critical	 to	achieve	a	significant	clinical	 response.	Expression	of	PD-1	 is	
already	 high	 by	 antigen	 specific	 T	 cells,	 whereas	 expression	 of	 PD-L1	 or	 PD-L2	 by	 APC	 is	
enhanced	upon	stimulation	(Wong	et	al.,	2007).	Enhancing	the	level	of	PD-L1	or	PD-L2	may	
prove	to	be	beneficial	if	Nivolumab	is	used	to	enhance	the	anti-cancer	immune	response.	
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During	 the	 migratory	 process,	 BDC	 undergo	 activation	 that	 results	 in	 morphological	 and	
phenotypic	 changes	as	a	 result	of	exposure	 to	 signals	 through	TLR.	Signals	 include	ssRNA,	
flagellin	 and	 LPS	 (Takeda	 and	 Akira,	 2005).	 BDC	 activation	 is	 a	 complex	 process	 involving	
signalling	protein	and	transcription	factors.	MyD88	is	a	signalling	protein	that	is	utilised	by	
most	TLRs	not	including	TLR3	(Chen	et	al.,	2011).	The	TRIF	signalling	pathway	is	responsible	
for	secretion	of	type	I	IFN	after	TLR3	ligation	(Kawai	and	Akira,	2010).	The	MyD88	signalling	
cascade	 leads	 to	 the	eventual	activation	of	 the	NF-κB	 transcription	 factor,	 resulting	 in	 the	
secretion	of	cytokines,	cell	proliferation	and	expression	of	adhesion	and	co-stimulatory	cell	
surface	molecules	such	as	CD80	(Martin	and	Wesche,	2002,	Ferreira	et	al.,	1999,	Rescigno	et	
al.,	1998,	Yoshimura	et	al.,	2001).	hCMRF-56+	immune	selected	BDC	display	a	phenotype	of	
intermediate	 to	 high	 expression	 of	 CD40,	 CD54,	 CD83,	 CD86	 and	 CCR7.	 However,	 CD80	
expression	by	hCMRF-56+	 immune	 selected	BDC	was	 low.	Engagement	of	CD80	and	CD86	
with	its	ligand,	CTLA-4,	results	in	PI3K	signalling	that	eventually	results	in	the	expression	of	
IL-6	(Koorella	et	al.,	2014).	This	is	different	to	CD40	ligation	by	CD40	ligand	as	this	results	in	
NF-κB	or	JNK	signalling	(Elgueta	et	al.,	2009).	Ligation	between	CD80	and	CTLA-4	results	 in	
greater	stimulation	and	production	of	IL-6	compared	to	CD86	ligation	with	CTLA-4	(Slavik	et	
al.,	1999).	Therefore	observing	an	increase	in	CD80	may	indicate	an	increase	in	IL-6	and	has	
been	 described	 to	 have	 pro-inflammatory	 and	 regulatory	 effects	 depending	 on	 the	
environment	and	skew	the	T	cell	compartment	(Dienz	and	Rincon,	2009,	Hunter	and	Jones,	
2015,	 Kamimura	 et	 al.,	 2003,	 Scheller	 et	 al.,	 2011).	 Therefore,	 CD80	 expression	 is	 a	 good	
surrogate	molecule	that	is	able	to	measure	BDC	stimulation.	
CD80	was	employed	to	measure	hCMRF-56+	immune	selected	BDC	stimulatory	response	to	
IL-1β,	Pam3CSK4	and	anti-CD40	or	in	combination	with	GM-CSF.	Stimulation	with	IL-1β	and	
Pam3CSK4	 results	 in	 activation	 of	 NF-κB	 and	 production	 of	 inflammatory	 cytokines	
(Hennessy	 et	 al.,	 2010,	 Risbud	 and	 Shapiro,	 2014).	 Cytokines	 were	 detected	 in	 the	
supernatants	 of	 hCMRF-56+	 immune	 selected	 cells	 after	 stimulation	 with	 GM-CSF,	 IL-1β,	
Pam3CSK4	 and	 anti-CD40.	 Stimulation	 of	 hCMRF-56+	 immune	 selected	 BDC	 with	 IL-1β,	
Pam3CSK4	 and	 anti-CD40	 all	 resulted	 in	 elevated	 CD80	 expression	 that	was	 greater	 than	
GM-CSF	stimulation.	The	three	reagents	were	combined	with	GM-CSF	and	resulted	with	no	
additional	 significant	 increase	 in	 CD80	 expression.	 Compared	 to	 previous	 data	 in	 4.2.3	
where	 hCMRF-56+	 immune	 selected	 cells	 transfected	 with	 IVT	 mRNA	 or	 mock	 and	
stimulated	 with	 GM-CSF,	 stimulation	 of	 hCMRF-56+	 immune	 selected	 cells	 with	 IL-1β	 or	
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Pam3CSK4	resulted	in	enhanced	TNF	and	IL-6	secretion.	Stimulation	of	hCMRF-56+	immune	
selected	cells	with	IL-1β	or	Pam3CSK4	did	not	result	in	a	significant	increase	in	CD80.	
1.	 The	 pro-inflammatory	 cytokine	 IL-1β	 is	 secreted	 by	 many	 immune	 cells	 including	
macrophages,	monocytes	and	BDC	as	an	exogenous	cytokine	in	response	to	PAMPs.	It	is	also	
used	 as	 a	 stimulatory	 reagent	 due	 to	 its	 induction	 of	 the	 MyD88	 pathway.	 The	 IL-1β	
receptor	exists	as	a	heterodimer	complex	comprising	of	the	IL-1R1	ligand	binding	chain	and	
IL-1R3	 accessory	 chain	 (Boraschi	 and	 Tagliabue,	 2013).	 Binding	 of	 IL-1β	 to	 IL-1R1	 binding	
chain	 in	 the	 presence	 of	 IL-1R3	 induces	 the	 MyD88	 signalling	 pathway	 and	 eventual	
activation	of	NF-κB	(Martin	and	Wesche,	2002).	Stimulation	of	the	NF-κB	transcription	factor	
eventually	results	in	the	secretion	of	cytokines	including	IL-6	and	TNF,	and	induction	of	cell	
surface	molecules	such	as	CD40	 (Ade	et	al.,	2007,	Hoesel	and	Schmid,	2013).	Detection	of	
IFNα,	 TNF,	 CCL2,	 IL-6,	 IL-10,	 IL-12p70,	 IL-18,	 IL-23	 and	 IL-33	 was	 detected	 in	 the	
supernatants	of	IL-1β	stimulated	hCMRF-56+	immune	selected	cells	and	all	failed	to	achieve	
a	significant	difference	compared	to	GM-CSF	stimulated	hCMRF-56+	immune	selected	BDC.	
All	values	were	less	than	Pam3CSK4	stimulated	hCMRF-56+	immune	selected	cells	except	for	
IL-23,	which	also	was	not	significantly	different	to	GM-CSF	stimulated	hCMRF-56+	 immune	
selected	BDC.	NF-κB	 signalling	 is	 responsible	 for	 the	 secretion	of	 IL-23	by	Mo-DC	 (Welsby	
and	Goriely,	2016).	IL-23	has	been	involved	in	the	differentiation	of	pro-inflammatory	Th17	
cells,	 especially	 in	 the	 presence	 of	 IL-6	 and	 TGFβ	 (Morishima	 et	 al.,	 2009).	 Therefore	
stimulation	 of	 hCMRF-56+	 immune	 selected	 BDC	 with	 IL-1β	 may	 not	 be	 suitable	 due	 to	
secretion	of	 IL-6.	The	se	cells	are	often	present	at	 sites	of	 inflammation	and	autoimmune	
diseases	(Gaffen	et	al.,	2014,	Lee	et	al.,	2012).	Furthermore,	 IL-23	has	been	found	to	be	a	
mediator	 in	 autoimmune	 conditions	 such	 as	 inflammatory	 bowel	 disease,	 rheumatoid	
arthritis	and	psoriasis	 (Di	Cesare	et	al.,	2009,	Duvallet	et	al.,	2011,	McGovern	and	Powrie,	
2007).	
2.	 Pam3CSK4	 is	 a	 synthetic	 peptide	 that	mimics	 bacterial	 lipoprotein	 acting	 through	 TLR2	
stimulation	following	with	the	NF-κB	pathway	(Funderburg	et	al.,	2011).	Isolated	BDC	have	
shown	 surface	 and	 intracellular	 TLR2	 expression,	 whereas	 Mo-DC	 express	 only	 express	
intracellular	 TLR2	 (Thoma-Uszynski	 et	 al.,	 2000,	 Uronen-Hansson	 et	 al.,	 2004).	 This	 may	
prove	 to	 be	 a	 phenotypic	 difference	 between	 the	 two	 cells	 and	 their	 response	 when	
stimulated	with	Pam3CSK4.	PBMC	incubated	with	TLR2	blocking	mAbs	 inhibited	monocyte	
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CD80	expression	when	stimulated	with	Pam3CSK4	(Funderburg	et	al.,	2007).	Furthermore,	it	
was	found	that	Pam3CSK4	induced	IL-10	production	but	downregulated	CD86	expression	by	
monocytes	 (Funderburg	 et	 al.,	 2011).	 Stimulation	 of	 hCMRF-56+	 immune	 selected	 by	
Pam3CSK4	resulted	in	the	detection	of	a	combination	of	cytokines	including	IFNα,	IL-12p70,	
IL-18	and	IL-33.	However,	I	was	able	to	detect	a	significant	increase	in	TNF,	CCL2,	IL-6	and	IL-
10	after	stimulation	of	hCMRF-56+	immune	selected	by	Pam3CSK4.	Mo-DC	matured	with	a	
cytokine	 cocktail	 containing	 IL-1β,	 IL-6,	 TNF,	 PGE2	 and	 IL-10	 induced	 tolerogenic	 Mo-DC	
(Steinbrink	et	al.,	1999).	Notably	the	secretion	of	IL-10	by	BDC	has	been	reported	to	be	drive	
naïve	T	cell	differentiation	to	a	regulatory	T	cells	(Raker	et	al.,	2015).	Tolerogenic	BDC	still	
present	 peptide	 bound	 by	 MHC	 class	 I	 or	 II	 to	 TCR	 but	 have	 lower	 expression	 of	 co-
stimulatory	molecules	such	as	CD80	and	CD86,	which	results	in	reduced	T	cell	proliferation	
(Hubo	et	al.,	2013).	 In	addition,	Steinbrink	et	al.	 (1999)	describe	poor	cytotoxicity	towards	
melanoma	cells	by	Tyrosinase	specific	CD8+	T	cells	expanded	with	Mo-DC	matured	with	IL-
1β,	IL-6,	TNF,	PGE2	and	IL-10.	This	proposes	that	the	presence	of	IL-1β,	IL-6,	TNF,	PGE2	and	
IL-10	 during	 T	 cell	 expansion	 may	 result	 in	 poor	 T	 cell	 expansion	 and	 antigen	 specific	
cytotoxicity.	 However	 roles	 for	 tolerogenic	 BDC	 have	 been	 suggested	 with	 autoimmune	
diseases	and	solid	organ	transplantation	(Marín	et	al.,	2016,	Thomson	and	Robbins,	2008).	
3.	The	CD40	co-stimulatory	cell	surface	molecule	has	been	described	as	crucial	for	BDC	and	
lymphocyte	cross	talk	(Pinchuk	et	al.,	1996).	Nizzoli	et	al.	(2013)	describe	the	abundance	of	
secreted	 IL-12p70	 after	 BDC	 ligation	 with	 anti-CD40.	 However,	 detection	 of	 IL-12p70	 by	
hCMRF-56+	 immune	 selected	 cells	 activated	 with	 anti-CD40	 was	 limited	 to	 background	
detection	 levels.	 Simultaneous	 ligation	 of	 CD40	 and	 TLR	 results	 in	 the	MyD88	 activation	
pathway,	which	was	observed	with	IL-1β	and	Pam3CSK4	stimulation.	Despite	following	the	
same	activation	pathway,	the	hCMRF-56+	immune	selected	BDC	CD80	expression	was	not	as	
great	as	 IL-1β	and	Pam3CSK4	stimulation.	This	may	indicate	an	antagonistic	factor	present	
resulting	is	reduced	expression.	While	I	was	able	to	detected	IFNα,	IFNγ,	TNF,	CCL2,	IL-8	and	
IL-12p70	 after	 hCMRF-56+	 immune	 cells	 were	 stimulated	 with	 anti-CD40,	 no	 difference	
cytokine	 production	 compared	 to	 hCMRF-56+	 immune	 selected	 cells	 stimulated	with	GM-
CSF	was	observed.	Stimulation	with	anti-CD40	has	been	reported	to	increase	the	production	
of	IL-6	in	murine	splenic	DC,	and	IL-23	in	Mo-DC	(Sender	et	al.,	2010,	Yanagawa	and	Onoe,	
2006).	Neither	 IL-6	nor	 IL-23	was	detected	from	anti-CD40	stimulated	hCMRF-56+	 immune	
selected	 cells.	 hCMRF-56+	 immune	 selection	 enriches	 for	 more	 than	 one	 immune	 cell	
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population.	 While	 multiparameter	 flow	 cytometry	 was	 used	 to	 detect	 peptide:MHC	
complexes	 by	 a	 heterogeneous	 population	 of	 cells,	 detecting	 cytokines	 secreted	 by	 a	
heterogeneous	population	of	cells	would	require	FACS	cells.	Sender	et	al.	commented	that	
increased	IL-23	is	produced	with	the	addition	of	concurrent	anti-CD40	and	RNA	stimulation	
by	Mo-DC.	IVT	mRNA	transfection	and	stimulation	of	hCMRF-56+	immune	selected	cells	with	
anti-CD40	may	enhance	the	activation	and	IL-23	production.	The	secretion	of	IL-23	and	the	
link	to	inflammatory	diseases	such	as	has	been	previously	discussed	(Duerr	et	al.,	2006,	Yen	
et	al.,	2006).	Therefore,	the	secretion	of	IL-23	may	provide	an	undesired	effect.	
As	IL-1β,	Pam3CSK4	and	anti-CD40	upregulated	CD80	on	hCMRF-56+	immune	selected	BDC	
after	2hrs,	this	demonstrates	the	potency	of	these	stimulation	reagents	and	they	should	be	
further	investigated	by	determining	optimal	concentration	and	incubation	time.	
5.4 Conclusion	
The	anti-PD-1	inhibitor	Nivolumab	has	been	successfully	implemented	in	to	clinical	practice	
for	 the	 treatment	 of	 melanoma,	 renal	 cell	 carcinoma	 and	 non-small	 cell	 lung	 cancer.	
Expression	of	PD-L1	was	confirmed	on	hCMRF-56+	immune	selected	cell	subsets.	Incubating	
hCMRF-56+	immune	selected	cells	and	autologous	T	cells	with	Nivolumab	showed	that	there	
is	no	increase	in	CD4+	or	CD8+	T	cell	degranulation,	or	expansion	of	antigen	specific	CD8+	T	
cells.	Although	there	was	no	statistical	difference,	a	trend	of	greater	intracellular	CD107a	for	
CD4+	 T	 cells	 was	 observed,	 demonstrating	 the	 importance	 of	 CD4+	 T	 cell	 help	 and	 the	
generation	 of	 antigen	 specific	 CD4+	 T	 cells.	 MLR	 experiments	 with	 Nivolumab	 added	 on	
different	 days	 shows	 an	 increase	 in	 T	 cells	 proliferation,	 in	 particular	 CD4+	 T	 cells,	 when	
added	early.	This	indicates	that	the	time	of	administration	is	critical	to	achieve	greater	T	cell	
proliferation.	 Responding	 T	 cells	 subsets	 incubated	with	Nivolumab	did	not	 result	 in	 non-
specific	 proliferation	 despite	 not	 being	 in	 a	 state	 of	 chronic	 exhaustion.	 However,	 with	
further	 research	 these	 results	 support	 why	 Nivolumab	 has	 been	 successful	 with	 solid	
tumours	as	inhibiting	ligation	between	chronically	activated	T	cells	and	immune	cells.		
Stimulation	of	hCMRF-56+	BDC	with	IL-1β,	Pam3CSK4	and	anti-CD40	all	resulted	in	increased	
CD80	 expression.	 Stimulation	 of	 hCMRF-56+	 immune	 selected	 cells	 with	 Pam3CSK4	
significantly	increased	the	production	of	TNF,	CCL2,	IL-6	and	IL-10	compared	to	hCMRF-56+	
immune	 selected	 cells	 not	 stimulated.	 Pam3CSK4	 stimulated	 TAA	 IVT	 mRNA	 transfected	
150	
	
hCMRF-56+	 immune	 selected	 cells	 should	 be	 compared	 with	 GM-CSF	 stimulation	 to	
determine	if	a	greater	antigen	specific	T	cell	response	can	be	observed	and	then	tested	this	
stimulation	method	can	be	safely	 implemented	 into	clinical	practice.	Extrapolation	of	data	
obtained	from	this	research	shows	that	CD40	and	CD86	co-stimulatory	hCMRF-56+	immune	
selected	 BDC	 surface	 molecules	 do	 not	 significantly	 increase	 after	 transfection	 with	 IVT	
mRNA.	 Only	 expression	 of	 CD80	 by	 hCMRF-56+	 immune	 selected	 BDC	 was	 significantly	
increased	 after	 IVT	 mRNA	 transfection.	 Although	 expression	 of	 PD-L1	 by	 hCMRF-56+	
immune	 selected	 BDC	 was	 not	 examined	 after	 IVT	 mRNA	 transfection,	 it	 would	 be	
important	to	establish	PD-L1	expression	after	IVT	mRNA	transfection	to	ensure	Nivolumab	is	
able	to	inhibit	PD-1	and	PD-L1	ligation.		 	
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6 CONCLUSIONS	AND	FUTURE	DIRECTIONS	
6.1 Significant	results	
Current	common	cancer	 treatments	are	designed	 to	 reduce	 the	 tumour	burden	and	drive	
the	patient	in	to	remission.	However,	these	treatment	options	are	not	risk-free.	The	mode	
of	action	 for	 chemotherapy	and	 radiotherapy	 involve	killing	both	cancer	 cells	and	healthy	
cells.	Bone	marrow	transplantation	 involves	the	engraftment	of	donor	stem	cells	 in	to	the	
host.	 Immune	 therapies	 are	 considered	 to	 be	 an	 exciting	 approach	 to	 treat	 multiple	
diseases,	 including	 some	 cancers.	 Immune	 therapies	 rely	 on	 exploiting	 functions	 of	 the	
immune	system	to	achieve	a	response	that	will	manage	the	disease.	This	may	be	specific	or	
non-specific,	 active	 or	 passive.	 Therefore	 a	 need	 to	 develop	 cancer	 treatments	 with	 less	
adverse	toxicities	 is	required.	 I	have	focussed	this	thesis	on	evaluating	the	antigen	specific	
immune	response	after	hCMRF-56+	immune	selected	cells	were	transfected	with	IVT-mRNA.	
Significant	 results	 from	 this	 research	 are	 hCMRF-56	 validation,	 hCMRF-56+	 BDC	 immune	
selection,	 loading	 BDC	 with	 IVT	 mRNA,	 combining	 IVT	 mRNA	 transfected	 hCMRF-56+	
immune	selected	cells	with	checkpoint	inhibition,	and	investigation	of	clinically	appropriate	
activation	strategies	for	hCMRF-56+	immune	selected	BDC.	
1.	BDC	 therapy	 stimulates	 an	active	antigen	 specific	 immune	 response	 that	 is	 required	 to	
generate	an	anti-cancer	 immune	response.	BDC	therapy	relies	the	 isolation	and	 loading	of	
BDC	with	tumour	antigen	then	the	antigen	is	presented	to	autologous	T	cells	to	generate	an	
antigen	specific	T	cell	 immune	response.	However,	 isolating	BDC	 is	challenging	due	to	 the	
lack	 of	 specific	 BDC	 surface	 molecules.	 Clinical	 studies	 have	 resorted	 to	 using	 in	 vitro	
manufactured	Mo-DC.	 hCMRF-56	 is	 an	 IgG4	 human	 chimeric	mAb	 that	 detects	 a	 surface	
molecule	expressed	by	BDC	and	other	APC	such	as	B	cells	and	monocytes,	to	allow	for	the	
immune	 selection	 of	 these	 cells	 by	 positive	 magnetic	 selection.	 The	 IgG4	 isotype	 was	
selected	 over	 other	 mAb	 isotypes	 to	 minimise	 ADCC	 and	 CDC	 activity.	 However,	 IgG4	
molecules	are	subject	 to	Fab	arms	exchange,	creating	bi-specific	mAbs	with	the	specificity	
undetermined.	Mutation	of	the	disulphide	bonds	situated	in	the	hinge	region	results	 in	an	
IgG1-like	molecule,	thereby	reducing	Fab	switching	and	improves	the	mAb	stability	(Peters	
et	al.,	2012,	Silva,	2014).	
2.	APC	are	 immune	cells	 responsible	 for	 initiating	an	antigen	specific	T	cell	 response.	BDC	
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are	often	referred	to	the	most	powerful	 initiators	of	an	antigen	specific	 immune	response	
and	comprise	of	multiple	subsets	including	CD1c+	and	CD141+	BDC.	These	BDC	subsets	and	
other	APC	 are	 enriched	by	 hCMRF-56+	 immune	 selection,	which	 allows	ex	 vivo	 loading	 of	
TAA	antigen	to	initiate	an	antigen	specific	immune	response.	Isolation	of	BDC	from	patient	
blood	for	ex	vivo	loading	followed	by	administration	back	in	to	the	patient	reduces	potential	
immune	suppression	from	TME.	Transfection	of	hCMRF-56+	immune	selected	cells	with	WT1	
IVT	mRNA	generated	a	WT1	specific	 immune	response	measured	by:	expansion	of	antigen	
specific	T	cells,	cytokine	production	and	antigen	specific	cytotoxicity.	
3.	 HLA	 typing	 is	 a	 required	 so	 specific	 peptide	 sequences	 are	 efficiently	 exchanged	 on	 to	
MHC.	Full	length	TAA	mRNA	transfected	BDC	translate	protein	and	present	MHC	I	and	MHC	
II	 antigen	 to	T	 cells.	 The	addition	or	 substitution	of	other	 TAA	 IVT	mRNA	 is	 an	advantage	
compared	 to	 traditional	peptide	 loading,	where	 traditionally	one	peptide	 is	 loaded	at	one	
time.	 Some	 cancers	 such	 as	 multiple	 myeloma	 express	 multiple	 TAA.	 The	 inclusion	 of	
multiple	 TAA	 IVT	 mRNAs	 during	 transfection	 may	 create	 a	 diverse	 antigen	 immune	
response,	therefore	able	to	treat	cancers	with	multiple	TAA.	
IVT	 mRNA	 transfection	 does	 not	 impair	 the	 migration	 of	 hCMRF-56+	 BDC	 to	 CCL21,	 a	
chemokine	secreted	by	lymphatics	to	attract	BDC	to	T	cells.	When	the	migration	of	hCMRF-
56+	 BDC	 and	Mo-DC	were	 compared	 in	 a	 xeno	migration	 SCID	mouse	model,	 hCMRF-56+	
moderately	performed	better	than	Mo-DC.	However,	further	testing	in	a	model	such	as	NHP	
with	a	method	to	track	migration	would	be	more	suitable.	Radioisotope	labelling	of	Mo-DC	
has	been	used	to	track	migration	after	administration	in	patients	(Morse	et	al.,	1999,	Ridolfi	
et	 al.,	 2004).	 This	 method	 will	 also	 allow	 for	 the	 detection	 of	 cells	 in	 other	 anatomical	
locations,	and	not	only	the	harvested	site.	
4.	 It	was	 tested	 to	 determine	 if	WT1	 IVT	mRNA	 transfected	 hCMRF-56+	 immune	 selected	
cells	would	generate	a	 greater	 anti-WT1	CD8+	T	 cell	 immune	 response	 in	 the	presence	of	
Nivolumab.	Nivolumab	was	selected	due	to	the	strong	expression	of	PD-1	by	antigen	specific	
T	 cells,	 and	 the	 high	 expression	 of	 PD-L1	 by	 hCMRF-56+	 cells.	 No	 differences	 in	 T	 cell:	
stimulation,	cytokine	production	and	cytotoxicity	was	observed	when	Nivolumab	was	used	
in	 conjunction	with	WT1	 IVT	mRNA	 transfected	 hCMRF-56+	 immune	 selected	 cells.	 Other	
clinical	 therapeutic	mAbs	 such	as	Pembrolizumab	or	Avelumab	 to	block	 the	PD-1	and	PD-
L1or	 PD-L2	 interactions	may	 prove	 to	 be	more	 appropriate	 for	 generating	 an	 anti-cancer	
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immune	 response	 from	 IVT	 mRNA	 transfected	 hCMRF-56+	 immune	 selected	 cells.	
Ipilimumab	is	another	immune	regulating	mAb	that	binds	to	CD152	(CTLA-4)	expressed	by	T	
cells	(Camacho,	2015,	Hegel	et	al.,	2009).	CD28	and	CD152	both	compete	for	ligation	to	the	
same	receptors,	CD80	and	CD86.	Blocking	CD152	binding	to	CD80	or	CD86	with	Ipilimumab	
results	 in	 enhanced	 IFNγ	 and	 proliferation	 by	 CD45RO+,	 CD8+	 T	 cells	 (Hegel	 et	 al.,	 2009,	
Tietze	et	al.,	2017).	Ipilimumab	has	been	approved	for	the	treatment	of	melanoma	(Fellner,	
2012,	Snyder	et	al.,	2014).	
An	increase	in	CD4+	T	cell	proliferation	was	observed	in	MLR	when	Nivolumab	was	added	on	
first	 or	 second	 day.	 All	 peptides	 unless	 otherwise	 described	 were	 designed	 for	 MHC	 I	
exchange.	 Therefore	 T	 cell	 experiments	 measuring:	 stimulation,	 cytokine	 production	 and	
cytotoxicity	 experiments	 used	 the	 peptide	 that	 is	 suitable	 for	 detecting	 a	 CD8+	 T	 cell	
response.	Although	a	CD4+	T	cell	response	may	be	detected	using	this	method,	the	use	of	an	
APC	 processed	 long	 peptide	 to	 present	 MHC	 II	 antigen	 may	 increase	 the	 CD4+	 T	 cell	
response,	 which	 has	 been	 previously	 discussed	 to	 enhance	 the	 antigen	 specific	 immune	
response.	
5.	 Stimulation	 is	 required	 for	 BDC	 maturation,	 which	 is	 demonstrated	 by	 elevated	
expression	 of	 activation	 and	 co-stimulatory	 cell	 surface	 molecules.	 GM-CSF	 stimulation	
resulted	 in	 the	 increased	expression	of	CD40,	CD54,	CD83,	CD86	and	CCR7	for	hCMRF-56+	
immune	selected	BDC.	However,	GM-CSF	stimulation	of	hCMRF-56+	 immune	selected	BDC	
resulted	in	stable	low	expression	of	CD80.	In	an	attempt	to	increase	the	expression	of	CD80,	
other	clinically	applicable	stimulating	reagents	combined	in	the	presence	of	absence	of	GM-
CSF	were	 examined	 for	 their	 ability	 to	 increase	 CD80	 expression.	No	 reagent	 significantly	
increased	CD80	expression.	However,	 stimulation	with	Pam3CSK4	 resulted	 in	higher	CD80	
expression	 compared	 to	GM-CSF	 stimulation.	 Stimulation	of	hCMRF-56+	 immune	 selected	
cells	 with	 Pam3CSK4	 and	 IL-1β	 resulted	 in	 the	 greatest	 number	 of	 different	 cytokines	
detected	by	CBA.	Regulatory	cytokines	such	as	IL-6	and	IL-10	were	detected	after	Pam3CSK4	
and	 IL-1β	stimulation,	even	 though	 IL-12p70	was	detected.	T	cell	 immune	responses	 from	
stimulating	 TAA	 IVT	mRNA	 transfected	 hCMRF-56+	 immune	 selected	 cells	with	 Pam3CSK4	
and	IL-1β	will	need	to	be	assessed	using	comparable	methods.	
6.2 Future	directions	
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Mouse	 anti-CMRF-56	was	 engineered	 into	 a	 hCMRF-56	 IgG4.	Mutation	 of	 the	 cysteine	 to	
serine	located	on	the	heavy	chain	will	further	improve	the	thermal	stability	and	integrity	of	
the	IgG4	mAb	(Peters	et	al.,	2012).	This	is	important	to	ensure	maximum	function	from	the	
mAb	 including	 immune	 selection	 of	 hCMRF-56+	 cells	 and	 prevention	 of	 ADCC	 and	 CDC.	
Stability	studies	of	the	hCMRF-56+	immune	selected	cells	 including	viability	and	expression	
of	hCMRF-56	antigen	should	be	evaluated	pre-immune	selection,	during	the	production	of	
the	 IVT-mRNA	 transfected	 hCMRF-56+	 immune	 selected	 cell	 therapy	 product	 and	
transportation	to	the	patient.	These	findings	may	be	important	to	the	quality	control	release	
of	 the	 hCMRF-56+	 immune	 selected	 cell	 therapy	 product	 to	 the	 patient.	WT1	 IVT	mRNA	
transfected	hCMRF-56+	immune	selected	cells	generate	a	WT1	immune	response	in	healthy	
patients.	 Further	 expanding	 on	 this	 study,	 a	 cohort	 of	 WT1+	 cancer	 patients	 should	 be	
enrolled	with	appropriate	ethics	to	confirm	the	enrichment	of	hCMRF-56+	immune	selected	
BDC	 subsets	 and	other	APC.	After	 the	enrichment	of	 hCMRF-56+	 immune	 selected	BDC	 is	
confirmed,	generating	a	WT1	T	cell	 immune	response	from	IVT	mRNA	transfected	hCMRF-
56+	 immune	 selected	 cells	 and	 autologous	 T	 cells	 will	 be	 assessed	 to	 confirm	 the	
functionality	of	hCMRF-56+	 immune	 selected	cells	 and	T	 cells.	A	 similar	methodology	 that	
was	 used	 in	 this	 study	 should	 be	 used	 to	 confirm	 the	WT1	 T	 cell	 immune	 response	 and	
measure	stimulation,	cytokine	production	and	cytotoxicity	of	T	cells.	Using	this	methodology	
will	 confirm	 the	 antigen	 presentation	 by	 hCMRF-56+	 immune	 selected	 cells	 and	 T	 cell	
activity.		
Nivolumab	was	 added	 to	 determine	 if	 the	 presence	will	 enhance	 the	 generation	 of	WT1	
specific	T	cell	immune	response.	No	difference	was	found	with	the	presence	or	absence	of	
Nivolumab.	Other	mAbs	designed	 to	block	 the	 ligation	of	PD-1	 to	PD-L1	or	other	 immune	
regulators	may	be	used	to	enhance	the	generation	of	an	antigen	specific	immune	response.	
A	significant	difference	in	CD4+	T	cell	proliferation	was	observed	in	an	MLR	when	Nivolumab	
was	added	on	day	one	or	day	two.	As	the	experiments	performed	were	designed	to	assess	
the	WT1	CD8+	T	cell	 immune	response,	 the	WT1+	CD4+	T	cell	 immune	response	should	be	
investigated.	
Antigen	specific	immune	responses	from	hCMRF-56+	immune	selected	cells	stimulated	with	
Pam3CSK4	are	to	be	confirmed	by	comparing	to	stimulation	of	hCMRF-56+	immune	selected	
cells	with	 GM-CSF	 from	WT1+	 cancer	 patients.	 This	 includes	measuring	 the	 expression	 of	
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other	 hCMRF-56+	 BDC	 activation,	 co-stimulatory	 surface	 molecules	 and	 chemokine	
receptors,	and	measuring	antigen	specific	T	cell	immune	responses.	These	future	directions	
will	 pave	 the	way	 forward	 for	 future	 clinical	 studies	 to	 establish	 the	 optimal	method	 for	
activating	hCMRF-56+	 immune	selected	BDC	and	transfection	with	IVT	mRNA	to	an	initiate	
anti-cancer	immune	response	for	cancer	patients.		 	
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